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“The tipping point is that moment when an idea, trend, or social behavior crosses a 
threshold, tips, and spreads like wildfire.” 
  
― Malcolm Gladwell,  
The Tipping Point: How Little Things Can Make a Big Difference 
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ABSTRACT 
Cell-associated Heparan Sulphate (HS) binds the V3 loop of gp120 of HIV-1 thus aiding in 
viral infectivity. However, a soluble polyanion (HS12) has anti-viral properties once 
conjugated to CD4 (mCD4-HS12), and showed nM activity against HIV-1 in vitro. Due to the 
structural complexity of HS, screening differently sulphated-oligosaccharides to improve the 
molecule’s activity would be too cumbersome, thus in order to obtain a more specific, higher 
affinity and easier to produce moiety, collaborators synthesized HS mimetic peptides. We 
aimed to screen these peptides and other anionic molecules for their capacity to inhibit HIV-1 
entry. Thus we set-up a platform whereby solubilised CCR5 and CXCR4 were immobilized 
on biosensors (biacore) and used to screen for molecules that inhibited gp120-CD4 binding to 
the coreceptors. To control the solubilization process, CXCL12, the natural ligand of CXCR4, 
was injected over the immobilized CXCR4. The affinities of CXCL12 isoforms (α and γ) for 
CXCR4 were calculated within the ranges of previously described values with different 
techniques thus proving the functionality of our system. We show for the first time that HS 
differently regulates the binding mechanisms of these two isoforms and we propose a novel 
mode of action for the unusually basic C-terminal of CXCL12 γ with CXCR4. The system 
was subsequently used to screen the inhibitory capacity of the HS mimetic peptides. Each 
peptide, [S(XDXS)n], contained amino acids that mimic the hydroxyl, carboxyl and sulphate 
groups on HS chains. The peptide containing sulphotyrosine residues, when conjugated to 
mCD4 (mCD4-P3YSO3), displayed nM IC50 for simultaneously inhibiting gp120 binding to 
HS, CD4, antibody, coreceptors and HIV-1 infection in vitro. This is the first bivalent entry 
inhibitor that targets both R5 and X4 viruses and the concept of a HS-mimetic peptide lends 
itself to structural-functional analysis of HS chains binding to proteins, a novel technique in 
this field. 
La gp120 du VIH-1 se fixe aux héparane sulfate (HS) cellulaires, par le biais de la boucle V3 
ce qui favorise l'infectivité virale. Cependant, une polyanion solubles (HS12), conjugués à 
CD4 (mCD4-HS12) a des propriétés antivirales et a montré in vitro une activité contre le VIH-
1 à de concentrations nM. En raison de la complexité structurale des HS, le criblage 
d’oligosaccharides différenciellement sulfatés pour améliorer l'activité de la molécule serait 
trop difficile. En vue d'obtenir une molécule plus spécifique, de plus haute affinité et plus 
facile à produire, des peptides mimant les HS ont été synthétisés par nos collaborateurs. Notre 
but était de cribler ces peptides pour leur capacité à inhiber l'entrée de VIH-1. Nous avons mis 
en place une plateforme permettant d’immobiliser CCR5 et CXCR4 solubilisés sur des 
biocapteurs pour cribler des molécules qui inhibent la liaison de gp120-CD4 aux corécepteurs. 
Pour contrôler le processus de solubilisation, CXCL12, le ligand naturel de CXCR4, a été 
injecté sur CXCR4 immobilisé. Les affinités des isoformes CXCL12 (α et γ) pour CXCR4 ont 
été calculées dans les fourchettes de valeurs précédemment décrites avec des techniques 
différentes prouvant la fonctionnalité de notre système. Nous montrons pour la première fois 
que les HS régulent différemment les mécanismes de liaison de ces deux isoformes et nous 
proposons un nouveau mode d'action pour le domaine C-terminal particulièrement basique de 
CXCL12 γ vis-à-vis de CXCR4. Le système a ensuite été utilisé pour cribler la capacité 
d'inhibition des peptides mimétiques du HS. Chaque peptide, [S(XDXS)n] contient des acides 
aminés qui imitent les groupes hydroxyles, carboxyles et sulfates des HS. Le peptide 
contenant des résidus sulphotyrosines, une fois conjugué à mCD4 (mCD4-P3YSO3), montre 
un IC50 de l’ordre du nM, pour l’inhibition simultanée de la liaison de gp120 aux HS, à CD4, 
aux anticorps, aux corécepteurs ainsi que l’infection par VIH-1 in cellulo. Il constitue le  
premier inhibiteur bivalent de l’entrée qui cible à la fois les virus R5 et X4 et le concept d'un 
peptide mimétique des HS se prête à une analyse structurale et fonctionnelle de la liaison des 
chaînes HS aux protéines, une nouvelle technique dans ce domaine. 
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Chapter 1: HIV 
1.1 The Global HIV/AIDS pandemic 
1.1.1 Discovery and epidemiology 
Acquired Immunodeficiency Syndrome (AIDS) was first detected in May 1981 
among four homosexual men in Los Angeles, United States of America who 
presented with infections such as Pneumocystis carinii pneumonia (PCP), 
Kaposi’s sarcoma, prolonged fever and Candida infections (1981; Gottlieb, 
Schroff et al. 1981). The apparent sexually transmitted immune deficiency in 
these patients was thought to be due to cytomegalovirus (CMV) infections in 
homosexual men, and called Gay-Related Immune Deficiency Syndrome 
(GRIDS) (1981; Gottlieb, Schroff et al. 1981; Hymes, Cheung et al. 1981; Masur, 
Michelis et al. 1981; Siegal, Lopez et al. 1981). However, this disease was not 
only seen in homosexual men; by 1983 groups of intravenous drug abusers, 
individuals receiving blood and blood products and heterosexual Haitians in 
America, presented with AIDS (1982; Harris, Small et al. 1983). 
The causative agent of AIDS is a retrovirus that was first isolated from patients 
and demonstrated cytopathic effects on CD4+ T cells, which was clearly distinct 
from  the Human T-cell leukaemia virus (HTLV) and was thus classified as a 
Lymphadenopathy-Associated Virus (LAV); thus a member of the T-
lymphotropic retroviruses (Barre-Sinoussi, Chermann et al. 1983; Gallo, 
Salahuddin et al. 1984; Gallo and Montagnier 2003). This virus is now called 
Human Immunodeficiency Virus (HIV), the etiologic agent of AIDS. HIV-1 
crossed the species barrier from chimpanzees to humans during the early twentieth 
century and has since infected millions of humans. Origins of HIV-1 have thus 
been linked to the simian immunodeficiency virus (SIV) from the genus 
Lentiviruses of the family Retroviridae (Chakrabarti, Guyader et al. 1987; 
Desrosiers and Ringler 1989; Gao, Bailes et al. 1999; Hillis 2000). Currently, one 
percent of the world’s population is infected with the worlds’ fastest evolving 
pathogen, HIV-1 (Korber, Muldoon et al. 2000).  
AIDS is characterized by the progressive depletion of CD4+ T lymphocytes which 
play an important role in establishing and enhancing the cell-mediated and 
humoral immune response (Gottlieb, Schroff et al. 1981; Siegal, Lopez et al. 
1981). When individuals suffer severe damage to their immune system, their 
vulnerability to opportunistic infections (OIs) and malignancies is heightened due 
to the loss of the individuals’ ability to mount an effective immune response. 
Ultimately death results after many years of untreated infection (Gallo, 
Salahuddin et al. 1984).   
As worldwide efforts to create awareness, prevention and treatment programs 
increase, so does the total number of people living with the virus. According to 
the UNAIDS report on the global epidemic in 2010, there were 2.6 million newly 
infected people in 2009 and 1.8 million AIDS deaths, bringing the total number of 
people living with HIV-1 as reported at the end of 2009 to 33.3 million (UNAIDS 
2011). These figures are almost equivalent to 7,123 new infections and 4.931 
 
 
3
deaths per day due to AIDS. The emergence of this pandemic has arguably been 
the most catastrophic event in medicine in the last 30 years (Figure 1.1).  
While all countries are currently fighting the impact of this disease, sub-Saharan 
Africa, and Southern Africa in particular continue to bear the greatest burden of 
people infected with and affected by HIV-1. Just over 10% of the world’s 
population inhabits sub-Saharan Africa, yet this region is home to 67.5% of 
people living with HIV-1 worldwide. In 2009, new infections in this region 
totalled more than those in all other regions of the world combined. In South 
Africa there are an estimated 5.6 million infected individuals which represents the 
largest number of individuals living with the virus in a single country. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1Diagrammatic representation of the global prevalence of HIV infected adults and 
children living with HIV at the end of 2009 (UNAIDS 2011).  
1.1.2 Heterogeneity 
Genetic diversity of HIV-1 exists along the entire length of the genome between 
viral isolates from different individuals and between viral quasispecies within the 
same individual. The unique and unstable characteristics of HIV-1 are its inherent 
variability and capability of generating quasispecies as a direct result of two 
features; lack of a proof-reading mechanism by the viral reverse transcriptase 
(RT) enzyme during replication (Roberts, Bebenek et al. 1988) and its rapid 
replication rate (Ho, Neumann et al. 1995; Wei, Ghosh et al. 1995). The error 
prone RT has an estimated misincorporation (insertions/deletions) rate of 1 x 10-4 
- 3.4 x 10-5 per base pair per replication cycle (Preston, Poiesz et al. 1988; 
Roberts, Bebenek et al. 1988; Nowak 1990; Pathak and Temin 1990; Mansky and 
Temin 1995; Mansky 1998). This equates to about one nucleotide being miss-
incorporated per replication cycle of 9.7 kb. This process is exacerbated by the 
high production of approximately 1 x 1010 viral particles daily and in the absence 
of proof-reading mechanisms, this results in extensive viral heterogeneity 
(Preston, Poiesz et al. 1988; Coffin 1995; Ho, Neumann et al. 1995; Wei, Ghosh 
et al. 1995; Perelson, Neumann et al. 1996; Zhang, Schuler et al. 1999).  
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Recombination between two RNA genomes also results in major gene-
rearrangements and generation of diversity within the subpopulations within the 
host (Jung, Maier et al. 2002; Zhuang, Jetzt et al. 2002; Levy, Aldrovandi et al. 
2004). Together, these features allow HIV to rapidly mutate its genome, enabling 
the virus to constantly evolve and increase genetic variability. This impacts on 
factors such as the genotypic viral diversity amongst different isolates, immune 
escape and emergence of Antiretroviral (ARV) drug resistance (Mansky 1998). 
1.1.3 Origins and Classification 
To date, two main types of HIV have been identified with origins as zoonotic 
lentiviruses; HIV-1 is believed to have originated from a SIVCPZ from the 
chimpanzee (Pan troglodytes) population (Gao, Bailes et al. 1999; Santiago, 
Rodenburg et al. 2002) and HIV-2 is believed to have originated from the SIVSM 
sooty mangabey (Cercocebus atys); SIV infections originated from mangabeys 
and ppears to be non-pathogenic, however, SIV causes AIDS-like symptoms in 
the Asian rhesus macaques (Gao, Yue et al. 1992; Rambaut, Posada et al. 2004). 
HIV-1 and 2 are transmitted in the same fashion yet HIV-2 has a lower rate of 
transmission, longer asymptomatic period and lower viral load; hence it is less 
pathogenic (Pepin, Morgan et al. 1991; Marlink, Kanki et al. 1994). HIV-2 is 
endemic in West Central Africa and to a lesser extent elsewhere in the world such 
as Europe and the West coast of India (Rubsamen-Waigmann, Briesen et al. 1991; 
Babu, Saraswathi et al. 1993). However, HIV-1 predominates worldwide and has 
a three times higher mortality rate than HIV-2 (Whittle, Morris et al. 1994).  
In addition to the two main types of HIV, further classification systems have been 
constructed from the copious phylogenetic data analyses of the many strains of 
HIV-1 and HIV-2 isolated and analyzed worldwide. There are four sub-
classifications for HIV-1: groups, subtypes, sub-subtypes and circulating 
recombinant forms (CRFs). Of the groups, the Major group (Group M) is 
responsible for the current global pandemic (98% of HIV-1 infections worldwide) 
and the Outlier Group (Group O) and New group (Group N; consisting of non-O 
and non-M viruses) are less globally distributed. Groups O and N are genetically 
both highly divergent from group M and sparsely distributed in Cameroon and 
West Central Africa (Charneau, Borman et al. 1994; Mauclere, Loussert-Ajaka et 
al. 1997; Peeters, Gueye et al. 1997; Simon, Mauclere et al. 1998).  
Group M is further subdivided up into 9 distinct subtypes, namely A, B, C, D, F, 
G, H, J, K wherein there are two sets of sub-subtypes A1, A2 and F1, F2 
respectively (Louwagie, McCutchan et al. 1993; Robertson, Anderson et al. 2000). 
The emergence of Circulating Recombinant Forms (CRFs) has resulted from 
many recombination events between different HIV-1 viruses and already 34 CRFs  
have been described (Karlsson, Parsmyr et al. 1994; Casado, Thomson et al. 2005; 
2007). These viruses share an identical mosaic structure in their genomes as they 
have descended from the same recombination events (Robertson, Anderson et al. 
1999). 
Phylogenetic analysis has revealed that the origin of HIV-1 came from four 
different cross-species transmissions from chimpanzees and one or two of these 
transmissions have been by gorillas (Sharp and Hahn 2010). It is generally 
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accepted that humans became infected by HIV-1 due to an inter-species 
transmission between SIV infected primates and humans. African people used to 
ingest simian meat that they hunted or acquired at "bushmeat markets". In this 
way, they were exposed to the contaminated meat. 
1.1.4 Transmission 
HIV-1 is transmitted through bodily fluids such as blood, semen and breast milk. 
Thus there are several pathways through which the virus can be transmitted 
between human beings; sexual transmission is the most common type of 
transmission. The epidemic in sub-Saharen Africa, which is responsible for almost 
70% of the global infected population, is brought about (for the majaroity) by 
heterosexual transmission. However, in America and Europe, the epidemic is 
largly due to homosexual transmission. According to UNAIDS, the sharing of 
infected needles among injection drug users (IDU) is responsible for more than 
80% of all HIV-1 infections in Eastern Europe and Central Asia. Another mode of 
HIV-1 transmission, also rife in sub-Saharan Africa, is the transmission from 
mother to child during natural child birth and during breast-feeding in conjunction 
with the use of formula milk. 
1.1.5 Disease Pathogenesis and Progression 
HIV-1 infection is characterised by a gradual deterioration in immune function 
and ultimately AIDS. Pathogenesis studies of HIV-1 explore the diverse 
mechanisms that lead to this immune system destruction and understanding how 
the virus establishes infection is essential to the identification and development of 
effective therapeutics and vaccines.  
HIV-1 infection consists of an initial acute phase of infection followed by a period 
of clinical latency and finally a chronic phase. The acute phase is characterised by 
an increase in viral RNA (viral load) and the consequent decline in CD4+ T cells 
in peripheral blood (Clark and Shaw 1993). The activation of the immune system 
subsequently results in the suppression of viremia to a low steady state level 
termed the viral setpoint, and an increase in CD4+ T cells. During the clinical 
latency phase, viral load as well as the number of CD4+ T cells may remain 
constant for several years with the patient remaining largely asymptomatic. 
However the steady replication of HIV particles eventually overwhelms the 
immune system, resulting in a gradual rise in viremia and a steady decrease in 
CD4+ T cells until the patient is severely immunocompromised, resulting in 
increased susceptibility to opportunistic infections and the development of AIDS 
(Figure 1.2). 
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Figure 1.2 Early after primary infection there is widespread dissemination of virus and a 
sharp decrease in CD4+ T cells count in peripheral blood. The host launches an immune 
response to HIV-1 characterised by a decrease in detectable viremia followed by a prolonged 
period of clinical latency. The CD4+ T-cell count continues to decrease during the following 
years (in un-treated patients), until it reaches a critical level below which there is a 
substantial risk of opportunistic infections (Pantaleo, Graziosi et al. 1993). 
1.2 The structure and Life cycle 
1.2.1 Viral particle and genome 
An intact, mature T-lymphotropic HIV-1 retrovirus is spherical in shape, with a 
diameter of approximately 80 to 120 nm (Barre-Sinoussi, Chermann et al. 1983). 
As in all retroviruses, HIV-1 has two copies (diploid) of identical plus-strand 
genomic RNA. The viral regulatory, structural and accessory proteins and 
enzymes are encoded by 9 partially overlapping genes spanning approximately 9.7 
kb of genetic material (Figure 1.3). These 9 open reading frames code for at least 
16 distinct proteins. Three of these genes encode structural proteins; Gag [group-
specific antigen], Pol [polymerase] and Env [envelope]), encoded by gag, pol and 
env respectively. The Gag protein precursor is cleaved by the viral protease into 
the p17 matrix (MA), p24 capsid (CA), the p7 nucleocapsid protein (NC) and the 
P6 protein essential for viral assembly (Ganser-Pornillos, Yeager et al. 2008). The 
Pol protein is also cleaved by viral proteases to yield the protease (PR), reverse 
transcriptase (RT), RNAse and  integrase (IN) enzymes which are all involved in 
the viral replication (Hill, Tachedjian et al. 2005).  
The gp160 Envelope (Env) glycoprotein is cleaved by furin into the surface gp120 
and transmembrane gp41 subunits, which are necessary for binding to the host 
primary receptor, CD4, and coreceptors CCR5 and CXCR4 on the surface of 
CD4+ T cells. There are two genes that encode regulatory proteins; (Tat 
[transcriptional transactivator] and Rev [regulator of virion gene expression]). 
There are also four genes that encode accessory proteins (Vif [viral infectivity 
factor], Vpr [viral protein r], Vpu [viral protein u] and Nef [negative factor]) 
(Frankel and Young 1998; Turner and Summers 1999). The viral envelope 
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encases a matrix protein membrane (p17/MA), which provides further structure to 
the virion as well as encompasses the single layer of structural capsid/core 
proteins (p24/CA). The capsid contains the viral RNA, PR, RT heterodimer 
(comprised of two subunits; the RNAse H (p66) subunit and the RT (p51) 
subunit), and IN (Figure 1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 HIV structure and genome organisation: the 9 viral genes are depicted (9.7 kb) 
which encode open reading frames for at least 16 structural, regulatory, accessory and 
enzymatic proteins. The gag, pol and env genes encode protein precursors (pr55, pr160 and 
gp160 respectively) which require further processing by either viral or cellular proteases to 
generate structural proteins necessary for the formation of a mature virion. 
1.2.2 Gp120 
Viral attachment and entry into target cells is mediated by the envelope 
glycoprotein (env/gp160) which is initially transcribed as a non-glycosylated 
precursor (90 kDa).  
 
 
8
The precursor is translated in the endoplasmic reticulum where it undergoes 
folding, disulphide bond formation and extensive glycosylation. About 31 
oligosaccharide chains (rich in mannose) are attached to the gp120 protein at 
specific asparagine N-linked sites (Asn-X-Ser, Asn-X-Thr) and this glycosylation 
represents about 50% of the total mass of the protein (Allan, Coligan et al. 1985). 
The typical envelope glycoprotein has approximately 24 N-linked glycosylation 
sites in gp120 (Leonard, Spellman et al. 1990), as well as three or four sites in 
gp41 (Starcich, Hahn et al. 1986). Experimental data has revealed the presence of 
both complex-type, as well as high mannose or hybrid-type carbohydrates on 
gp120 (Leonard, Spellman et al. 1990) and these N-linked glycosylations play an 
essential role in neutralisation escape by HIV-1 (Figure 1.4). In this model, the 
coreceptor binding site is aimed directly towards the target cell membrane and is 
not glycosylated,  and the carbohydrates shown here represent approximately half 
the carbohydrate on gp120, with the rest extending further from the gp120 surface 
(Kwong, Wyatt et al. 2000). The glycan shield protects the viral envelope from 
surveillance by the host immune system as the glycans are lowly immunogenic, 
contrary to the highly immunogenic viral proteins. This glycan shield can evolve 
and change rapidly, thus evading detection by the host immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4 Model of gp120 trimer from the orientation of the viral membrane. The gp120 
core is a copper brown and carbohydrate core structures are blue. Picture taken from 
(Kwong, Wyatt et al. 2000) 
After glycosylation, the gp160 precursor is cleaved by convertases; furin and PC7 
in the golgi apparatus into the gp120 / gp41 heterodimer, the surface and 
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transmembrane subunits respectively (Veronese, DeVico et al. 1985; McCune, 
Rabin et al. 1988; Willey, Bonifacino et al. 1988; Stein and Engleman 1990; Earl, 
Moss et al. 1991). The host proteases bind to a highly conserved arginine-rich 
cleavage site junction situated between the gp120 and gp41 peptides (Veronese, 
DeVico et al. 1985; Starcich, Hahn et al. 1986) (Figure 1.5 A). 
Once the precursor protein is cleaved, gp120 associates non-covalently with gp41 
in trimeric clusters which are transported onto the surface of budding virions 
(Stein, Gowda et al. 1987; Center, Leapman et al. 2002). Cryo-electron 
microscopy has demonstrated that despite the large variation, there are on average 
14 trimeric spikes per virion which appear to be clustered (Zhu, Liu et al. 2006). 
1.2.3 Structure of gp120 
The gp120 envelope protein can be recognized by its five conserved regions (C1-
5) and 5 variable (V1-5) regions with 18 highly conserved cysteine residues (9 
disulphide bridges) (Modrow, Hahn et al. 1987; Leonard, Spellman et al. 1990). 
Since the advent of the structure determination of gp120, major advances have 
been made in understanding viral pathogenesis and the design of novel HIV entry 
inhibitors. Due to the extensive glycosylation of the viral envelope and the 
presence of poorly organized variable loops, crystallographic studies have been 
enormously challenging. The first crystal structure of gp120 (HXBc2) core protein 
was achieved by utilizing a truncated form of 120 (variable loops V1, V2 and V3 
removed) in complex with domains D1 and D2 of CD4 as well as a fragment 
antigen binding (Fab) 17b region to stabilize the complex (Kwong, Wyatt et al. 
1998). Later in 2000, the structure of a different envelope (YU2) was determined 
and in 2005 an HIV-1 envelope in complex with CD4 and a neutralizing antibody 
enabled the elucidation of the V3 loop structure (Huang, Tang et al. 2005).   
HIV-1 entry requires that gp120 binds to its primary receptor CD4 and one of the 
family of G-coupled seven-transmembrane domain chemokine receptors, 
principally CXCR4 and/or CCR5 (Alkhatib, Combadiere et al. 1996; Choe, 
Farzan et al. 1996; Deng, Liu et al. 1996; Doranz, Rucker et al. 1996; Dragic, 
Litwin et al. 1996). Upon binding of CD4, gp120 undergoes drastic 
conformational rearrangements which causes the exposure/creation of the 
discontinuous coreceptor binding site or CD4 induced site (CD4i) (Dalgleish, 
Beverley et al. 1984; Klatzmann, Champagne et al. 1984; Maddon, Dalgleish et al. 
1986; Thali, Moore et al. 1993; Kwong, Wyatt et al. 1998; Myszka, Sweet et al. 
2000; Center, Leapman et al. 2002).  In Peter Kwongs’ first structure of the 
deglycosylated gp120, two major domains are revealed; an inner domain 
(containing the N and C terminus) and a stacked double-barrel outer domain 
(including the V4 and V5 loops) (Kwong, Wyatt et al. 1998). After CD4 binding, 
the envelope undergoes a significant re-arrangement which causes the exposure of 
the coreceptor binding site; the inner and outer domains of gp120 pull together in 
order to form the anti-paralled 4 stranded β bridging sheet (Myszka, Sweet et al. 
2000). Here, the CD4 is bound at the interface between the two domains and the 
CD4i site flanked by the V1, V2 and V3 loops is oriented towards the cellular 
membrane (Figure 1.5 C) while loops V4 and V5 are situated in the outer domain. 
The CD4 un-bound state is also depicted, taken from Chen et al., 2005 where they 
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solved the structure of SIV envelope glycoprotein in the absence of CD4 and thus 
the bridging sheet is not formed (Chen, Vogan et al. 2005) (Figure 1.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Architecture and structure of gp120. (A) The gp160 protein is cleaved by furin to 
produce gp120 (Env, binds to CD4 and the coreceptors) and gp41 (transmembrane fusion 
protein). Crystal structures of unliganded (B) and liganded (C) gp120 adapted from Kwong 
et al. (Kwong, Wyatt et al. 1998) and Chen et al. (Chen, Vogan et al. 2005) 
Thermodynamic data has shown that gp120 undergoes a significant global re-
arrangement upon CD4 binding, about 126 residues are re-organised and that in 
this CD4-bound state, the protein is much more stable and rigid compared to the 
unbound state (Myszka, Sweet et al. 2000; Zhou, Xu et al. 2007). Oligomeric 
modeling of gp120 suggests that the variable loops and the CD4 and neutralizing 
antibody binding epitopes are exposed on the gp120 before HIV-1 entry (Kwong, 
Wyatt et al. 2000). The model also shows that the non-glycosylated coreceptor 
binding domain is directed towards the host membrane with the CD4 molecules 
binding at angles so as not to sterically hinder each other. Thus this model 
proposed simultaneous binding of CD4 and the coreceptors to the trimeric gp120 
heads. In order to obtain a clearer picture of how the envelope complex moves pre 
and post CD4 binding, Wu and colleagues have reconstructed the 3D structures of 
the unliganded and CD4-bound HIV-1 spikes using structural cryo-electron 
microscopy approaches (cryoEM), showing that the unliganded spike has a tripod 
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structure with distinct legs occupied by N and C termini (N/C) and the roof 
occupied by the variable loops. This tripod structure drastically changes when 
CD4 binds, as the base of the tripod becomes more dense with the variable loops 
moving outwards, the V3 loop lifting up ready to engage the coreceptor and with 
gp41 able to reach its target (Wu, Loving et al. 2010) (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 (Left) Fitting of the unliganded gp120 core (crystallographic structure) into a 
cryo-EM reconstruction of the unliganded HIV-1 spike. The outer and inner domains of the 
core gp120 are coloured red and gray, respectively, and the N/C extension blue. The stub of 
the V1/V2 loop is orange, whereas the stem of the V3 loop is green. The stems of the loops are 
additionally indicated by orange and green arrows. (Right) Fitting of the CD4-complexed 
gp120 core to cryo-EM reconstruction of the CD4 bound HIV-1 spike. CD4 binding loop 
(residues 364-374) are shown as spheres in yellow (left) and full length CD4 is in yellow on 
the right. Scale bar represents 50 Å. Adapted from Wu et al. (Wu, Loving et al. 2010) 
1.2.4 The V3 Loop 
In 2005, the crystal structure of gp120 in complex with CD4 and an antigen-
binding fragment (Fab) of the X5 antibody (broadly neutralizing antibody directed 
against coreceptor-induced gp120 epitopes) was published revealing the third 
variable loop (V3 loop) which plays a critical role in coreceptor usage 
determination of HIV-1 and host cell tropism (Hwang, Boyle et al. 1991; Chan, 
Speck et al. 1999; Shimizu, Haraguchi et al. 1999; Hartley, Klasse et al. 2005; 
Huang, Tang et al. 2005). The V3 region is usually 35 amino acids in length [(31-
39) amino acid positions 1 through 35 correspond to 296 through 332 in the 
standard reference HXBc2] with a conserved disulfide bridge at its base, a flexible 
stem and a β-hairpin tip. It is characteristically highly glycosylated and 
hypervariable however, a conserved Proline - Glycine motif on the tip of the V3 
loop projects 30 Å towards to host cell membrane from the gp120 core.  
This allows interaction of a four-stranded bridging sheet with the N-terminus of 
the CCR5 coreceptor; as the V3 tip binds to the Extracellular Cellular Loop 2 
(ECL2) of CCR5 and the conserved base interacts with the sulphated CCR5 N-
terminus (Huang, Tang et al. 2005; Huang, Lam et al. 2007). An indication of 
coreceptor usage can be made by analysing the sequence of the V3 loop; the 
CCR5 utilizing phenotype may be predicted (in many cases, but not all) by the 
presence of a neutral amino acid at position 11 in the V3 loop as well as a 
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negatively charged amino acid at position 25 (De Jong, De Ronde et al. 1992; 
Fouchier, Groenink et al. 1992; Milich, Margolin et al. 1993; Fouchier, Brouwer 
et al. 1995; Xiao, Owen et al. 1998; Hoffman, Seillier-Moiseiwitsch et al. 2002). 
Conversely, if a basic amino acid is found at position 11 and/or 24 and 25, this 
overall positive charge will strongly correlate with CXCR4 utilizing phenotype 
that binds to the negatively charged residues in the CXCR4 ECLs, however the 
absence of these positive residues does not rule out CXCR4 usage (De Jong, De 
Ronde et al. 1992; Fouchier, Groenink et al. 1992; Shioda, Oka et al. 1994; 
Fouchier, Brouwer et al. 1995; Milich, Margolin et al. 1997; Hoffman, Stephens 
et al. 1998; Brumme, Dong et al. 2004; Brumme, Goodrich et al. 2005).  
There are two potential N-linked glycosylation sites within the HIV-1 subtype B 
V3 loop reference sequence; one appears at the N-terminal near the base of the 
loop (N-linked glycosylation site) and the other is found from position 6-8 (NNT). 
The latter, has been implicated in CCR5 usage and decreasing sensitivity to 
antibody neutralization (Back, Smit et al. 1994; Schonning, Jansson et al. 1996). 
The loss of this N-linked glycan is associated with less frequent use of the CCR5 
coreceptor and in some cases, lack of the glycan is associated with exclusive 
CXCR4 usage (Ogert, Lee et al. 2001; Polzer, Dittmar et al. 2002). 
During the course of HIV-1 infection, the transmitted virions initially enter target 
cells through the usage of the CCR5 coreceptor (Schuitemaker, Koot et al. 1992; 
van't Wout, Kootstra et al. 1994), however these virions may acquire the ability to 
use CXCR4 to enter the host cells (Karlsson, Parsmyr et al. 1994; Connor, 
Sheridan et al. 1997; Huang, Eshleman et al. 2007) – this change in tropism is 
generally associated with a faster progression towards AIDS. This switch in 
coreceptor use can sometimes be attributed to mutations within the V3 loop 
(Hartley, Klasse et al. 2005). Although mechanistically and structurally it is 
generally unclear how CXCR4 tropism is determined, the acquisition of positively 
charged residues in the V3 stem and perhaps other Env domains such as the V1 
/V2 and gp41 may also contribute to coreceptor switching (Groenink, Fouchier et 
al. 1993; Koito, Harrowe et al. 1994; Koito, Stamatatos et al. 1995; Carrillo and 
Ratner 1996; Ross and Cullen 1998; Ogert, Lee et al. 2001; Pastore, Nedellec et 
al. 2006; Huang, Toma et al. 2008). 
1.2.5 CD4 
Cluster of differentiation 4 (CD4) is a transmembrane glycoprotein (59 kDa) and 
belongs to the immunoglobulin superfamily (Maddon, Littman et al. 1985). CD4 
is expressed on T helper lymphocytes, macrophages, monocytes, langerhans cells, 
dendritic cells and microglial cells. CD4 consists of an extracellular region, a 
transmembrane region and a cytoplasmic region which is associated with a 
tyrosine kinase p56Lck. The extracellular region of CD4 is composed of four 
immunoglobulin domains (D1-D4). D1 and D3 are variable immunoglobulin 
domains (IgV) and D2 and D4 are constant immunoglobulin domains (IgC). All 
the domains, exept for D3, posses disulphide bridges at their bases and D3 and D4 
posses N-linked glycosylations (Maddon, Littman et al. 1985; Clark, Jefferies et 
al. 1987; Maddon, Molineaux et al. 1987). CD4 on the surface of T helper 
lymphocytes, interacts with the β2-domain of MHC class II molecules via its D1 
domain and increases the avidity between the T lymphocyte and the antigen-
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presenting cell. In addition, the IL-16 chemokine binds to CD4 which plays a role 
in T-cell chemotraction (Cruikshank, Kornfeld et al. 1998).  
The progressive loss of circulating T-cell lymphocytes is the hallmark of immuno-
deficiency marked by disease and thus the focus of much research. This is what 
drove the discovery of CD4 being the primary receptor for HIV-1 (Dalgleish, 
Beverley et al. 1984; Klatzmann, Champagne et al. 1984) and that antibodies 
targeting CD4 were able to block HIV-1 entry. Through site-directed mutagenesis 
and x-ray chrystallography, the binding site for HIV-1 was located in the D1 
domain of CD4. Most importantly, two residues of CD4, Arg59 and Phe43, form 
crucial interactions between gp120 and CD4. Arg59 interacts with a hydrophobic 
pocket (Asp368 and Val430) of gp120, while Phe43 interacts with Asp368, 
Glu370, Ile371, Asn425, Met426, Trp427 and Gly473 (Kwong, Wyatt et al. 
1998). 
1.2.6 HIV­1 Co­Receptors 
Entry of HIV-1 into target cells is initiated by the interaction of gp120 and the 
host cell surface receptor CD4 (Dalgleish, Beverley et al. 1984; Klatzmann, 
Champagne et al. 1984), as mentioned previously in section 1.2.3. This causes 
large conformational changes in gp120, resulting in exposure of the V3 loop as 
well as movement of the V1/V2 loop revealing the previously masked coreceptor 
binding domain or CD4 induced site (CD4i) as well as gp41 epitopes (Sattentau 
and Moore 1991). Although numerous coreceptors have been identified in vitro, 
β-chemokine CCR5 (Alkhatib, Combadiere et al. 1996; Choe, Farzan et al. 1996; 
Deng, Liu et al. 1996; Doranz, Rucker et al. 1996; Dragic, Litwin et al. 1996) and 
α-chemokine CXCR4 receptors (Feng, Broder et al. 1996) are the main HIV-1 
coreceptors. Both these coreceptors are guanine nucleotide-binding protein (G-
protein)-coupled receptors [GPCRs] that regulate migration of many different cell 
types once bound to their chemokine protein ligands (Baggiolini 1998; Buurman, 
Bradley et al. 2001; Mackay 2001).  
GPCRs are the largest family of cell surface signal transduction receptors in the 
human genome and are involved in a multitude of systems from mediation of 
physiological processes associated with immunity, neuronal signalling and 
homeostasis to regulation of cell development, maturation and death, rendering 
them important targets for therapeutic and pharmaceutical intervention. This is 
highlighted by the fact that 30% of all known marketed medicines and drugs 
target GPCRs (Overington, Al-Lazikani et al. 2006). In order to better understand 
and design inhibitors of the gp120-CD4-GPCR interaction, structural data at the 
atomic scale is required for these large hydrophobic GPCRs.  
From the three dimensional structures of bacteriorhodopsin and rhodopsin, related 
GPCRs (CCR5 and CXCR4) are predicted to contain seven membrane-spanning 
α-helices which assume a barrel shape in the lipid bilayer as a result of the two 
potential extracellular disulphide linkages linking their extracellular N-terminus 
and intracellular C-terminus. Recently, Wu et al., determined the crystal structures 
of several CXCR4 homodimers in complex with small molecules, confirming the 
tertiary structural predictions and bringing to light the atomic level detail of this 
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protein which is vastly significant and important for better understanding viral 
entry as well as drug design (Wu, Chien et al. 2010) (Figure 1.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Model taken from Wu et al., (A) This is a model of the entry complex in which the 
crystal structure of the CXCR4 homodimer has been placed below the structures of two 
gp120-CD4 complexes. V3 loops are show in magenta. (B) Close-up of the V3 loop (magenta) 
binding to hypothetical sulphotyrosines (circled in yellow) in the N terminus of CXCR4 at 
site 1 which then induces further conformational changes in gp120 allowing the V3 loop to 
interact with ECL2 and ECL3 at site 2. CXCR4 residues that have previously been shown to 
participate in gp120 binding are shown in orange and the hypothetical path of the N 
Terminus is shown as a blue dashed line, on the left of site 1. 
CCR5 undergoes O-linked glycosylation (Farzan, Babcock et al. 2002) and during 
mammalian expression, CCR5 and CXCR4 undergo N-linked glycosylation at one 
and two potential sites respectively (Helmreich and Hofmann 1996). The two 
potential glycosylation sites in CXCR4 (Asn11 and Asn176) were shown to be 
important for X4 and R5X4 viral entry. Mutation of the two N-linked 
glycosylation sites allows R5 viral entry through the CXCR4 (Chabot, Chen et al. 
2000).  
Both CCR5 and CXCR4 undergo tyrosine O-sulphation in the N-terminal which 
is thought to occur after O-linked glycosylation in the case of CCR5 (Mirzabekov, 
Bannert et al. 1999; Chabot, Chen et al. 2000). Tyrosine sulphation is a relatively 
widespread post-translational modification that is found in secreted, lysosymal 
and transmembrane proteins of multicellular organisms (Moore 2003). It has been 
implicated as a determinant of protein-protein interactions such as leukocyte 
adhesion, haemostasis and chemokine signalling (Kehoe and Bertozzi 2000). The 
prevalence of tyrosine sulphation is not known as there is no defined consensus 
sequence defined for tyrosine sulphation, however, the presence of an acidic or 
neutral amino acid residue directly before a tyrosine to be sulphated is correlated 
with tyrosine sulphation and for the case of CXCR3, CXCR4, CCR2b and CCR5. 
The tyrosine which is about ten amino acids on the N-Terminal side of a 
conserved cysteine, is O-sulphated (Liu, Louie et al. 2008; Stone, Chuang et al. 
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2009). This process occurs in the trans-Golgi network and is catalysed by specific 
sulphotransferase enzymes (Baeuerle and Huttner 1987). Up to 1% of all tyrosine 
residues in the total protein content of the cell can be sulphated however, the 
regulation of this post-translational modification is not well understood.  
The modification on the tyrosine is created by the transfer of sulphate from 
adenosine 3’ phospho-adenosine 5’ phosphosulphate (PAPS) to the hydroxyl 
group of the tyrosine to be modified (Lee and Huttner 1983). In humans, 
tyrosylprotein sulfotransferase (TPST-1) and TPST-2, catalyze this reaction and 
TPSTs appear to be constitutively active. Both prokaryotic and eukaryotic 
arylsulphatases exist and reside in the lysosome and might participate in the 
degradation of a large array of tyrosine sulphated proteins, however, the 
regulation of this enzyme is not known (Parenti, Meroni et al. 1997). 
Entry of CCR5 utilizing HIV-1 (R5) isolates depends largely on the amino 
terminus and second extracellular loop of CCR5 (Atchison, Gosling et al. 1996; 
Rucker, Samson et al. 1996; Doranz, Lu et al. 1997; Farzan, Choe et al. 1997) and 
all R5 isolates examined to date are sensitive to the loss of one or more of these 
sulphates. Sulphations at residues 10 and 14 in CCR5 are sufficient to facilitate 
interaction with HIV-1 (Cormier, Persuh et al. 2000). Not surprisingly, sulphated 
peptides corresponding in sequence to the CCR5 amino-terminus can slow 
infection of R5 isolates (Cormier, Persuh et al. 2000; Farzan, Vasilieva et al. 
2000). This matter will be discussed further in Section 2.5 (Therapeutic 
applications of HS in HIV infection). In contrast, CXCR4 sulphation does not 
seem to be indispensable for the interaction of CXCR4 with HIV-1 gp120-CD4 
(Lu, Berson et al. 1997; Picard, Wilkinson et al. 1997; Farzan, Babcock et al. 
2002).  
1.2.7 Viral Entry  
Viral tropism (previously referred to as Macrophage- or T-cell tropism) is linked 
to coreceptor usage, with R5 viruses being M-Tropic and non syncytium-inducing 
(NSI) and X4 viruses being T-tropic and syncytium-inducing (SI) (Alkhatib, 
Combadiere et al. 1996; Choe, Farzan et al. 1996; Deng, Liu et al. 1996; Doranz, 
Rucker et al. 1996; Dragic, Litwin et al. 1996; Feng, Broder et al. 1996; Bjorndal, 
Deng et al. 1997; de Roda Husman, van Rij et al. 1999). R5 viruses are critical for 
HIV-1 transmission as they infect CD4+ T Cells, macrophages and dendritic cells 
and predominate during the early stages of infection (Schuitemaker, Koot et al. 
1992; van't Wout, Kootstra et al. 1994). The importance of the CCR5 coreceptor 
for HIV-1 transmission is emphasised by the fact that individuals bearing a 
homozygous 32-bp deletion in the CCR5 gene (ccr5- Δ32) are generally resistant 
to HIV-1 infection (Dean, Carrington et al. 1996; Liu, Paxton et al. 1996; Samson, 
Libert et al. 1996). Although R5 viruses typically persist into late disease stages, 
viruses that can infect CD4+ T cells through binding to CXCR4, either alone (X4 
viruses) or in addition to CCR5 (R5X4 viruses), emerge in approximately 50% of 
individuals infected with subtype B or D viruses (Karlsson, Parsmyr et al. 1994; 
Connor, Sheridan et al. 1997; Huang, Eshleman et al. 2007) and an increase in X4 
emergence has been detected in subtype C viruses (Connell, Michler et al. 2008).  
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Although not required for disease progression, the appearance of X4 and/or R5X4 
viruses is associated with a more rapid depletion of CD4+ T cells in peripheral 
blood and faster progression to AIDS (Schuitemaker, Koot et al. 1992; Karlsson, 
Parsmyr et al. 1994; Connor, Sheridan et al. 1997; Reeves, Lee et al. 2005). 
However, it remains unclear whether these viruses are a cause or a consequence of 
accelerated CD4+ T cell decline. The emergence of CXCR4-using viruses has also 
complicated the use of CCR5 antagonists as anti-HIV-therapeutics as these 
compounds can select for the outgrowth of X4 or R5X4 escape variants (Westby, 
Lewis et al. 2006).  
HIV-1 and SIV entry into a host cell is a dynamic and complex, multi-step, 
cascade process. Viral entry was introduced in section 1.2.3 and here we depict 
the process as a three-step process. The structural intermediate (post CD4 binding 
and pre-coreceptor binding) is responsible for the exposure and/or formation of a 
chemokine coreceptor binding site, which forms the basis of the interest of the 
work presented here (Figure 1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic of the three classic stages of viral entry; initially the HIV-1 viral 
particle approaches the host cell and gp120 binds to CD4, this liaison exposes/creates the 
CD4i coreceptor binding domain which then permits the gp120 to recognise and bind the 
coreceptor CCR5 and/or CXCR4. 
Actual binding of gp120 to the coreceptor (in this case CCR5) involves the V3 
loop as well as the fourth constant region (C4) of gp120 (Feng, Broder et al. 1996; 
Trkola, Dragic et al. 1996; Wu, Gerard et al. 1996; Rizzuto, Wyatt et al. 1998; 
Cormier and Dragic 2002). HIV-1 neutralizing antibodies that have been raised 
against either the V3 loop or the C4 region are actually able to block the binding 
of gp120/soluble CD4 complexes to CCR5 expressing cells and prevent fusion of 
the virus with target cells (Feng, Broder et al. 1996; Wu, Gerard et al. 1996). 
After the HIV-1 virus has bound the cell-surface CD4 and co-receptor, the gp120 
protein may dissociate from the gp41 protein which is stably anchored/inserted 
within the viral membrane (Chen, Vogan et al. 2005). Gp41 catalyses membrane 
fusion. Post coreceptor binding, the gp41 fusion peptide is exposed and is 
harpooned and interacts with the target cell membrane, forming a pre-hairpin state 
that brings together the two membranes. This induces further conformational 
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rearrangements within the gp41, involving the antiparallel association of the two 
coiled heptad repeats (HR-1 and HR-2), forming a fusion active six-stranded helix 
bundle/hairpin core structure. This is the transition that catalyses membrane 
fusion. The six-helix bundle is formed before the fusion pore opening and 
experimental evidence suggests that fusion proceeds by lipidic intermediate states, 
a membrane stalk and the opening and expansion of the fusion pore (Lu, Blacklow 
et al. 1995; Sattentau, Zolla-Pazner et al. 1995; Chan, Fass et al. 1997; 
Weissenhorn, Dessen et al. 1997; Melikyan, Markosyan et al. 2000; Gallo, 
Finnegan et al. 2003; Pierson and Doms 2003; Buzon, Natrajan et al. 2010). 
 
1.2.7.1 CD4­binding site and Coreceptor binding site 
CD4 binding followed by coreceptor binding are the two major steps of viral entry 
preceeding membrane fusion. Better understanding these crucial steps from a 
structural and biochemical point of view will elucidate key information to 
designing better inhibitors of these steps. In addition, elucidation of the structure 
of the trimeric envelope in the different conformational states will be very 
beneficial for vaccine development. Liu and collegues fitted the known crystal 
structures of the monomeric gp120 in the unliganded and CD4-liganded 
conformations (Kwong, Wyatt et al. 1998; Zhou, Xu et al. 2007) into electron 
density maps derived by electron tomography to obtain molecular models of the 
HIV-1 trimer in the unliganded and CD4-bound states (Liu, Bartesaghi et al. 
2008) (Figure 1.9). The viral spike contains three ‘propellar-like’ globular 
domains displaying three-fold symmetry. They demonstrate, that the CD4 binding 
sites on the unliganded gp120 timer are recessed about 20 Å from the top of the 
trimer spike with the V1/V2 and carbohydrate moieties forming a sheath at the 
top. Then, upon CD4 binding, each gp120 monomer rotates 45° outwards around 
an axis parallel to the central three-fold axis, causing a major reorganization of the 
gp120 trimer with an upward displacement of ~15 Å of the overall centre of mass.  
Firstly the V1/V2 stem moves from the central axis of symmetry towards the 
lateral part of the trimer, simultaneously causing V3 loop movement to the distal 
end of the trimer directly opposite the host membrane, causing it to stick out by 30 
Å above the gp120. The second coreceptor binding site is the discontinuous four 
antiparallel beta sheet called the briding sheet which is formed by the coming 
together of two beta sheets from each the inner and outer domains of gp120. 
According to the thermodynamic profiles (great magnitudes of both entropy and 
enthalpy) calculated for the gp120-CD4 interaction by Myszka et al., about 100 
amino acids from gp120 change confirmation upon CD4 binding – this is greater 
than most other protein-protein binding interactions (Myszka, Sweet et al. 2000). 
Finally, there is also a rearrangement of the gp41 along the central axis of the 
trimer upon CD4 binding, most likely due to the formation of the six-helix-bundle 
before membrane fusion. 
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Figure 1.9 (A) Averaged three dimensional structure of the native gp120 trimeric spike 
surface density map. (B) Front view of the surface density map fitted with the coordinates 
for gp120  core (red), the V1/V2 loops (yellow) and the V3 loop (green) derived from the 
complex with X5 (PDB ID 2B4C). (C and D) Front and top views of the X-ray coordinates of 
the ternary complex of the gp120 core (red) in complex with CD4 (yellow) and Fab fragment 
17b (cyan). The arrow in C points to the likely location of the V1/V2 loops. (E and F) top 
view showing the change from unliganded (E) to CD4-bound (F) conformational change in 
the gp120 trimer, gp120, CD4, V1/V2 and V3 are shown in white, yellow, red and green 
respectively. (G) Schematic representation showing gp41 (blue), gp120 (red/purple) regions 
of the trimeric spike and the conformational changes associated with CD4 (yellow) binding. 
The yellow spots on the gp120 show where the CD4 potentially will bind the unliganded 
spike and the green dots on gp120 shown the position of the V3 loops post CD4 binding (Liu, 
Bartesaghi et al. 2008). 
 
1.2.8 HIV­1 Replication  
The viral core is released into the cellular environment and uncoated, releasing the 
viral genome (Dvorin and Malim 2003). The viral RNA genome is reverse 
transcribed into cDNA in the cytoplasm by the viral RT (Figure 1.10) (Erikson 
and Erikson 1971; Sawyer, Harada et al. 1974; Marquet, Isel et al. 1995). Then the 
pre-integration complex (PIC) forms, consisting of an aggregation of the nascent 
viral cDNA, viral RT, matrix protein, integrase and Vpr. Unique nuclear 
localization signals (NLS) on karyophiles associated with the cell’s microtubule 
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network direct the PIC through the host cell nuclear pores to its destination within 
the host nucleus (Gallay, Swingler et al. 1995; Fouchier, Meyer et al. 1998; 
Depienne, Mousnier et al. 2001) in both actively dividing and quiescent cells.  
Viral cDNA is then irreversibly integrated into integrase-cleaved active host  
euchromatin to form the provirus (Sanchez-Pescador, Power et al. 1985; Bouyac-
Bertoia, Dvorin et al. 2001). The provirus is flanked by the 5’ LTR which serves 
as a promoter for transcription and the 3’ LTR which provides the termination 
site. Phosphorylated RNA Pol II enables elongation and synthesis of full length 
viral transcripts (reviewed in (Jones and Peterlin 1994)). Early phase transcripts 
encoding the Tat, Rev and Nef proteins are spliced and are exported from the 
nucleus by cellular machinery. Unspliced transcripts including genomic RNA and 
Gag-Pol precursors as well as incompletely spliced mRNAs encoding Env, Vif, 
Vpr and Vpu, require the interaction between the regulatory Rev protein and the 
Rev responsive element present within these transcripts for nuclear export into the 
cytoplasm (reviewed in (Pollard and Malim 1998)).  
1.2.9 Assembly, maturation and budding 
Following translation, structural and enzymatic proteins collect with two copies of 
the viral RNA genome and assemble into immature progeny virions at the inner 
surface of the host cell membrane in cholesterol rich lipid rafts (Nguyen and 
Hildreth 2000; Liao, Cimakasky et al. 2001). Env proteins are processed into their 
respective subunits which also gather at the cell membrane. Nascent virions 
budding from the host cell results in virus particles containing trimeric Env 
glycoproteins embedded in host-derived membrane lipids within the viral 
membrane (Sakalian and Hunter 1998; Gottlinger 2001). This allows HIV to 
remain similar in phenotype to the host cell, contributing to the viral strategy of 
avoiding recognition by the host’s immune system. Generally, HIV assembles at, 
and buds from the plasma membrane of host cells (Gelderblom 1991). However, 
in macrophages HIV assembles at, and buds into internal late endosomal and 
multivesicular body (MVB) membranes which are then transported to the cell 
surface and exocytosed (Orenstein, Meltzer et al. 1988; Pelchen-Matthews, 
Kramer et al. 2003; Pelchen-Matthews, Raposo et al. 2004). To facilitate the 
fission event whereby the nascent viral particle membrane is pinched off from the 
host membrane, a complex membrane remodelling machinery pathway is hijacked 
– the endosomal sorting complex required for transport (ESCRT). Gag is the 
principle viral protein that participates in the orchestration of HIV-1 assembly and 
release. At the time of viral budding, Gag associates at the inner plasma 
membrane, oligomerising into a type of “shell” formation, distorting the bilayer 
until a spherical particle buds off. It is not precisely known when, however, during 
or after budding, Gag is cleaved by viral proteases into the matrix protein, capsid 
protein and nucleocapsid proteins which are essential for viral maturation. See 
review (Weiss and Gottlinger 2011). Essentially, Gag hijacks the cell’s machinery 
to cause the fission event between the viral and cellular membranes that allows for 
budding to occur. Maturation of progeny virions occurs following processing of 
the Gag and Gag-Pol polyprotein precursors extracellularly by the viral protease 
(Ganser-Pornillos, Yeager et al. 2008) and a single infected CD4+ T cell can 
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produce between 10.3 x 109 - 10 x 1010 new virions per day (Ho, Neumann et al. 
1995; Wei, Ghosh et al. 1995; Perelson, Neumann et al. 1996) (Figure 1.10). 
 
 
Figure 1.10 Schematic representation of the HIV-1 viral life-cycle. HIV-1 virions bind their 
host cell through the initial attachment to primary CD4 receptor and subsequent binding to 
the chemokine coreceptor CCR5 or CXCR4. Receptor binding induces fusion of viral and 
cellular membranes resulting in the release of the viral core and subsequent release of the 
viral genome into the cytoplasm of the host cell. The viral RNA genome is reverse 
transcribed into cDNA, transported into the nucleus where it is subsequently integrated into 
the host genome. The integrated provirus serves as a template for the transcription of viral 
genomic RNA copies as well as viral mRNA which is exported to the cytoplasm for 
translation. Structural and enzymatic proteins and two copies of the RNA genome assemble 
into nascent virion particles at the cellular membrane and bud from the cell. After their 
release, maturation occurs. Maturation is mediated by the protease that cleaves Gag during 
assembly into MA, CA, NC, SP2 an P6 proteins. 
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1.2.10 Host cells  
HIV-1 principally binds CD4 and a GPCR to gain entry into its host cell however, 
other cell surface receptors also interact with gp120 and aid in the attachment / 
tissue invasion of the viral particles, such as lectin, DC-SIGN (Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-integrin), 
glycosphyngolipides or even glycosaminoglycans (GAG), in particular heparan 
sulphate (HS) (Ugolini, Mondor et al. 1999). 
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Table 1. Cell surface receptors implicated in binding HIV virions 
Receptor E R  
In
 xpression ole in attachment and
fection 
Reference
Gal-C Neuronal and glial  Aids attachment (Harouse, 
Laughlin ecells t al. 
1991) 
(Fantini, Cook
al. 1993; Sedd
Ramdani et al.
1994; Delezay, 
Sulphatide 
(sulphate 
derivative of 
Gal-C) 
C
e cells and 
p
macrophages 
C
C
C
in
T
 et 
iki, 
 
t al. 1997) 
olorectal 
pithelial 
rimary 
onfers efficient 
XCR4-dependant, 
D4-independent 
fection by NDK, a 
CLA HIV-1 strain Koch e
Placental 
membrane 
binding 
protein 
Cloned from Binds virus particles to 
p  cDNA lacental th us e cell surface and th
library en ity hances infectiv
(Curtis, 
Scharnowske et 
al. 1992; 
Geijtenbeek, 
Kwon et al. 2
(Pohl
000) 
DC-SIGN DC-
SIGNR 
D
e
l
and lymph node 
sinus endothelial 
c
DC-SIGNR acts in the 
sa N 
by
m
co teins
mann, 
Soilleux et al. 
2001) 
endritic cells, 
ndothelial cells, 
iver, sinusoidal 
ells 
me way as DC-SIG
 recognizing high-
annose-
ntaining glycopro
Mannose-
specific 
macrophage 
endocytosis 
receptor 
(MMR) 
Macrophages Binds gp120 and (Larkin, Childs et 
transmits the virus much 
like DC-SIGN does and 
MMR can internalize 
the virus 
al. 1989) 
Heparan 
Sulphates 
Many cell types A ticles 
to
in the V3 
lo
in D4 and 
co
pr
CXCR4-using viruses 
(Mondor, Ugolini 
et al. 1998) 
ttaches virus par
 cell surfaces via an 
teraction with 
op thus enhancing 
fectivity via C
receptors. Acts 
edominantly for 
LFA-1/ICAM-
1 
LFA-1 is 
expressed on 
haematopoietic 
cells, ICAM-1 is 
on a wide variety 
of cell types 
ICAM-1 incorporated (Paquette, Fortin 
onto virions which et al. 1998; Fortin, 
Barbeau et al. 
1999) 
en  hances attachment
and infection of LFA-1+ 
cells 
  
1.2.10.1 DC­SIGN 
 
 
23
Many epidem  shown that the first cells to come into contact 
.2 Mannose Binding Proteins (MBP) 
With ted to N-linked 
lactosyl Ceramide (GalCer) 
During pical side of epithelial 
These are c  a large quantity at the surface of 
iological studies have
with HIV-1 are dendritic cells (DCs) in the epidermis and mucosa (Cameron, 
Freudenthal et al. 1992; Weissman, Li et al. 1995). HIV-1’s gp120 interacts with 
DCs via the DC-SIGN receptor. The dendritic cell population is highly 
heterogeneous and thus not all of these cells express DC-SIGN. In these cases, 
other lectins are expressed which have similar functions to that of DC-SIGN; e.g. 
the mannose receptor and langerin are expressed on the surface of Langerhans 
cells (Turville, Cameron et al. 2002; Nguyen and Hildreth 2003). There have been 
studies that suggest that langerin inhibits transmission of HIV-1 through the 
epithelial mucosa by endocytosing the virus into the granules of Birbeck (de 
Witte, Nabatov et al. 2007). The homolog of DC-SIGN, DC-SIGNR is also 
expressed at the surface of endothelial cells and can bind to HIV-1, in this way 
presenting the virus to target cells and infection occurs in trans (Pohlmann, 
Soilleux et al. 2001). 
1.2.10
about half the molecular mass of gp120 attribu
carbohydrates, this is a formidable barrier for development of strong antibody 
responses to the virus. On the other hand, this carbohydrate barrier also provides a 
potential site of attack by the innate immune system through the C-type lectin 
mannose binding lectin (MBL) (Ji, Gewurz et al. 2005). A number of studies have 
shown that MBL binds to all tested HIV strains and MBL is able to inhibit DC-
SIGN binding to HIV-1 (Ji, Gewurz et al. 2005). However, further studies are 
needed to define the in vivo contribution of MBL to clearance and destruction of 
HIV, why MBL has low neutralization of HIV-1 and if possible, how to augment 
anti-viral effects of MBL. 
1.2.10.3 Ga
 early stages of infection, HIV-1 adsorbs onto the a
cells. The epithelial membrane has a characteristic lipid composition such that the 
outside layer is rich in glycosphingolipids e.g. GalCer. Galactosyl Ceramide is 
found on immature DCs and acts as a mucosal epithelial receptor for HIV-1, 
binding to gp41 (Magerus-Chatinet, Yu et al. 2007). Blocking both GalCer and 
CD4 with specific mAbs results in a >95% transfer inhibition of HIV-1 from 
human monocyte-derived DCs to autologous resting T cells (Magerus-Chatinet, 
Yu et al. 2007). The GalCer interaction with HIV-1 controls the early infection-
independent phase of HIV-1 transfer to T cells. Thus, GalCer appears as an initial 
receptor for HIV-1, common to both mucosal epithelial cells and immature DCs. 
1.2.10.4 Heparan Sulphates 
omplex polysaccharides present in
most cells (see Chapter 2: for more detail). The essential property of these 
molecules is that they can bind a myriad of proteins, thereby altering their 
structure, reactivity, localization in tissues and thus have an extensive functional 
repertoire, see review (Whitelock and Iozzo 2005; Sarrazin, Lamanna et al. 2011). 
Since 1988, soluble heparan sulphates have been known to inhibit the cellular 
entry of enveloped viruses (Baba, Snoeck et al. 1988). In 1993, studies showed 
that HIV-1 interacts with heparan sulphate (HS) (Patel, Yanagishita et al. 1993; 
Roderiquez, Oravecz et al. 1995). Then Mondor et al. confirmed that HIV was 
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able to attach to HeLa cells via interactions between gp120 and HS (Mondor, 
Ugolini et al. 1998). This interaction has been demonstrated for X4 and R5X4 
viruses, but is less efficient for R5 viruses (due to the number of positive charges 
found in the V3 loop). Since the interaction between HS and gp120 forms the base 
of this thesis, this subject will be discussed in further detail in Section 2.4.2.  
1.2.10.5 LFA­1 / ICAM­1 
Budding viruses from any host cell-surface proteins 
and li  et al. 1998)) as well as cell adhesion 
y of HIV-1, there is still no therapeutic cure 
V/AIDS. However, enormous efforts have 
nhibit RT (de 
ibitors  
 an infected host cell contain m
pids (reviewed in (Tremblay, Fortin
molecules that are thought to play a role in cell adhesion and leukocyte 
trafficking. Viral incorporation of foreign ICAM-1 into their membranes increases 
the attraction of the viral particle for the cell membrane expressing the LFA-1 
integrin (Fortin, Cantin et al. 1997; Rizzuto and Sodroski 1997) and may decrease 
the dependence on the gp120-CD4 interaction for infection. This is confirmed by 
the studies that show that agents blocking the gp120-CD4 interaction are less 
effective at neutralizing ICAM-1 containing viruses than isogenic viruses lacking 
the ICAM-1 receptor (Fortin, Cantin et al. 1997; Rizzuto and Sodroski 1997).  
1.3 Therapeutic Strategies 
Thirty years after since the discover
for, nor an effective vaccine against HI
been made to combat the virus. The four main classes of Food and Drug 
Administration (FDA) and European Medical Agency (EMEA)-approved current 
Antiretroviral Therapies (ARTs) for use in HIV-1 infection are; Reverse 
Transcriptase Inhibitors (RTIs, e.g. nucleoside/nucleotide reverse transcriptase 
inhibitors, NRTIs; and non-nucleoside reverse transcriptase inhibitors, NNRTIs), 
Protease Inhibitors (PIs), Integrase Inhibitors and Entry Inhibitors (EIs) (Fauci 
2003). However, the huge burden of ART in developing countries as well as the 
increasing incidence of drug resistant viral strains, obliges continuous efforts for 
the development of new anti-HIV-1 agents. Thus the emergence of three new 
classes of drug targets for ART has occurred; The three classes are inhibitors 
targeting (i) NCp7 Zn finger inhibitors, (ii) rev/tat and (iii) viral maturation 
inhibitors (Huang, Maynard et al. 1998; Unwalla, Chakraborti et al. 2006; Zhou, 
Chen et al. 2006; Daelemans, Lu et al. 2007; Liu, Wu et al. 2007). To augment the 
potency of currently available ART, new approaches and more effective drugs are 
necessitated. Drugs targeting HIV-1 attachment and fusion are likely to be good 
targets for novel treatment strategies of HIV drug-resistant strains. 
Today, there are 25 antiretroviral drugs available in 6 different classes (Zolopa 
2010). These include the NNRTIs which bind directly to and i
Bethune 2010); entry inhibitors (CCR5 antagonists and fusion inhibitors) (Tilton 
and Doms 2010); and integrase inhibitors which prevent integration of the 
provirus into the host chromosome (McColl and Chen 2010). A novel class of 
antiretrovirals still undergoing clinical trial is that of the maturation inhibitors 
which inhibit cleavage of the capsid precursor (Temesgen and Feinberg 2006; 
Martin, Salzwedel et al. 2008). 
1.3.1 Replication Inh
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The first N e out in 1987 (Ezzell 1987) inhibited 
the viral reverse transcriptase enzyme by acting as a nucleoside analogue, thus 
Since e in HIV-1 entry, it is an attractive target for 
drug design, and thus a number of strategies have been aimed at disrupting the 
pted. Logically, efforts were 
The id  block the gp120-CD4 
interac tudies yielded 
thus block CD4 binding to gp120 (Bristol Myers Squibb) 
RTI antiretroviral drug that cam
preventing the complete synthesis of proviral DNA (Furman and Barry 1988). 
However, monotherapy was not successful at repressing viral replication (Gershon 
1991) and thus protease inhibitors were developed to target alternative viral 
components in the life cycle. These drugs inhibit viral production of mature viral 
proteins (Venaud, Yahi et al. 1992) and when used in combination with two 
NRTIs, triple therapy or highly active antiretroviral therapy (HAART) came about 
(Hammer, Squires et al. 1997; Hirsch, Steigbigel et al. 1999).  
1.3.2 Entry Inhibition  
 gp120 has such a crucial rol
interactions between gp120 and the host receptors. 
Owing to the success of entry inhibitors, an increase in the interest in the 
discovery and development of new molecules eru
focused onto smaller molecules that could access the conserved and critical 
regions required for entry as well as be more cost-effective and easier to 
administer (recombinant proteins were administered through injection). For 
developing countries, that are most affected by the HIV epidemic, administering 
entry inhibitors to mucosal areas in a topical gel as a microbicide is highly 
suitable to the cultural and social constraints in these countries that contribute to 
the severity of the epidemic. 
1.3.2.1 gp120­CD4 Binding Inhibitors 
ea of using soluble CD4 (sCD4) as a competitor to
tion was explored early in the HIV epidemic. Initially, these s
promising results (Smith, Byrn et al. 1987; Deen, McDougal et al. 1988), 
however, sCD4 was only effective against HIV-1 laboratory-adapted strains and 
not primary isolates (Daar, Li et al. 1990). Seven years later a recombinant CD4-
based fusion protein, Pro542 (Allaway, Davis-Bruno et al. 1995; Zhu, Olson et al. 
2001) was used to block the gp120-CD4 interaction. This molecule comprises 
human IgG2, in which the variable domain (Fv) portions of both heavy and light 
chains have been replaced by the D1 and D2 domains of human CD4. Due to its 
tetravalent structure, Pro542 can bind Env with higher avidity than sCD4. Despite 
the promising results (Jacobson, Israel et al. 2004), the development of Pro542 
was halted as in some cases these compounds may enhance virus entry into 
CCR5-expressing cells lacking CD4 (Madani, Schon et al. 2008). Recently, a 
functional mimetic of CD4 (M48-U1), was shown to have an EC50 of 25nM 
against SHIV162P3 due to its high affinity binding of gp120 (Van Herrewege, 
Morellato et al. 2008). 
Small molecules that also target the CD4-binding site of gp120 are BMS-378806 
and BMS-488043 and 
(Guo, Ho et al. 2003; Lin, Blair et al. 2003; Wang, Zhang et al. 2003), however, 
their mode of action remains unclear (either by competing with CD4 to interact 
with gp120 or preventing the conformational change of gp120 required for 
coreceptor recognition). BMS-378806 was discontinued in Phase 1 and BMS-
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488043 is in its phase IIa clinical trial. They neutralise both laboratory-adapted 
and primary virus isolates, including those resistant to protease and reverse 
transcriptase inhibitors. However, these molecules were shown to have a 
decreased activity against subtype C, as well as other HIV-1 subtypes when 
compared to its efficacy against subtype B strains (Lin, Blair et al. 2003), 
probably due to the inherent variability between HIV-1 envelope proteins and the 
use of a subtype B virus in the screening process. This drug was under 
investigation as a microbicide and subsequently discontinued in phase II trials 
(Veazey, Klasse et al. 2005), due to 40-500 fold resistance to the drug resulting 
from few mutations in gp120. Ibalizumab (formerly know as TNX-355) is a first-
in-class, monoclonal antibody inhibitor which blocks receptor-mediated virus 
entry by binding to the extracellular domain 2 of the CD4. This antibody has 
passed the phase II trials and is mentioned in section 1.3.2.3 (Kuritzkes, Jacobson 
et al. 2004; Jacobson, Kuritzkes et al. 2009; Toma, Weinheimer et al. 2011).  
1.3.2.2 Gp120­coreceptor binding inhibitors 
A num nds of CCR5 or 
CXCR action between 
s little to no effect on patients’ immune systems and general 
gonist, was discovered through a high 
ber of naturally occurring chemoattractant proteins are liga
4 and thus have antiviral effects by preventing the inter
gp120 and coreceptor and/or inducing cellular internalization of the coreceptor 
(Amara, Gall et al. 1997). However their clinical uses are difficult due to their 
intrinsic bioactivity. Derivatives of these chemokines (such as PSC-RANTES) 
have been engineered to reduce their agonistic effects on CCR5, and PSC-
RANTES is currently being evaluated as a potential microbicide (Lederman, 
Veazey et al. 2004). 
Blocking CCR5 is particularly attractive since the natural expression of CCR5 
Δ32 homozygotes ha
health and such individuals are highly protected against HIV-1 infection (Dean, 
Carrington et al. 1996; Dragic, Litwin et al. 1996; Liu, Paxton et al. 1996; 
Samson, Libert et al. 1996). There have been many small molecule antagonists of 
CCR5 blocking HIV-1 entry that have been pursued by pharmaceutical 
companies. These molecules are antagonists and bind within the pocket formed by 
the transmembrane helices (Dragic, Trkola et al. 2000; Castonguay, Weng et al. 
2003; Tsamis, Gavrilov et al. 2003; Billick, Seibert et al. 2004; Nishikawa, 
Takashima et al. 2005; Maeda, Das et al. 2006; Seibert, Ying et al. 2006; Kondru, 
Zhang et al. 2008; Stupple and Ball 2011).  
In August 2007, Maraviroc (UK-427857, marketed as Selzentry or Celsentry), an 
imidazopyridine small molecule CCR5 anta
throughput screen of a Pfizer compound file (Dorr, Westby et al. 2005). 
Maraviroc demonstrated potent anti-viral activity against R5 primary viruses as 
well as clinically derived HIV-1 envelope-recombinant pseudoviruses, as well as 
viruses derived from drug-resistant patients. After positive results in clinical trials, 
Maraviroc was approved for use by the FDA and EMEA in 2009 (Dorr, Westby et 
al. 2005; Kromdijk, Huitema et al. 2010). The molecular mode of action with 
which Maraviroc prevents gp120 from binding to CCR5 is not clearly understood 
however, mutational studies and molecular modelling have shown that this small 
nonpeptidic ligand lodges in a hydrophobic cavity located between the 
transmembrane domains of the receptor, thus inhibiting gp120 binding (CCR5 
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unrecognisable by gp120) and chemokine signalling (MIP-1α and RANTES) by 
inducing conformational changes in the coreceptor (allosteric inhibition) (Dragic, 
Trkola et al. 2000; Tsamis, Gavrilov et al. 2003; Maeda, Das et al. 2006; Kondru, 
Zhang et al. 2008; Garcia-Perez, Rueda et al. 2011).  
There have been other CCR5 antagonists, however, they have been less 
successful; TAK-779, a non-peptide compound (Baba, Nishimura et al. 1999), 
g viruses, however, in patients with detectable 
l for a myriad of normal cell 
Pro140 (Pro ouse monoclonal antibody 
directe  at concentrations that do not 
showed poor pharmacological and toxicological properties as well as a lack of 
bioavailability during clinical trails (Palani and Tagat 2006). A recent study has 
shown that TAK-779, like Maraviroc, also blocks HIV-1 infection through 
allosteric inhibition, inducing conformational changes in CCR5 thus blocking 
gp120 binding to CCR5 (Garcia-Perez, Rueda et al. 2011). Several other small 
CCR5 antagonists have demonstrated interesting efficacy against HIV. Amongst 
them are Aplaviroc (GW873140; GSK,) which made it to phase IIb, but was 
discontinued due to hepatotoxicity, and Vicriviroc (SCH-417690) is another small 
molecular entry inhibitor from Schering-Plough which made it to phase III trails. 
However, the primary efficacy endpoint was not obtained in treatment-
experienced HIV-1 positive patients, thus this drug will also not be pursued 
(Labrecque, Metz et al. 2011).  
Inhibiting the interaction between CCR5 and gp120 is successful in patients 
harbouring only CCR5-utilizin
levels of CXCR4-utilizing viruses, there is a strong risk that the latter population 
becomes dominant. The outgrowth of a CXCR4-utilizing viral population is a 
great concern as this is associated with accelerated CD4+ T cell loss, viral load 
increase and disease progression (Schuitemaker, Koot et al. 1992; Karlsson, 
Parsmyr et al. 1994; Connor, Sheridan et al. 1997).  
Hence the necessity for drugs that target the interaction between gp120 and 
CXCR4, however unlike CCR5, CXCR4 is essentia
functional processes, and blocking coreceptors will have negative consequences. 
Several peptides mimicking the natural chemokine ligand of CXCR4 (CXCL12), 
have been described (T-22, T-134, T-14). One such antagonist of CXCR4 is the 
bicyclam analogue, AMD3100 (Genzyme), which demonstrated potent activity 
against CXCR4-using HIV-1 in vitro. However, its clinical development as an 
antiretroviral agent was halted due to cardiac abnormalities (Dai, Yuan et al. 
2010). Similarly, the development of AMD070 (Donzella, Schols et al. 1998), a 
third generation orally bioavailable small CXCR4 antagonist, was stopped due to 
liver toxicity. 
1.3.2.3 Monoclonal Antibodies 
genic Pharmaceuticals) is a humanized m
d against CCR5 that inhibits HIV-1 entry
affect the chemokine receptor activity (Trkola, Ketas et al. 2001). Another 
monoclonal antibody that shows potential as an entry inhibitor is TNX-355 
(Ibalizumab-TaiMed Biologics). TNX-355 (previously called Hu5A8) is a 
humanized IgG4 monoclonal antibody inhibitor that binds to the second domain 
of CD4 (D2) and does not prevent CD4 binding to gp120, but has shown to 
prevent further conformational changes in gp120 necessary for viral entry 
(Burkly, Olson et al. 1992; Moore, Sattentau et al. 1992). Clinical trails using this 
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antibody have shown some success (Jacobson, Kuritzkes et al. 2009) with weekly 
or biweekly dosing and phase II trials are currently underway (Toma, Weinheimer 
et al. 2011). 
1.3.2.4 Fusions Inhibitors 
Fusions inhibitors are m p41-mediated membrane fusion. The olecules that block g
only f by the FDA and EMEA in 2003 is a usion inhibitor that has been approved 
36 mer synthetic peptide called T20 (Enfuvirtide/Fuzeon, Trimeris-Roche) which 
is derived from the HR2 region of gp41 (Wild, Shugars et al. 1994). T20 is able to 
block the formation of the six-helix bundle through its interaction with HR1, 
thereby preventing gp41-mediated fusion with the host membrane (Wild, Shugars 
et al. 1994; Kilby, Hopkins et al. 1998). This molecule is effective only after CD4 
binding but prior to gp41-mediated fusion and thus has a relatively limited 
window during which it is active. Enfurvitide is administrated twice-daily by 
subcutaneous injections, however, this often results in skin sensitivity reactions at 
the site of injection and many patients stop treatment due to its side effects. This 
molecule has a relatively low genetic barrier to resistance and single amino acid 
mutations can lead to high levels of resistance. T-1249 is the second generation 
fusion peptide (Tifuvirtide) and inhibits HIV-1, HIV-2, SIV and strains that have 
developed resistance to T-20,  however, the production of this molecule is very 
complex and has thus been suspended (Lalezari, Bellos et al. 2005). 
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Table 2: Overview of the different HIV-1 Entry Inhibitors (Castagna, Biswas et al. 2005; 
Kuritzkes 2009) 
Entry 
Inhibitor 
Target Type Administrat
ion 
Clinical Trial status Company 
Dextrin-2-
sulphate 
Positively charged 
groups on surface 
of HIV-1 
molecule vaginal gel Phase II ML Laboratories 
PRO 542 CD4-binding site 
on gp120 
antibody intravenous 
injection 
Phase II Progenics 
TNX-355 
(Ibalizumab 
or Hu5A8) 
CD4 monoclonal 
antibody 
intravenous 
injection 
Phase II completed Tanox 
TaiMed Biologics 
BMS-
488043 
gp120 molecule oral Development 
discontinued 
Bristol Myers 
Squibb 
Aplaviroc 
(GSK-
873140) 
CCR5 molecule oral Development 
discontinued 
GlaxoSmithKline 
Maraviroc 
(UK 427, 
857) 
CCR5 molecule oral FDA and EMEA 
Approved for 
clinical use 
Pfizer 
INCB009471 CCR5 molecule oral Phase I/IIa 
completed 
Incyte 
HGS004 CCR5 antibody intravenous 
injection 
Phase I completed Human genomic 
sciences 
Vicriviroc 
(SCH417692 
or SCH-D) 
CCR5 molecule oral Phase III completed Shering-Plough 
TBR-652  CCR5 molecule oral Phase II completed Tobira 
Therapeutics 
PRO 140 CCR5 antibody injection Phase II Progenics 
TAK 220 CCR5 molecule oral Pre-clinical Takeda 
AMD 3100 
(plerixafor) 
CXCR4 molecule oral Development as 
antiretroviral 
discontinued  
AnorMED 
Genzyme 
KRH-2731 CXCR4 molecule oral Pre-clinical Kureha 
Enfuvirtide 
(T-20) 
gp41 peptide sub-
cutaneous 
injection 
FDA and EMEA 
Approved for 
clinical use 
Trimeris/Roche 
 
The two licensed entry-inhibitors are highlighted in pink 
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1.3.3 Neutralising Antibodies 
The remarkable diversity, extensive glycosylation and conformational flexibility 
of the HIV-1 envelope, including the substantial rearrangement of the gp120 
glycoprotein upon binding the CD4 receptor, allow it to evade antibody-mediated 
neutralization. Neutralizing antibodies are believed to be crucial in the protective 
immune response against many viral infections, yet their role in HIV-1 infection 
remains controversial. During classical HIV-1 infection, neutralizing antibodies 
appear to have little effect on acute viremia, as they arise too late and the virus 
readily escapes type-specific neutralizing antibodies (Richman, Wrin et al. 2003; 
Wei, Decker et al. 2003; Rong, Li et al. 2009). However, passive transfer of 
broadly neutralizing monoclonal antibodies (MAbs) has proven to be protective in 
nonhuman primate models (Baba, Liska et al. 2000; Mascola, Stiegler et al. 2000; 
Veazey, Shattock et al. 2003; Hessell, Poignard et al. 2009), supporting the 
hypothesis that a vaccine capable of inducing these types of antibodies is likely to 
be effective. 
1.3.4 Vaccine and Pre­exposure Prophylaxis 
Efforts to develop an effective vaccine against HIV-1 began as early as 1987, with 
over 80 studies making it to phase I and II trials and about 30 different candidate 
vaccines. However, due to the high mutation rate and replicative turnover of the 
virus, an effective vaccine is a difficult target to reach. Some vaccine strategies 
are to use inactivated or live-attenuated viruses to prime the host’s immune 
system, however, they risk the eventual appearance of an active virus. Just over 10 
years ago recombinant live-attenuated or replication-deficient viruses were 
investigated as vaccine platforms and have been licensed for animals. However, 
viral-based vaccines for humans are taking slightly longer and have to deal with 
the potential problem of pre-existing anti-vector immunity. 
A strategy whereby viral proteins derived from the envelope were used to 
stimulate the production of neutralizing antibodies was recently tried (Thai Trial). 
This Vaccine (developed by VaxGen) entered phase III clinical trials in the U.S.A 
and Thailand, but has not shown a protective effect against HIV-1 infection 
(Desrosiers 2004; Pitisuttithum, Berman et al. 2004). Possible reasons for the 
failure of this vaccine are due to the heterogeneous structure of gp120 and the fact 
that critical coreceptor binding sites are hidden under the mass of glycans and 
variable loops and thus inaccessible to neutralizing antibodies.  
Another strategy for vaccine design is to stimulate the host immune system 
(dendritic and natural killer T Cells) with viral fragments, such as “naked DNA” 
so that target host cells that integrate this fragment, synthesize the corresponding 
viral protein and present the antigen to the immune system (Nair, Heiser et al. 
2000; Liao, Li et al. 2004; Melhem, Liu et al. 2007; Dell, Klein et al. 2008).  
In 2009, a large phase III trial of an ALVAC and AIDSVAX vaccine (RV144) 
demonstrated modest protection from infection with HIV-1, with a 31% reduction 
among trial volunteers (Rerks-Ngarm, Pitisuttithum et al. 2009). Here, a vector-
based canarypox virus and adenovirus type 5 were developed by Sanofi-Pasteur to 
elicit antibodies and cellular immune responses to HIV-1. A protection of 31% is 
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barely something to celebrate. Recently, investigators have reported the 
development of broadly neutralizing antibodies, which provide potential new 
targets for vaccine development (Wu, Yang et al. 2010; Zhou, Georgiev et al. 
2010). 
However, there is some hope. A private biopharmaceutical company, SEEK, is 
planning the final stages of development of its HIV-v vaccine, after announcing 
that the product has demonstrated proof of efficacy in a Phase Ib/II study. HIV-v 
is a T and B cell vaccine against the conserved regions (internal proteins NEF, 
REV, VIF and VPR) of the HIV virus and it is the first vaccine to form an 
antibody response against a conserved internal protein. A therapeutic trial of 55 
HIV patients at 6 centres in the UK has shown a 90% reduction in the viral load of 
vaccinated patients compared with natural disease progression 
(http://www.seekacure.com/about/factsheet-HIV-v.html Access 20/07/2011). 
Up until now, microbicides used to prevent vaginal transmission of HIV-1 have 
proved either ineffective or have even enhanced transmission in human trials 
(Rerks-Ngarm, Pitisuttithum et al. 2009), however, there is hope that the VOICE 
trail (microbicides and pre-exposure prophylaxis with ARVs targeting viral 
replication) will prove efficacious (Rossi 2009). Interestingly, male circumcision 
has provided remarkable protection from transmission, however the mechanisms 
are still unknown (Auvert, Taljaard et al. 2005; Bailey, Moses et al. 2007; Gray, 
Kigozi et al. 2007).  
Results of two new studies (13 July 2011) have provided more compelling 
evidence that daily pre-exposure prophylaxis (PrEP) treatment with ARTs can 
prevent the spread of HIV-1 infection – demonstrating for the first time that the 
drugs significantly reduced the risk of acquiring the AIDS-causing virus in 
heterosexual men and women, the population hardest hit by the disease. This is 
ground-breaking news and future efforts at curbing the HIV-1 epidemic will be 
focused on PrEP in combination with treatment. The PrEP drugs used in the trials 
were Gilead's Viread (tenofovir) and its combination drug Truvada (emtricitabine 
and tenofovir disoproxil fumarate), which the firm supplied for both studies 
(Roehr 2011).  
Given the lack of an effective vaccine on the market, emergence of drug 
resistance to and viral escape from virtually all known antiretrovirals as well as 
the raging pandemic caused by this virus, new strategies to target and block the 
virus are of paramount importance. 
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Chapter 2: The Role  of Glycosaminoglycans  (GAGs)  in 
HIV­1 attachment  
 
Amongst the molecules that bind to HIV-1 are proteoglycans (PG), a cell surface 
component, used by many pathogens (viruses, bacteria, parasites) for attachment 
to the host cell. PGs are complex glycoproteins which are ubiquitous in 
mammalian tissues; they are composed of a protein core to which one or more 
glycosaminoglycan (GAG) chains is/are covalently attached. These complex 
glycoproteins are found in abundance in the extracellular matrix (ECM) as well as 
on the cell surface (glycocalyx) where they play essential roles in multiple 
biological processes due to their strategic placement at the interface of the 
communication between the cell and the external signaling environment. There is 
no blue print or code for the composition of GAGs, yet they are necessary for a 
myriad of essential processes (migration, adhesion, proliferation differentiation, 
coagulation, hydration, embryo development, tumor growth and pathogen 
attachment and entry) (Bernfield, Gotte et al. 1999; Perrimon and Bernfield 2000; 
Spillmann 2001; Sasisekharan, Shriver et al. 2002; Whitelock and Iozzo 2005; 
Sarrazin, Lamanna et al. 2011). In order to be implicated in such a vast array of 
processes, it is no surprise that GAGs bind to a plethora of different proteins 
(growth factors, cytokines, morphogens, enzymes, structural proteins, viral 
envelopes or capsid proteins etc) and these interactions seem to be coordinated 
and regulated. This is why the complexity of GAGs is so intriguing and needs to 
be better understood. 
2.1 The Glycosaminoglycan Families 
2.1.1 Galactosaminoglycans and Glucosaminoglycans 
Proteoglycans can be classified according to the nature of the polysaccharide 
chains that are covalently attached to the protein core; PG attached to chains of 
heparan sulphate are referred to as (HSPG), attached to chondroitin sulphate 
(CSPG), attached to dermatan sulphate (DSPG) or keratan sulphate (KSPG). 
Serglycine is a single PG to which chains of heparin are attached, which is found 
in connective tissue as a specific highly sulphated HS and found in mucosal tissue 
as CS. As for the core proteins, they determine the localisation and the degree of 
expression of the polysaccharide chains. The PG’s are generally classified into 
four large families based on their spatial placement; the membrane PGs, the 
extraceluular matrix PGs, the intracellular PGs and the circulating PGs and their 
molecular masses vary between 32 – 500 kDa (Esko and Selleck 2002). Heparan 
sulphates found in the intracellular space are attached to serglycine, HS found at 
the membrane is generally associated with syndecans, glypicans, betaglycans and 
CD44 isoforms. HS can also be associated with perlecan, agrine and collagen 
XVIII found in the extracellular matrix. 
On the other hand, GAGs are long polysaccharides characterised by a repeating 
non-hydrolysable core disaccharide motif comprising one hexuronic acid (either a 
βD glucuronic acid [GlcA] or an αL iduronic acid [IdoA]) and a hexosamine 
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(either a glucosamine [GlcN] or a galactosamine [GalN]). With such a basic 
starting unit, an enormous molecular diversity is generated on three different 
levels for GAGs; firstly, the length of these chains can vary (chain lengths can 
range from few to - 25 000 disaccharide units) as well as the structural 
modifications (N- and O-sulphations and epimerisations [see below]) and thirdly 
the number and combinations of sulphated regions along an oligosaccharide chain 
can vary (Figure 2.1). If we look at the disaccharides in more detail, six members 
of the glycosaminoglycans emerge, grouped into two main veins; the 
galactosaminoglycans and the glucosaminoglycans (Figure 2.1). 
The galactosaminoglycans comprise chondroitin sulphate (CS) and dermatan 
sulphate (DS) and are polysaccharides composed of repeating N-acetylated 
galactosamine (GalNAc) units associated with a glucuronic acid (GlcA) (as is the 
case for CS), linked together through a β1-3 liaison. In DS, the C5 carbon of some 
of the glucoronic acid is epimerised into iduronic acid (IdoA). Chondroitin 
sulphate, as their name depicts, are the GAGs that are found in large amounts in 
connective tissues and cartilage. They play an important role in resisting 
compression in certain tissues due to their elastic properties. CS are variably 
sulphated along their length and thus give rise to different types of CS; the most 
abundant dissacharides (~82%) are the monosulphated ones; when the carbon (C) 
4 of the N-acetyl galactosamine is sulphated this is CS type A (CSA) and when 
sulphated on C6, this is CS type C (CSC). The non-sulphated form constitutes 11-
12% and the more rare form of CS which has been initially identified in sharks 
and certain crustaceans called ‘di-sulphated’ with both C2 and C6 sulphations 
(CSD), C4 and C6 sulphations (CSE) and C2 in the uronic acid and C4 of the 
galactosamine (CSB). It can also be found in mammals (Sugahara, Masuda et al. 
1991; Sarrazin, Lyon et al. 2010). 
Dermatan sulphate has been considered a sub-class of CS, thus it can also go by 
the name of CS type B. This ambiguity is due to the fact that DS posseses a 
structure much like that of CS (as it contains many glucuronic acids along the 
length of its chain), however, DS also posseses iduronic acid due to the C5 
epimerisation. This epimerisation of the C5 from glucuronic to iduronic acid 
favours for subsequent O-sulphation on the uronic acid at C2; and in order for a 
favourable epimerisation reaction to occur, the C4 should be preferentially O-
sulphated. This difference in the epimerisation of the hexuronic acid C5 may be a 
subtle structural difference, however, it can determine protein ligand specificity as 
DS can bind to heparin cofactor II and CSA cannot (Mascellani, Liverani et al. 
1993).  
The glucosaminoglycans comprise hyaluronic acid (HA), heparan sulphate (HS) 
and heparin (hexosamines linked to a hexuronic acid). HA is a GAG found in 
conjunctive tissues, epithelium and nervous tissues, vitreous humour, synovial 
fluids and the skin. Its function is to maintain the hydration of the extracellular 
matrix and is also implicated in physiological and pathophysiological processes 
such as cellular adhesion, migration, tumour growth etc…). HA is not linked to a 
protein core and has the most simple structure out of all the GAGs as it is not 
sulphated; it is composed of a glucuronic acid (GlcA) linked via a β1-3 liaison to 
a N-acetyl glucosamine (GlcNAc). 
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Keratan sulphate was first discovered in cornea extracts in 1939 and once it was 
characterised in 1953 (Meyer, Linker et al. 1953), was found to be composed of a 
N-acetyl glucosamine linked via a β1-4 liaison to a glucose (instead of a 
hexuronic acid). Interestingly, both of the sugars can contain O-sulphations at 
position C6. Three different types of KS have been characterised; namely KS type 
I which is mainly found in the cornea and cartilage, KS II and KS III. They differ 
by the way in which they are linked to their protein cores; KSI is linked through 
an N-sulphated asparagine, however KSII and KSIII are linked through O-
sulphated serines or threonines respectively. KSIII can also be linked to its core 
protein through a mannose residue (Krusius, Finne et al. 1986). 
Heparin and heparan sulphate (HS) are the GAGs that possess the highest degree 
of sulphation and have the highest degree of structural complexity which is why 
they bind to the largest array of proteins. It is for this reason that heparin and HS 
have vast repertoires of biological and therapeutic activities and are of such great 
interest. This is a main topic of the current work and hence it will be described in 
further detail in section 2.1.2.  
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Figure 2.1 (A) This is an electron micrograph depicting a lymphocyte cell stained in 
ruthenium red showing the thick glycocalyx layer, which can reach up to 0.5µm. This is the 
interface through which the cell conducts its liaison for all biological processes (Alberts, 
Johnson et al. 2002). Heparan sulphates were immunostained with FITC-labelled antibodies 
and the image was obtained using a confocal microscope (Stevens, Hlady et al. 2007). (B) 
Glycosaminoglycan chains are shown covalently attached to their protein core imbedded in 
the cell membrane. (C) The HS disaccharide unit composed of a hexuronic acid and an N-
acetylated glucosamine (4GlcA1-4GlcNAc 1) is repeated n times and can contain the 
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following modifications: a de-acetylation of the GlcNAc and sulphation at this residue, 
sulphations at positions 3 and 6 on the GlcNS and on position 2 of the hexosamine and the C5 
of the uronic acid can undergo epimerisation and change from a glucuronic acid (GlcA) to 
an iduronic acid (IdoA). (D) Domain organisation of HS and Heparin. Highly sulphated 
domains (NS domains - red) are the main component of heparin, and are less frequent in HS, 
where there is a larger occurrence of non-sulphated domains (NA domains). The domain 
organisation is cell-specific and HS can be modified on so many levels, the structural 
diversity is vast and thus a vast number of protein binding sites exist. (E) The 
Glycosaminoglycan (GAG) family. GalNAc: N-acetyl Galactosamine, GlcNAc/S: N-acetyl / 
N-sulpho glucosamine, HexA: Hexuronic Acid, Gal: Galactose, GlcA: Glucuronic Acid, 
IdoA: Iduronic Acid. 
2.1.2 Heparin and Heparan Sulphate 
Heparin was discovered by accident by Mc Lean in 1916 when he demonstrated 
the anticoagulant activity of material fractionated from liver (hepatocytes) (Mc 
Lean 1916). This activity is linked to the ability of Heparin to bind and activate 
antithrombin III, thus inhibiting Factor Xa and thrombin. Heparin was being used 
to treat pulmonary emboli in the 1930’s through intravenous injections and by the 
1970’s it was being administered by sub-cutaneous injection (McLachlin, Carroll 
et al. 1970). 
Both heparin and HS have elevated sulphation levels and are comprised of the 
repeating disaccharide composed of a glucuronic acid (GlcA) linked to a N-
acetylated glucosamine (GlcNAc) linked via a α1-4 liaison (4GlcA1-4GlcNAc1). 
Both units of the disaccharide can be enzymatically modified during their 
biosynthesis to contain different modifications. More precisely, these 
modifications include; N-deacetylation/N-sulphation of the glucosamine (GlcNAc 
to GlcNS), C5 epimerisation of glucuronic acid (GlcA) to iduronic acid (IdoA) 
and variable number of sulphations at position C2 of the GlcA(2S)/IdoA(2S) or 
positions 6 [GlcNAc(6S) or GlcNS(6S)] and 3 [GlcNS(3S) or GlcNS(6S,3S) 
(rare)] of the glucosamine (GlcN) residue. In addition, the Glucosamine can 
sometimes be non-substituted at the amine position, giving rise to free GlcN. So 
with all these modifications, 48 different disaccharide units can be generated 
which suggests an inconceivable structural diversity along the length of these 
polysaccharides leading to an equivalent functional diversity (Figure 2.1).  
Sulphations occur in certain regions/domains along the polysaccharide chain. 
There are two types of domain; N-acetylated glucosamine (NAc domains) or N-
sulphated glucosamine (NS domains) and mixed NA/NS domains have properties 
in between the two. In HS, about 30 - 70% of the chains consist of NS domains, 
however the sulphation level in heparin is significantly higher with about 80% 
attributed to NS domains. The major disaccharidic motif found in heparin is [IdoA 
2S – GlcNS 6S].  
Despite their similarities, heparin and heparan sulphate have different functions 
and are synthesized in different locations. Heparin is mostly expressed in 
mastocytes in connective and mucosal tissues and HS are expressed in all cells. 
Heparin is expressed in the proteoglycan form (Mr 750 000 kDa – 100 000 kDa) 
and many chains can be attached to serglycin, the core protein. Once the synthesis 
is complete, smaller fragments (Mr 5000 – 25 000 kDa) of heparin chains are 
cleaved at random points and stored in granules that will be secreted into the 
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cytoplasm of the mastocytes or outside of the cell. On the other hand, HS are 
rarely found as free oligosaccharide entities and are mostly attached to their core 
proteins (HSPGs) in the extracellular matrix and at the surface of cells 
(glycocalyx). 
2.2 Biosynthesis and Degradation of GAGs 
2.2.1 Biosynthesis and organisation 
As explained above, many different members of the GAG family exist (HP/HS, 
CS/DS, KS and HA) and each GAG differs according to its structure, size, place 
of biosynthesis, post-synthesis modifications, functions and localisation. In order 
to produce such diversity among the different GAG families, there is a large range 
of specific enzymes that orchestrate the finely controlled process of GAG 
biosynthesis, post-synthesis modifications and proteoglycan turnover depending 
on the microenvironment. The extent of GAG sulphation is what largely governs 
their protein binding and modulating properties; thus their synthesis, structure and 
renewal is highly regulated in order to fine tune biological processes.    
GAG biosynthesis can be divided into two groups; GAGs that are not linked to a 
core protein during chain elongation (HA) and GAGs that are synthesized from an 
anchorage point, the protein core during chain synthesis (HP/HS, KS, CS/DS).  
GAG synthesis is a complex and highly regulated process and it can be broken 
down into three main steps; i) Initiation: formation of the tetrasaccharide linker 
which allows the attachment of the polysaccharide chain onto the core protein at a 
dipeptide serine-glycine; ii) Polymerization: then follows the synthesis of an 
immature saccharide chain (pro-heparan) consisting of GlcA and GlcNAc residues 
exclusively (for HS); iii) Polymer Modification: finally maturation of the chain 
occurs. For HS, N-deacetylation/N-sulphation of the glucosamines, C5 
epimerisation of the GlcA to IdoA, 2-O-sulphation of the IdoA and 6-O-
sulphation (and eventually 3-O-sulphation) of the glucosamines, takes place (Esko 
and Selleck 2002; Merry and Gallagher 2002; Rabenstein 2002; Kusche-Gullberg 
and Kjellen 2003; Lindahl and Li 2009). 
2.2.1.1 Formation of the tetrasaccharide linker 
Except for hyaluronic acid, biosynthesis of all GAGs is initiated by the formation 
of an O-glycosidic bond between the hydroxyl of the serine (occasionally a 
threonine) side chain in the core protein and a xylose in the tetrasaccharide motif 
GlcA(β1-3)Gal(β1-3)-Gal(β1-4)-Xyl(β1-O)-Ser (Lindahl and Hook 1978; Kjellen 
and Lindahl 1991; Esko and Lindahl 2001; Zhang 2010). The UDP-xylose is the 
donor which is transferred to the serine by xylose-transferase (XylT-1 and XylT-
2) and this occurs in the endoplasmic reticulum. Following the xylose transfer, 
galactosyltransferases (GalT1 and 2) add the two galactoses and finally 
glucuronyltransferase (GlcAT-I) adds the glucuronic acid (Esko, Kimata et al. 
2009) (Figure 2.2).  
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Figure 2.2 The biosynthesis of CS (left chain) and HS (right chain) is initiated by the 
formation of the tetrasaccharide linker between the core protein ser-gly and the 
polysaccharide chain. Addition of the first hexosamine decides weather the chain becomes 
CS (GalNAc) or HS (GlcNAc). Taken from (Esko, Kimata et al. 2009) 
 
2.2.1.2 Chain Elongation 
The next step in the biosynthesis is the subsequent addition of a hexosamine 
(either a galatosamine [αGalNAc] or a glucosamine [βGlcNAc]) and this will 
orient the biosynthesis in the direction of either CS/DS assembly or HS assembly 
respectively. The following saccharide that is added, determines the type of newly 
synthesized GAG chain that will be created. A GlcNAc will prime the synthesis of 
an HS chain, however a GalNAc will prime the CS/DS formation. This process 
and its regulation is not fully understood. For many years, the mechanism that 
determines the choice of synthesis of either a glucosaminoglycan or a 
galactosaminoglycan was unknown, however studies have shown that the 
structure of the core protein, the neighboring acidic residues, hydrophobic amino 
acids and the spacing of glycosylation sites all influence glycosaminoglycan 
assembly (Esko and Zhang 1996). 
The discovery of GlcNAc Transferase I (GlcNAcT 1) and chondroitin GalNAc 
transferase (chondroitin GalNAcT 1 or 2) has also shed light on this matter. Many 
enzymes are implicated in this process; addition of the glucosamine is performed 
by enzymes EXTL 2 and EXTL 3 and addition of a galactosamine is executed by 
enzymes GalNAcT 1 and GalNAcT 2 (Figure 2.3) (Rohrmann, Niemann et al. 
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1985). EXTL 2 is a homologue of GlcNAcT I which adds a GalNAc with a α1-4 
liaison onto the GlcA residue situated at the reducing end of the tetrasaccharide, 
however in order to initiate CS/DS synthesis a β1-4 liaison is required. Up to now, 
the biological role of this enzymatic activity of EXTL2 has not yet been 
determined.  
These enzymes initiate the biosynthesis of HP/HS chains or CS/DS chains, 
however the choice of which type of polysaccharide chain to add does not depend 
on which enzymes are present at the time in the environment but rather on the 
amino acid sequence around the serine of the core protein to which the chains are 
being attached.  
HP/HS polymerization begins with the alternating addition of GlcA and GlcNAc 
to the non-reducing end of the chain by the enzymes EXT1 and EXT2 in the golgi 
apparatus where they form the HS polymerase (McCormick, Duncan et al. 2000). 
CS/DS polymerization has taken many years to clearly understand; the 
chondroitin synthase (ChSy) has different enzymatic activities (β1-3-GlcA and 
β1-4-GalNAc transferase) and is responsible for CS chain polymerization 
(Kitagawa, Uyama et al. 2001). 
 
2.2.1.3 Chain Maturation 
The last stage of polysaccharide biosynthesis is an ordered process of chain 
modification catalysed by several different enzymes, which will generate mature 
and structurally diverse polysaccharides. 
In HS, the first step is the prerequisite for all further modifications, it is the 
replacement of the acetyl group on the glucosamine for a sulphate group. These 
two reactions are catalysed by N-deacetylase / N-sulphotransferase (NDST) of 
which there are four members in humans (NDST1-4). NDST1 and NDST2 have 
broad expression patterns (found in most cell types and tissues), however NDST3 
and NDST4 have a much more restricted expression pattern (Aikawa, Grobe et al. 
2001). The first modification that takes place is extremely important for the 
downstream maturation of the GAG chain. Since NDST is the first-acting enzyme, 
it ‘defines’ the size and number of S domains along the GAG chain length and 
thus influences the action of all the sequential enzymes implicated in the GAG 
maturation. NDST influences the degree of modification/sulphation of the 
polysaccharide and can thus regulate the principal criteria that distinguish heparin 
from HS. In fact, NDST exerts its action at the point of divergence between HP 
and HS and despite the importance if its role, very little is understood about the 
mechanisms of its regulation. On heparin polymers, most of the GlcNAc will be 
N-deacetylated and then N-sulphated by the NDST. However, in the case of 
heparan sulphate, only a few GlcNAc residues will be modified by NDST.  
Presto et al ., unexpectedly discovered that NDST1 competes with EXT1 for 
binding to EXT2 and that in the absence of EXT1, there is increased NDST1 
expression, increased NDST1 glycosylation and thus a resulting increased HS 
sulphation (Presto, Thuveson et al. 2008). In this work, they show beautifully how 
depending on the different ratios of EXT1, EXT2 and NDST1 present in the 
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GAGosome (physical complex of enzymes committed to HS assembly), the fate 
of the HS chain structure will change.  
The next steps of maturation are the catalysis of glucuronic acid (GlcA) to 
iduronic aid (IdoA) by the C5 epimerase (recently renamed Hsepi). This reaction 
is reversible and thus GlcA and IdoA residues are in equilibrium. The presence of 
IdoA favors the 2-O-sulphation of the uronic acids (by 2-OST) however, the 
addition of a 2-O-sulphation is an irreversible reaction and thus the IdoA 2S 
epimer is no longer in equilibrium with GlcA (Bernfield, Gotte et al. 1999; Li, 
Gong et al. 2003). The C5 epimerase also has substrate specificity as its activity 
depends on the presence of N-sulphated glucosamines and this is what explains 
the absence of IdoA in NAc domains. These two enzymes work together in 
concert and previous work has suggested that they exist as a heterodimer in the 
golgi apparatus.  
Following the 2-O-sulphation, the HS polysaccharides are then sulphated at the 
C6 position of the glucosamine by a family of enzymes called 6-O-
sulphotransferases (6-OST) of which there are 3 isoforms (6-OST1, 2 and 3). This 
modification is not strictly dependent on the preceding modifications and the 6S 
sulphation can be added onto either an N-acetylated glucosamine or an N-
sulphated glucosamine in the transition domains. Thus far, the substrate 
specificity for 6-OST is not clearly known, however, it is understood that 6-OST 1 
is responsible for the 6-O-sulphation of HS in most tissues (Habuchi, Nagai et al. 
2007).  
A final and rare step is the 3-O-sulphation of the N-sulphated glucosamines by 
one of 7 isoforms of 3-O-sulphotransferases (3-OST). This modification is 
important for the anticoagulant properties of heparin and HS and is required for 
antithrombin III fixation and it has been shown to play a crucial role in HSV entry 
(Yabe, Shukla et al. 2001). 
All of these modifications result in the production of polysaccharides with an 
enormous structural heterogeneity which allows these anionic molecules to bind 
to an array of ligands with great specificity (Figure 2.3). The NS domains which 
carry a strong negative charge interact with basic regions on protein ligands and 
this will be discussed further in section 2.3. 
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Figure 2.3 Heparan sulphate biosynthesis involves copolymerization of N-acetylglucosamine 
and glucuronic acid residues. A series of modification reactions including sulphation and 
epimerization of glucuronic acid to iduronic acid occurs; chain polymerization and 
modification are thought to occur simultaneously (PAPS) 3′-phosphoadenyl–5′-
phosphosulfate, the high-energy donor of sulphate groups. Taken from (Esko, Kimata et al. 
2009) 
2.2.2 GAG Catabolism: Remodelling and Recycling of GAGs 
In order for the cell to adapt to the rapid changes in its environment, the size, 
composition and structure of the proteoglycans and HS chains can be controlled 
by remodelling of the sulphate profile or recycling of the chains to liberate free 
disaccharides. It is important to distinguish between the two types of GAG 
catabolism; either the GAGs are functionally remodelled in order to refine their 
biological activity or they are physically removed (half life 3-4 hours) and then 
renewed at the cell surface (Yanagishita and Hascall 1984). 
The classic pathway for HS degradation is the endocytosis of proteoglycans. 
These internalized proteoglycans are initially degraded by proteases that cleave 
the core protein and then hydrolases (either exoglycosidases or endoglycosidases) 
such as heparanase which depolymerises the HS chains at a specific number of 
sites, depending on sequence (Esko, Kimata et al. 2009). These smaller degraded 
oligosaccharides eventually appear in the lysosome and undergo complete 
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degradation by way of a series of exoglycosidases and sulphatases which digest 
the chains into monosaccharides and inorganic sulphates (Brauker and Wang 
1987). Recycling of GAGs is a natural and essential process for the normal 
functioning of the cells. Mutations and or defects in the GAG catabolism 
machinery genes provoke an accumulation of partially degraded HS fragments 
and lead to pathologies such as mucopolysaccharidoses (MPS), rare autosomal 
recessive diseases that provoke irreversible lesions in the cells, tissues and organs 
(Ashworth, Biswas et al. 2006). 
The remodelling of GAGs involves heparanases, which also have an extracellular 
activity, where they are capable of remodelling the HSPGs secreted to the surface 
of cells during inflammation, angiogenesis and metastatic tumour growth (Ihrcke, 
Parker et al. 1998; Dempsey, Plummer et al. 2000; Sanderson, Yang et al. 2004; 
Vlodavsky, Abboud-Jarrous et al. 2006). For this reason, heparanases have 
become a major target for anti-cancer drugs (Ferro, Hammond et al. 2004; Miao, 
Liu et al. 2006; McKenzie 2007). Sulfs are a family of sulphatases that have been 
recently discovered and they are localised on the surfaces of cells and found in the 
extracellular matrix after being secreted from the golgi (Dhoot, Gustafsson et al. 
2001; Morimoto-Tomita, Uchimura et al. 2002). Two forms of Sulfs exist in 
humans (HSulf-1 and HSulf-2), and they posses an endo-glucosaminyl-6-O-
sulphatase activity. Numerous studies have shown that these enzymes which 
modify the specific profile of the 6-O-sulphation within the NS domains of HS 
can thus significantly alter the biological properties of these HS chains and in turn 
alter their capacity to modulate the activity of a number of chemokines, cytokines 
and morphogens (Ai, Do et al. 2003; Viviano, Paine-Saunders et al. 2004; 
Uchimura, Morimoto-Tomita et al. 2006). Despite the great interest that these 
enzymes provoke in the context of cell signalling regulation and perhaps viral-
host cell interaction, very little is known about their structure-function relationship 
and the regulation of their function. 
In the case of syndecan, matrix metalloproteinases (MMP) cleave the extracellular 
domains from the protein at a site close to the cell membrane during periods of 
injury or stress (Li, Park et al. 2002) and liberate soluble syndecan into the 
biological milieu. Interestingly, the soluble fragments can have a completely 
different function from that of the syndecans immobilized in the cell membrane; 
for example soluble syndecan inhibits Fibroblast growth factor 2 (FGF-2), 
however, the cell-bound form activates it’s signalling (Bernfield, Gotte et al. 
1999). 
2.2.3 GAG degradation enzymes in the laboratory 
Enzymes that are capable of digesting GAGs have been discovered in bacteria and 
these have been commercialized to be used for the purpose of GAG 
characterization in the laboratory. These enzymes recognize precise 
oligosaccharide sequences and this allows the removal, identification and isolation 
of specific structural sub-domains of GAG chains. Heparinases I, II and III digest 
HP and HS between the glucosamine and the uronic acid, and chondroitinases 
ABC digest chondroitin sulphate A, B and C between the N-acetylated 
galactosamine and a glucuronic acid (Figure 2.4). 
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Figure 2.4 (A) The heparinases cut the oligosaccharide at the α1-4 glycosidic liaison between 
a glucosamine and a uronic acid (GlcA or IdoA). Heparinase I cuts between a hexosamine 
and a 2-O-sulphated uronic acid. Heparinase II cuts between a hexosamine and a uronic acid 
and heparinise III cuts between a hexosamine and a glucuronic acid. (B) Chondroitinase 
ABC cut between the N-acetyl hexosamine and the uronic acid. 
2.3 HS­Protein Interactions 
Since GAGs are ubiquitous (present on the surface of almost all cells and in the 
extracellular matrix), it is natural that these poly-anionic molecules interact with a 
plethora of different proteins. The study of these interactions (structural studies, 
dynamics and functional studies) is paramount to understanding the biological 
phenomena associated with GAGs as well as harnessing their properties for 
therapeutic applications. 
2.3.1 Structure­Function Relations  
The binding interaction between proteins and heparan sulphate oligosaccharides is 
primarily electrostatic, involving interactions between cationic side chains within 
the protein (ammonium, guanidinium or imidazolium groups of lysine, arginine or 
histidine) and anionic sites on the HP or HS. Hundreds of diverse proteins have 
been identified as ‘heparin-binding proteins’ (HBP) such as enzymes, enzyme-
inhibitors, cytokines, morphogens, growth factors, matrix proteins, lipoproteins 
and proteins associated with disease etc (Kjellen and Lindahl 1991; Bernfield, 
Gotte et al. 1999; Bishop, Schuksz et al. 2007) (Table 3).  
Due to their strategic placement, GAGs are implicated in an enormous amount of 
biological processes and communication between cells; they induce 
conformational changes in certain proteins (as is the case for antithrombin III) 
(Petitou, Casu et al. 2003) allowing for target protein recognition (a protease as is 
the case for antithrombin III) (Olson, Bjork et al. 1992), they participate in 
protein-protein interactions, they function as coreceptors (as in the case for FGF) 
(Rapraeger, Krufka et al. 1991), and they can also act as a site of anchorage for 
certain pathogens, such as gp120 on HIV-1 (Moulard, Lortat-Jacob et al. 2000). 
GAGs are also implicated in cell adhesion and matrix assembly (Okamoto, Bachy 
et al. 2003) as well as the localisation and concentration of chemokines (e.g. 
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CXCL12) (Amara, Lorthioir et al. 1999; Sadir, Baleux et al. 2001; Lortat-Jacob, 
Grosdidier et al. 2002; Sweeney, Lortat-Jacob et al. 2002), cytokines (IFNγ) 
(Lortat-Jacob, Kleinman et al. 1991) and the protection of certain proteins from 
proteolysis (Lortat-Jacob, Baltzer et al. 1996; Sadir, Imberty et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 This is a gene ontology depicting the vast number of biological processes 
implicated in heparin/HS interactions, and thus called the ‘interactome’. Data for this map 
was provided from different databases of interacting proteins (e.g. NCBI Entrez GeneID). 
The node size is proportional to the number of heparin-binding proteins belonging to the 
functional category and the node shade or grey indicates the statistical significance (p value) 
of each pathways’ over representation (enrichment) in heparin binding proteins (HBP). I.e. 
the lighter the node, the stronger the enrichment in the interactome and the more studied the 
process is. Taken from (Ori, Wilkinson et al. 2011) 
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Table 3. Table showing the wide range of proteins that bind to heparin and heparan sulphate 
adapted from (Capila and Linhardt 2002; Ori, Wilkinson et al. 2011) 
Family of proteins Protein Function 
Protease/Esterase AT-III, SLPI, C1i, VCP, 
trypsin-like serine proteases, 
subtilase family 
Coagulation, metabolic 
pathways and the 
complement pathway, 
protein maturation by 
peptide bond cleavage 
Growth Factors FGFs, VEGR, HGF, PDGF, 
Insulin-like Growth Factor 
binding protein, TGF-β 
propeptide 
Regulation of cell 
proliferation, 
differentiation and cell 
migration, chemotaxis, 
angiogenesis, cell-cell 
signalling 
Morphogens Wnt, Hedgehog, BMP Development, 
embryogenesis, wound 
healing, blood vessel and 
vasculature development 
Cytokines IFNγ, IL-5,8,10, IL-8-like Inflammation response, 
response to wound 
healing, defense 
response, immune 
response 
Lipid-binding proteins Annexin V, ApoE Transport and 
metabolism of lipids 
Adhesion Proteins Selectins, fibronectin, 
Vitronectin, Collagen type 
V, Collagen triple helix 
repeat, fibrillar collagen,  
thrombospondin, Laminin, 
sushi domains 
Adhesion, migration, 
locomotory behaviour, 
cell motility 
Pathogens Proteins on: HIV-1, dengue 
virus, HSV, papillomavirus, 
Adenovirus, adeno-
associated virus (AAV), 
streptococcus pneumoniae, 
plasmodium falciparum… 
Infection 
 
2.3.1.1 Specificity 
Binding interactions between heparin binding proteins (HBP) and negatively 
charged heparin may lead to the false perception that proteins bind HS through a 
poorly-specific manner. However, it has been shown that there are certain 
sequences within the NS and NA/NS transition domains of HS that have specific 
interactions with proteins and that these interactions result in a regulation of the 
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proteins’ function (Salmivirta, Lidholt et al. 1996; Lindahl, Kusche-Gullberg et al. 
1998; Turnbull, Powell et al. 2001). Such selectivity can be achieved through ‘rare 
components’ such as N-acetylated glucosamine (3S, 6S) present in the anti-
thrombin binding pentasaccharide sequence of heparin which is essential for its 
anticoagulant activity (Lindahl, Kusche-Gullberg et al. 1998). Typically, between 
3-7 disaccharides are involved in protein-binding, however, longer fragments can 
also be involved as they wrap around the protein (Lortat-Jacob, Turnbull et al. 
1995; Lindahl, Kusche-Gullberg et al. 1998; Turnbull, Powell et al. 2001). 
After comparing heparin binding and non-heparin binding proteins, different 
consensus sequences for GAG binding based on clustered basic amino acid 
residues were identified, including; XBBXBX, XBBBXXBX and 
XBBBXXBBBXXBBX, where B and X are basic and neutral/hydrophobic amino 
acid residues, respectively (Cardin and Weintraub 1989; Sobel, Soler et al. 1992). 
In addition, the HP binding sites are not necessarily linear but can also include 
conformational epitopes comprising distant amino acids organized in a precise 
spatial orientation through the folding of the protein. This has been shown by 
several different techniques; site directed mutagenesis (Yamashita, Beck et al. 
2004), structural characterisation of protein/heparin complexes by NMR 
(Kuschert, Hoogewerf et al. 1998), X-ray crystallography (Mulloy and Linhardt 
2001), molecular modelling (Lortat-Jacob, Grosdidier et al. 2002) and the 
development of a new approach, which relies on the proteolytic digestion of 
protein/heparin complexes and the subsequent identification of the heparin bound 
peptides by N-terminus sequencing, (Vives, Crublet et al. 2004).  
2.3.2 GAGs as coreceptors and Internalisation 
GAGs used to be thought of as low affinity receptors, and over time they have 
been better defined to act as coreceptors; GAGs collaborate with conventional 
cell-surface receptor proteins, both in binding cells to the extracellular matrix and 
in initiating the response of cells to some growth factors.  
One of the most studied interactions between GAGs and proteins, is that of 
fibroblast growth factor (FGF) and heparan sulphate. Here, HS acts as a 
coreceptor and of the 23 different FGFs, FGF-1, 2 and 7 are the most studied. 
Yayon et al., showed that FGF-2 requires HS in order to bind to its receptor 
(FGFR1) and proposed that FGF underwent a conformational change when it 
bound to HS, allowing recognition of its receptor (Yayon, Klagsbrun et al. 1991). 
In the same year, Rapraeger et al., proposed that FGF forms a ternary complex 
with HP/HS and its receptor which consequently transmits the signal (Rapraeger, 
Krufka et al. 1991). Later in 1992, the controversial issue of how the FGF 
signalling complex is formed was further developed by Ornitz and colleagues, 
where they proposed that an octasaccharide HS is the minimum size to bind and 
cause the dimerisation of two FGFs, which then causes dimerisation on the 
receptors and downstream signalling (Ornitz, Yayon et al. 1992). It is now 
accepted after further structural studies that HS reinforces the interaction between 
the FGF-FGFR complex 2:2 and that this dimerisation of the receptors transduces 
the signal that leads to autophosphorylation of the kinase. Here, GAGs are shown 
to act as coreceptors and stabilize protein-protein interaction. 
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As mentioned above, GAGs are recycled by a means of internalisation and 
downstream transport into lysosomes in the cytoplasm where they are 
subsequently digested. During internalisation of the GAGs, proteins that are 
bound or associated with the GAGs will be cointernalised, such is the case for 
vitronectin, thrombospondin, FGF2, ATIII as well lipoprotein lipase (LPL). LPL 
is an enzyme produced by adipocytes and is essential to lipid metabolism. The 
monomeric form of LPL has a weak interaction with cell surface GAGs, however 
as a dimer it interacts strongly with HS with a low nM affinity (Lookene, Savonen 
et al. 1997). When associated with the GAGs, LPL is in close proximity to the 
lipoproteins and thus allows digestion. When the GAGs are internalised, so are the 
lipoproteins and LPL, leading to their endocytosis and catabolism. 
2.3.3 Capture, Release and Protection of proteins 
HSPGs can transiently capture growth factors and morphogens which may 
stabilize protein gradients to control the range of signalling (Lander, Nie et al. 
2002; Guimond and Turnbull 2004; Koziel, Kunath et al. 2004; Kirkpatrick and 
Selleck 2007) or protect proteins against degradation by proteases (Small, 
Nurcombe et al. 1992). On the other hand, proteins that are bound to the GAGs 
may be released through protease-mediated shedding of the PG ectodomains or 
through cleavage of the HS chains by heparanase (Lindahl and Li 2009). HSPGs 
can also act in trans, where the core protein of one HSPG attached to one cell will 
extend and deliver a protein to a ‘receptor’ located on a neighbouring cell. 
Through a balance of these signalling and structural roles, HSPG signalling 
coreceptors can either be tumour promoting or tumour suppressing and 
understanding the mechanism of action of these processes will enable effective 
targeting of the coreceptors and pathways for treatment of human disease. 
2.4 Role of HS in pathogenic Infections 
Other than their implication in a multitude of biological processes, HS are also 
exploited by a large number of pathogens as a site of anchorage onto the host cell 
from which they can gain entry. Pathogens use HS as an attachment site to 
increase the concentration of infectious particles at the surface of the cell as well 
as to spatially facilitate easy access to the host’s coreceptors. 
2.4.1 Attachment of bacteria and parasites 
Parasites such as Plasmodium falciparum (responsible for malaria), Trypanosoma 
cruzi (responsible for Chagas disease) and Toxoplasma gondii (causative agent for 
encephalitis) use GAGs to gain entry into host cells. P.falciparum binds to 
chondroitin sulphate A chains on the cells in the salivary gland in the mosquito 
(Barragan, Spillmann et al. 1999). GAGs are also a site of attachment for bacteria 
such as Pseudomonas aeruginosa, Helicobacter pylori, Listeria monocytogenes, 
Streptococcus pneumoniae… Some bacteria exploit the properties of 
oligosaccharide fragments as tools to augment their virulence. As in the case for 
P. aeruginosa, invasion of the host cell provokes signalling pathways that 
involves tyrosine kinases activation and downstream release of syndecans into the 
extracellular milieu (Schmidtchen, Frick et al. 2001). These liberated 
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polysaccharides are thus participating in the virulence of P. aeruginosa and are 
capable of binding to and inactivating host cationic anti-microbicidal peptides 
such as defensins. Conversely, mutant knock-out mice for the expression of 
syndecan-1 are more resistant to infection by P. aeruginosa than their wild type 
counterparts (Park, Pier et al. 2000). 
2.4.2 Attachment of viruses 
Many viruses are capable of binding to GAGs; HIV, herpes (HSV-1), adenovirus, 
papillomavirus and dengue virus. Primarily, HS serves as an attachment receptor 
that enables these viruses to concentrate on the host cell surface and gain 
proximity to the actual cell coreceptors and may influence viral tropism in vitro 
(Ugolini, Mondor et al. 1999; Spillmann 2001; Germi, Crance et al. 2002; Liu and 
Thorp 2002). Enzymatic treatment of T-cell lines with heparinases and removal of 
sulphates from GAG chains with sodium chlorate prevents HIV-1 (IIIB/Hx10) 
infection (Patel, Yanagishita et al. 1993; Mondor, Ugolini et al. 1998). Here, I will 
focus on the interaction between HS and HIV throughout the course of infection 
and the therapeutic applications of HS. 
2.4.2.1 HS binding to gp120 
HIV is able to bind to a range of molecules present on the cell surface, other than 
its classical primary receptor and coreceptors, CD4 and CCR5/CXCR4 
respectively (Ugolini, Mondor et al. 1999). As described in Section 1.2.10, such 
molecules are lectins, DC-SIGN, glycosphyngolipides and GAGs, particularly 
heparan sulphate. 
Like other pathogens (Vives, Lortat-Jacob et al. 2006), HIV exploits the 
properties of HS to attach to the cell surface however, the exact role of these 
polysaccharides during HIV infection remains unclear. Because of their 
abundance, HS were mainly considered as "attachment receptors" of the virus, the 
function of which was to facilitate the infection by concentrating viral particles on 
the surface of the host cell. This can be referred to as infection in cis. Various 
studies have shown that the elimination of HS expressed on the cell surface 
enabled these cells to become less permissive to infection, at least with lab-
adapted viruses (Roderiquez, Oravecz et al. 1995). In parallel, HS can mediate 
infection in trans, whereby HS expressed on non-permissive cells can bind to and 
collect the virus at the cell surface and then transfer the virus to permissive cells 
(Olinger, Saifuddin et al. 2000; Bobardt, Saphire et al. 2003).  
HIV-HS interactions can occur at different times in different situations and serve 
different purposes. At the point of HIV entry, the virus encounters host mucosal 
surfaces and the abundant HS molecules in the glycocalyx trap the viral molecules 
and efficiently allow the translocation of the virus through the epithelial layer 
towards their target cells (Bomsel and Alfsen 2003; Wu, Chen et al. 2003). In a 
similar fashion, HS expressed by endothelial cells of the blood-brain barrier 
sequester the viral particles and contribute to the process of neuro-invasion 
(Argyris, Acheampong et al. 2003; Banks, Robinson et al. 2004). Due to their 
anionic nature, HS will preferentially bind to CXCR4 utilizing HIV envelopes due 
to their overall basic charge and thus HS may play an important role in viral 
tropism during the course of infection.  
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The interaction between HIV-1 and HS depends on the quality and degree of 
sulphation of the oligosaccharides present at the cell surface and these parameters 
depend on the tissue of origin and the cell’s state of activation and differentiation 
(Maccarana, Sakura et al. 1996; Ohshiro, Murakami et al. 1996). Most of the 
research around HIV-1 and HS binding is conducted using cells that express high 
levels of HS, however, the natural hosts of HIV-1 do not express such high levels. 
CD4+ T Lymphocytes express weak amounts of HS which may vary as a function 
of their stage of differentiation and monocytes also express low amounts of HS. 
However, macrophages express low levels of CD4 and high levels of HS and it 
has been suggested that HS can compensate for low levels of CD4 on 
macrophages (Saphire, Bobardt et al. 2001). A study by Bobardt et al., 
characterising the oligosaccharide motifs that are involved in HIV-1 fixation onto 
HS has shown that the 6-O-sulphate residues are crucial for viral binding to 
epithelial cells (Bobardt, Chatterji et al. 2007). The characterisation of this 
binding interaction is highly complex and is vital to better understanding viral 
entry and the development of entry inhibitory compounds. 
2.4.2.2 Characterisation of the gp120/HS interaction 
In 1995, Roderiquez et al., showed that HIV-1 gp120 bound to heparan sulphate 
through its V3 loop (Roderiquez, Oravecz et al. 1995), however the structural and 
functional aspects of this interaction were not well understood. Moulard and 
colleagues showed that this interaction was largely due to the electrostatic 
attraction between the anionic HS on the cell surface and the global basic charge 
of the V3 loop (Moulard, Lortat-Jacob et al. 2000). A R5 HIV-1 variant typically 
possesses a net V3 loop positive charge of ≤ 5 and that of an X4 variant is 
typically ≥ 5 (Briggs, Tuttle et al. 2000). The prediction of CCR5 coreceptor 
usage from HIV-1 env sequences, is performed by the presence of neutral and 
negatively charged amino acids at positions 11 and 25 respectively, in the V3 loop 
(De Jong, De Ronde et al. 1992; Fouchier, Groenink et al. 1992; Milich, Margolin 
et al. 1993; Fouchier, Brouwer et al. 1995; Xiao, Owen et al. 1998; Hoffman, 
Seillier-Moiseiwitsch et al. 2002). Conversely, if a basic/positive amino acid is 
found at position 11 and/or 25 the sequence will probably represent a SI 
phenotype (De Jong, De Ronde et al. 1992; Fouchier, Groenink et al. 1992; 
Fouchier, Brouwer et al. 1995; Milich, Margolin et al. 1997; Brumme, Dong et al. 
2004; Brumme, Goodrich et al. 2005). Such small variations in the charge of the 
V3 loop can have great consequences for the affinity of the envelope for HS. 
2.4.2.2.1 Gp120 binding to HS is linked to Tropism 
CCR5 utilizing envelopes do not bind to HS as strongly as do CXCR4 utilizing 
envelopes, however, how this phenomenon is linked to early-stage infection is not 
fully understood. This has been confirmed in our laboratory when injecting 
different tropic gp120 over a surface of immobilized heparan sulphate using 
Surface Plasmon Resonance (SPR, section 8.10.5) technology. X4-tropic 
envelopes have a high affinity for the immobilized HS, shown by the low 
dissociation of the stable complex that is formed (Figure 2.6) and R5-tropic gp120 
binds with a much lower affinity than the X4-tropic envelopes due to the reduced 
number of positive charges in its V3 loop. As can been seen here, there is 
correlation between viral tropism and the ability for gp120 to bind to HS and since 
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there are such great differences between the two types of virus (their 
pathogenicity, distribution during infection), HS is likely to play a major role in 
these differences. Interestingly, the same effect is seen for whole viruses; X4 
viruses also form a stable complex when injected over an HS surface and R5 
viruses bind very weakly and dissociate off an HS surface (Moulard, Lortat-Jacob 
et al. 2000). 
 
 
 
 
 
 
 
 
Figure 2.6 Surface Plasmon Resonance (SPR) binding curves showing the interaction 
between X4 (A) and R5 (B) tropic envelopes binding to a HS surface. 60nM of each envelope 
was injected and negative binding surface data was subtracted. Taken from (Lortat-Jacob, 
Fender et al. 2005). The binding responses (in RU) were recorded as a function of time (in s) 
– these parameters will be used for all SPR sensograms throughout the manuscript. 
2.4.2.2.2 The  CD4  induced  (CD4i)  domain  is  an HS 
binding site 
As mentioned above, the V3 loop was established as being a point of attachment 
between the HS and gp120. In 2005 Vivès et al., showed that the CD4i site was a 
second binding site on gp120 for HS when they injected gp120 (HxBC2) either in 
the presence or absence of CD4 on an immobilized HS surface using an SPR-
based technique (Biacore) (Vives, Imberty et al. 2005). The gp120/CD4 complex 
had a much higher binding response for the HS as compared to the gp120 on its 
own (Figure 2.7 A and B). This result was confirmed by injecting gp120/CD4 
complexes over a 17b surface in the presence and absence of heparin. The 
monoclonal antibody 17b is used as a coreceptor surrogate as it belongs to a group 
of monoclonal antibodies defined as induced by CD4 (Thali, Moore et al. 1993), 
the epitopes of which on gp120 overlap the coreceptor binding surface.  
The gp120/CD4 complex binding to 17b is clearly inhibited by the presence of 
heparin, thus heparin binds to the coreceptor binding region of gp120 and inhibits 
recognition by the 17b antibody (Figure 2.7 C). 
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Figure 2.7 (A) 50nM of either gp120 alone (blue curve) or gp120 in the presence of equimolar 
amount of CD4 (red curve) over a Heparin surface. (B) Inhibition of gp120/CD4 (5 and 
10nM respectively) complex binding to 17b on the sensor chip surface in the presence of 
different concentrations of heparin (0-16.7nM). 
Molecular modelling has confirmed that an oligosaccharide can indeed interact 
with both the V3 loop and CD4i site simultaneously. The model suggests that the 
size of the oligosaccharide that is required to cover all the basic residues of these 
two domains is between 10-12 monosaccharides long (Figure 2.8A). This model 
was confirmed by inhibiting the binding of gp120/CD4 complexes onto a 17b 
surface with varying sizes of purified heparin oligosaccharides (dp [degree of 
polymerisation] 2 – 18). The experimental data was in clear agreement with the 
modelling data as an oligosaccharide of at least 10 monosaccharides is necessary 
to significantly inhibit the gp120/CD4 complex from binding to its coreceptor 
surrogate 17b (Figure 2.8B) (Vives, Imberty et al. 2005).  
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Figure 2.8 (A) Molecular modelling of the placement of a hexadecasaccharide of heparin 
onto the gp120 (HxBC2) crystallographic structure, showing that a dodeccasaccharide 
encompases both the V3 and CD4i binding sites. The MOLCAD surface of the gp120 is 
coloured according to its electrostatic potential (red for the basic residues and blue for the 
acidic residues). (B) Zoom up of the CD4i site with the basic amino acids involved in the 
GAG- binding interaction annotated. (C) The gp120/CD4 complexes (5 and 10nM 
respectively) were co-incubated with different lengths of heparin oligosaccharides before 
injecting them over a 17b surface on the Biacore. A decasaccharide is the smallest fragment 
required for significant inhibition of the complex binding to 17b. Images adapted from 
(Vives, Imberty et al. 2005). 
In order to investigate the structural basis of the HS-gp120 interaction in more 
detail, Crublet et al., used a mapping strategy and compared the heparin binding 
activity of wild type and mutant gp120 molecules using SPR based binding assays 
(Crublet, Andrieu et al. 2008). Through the use of several gp120 constructs 
containing mutated amino acids in the CD4i region, combined with the mapping 
strategy, four heparin binding domains were identified: In the V2 and V3 loops, in 
the C-terminal domain and within the CD4-induced bridging sheet. Three of these 
regions are areas that undergo structural re-arrangements upon the binding of CD4 
and are involved in co-receptor recognition. Residues Arg419, Lys421 and 
Lys432 are all involved in coreceptor recognition and are targeted by heparin and 
these sites are targets for viral entry inhibition (Rizzuto, Wyatt et al. 1998). 
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2.5 Therapeutic applications of HS in HIV infection 
2.5.1 Anionic Binders 
One of the promising strategies to combat HIV-1 entry is with the use of 
sulphated polysaccharides as they have been shown to inhibit HIV-1 infection 
(Ueno and Kuno 1987; Baba, Snoeck et al. 1988; Bagasra and Lischner 1988). 
Polyanions recognise proteins via the clusters of basic amino acids exposed on 
their surfaces (Whitelock and Iozzo 2005) and thus a large body of work has 
characterised the gp120/HS complex, showing that heparin, HS, polyanions and 
dextran sulphate bind to the V3 loop of gp120 and can compete with V3 loop 
specific monoclonal antibodies (Callahan, Phelan et al. 1991; Batinic and Robey 
1992; Rider, Coombe et al. 1994; Okada, Patterson et al. 1995).  
The bridging sheet and epitopes exposed upon CD4 binding (CD4i) are also 
involved in the binding of polyanions (Roderiquez, Oravecz et al. 1995; Moulard, 
Lortat-Jacob et al. 2000). The CD4i can also bind to negatively charged 
sulphotyrosine residues found in the complementary determining region of CD4i 
neutralizing monoclonal antibodies (412d and E51) and also found in the N-
terminal of both coreceptors, CCR5 and CXCR4 (Choe, Li et al. 2003; Huang, 
Venturi et al. 2004). 
Many sulphated polysaccharides have thus been studied for their antiviral 
properties and potential usage as microbicides. Sulphated polysaccharides 
extracted from marine sponges (Erylus discophorus) show strong anti viral 
activity (up to 95% inhibition of HIV-1) (Esteves, Nicolai et al. 2011). Dextran 
sulphate can possess 2-3 sulphate groups per D-glucose α (1-6) and can bind to 
V3 loop and CD4i of gp120 in the same fashion as HS (Callahan, Phelan et al. 
1991; Moulard, Lortat-Jacob et al. 2000). It is important to note that CCR5 
utilizing gp120 do not fix as strongly to these polyanions as do CXCR4 utilizing 
gp120 or dual tropic ones (Moulard, Lortat-Jacob et al. 2000). The bacterial 
derived lipopolysaccharide (LPS) has been shown to bind the V3 loop and inhibit 
gp120 binding to coreceptors and inhibit infection of U87 cells by pseudoviruses. 
Such a compound could potentially be used as an anti-HIV-1 therapy (Majerle, 
Pristovsek et al. 2011). 
As mentioned above, the CCR5 coreceptor of HIV-1 posses a certain number of 
sulphated tyrosines (in particular at positions 10 and 14) (Farzan, Mirzabekov et 
al. 1999; Cormier, Persuh et al. 2000) in its N-Terminal. (Section 1.2.5 – HIV 
coreceptors). Interestingly, several human HIV-1 neutralizing antibodies that are 
directed against the CD4i site in gp120, contain sulphotyrosines in their heavy 
chain CDR3  regions (complementary determining region 3) of their antigen 
binding sites (including mAb 412d, E51) which are crucial for binding to gp120 
and neutralizing infection (Choe, Li et al. 2003; Huang, Venturi et al. 2004; 
Huang, Lam et al. 2007). Recently, broadly neutralizing antibodies PG9 and PG16 
have been described to also contain sulphotyrosines (Walker, Phogat et al. 2009; 
Pejchal, Walker et al. 2010).  
Dorfman et al., described a tyrosine sulphated peptide derived from the heavy 
chain CDR3 region of E51 and showed that it bound and neutralised HIV-1 more 
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efficiently than sulphotyrosine-containing peptides directly based on the CCR5 
amino terminus sequence (Dorfman, Moore et al. 2006). This may be due to the 
peptides’ increased flexibility and solubility. Due to the conserved gp120 
sulphate-binding domains, this peptide is able to bind and neutralise both R5X4 
and X4 isolates.  
Very recently, Kwong et al., showed that when a 15 amino acid peptide mimetic 
of the CCR5 coreceptor was fused to a CD4 mimetic peptide and a dimeric 
antibody Fc domain (DM1-Ig), it can bind gp120 and neutralise R5, X4 and R5X4 
HIV-1 isolates (Kwong, Dorfman et al. 2011). Despite DM1-Ig promising results, 
it neutralises HIV-1 with much less efficiency than certain neutralizing antibodies 
and it does not neutralize many non-clade B isolates; thus improvements are 
necessary for this compound to be used in vivo. Here, the binding assays between 
gp120 proteins and the inhibitors were performed with immunoprecipitation 
experiments which do not yield accurate results compared to more sensitive 
techniques such as Surface Plasmon Resonance. In addition, the infection assays 
were not performed against whole infectious virus, but against co-transfections of 
gp120-encoding plasmids and NL4-3-encoding plasmids lacking env and nef and 
expressing GFP (Kwong, Dorfman et al. 2011).  
In conclusion, the concept of cooperatively inhibiting HIV-1 entry with a chimeric 
inhibitor capable of binding both i) the CD4 binding domain as well as ii) the 
CD4i region is novel, and most importantly it does inhibit both R5 and X4 viral 
entry into host cells. The challenge is to design and construct a molecule, with a 
high affinity and capacity to block binding to these two critical regions, that is not 
degraded upon administration, has little to no side effects and is economically 
viable. 
2.5.2 Concept  and  action  of  CD4­HS:  a  glycoconjugate  that 
inhibits HIV­1 attachment and entry 
From the above data, the role played by HS interacting with the CD4i during 
HIV-1 infection is not known. However, this conserved and cryptic domain 
(CD4i) is involved in the recognition of CCR5 and CXCR4, and observations 
described above strongly suggest a strategy to inhibit the interaction between 
gp120 and the coreceptor, based on the use of an HS oligosaccharide. In order for 
the cryptic coreceptor binding domain CD4i to be exposed and neutralised, gp120 
first needs to bind CD4. Based on these facts, a unique strategy was formed to 
target HIV-1 entry: once gp120 has bound CD4, the conformational re-
arrangement occurs in the gp120 protein which exposes/creates the cryptic CD4i 
which is favourably positioned to bind the coreceptor (CCR5/CXCR4) 
immediately after CD4 binding. Thus the concept of creating a bivalent inhibitory 
molecule (CD4-HS) that will trigger the gp120 conformational change and block 
viral entry. The CD4-HS molecule is able to initially bind the CD4-binding site on 
gp120 (with a CD4 moiety), thereby exposing the CD4i domain, after which the 
second part of the inhibitory molecule (the HS anionic moiety) is perfectly 
positioned to tightly bind the CD4i, thus blocking the gp120 from binding the host 
coreceptors.  
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Thus, with the idea of replacing full length CD4 with a small synthetic peptide 
mimetic, a chimeric molecule was conceptualised and constructed: mCD4-HS12 
(Baleux, Loureiro-Morais et al. 2009). This chimeric molecule is composed of a 
27 amino acid long peptide, mimicking CD4 (mCD4), covalently linked to a HS12 
and operates in the following way (Figure 2.9). 
 
 
 
 
 
 
 
 
 
Figure 2.9 CD4-HS12 mode of action: the glycoconjugate binds gp120 through the CD4 
moiety which then induces the formation of the coreceptor binding domain via the synthetic 
CD4, followed by the high affinity interaction of the anionic HS12 domain with coreceptor 
binding domain. The glycoconjugate blocks both CCR5 and CXCR4 viral entry. 
 
2.5.2.1 The CD4 moiety, mCD4 
Instead of using the full length CD4 receptor, a mimetic approach was used 
whereby CD4 was replaced by a peptide that was based on a short mini CD4, 
called CD4M33 (Martin, Stricher et al. 2003). In 2003, Martin et al., published 
the design of CD4M33, a 27 amino acid CD4 mimetic that contains the minimal 
amount of residues to obtain the optimal interaction with gp120 in order to 
unmask conserved neutralization epitopes on gp120 that are normally cryptic on 
the unbound protein (Martin, Stricher et al. 2003). After the structure resolution of 
CD4-gp120-17b antibody complex (Kwong, Wyatt et al. 1998), the ~800Å CD4 
binding pocket in gp120 was elucidated, revealing the Phe43 hydrophobic pocket. 
This structural insight spurred the design of CD4M33 which has potential to be 
used in vaccine formulations in complex with envelope proteins or for the use as a 
molecular target in phage display technology to develop broad-spectrum 
neutralizing antibodies. 
2.5.2.2 The HS Moiety, HS12  
A heparan sulphate dodecasaccharide (obtained by chemical synthesis) was 
created as this length of oligosaccharide was optimal for CD4i binding based on 
the SPR data as well as molecular docking experiments. Each repeating 
disaccharide contains three sulphates, namely the N-sulphate and the 6S sulphate 
on the Glucosamine and the 2S sulphate on the Iduronic acid. Thus, in total there 
are 18 sulphate residues found in the HS12 synthetic prototype (Baleux, Loureiro-
Morais et al. 2009). 
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2.5.2.3 mCD4­HS12 
Since the CD4 induced coreceptor binding site that is exposed upon CD4 binding 
is in such close proximity to the host membrane, neutralising antibodies are 
sterically inhibited from accessing the conserved and vulnerable region (Labrijn, 
Poignard et al. 2003). Hence, the ingenious idea of linking the miniCD4 molecule 
to the relatively small HS moiety. Owing to the covalent bond between the mCD4 
and the HS12, the glycoconjugate mCD4-HS12 has a very high affinity for the viral 
envelope. It simultaneously blocks the interaction of gp120 MN (CXCR4-tropic) 
and YU2 (CCR5-tropic) with three of its ligands: HS, CD4 and CD4i antibodies 
(17b, 48d and X51) (Baleux, Loureiro-Morais et al. 2009). The antibodies were 
used as coreceptor mimics and thus validated the mode of action described above; 
however the CD4-HS12 molecule, at this stage had never been tested using actual 
7 transmembrane GPCR coreceptors as gp120 ligands.  
This molecule is a strong HIV-1 entry inhibitor candidate as it inhibits attachment 
and entry of both CCR5 tropic and CXCR4 tropic HIV-1 strains with 1-5nM IC50 
for inhibition of viral replication (Baleux, Loureiro-Morais et al. 2009). Other 
advantages of the glycoconjugate is that it interacts with the virus and not the host 
cells and due to its unique mode of action, it simultaneously inhibits two 
important regions of gp120 crucial for entry; the CD4 binding region and the 
coreceptor binding domain. Drug resistance to this molecule is unlikely to occur 
as the CD4 binding region is required to remain conserved in order to continue 
binding CD4 and the basic region within gp120 required for the HS interaction is 
also conserved and crucial for the interaction with the coreceptors. Any mutations 
that might occur in these two regions are likely to be detrimental to the survival of 
the virus, thus this inhibitor has enormous potential not to evoke resistance. The 
concept of cooperatively inhibiting viral entry through the simultaneous blockage 
of two different critical domains required for viral entry, opens a novel strategy 
for viral entry inhibition in general. 
However, the limitations of mCD4-HS12 are its inherent complexity and extreme 
difficulty in synthesis of the anionic dodecasaccharide moiety. A novel strategy to 
mimic the anionic moiety was thus necessitated in order to reduce the complexity 
of the molecule for structure-function analysis and also to reduce the time 
required for the molecules’ synthesis/production. Therefore, in order to screen for 
various HS mimetics, a screening platform was required whereby HIV-1 envelope 
binding to its native coreceptors could be monitored and inhibited by various 
inhibitors. Native coreceptors are advantageous over soluble 17b, as 17b is only a 
partial coreceptor mimic and in order to inhibit binding to all the coreceptor 
epitopes involved in ‘gp120-CD4-coreceptor binding interaction’, the use of full 
length native coreceptors is advantageous. This work involved the setting up of a 
coreceptor binding assay whereby native coreceptors were immobilized on a 
platform in a lipid-detergent buffer. In order to test whether these coreceptors 
were functional, the system was validated by the use of binding a natural 
chemokine ligand to the coreceptors. This introduces the following chapter on the 
CXCL12 chemokine.   
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Chapter 3: CXCL12 / Stromal Derived Factor 1 (SDF1), 
natural ligand of CXCR4 
3.1 General 
Chemokines are small (8-10 kDa) chemotactic cytokines which comprise a large 
family of about 50 members. They have been identified to bind to a total of ~20 
receptors, meaning that there are many receptors which bind more than one 
chemokine (Figure 3.1). Chemokines and their receptors are important in dendritic 
cell maturation (Sozzani, Allavena et al. 1998) and T and B cell development 
(Forster, Emrich et al. 1994; Vicari, Figueroa et al. 1997). Thus they are essential 
to many developmental and physiological possesses. They direct the orientated 
migration of cells during development, inflammation, hematopoietic stem cell 
mobilization, homeostatic immune responses, organogenesis and neuronal 
communication. The major role of chemokines is to act as a chemoattractant to 
guide the migration of cells and they are the only members of the cytokine family 
that act on GPCRs. 
Some chemokines participate in immune surveillance and are referred to as 
homeostatic chemokines; they are constitutively expressed and direct lymphocytes 
to the lymph nodes so they can search for invading pathogens by interacting 
with antigen-presenting cells residing in these tissues. Other chemokines have 
roles in development; they promote angiogenesis, or guide cells to tissues that 
provide specific signals critical for cellular maturation. Another group is 
the inflammatory chemokines released from a wide variety of cells in response 
to bacterial infection, viral infection or agents (eg. silica) that cause physical 
damage (Alberts, Johnson et al. 2002). Thus if the cell’s normal ability to traffic 
cells is damaged or hijacked by any bacteria/virus or agent, the chemokine 
network can maintain and coordinate many disease states such as autoimmune 
diseases (multiple sclerosis, rheumatoid arthritis, and atherosclerosis) as well as in 
abnormal cell-growth conditions such as tumour metastasis and proinflammatory 
immune responses due to inappropriate cell recruitment (Baggiolini 2001; 
Proudfoot 2002; D'Ambrosio, Panina-Bordignon et al. 2003; Sun, Cheng et al. 
2010). Many studies have shown the link between chemokines and their receptors 
to disease and this is all summarized in Figure 3.1. Most of the disease 
associations are derived from animal studies, however, some human disease 
samples have confirmed the animal data. Thus, chemokine signalling has been the 
target of drug discovery efforts almost since the initial identification of 
chemokines, 25 years ago, due to their negative signalling effects in disease states. 
These efforts have tried to identify small molecule therapeutics that target their 
t that such a 
elicately balanced system can have many negative repercussions.    
receptors. 
From the Figure 3.1, it is clearly depicted that some chemokines have a 
promiscuous nature where they bind more than one coreceptor and the inverse is 
also true where certain receptors bind more than one ligand. For this reason, the 
structure-function relationships between the receptor and ligands are critically 
important for fine-tuned, healthy signal regulation. Thus it is eviden
d
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Figure 3.1The association of chemokines (outer ring in grey) and their receptors (second ring 
from the outside in pink) and the associated disease (first three rings from the inside towards 
the outside in blue, green and yellow, for clinical data, human data and animal data 
respectively). A selection of disease associations obtained from animal models using gene 
deletions, neutralizing antibodies and receptor antagonists, as well as expression data in 
human samples and positive results from clinical trials. abbreviations: Sep, Sepsis; RA, 
Rheumatoid arthritis; T, Transplant; IBD, Inflammatory Bowel Disease; Onc, Oncology; 
SLE, Systemic Lupus; MS, Multiple Sclerosis; Ath Scl, Atherosclerosis; COPD: Chronic 
Obstructive Pulmonary Disease; AMD, Acute macular degeneration; NP, Neuropathic pain; 
Asth, Asthma; At. Derm, Atopic dermatitis; Hep, Hepatitis; P
 
anc, Pancreatitis; Pso, 
Psoriasis; GVHD, Graft vs Host disease. (Garin and Proudfoot 2011) 
3.2 Chemokines ­ Nomenclature and classification 
The nomenclature of chemokines depends on the presence and structure of a 
conserved first two cysteine residues in the amino-terminal region of the 
molecule, thus forming four families (CC, CXC, CX3C and C) (Murphy, 
Baggiolini et al. 2000). The position of the cysteines is denoted by whether they 
are adjacent, CC (as in RANTES and monocyte chemoattractant protein 1 (MCP-
1) and macrophage inflammatory protein 1 (MIP-1α and β)), or are separated by 
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residues, CXC (as in Interleukin-8 (IL-8)), CX3C (neuroactin/fraktalkine) or just 
singular, C (lymphotactin) (Baggiolini, Dewald et al. 1997; Rollins 1997). This 
motif is followed by an L (ligand) and finally an identifying number. Similarly, 
the receptors (R) for these molecules are named by the chemokine class that they 
recognise and are numbered in order of their discovery. 
3.3 Chemotaxis 
3.3.1 The Chemokine side 
 et al. 1999; Blaszczyk, Coillie 
 and chemokines (in particular 
CXCL12α) will be described in more detail later. 
3.3.2 The Cell side 
hophoinositides and calcium) (Reif and 
In terms of their structure, chemokines generally share a similar tertiary structure, 
despite the fact that their sequence homology is highly variable (ranging from less 
than 20% to over 90%). Owing to NMR and X-Ray crystallographic techniques, 
structures have revealed that the chemokines tertiary structure consists of a 
disordered N-terminus (which functions as the key signalling domain), followed 
by a N-loop which ends in a 310 helix, followed by a three-stranded β-sheet and a 
small C-terminal helix (Clore, Appella et al. 1990; Lodi, Garrett et al. 1994; 
Skelton, Aspiras et al. 1995; Handel and Domaille 1996; Crump, Rajarathnam et 
al. 1998; Liwang, Wang et al. 1999; Mizoue, Bazan
et al. 2000; Swaminathan, Holloway et al. 2003).  
After translation, chemokines are secreted from the cell in response to different 
stimuli where they interact with their receptors, except for chemokines CX3CL1 
and CXCL16 which are tethered to the extracellular surface. The secreted 
chemokines action is executed by binding to and activating specific GPCRs to 
induce cell migration along a gradient of increasing concentration of chemokine 
towards the origin or source of secretion (chemotaxis) (Rot 1993; Veldkamp, 
Seibert et al. 2008) (Figure 3.2). Secreted chemokines are protected from 
proteolysis (Sadir, Imberty et al. 2004) and prevented from diffusing away from 
their sites of production and dispersing under the influence of flow and retained 
and presented to their coreceptors by glycosaminoglycans (Ali, Palmer et al. 
2000). The binding between glycosaminoglycans
Once the chemokine has bound to its receptor, the chemokines activate cascades 
of complex signal transduction pathways; involving the heterotrimeric G-proteins, 
adenyl cyclase, phospholipases (PL), protein tyrosine and serine/threonine 
kinases, lipid kinases, the Rho family of small GTPases and triggering of 
intracellular second messengers (cAMP, p
Cantrell 1998; Ward, Bacon et al. 1998).  
Heterotrimeric G proteins (α, β and γ subunits) are bound by many GPCRs via 
their C-terminal and the cytoplasmic loops. The G-protein's α subunit is bound to 
a GDP in its resting state, and when the GPCR is activated, the GDP is replaced 
by a GTP and the α-GTP complex then dissociates from the bound βγ subunits to 
further affect intracellular signalling proteins or target functional proteins directly 
depending on the α subunit type. To increase the complexity of this system, 
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GPCRs can associate into dimers and oligomers which enhances sensitivity and 
the specificity of each response (more on this later). One of the signalling 
pathways is the mitogen-activated protein kinase pathway (MAPK pathway) the 
activation of which results in the stimulation of transcription factors and the 
regulation of the expression of cell cycle proteins. One of the three MAPK classes 
is the extracellular signal-regulated kinases (ERK), the phosphorylation of which 
we detect in the laboratory as a sign of GPCR activation and successful cell 
 executing the directional migration 
okoch 1995; Ward, Bacon et al. 1998). 
sion, rolling 
signalling.  
All these complex signalling cascades cause leukocytes to migrate from the 
bloodstream across the wall of microvessels to the underlying tissue which is the 
essential step in inflammation and response to infection. In order for a cell to 
initiate migration, it must undergo a polarization in its morphology which will 
enable it to convert cytoskeletal forces into a net cell-body displacement. These 
morphological changes involve the rearrangement of the cytoskeleton, changes in 
filamentous F-actin and the formation of integrin-mediated focal adhesions. The 
cell binds and detaches from the substrate in a co-ordinated manner with 
extension and retraction of pseudopods
(B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 A classical cartoon depicting the basic steps in cell migration in response to 
chemokine production. Chemokines are presented on the endothelial surface GAGs to 
chemokine receptors on leucocytes in the blood; chemokines may oligomerise on the GAGs. 
Whether the chemokines bind simultaneously to GAGs and chemokine receptors is not yet 
fully understood. Leukocyte recruitment is a multi-step process involving cytokines and 
chemokines driving selectin-mediated adhesion, subsequent arrest, firm adhe
and transmigration. This image was adapted from (Salanga and Handel 2011).  
This chapter focuses on the chemokine called stromal derived factor 1α (SDF-1α), 
also known as CXCL12α which is constitutively expressed in the bone marrow, 
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lungs and liver. This chemokine shares the same two ligands as CXCR4 utilizing 
gp120, which are CXCR4 and heparan sulphate. Studying the interactions 
between CXCL12, CXCR4 and HS can provide insight and bring about a better 
understanding of these two ligands which are very important for HIV-1 
attachment too. 
3.4 The CXCL12 chemokine 
3.4.1 Gene expression of CXCL12  
awa, 
). For the purpose of this study, I will only focus on CXCL12α 
and CXCL12γ.  
3.4.2 Structure of CXCL12α  
 it is for this 
urpose that the biochemical studies were persued for this isoform. 
CXCL12α was originally identified in bone marrow stromal cells and was 
characterised as a pre-B-cell stimulatory factor (Nagasawa, Hirota et al. 1996). It 
is constitutively expressed and secreted in the bone marrow, lung, liver and lymph 
nodes (Zlotnik 2006) and highly conserved among mammalian species.  
CXCL12α orchestrates a large array of essential functions, both during embryonic 
development and postnatal life. This is confirmed by mutant mice (sdf1-/- or 
Cxcr4-/-) which die in utero due to grave developmental defects (Nagas
Hirota et al. 1996; Tachibana, Hirota et al. 1998; Zou, Kottmann et al. 1998). 
CXCL12 is regulated at the splicing level and not at the transcriptional level; a 
single mRNA strand is alternatively spliced to produce six different isoforms (α, 
β, γ, δ, ε, and φ) of this chemokine which have been found in humans (Yu, Cecil 
et al. 2006). All isoforms share the first three exons found in the α isoform 
(residues 1-68), however the other isoforms vary in their fourth exon at the C-
terminal– thus giving rise to specialized C-terminal domains (Figure 3.3) The 
alternate splicing has been thought of as a natural mechanism to generate 
functional diversity, without structural modifications and complications (Romero, 
Zaidi et al. 2006
 
The three-dimensional structure of CXCL12α was determined by NMR (Crump, 
Gong et al. 1997) and by X-ray crystallography (Dealwis, Fernandez et al. 1998). 
CXCL12α is a monomer with a disordered N-Terminal region (Lys 1 – Tyr 8), 
followed by a long flexible loop, a 310 helix, a triple stranded antiparalled β-sheet 
(β(1), β(2), β(3)), covered by a C-terminal α helix α(C). The N-terminus is anchored 
to the rest of the molecule by disulphide bridges (Allen, Crown et al. 2007) 
(Figure 3.3). Figure 3.3 and Table 4 summarise the basic sequence information of 
the different chemokine isoforms and mutant used in this study. The CXCL12γ 
isoform has an elongated 30 amino acid C-terminal with multiple HS binding 
domains (BBXB) witch are unique to this isoform. However, the structure-
function relationships of this C-terminal are not fully defined and
p
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Figure 3.3 Alternate splicing of the two main isoforms relevant for this work, CXCL12α and 
CXCL12γ. The basic amino acids (K and R) that are highlighted in red in the sequences are 
amino acids that have been shown to be implicated in GAG-binding. ** KP signalling 
residues, ****** RFFESH initial contact/docking site with receptor and GAG-binding 
domains (BBXB) are indicated in the CXCL12γ sequence by the black brackets and the 
structures of each isoform are shown. Chemical shift variations upon GAG addition (dp4) 
are represented on CXCL12α and CXCL12γ in colour; Red residues bind the most to GAGs 
 
and orange residues bind less and yellow residues bind the least (Laguri, Sadir et al. 2007; 
Laguri, Arenzana-Seisdedos et al. 2008).   
Table 4. List of physical attributes of the different orms use y. 
L12α CXCL12γ 
 CXCL12 isof d in this stud
 CXC
# of amino acids 68 98 
Molecular Weight 2 7 7835. 11565.
Theoretical PI 9.81 10.61 
3.4.3 Physiological roles of CXCL12 and pathogenic effects 
In embryonic life, CXCL12α plays non-redundant roles in the development of the 
cardiovascular system, the central nervous system, haematopoiesis and 
colonisation of the gonads with primordial germ cells (Ma, Jones et al. 1998; 
Nagasawa, Tachibana et al. 1998; Zou, Kottmann et al. 1998; Klein, Rubin et al. 
2001; Ara, Nakamura et al. 2003). In post-natal life, CXCL12α is involved in 
trans-endothelial migration of leukocytes, homing and egress of stem cells from 
the bone marrow and their migration into peripheral tissues (Aiuti, Webb et al. 
1997; Campbell, Hedrick et al. 1998). The CXCL12α / CXCR4 axis also been 
shown to play critical roles in pathophysiological processes such as chronic 
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inflammatory disorders, angiogenesis, wound healing and tumour cell 
proliferation (Nanki, Hayashida et al. 2000; Burger and Kipps 2006). 
CXCR4 is found in cells from over 20 types of cancer which metastasize towards 
tissues that secrete CXCL12α (bone marrow, lung, liver, lymph nodes) (Zlotnik 
2006). The current paradigm suggests that increased CXCR4 expression leads to 
12α 
cently Dar et al., have speculated that CXCL12α release 
), however CXCL12γ has 
the ability of carcinoma cells to metastasize to organs such as the bone marrow 
and liver that express high amounts of CXCL12α (Balkwill 2004).  
However, hypermethylation of CXCL12α promoter cytosines causes the absence 
of CXCL12α expression which has been detected in 40-62% of tumours. This 
varying percentage indicates an alternate mechanism for modifying the expression 
of CXCL12α. A study by Wendt et al., showed that an elevated migratory 
signalling response to ectopic CXCL12α, contributes to the metastatic potential of 
CXCR4-expressing mammary carcinoma cells subsequent to epigenetic silencing 
of the autocrine Cxcl12 promoter (by methylation). Congruently, the re-
establishment of CXCL12α production in CXCR4-expressing mammary 
carcinoma cells, increased proliferation and primary tumour growth and decreased 
chemotaxis and metastasis (Wendt, Johanesen et al. 2006; Wendt, Cooper et al. 
2008). This suggests that the primary tumour cells that silence CXCL12α are at a 
selective advantage for metastasis through ectopic CXCL12α, and when 
endogenous CXCL12α is produced, proliferation is favoured and not metastasis as 
the cancer cell producing CXCL12α will disrupt the haptotactic gradient. This is 
why metastatic tumours are commonly located in organs of high CXCL
concentration (e.g. lungs, bones, adrenal glands) and not in the organs where low 
CXCL12α levels are detected (heart, kidneys) (Phillips, Burdick et al. 2003). 
Stem cell mobilization and hematopoietic stem cell homing to bone marrow 
following transplantation, are two crucial processes which are also both mediated 
by CXCL12α. In order for stem cells to mobilize, CXCL12α binding to CXCR4 in 
the bone marrow is disrupted, causing a reversion in the bone marrow-blood 
CXCL12α gradient (i.e. higher concentration of CXCL12α in the blood), thus 
resulting in the release of CXCR4 expressing cells into the blood. The cytokine 
called granulocyte-colony stimulating factor (G-CSF) augments the activity of 
certain proteases in the bone marrow which degrade both CXCL12α and, to a 
lesser extent, CXCR4. This is what decreases the CXCL12α binding to CXCR4 in 
the bone marrow, which allows for stem cell mobilization with reduced 
chemotactic ability due to the partial destruction of CXCR4 (Weidt, Niggemann et 
al. 2007). This is why the CXCR4 bicyclam antagonist AMD3100, in combination 
with G-CSF is used in stem-cell transplantation in patients with multiple myeloma 
and non-Hodgkin lymphoma who had received prior chemotherapy (Flomenberg, 
Devine et al. 2005). AMD3100 specifically and reversibly blocks CXCL12α from 
binding to CXCR4 and re
from bone marrow cells into the circulation is caused by AMD3100 (Dar, 
Schajnovitz et al. 2011). 
Most studies have focused on CXCL12α and its role played in normal immune 
functioning and disease states, however, very little is known about the CXCL12γ 
isoform. CXCL12α is detected in all organs, mostly those which are associated to 
the immune system (bone marrow, thymus, tonsils etc.
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shown distinct mRNA expression profiles during organogenesis in several cell 
types during development (Franco, Rueda et al. 2009).  
Few studies have demonstrated comparisons between CXCL12α and CXCL12γ 
signalling effects in vivo. Intraperitoneal administration of CXCL12α and 
CXCL12γ produces virtually the same local inflammatory response after 3 hours, 
but after 16 hours, an inflammatory reaction was still present in animals injected 
with CXCL12γ and not with CXCL12α (Yu, Cecil et al. 2006; Rueda, Balabanian 
et al. 2008). This demonstrates that the signalling of CXCL12α is much more 
short lived compared to the prolonged signalling effects of CXCL12γ. Structural 
6; Amara, Gall 
 splice variants is 
not fu undamental information 
on the ning. 
 interested in the CXCL12α-CXCR4 binding 
differences between the two chemokines could explain the differences in observed 
functions and their relative ability to bind GAGs. This will be elaborated on later. 
Shortly after CXCR4 was discovered as being a coreceptor for HIV-1, CXCL12α 
was subsequently reported as being the only natural ligand of CXCR4 which is 
able to prevent entry of CXCR4 utilizing HIV-1 through coreceptor occupancy, 
downregulation and internalisation (Bleul, Farzan et al. 1996; D'Souza and 
Harden 1996; Feng, Broder et al. 1996; Oberlin, Amara et al. 199
et al. 1997). Interestingly, CXCL12γ was shown to be the strongest HIV-1 
inhibiting CXCL12 isoform (Altenburg, Broxmeyer et al. 2007).  
As mentioned above, aberrant expression of chemokines plays essential roles in 
chronic inflammatory processes. Thus, small molecule antagonists of CXCR4 will 
not only inhibit CXCR4 utilizing HIV-1, but also chronic inflammatory disorders 
too. The functional role for having so many different CXCL12
lly understood and deciphering this will elucidate f
 regulation of normal and disrupted immune functio
3.4.4 GAGs, CXCR4, CXCR7 and CXCL12α 
GAGs, CXCR4 and CXCR7 are all binding partners for CXCL12α. Once 
CXCL12α has been secreted into the extracellular space, it binds to the cell-
surface glycosaminoglycans which play a key role in ensuring the correct 
positioning of the chemokine within tissues and maintaining haptotactic 
concentration gradients along which CXCR4 expressing cells can migrate 
directionally (chemotaxis). The glycosaminoglycans not only provide a scaffold 
for haptotactic gradient formation by chemokines, but also modify their 
conformation, stability, reactivity and protect the chemokines from proteolysis as 
well as present them to their receptors. Unlike other chemokines, CXCL12α is 
less promiscuous and has been know to bind only to CXCR4 and CXCR7. Thus, 
HIV-1’s glycoprotein, gp120, and CXCL12α share a common binding partner and 
it is for this reason that we are
interaction – as it may help us gain insight into how gp120 binds CXCR4 and how 
this interaction may be blocked.  
Recently, CXCR7 (formerly known as RDC1) has also been identified as a 
CXCL12α second receptor (Balabanian, Lagane et al. 2005; Burns, Summers et 
al. 2006; Altenburg, Broxmeyer et al. 2007). CXCR7 has phylogenetic similarity 
to GPCRs but does not couple G-proteins and does not induce typical chemokine 
receptor mediated cellular responses, however, it was found to be implicated in 
cardiovascular system development in CXCR7 deficient mice. In humans, 
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CXCR7 is expressed in embryonic neuronal and heart tissue, in hematopoietic 
cells and activated endothelium (Sierro, Biben et al. 2007). Elevated levels of 
CXCR7 expression correlate with aggressiveness of prostate cancer and promote 
growth and metastasis of mouse tumour models (Miao, Luker et al. 2007; Wang, 
Shiozawa et al. 2008). Interestingly, some studies suggest that CXCL12α 
signalling can be modulated through the heterodimerisation of CXCR4 and 
CXCR7; this will be discussed later (Sierro, Biben et al. 2007; Levoye, 
Balabanian et al. 2009). Also, it is important to note that the affinity of CXCL12α 
for CXCR7 (KD ~ 0.3nM) is much higher than for CXCR4 (KD ~ 4nM) (Crump, 
Gong et al. 1997; Balabanian, Lagane et al. 2005; Burns, Summers et al. 2006) 
and it has been postulated that posterior CXCR7 removal of CXCL12α sharpens 
e for binding to CXCR7, both CXCL12α and 
scribed and accepted for many years. Thus, described below are the GAG-
CXCL12α interactions and CXCR4-CXCL12α interactions respectively in more 
detail. 
chemotactic gradients promoting CXCR4-mediated migration of primordial germ 
cells (Boldajipour, Doitsidou et al. 2011).  
Very recently, CXCR7 has been proposed as a scavenger for CXCL12α mediating 
ligand internalisation and subsequent targeting of the ligand for degradation 
(Naumann, Cameroni et al. 2010). This role may be important for the fine tuning 
of the mobility of hematopoietic cells in the bone marrow and lymphoid organs. 
The presence of 10µM AMD3100 had no effect on CXCR7-mediated CXCL12α 
scavenging and the deletion of the C-terminus of CXCR7, completely abolished 
CXCL12α degradation. This means that CXCL12α binds CXCR7 in a different 
way compared to how it binds CXCR4 and that the C-terminal of CXCR7 is 
required for trafficking of the receptor (Naumann, Cameroni et al. 2010). To date, 
there have not been any investigations into the role of the different CXCL12 
splice variants on CXCR7 function, however, Reuda and colleagues have shown 
that when analysing the ability of a wild type chemokine to compete with a C-ter 
biotinylated CXCL12α chemokin
CXCL12γ bind similarly to CXCR7 (IC50 = 6.56 nM and 10.37 nM respectively) 
(Rueda, Balabanian et al. 2008). 
Since the role of CXCR7 in CXCL12 signalling is relatively recent and 
controversial, I shall only go into more detail on the interactions that have been 
well-de
3.4.5 Characterisation of the GAG­CXCL12 complex 
At the site of secretion, chemokines (usually highly basic proteins) are released 
into the extracellular space and they bind to glycosaminoglycans (high density of 
negative change) so as to be retained at the inflamed site creating high local 
concentrations of chemokine. They form concentration gradients to provide 
directional signals for migrating cells (Lau, Allen et al. 2004; Handel, Johnson et 
al. 2005; Johnson, Proudfoot et al. 2005; Proudfoot 2006). This ionic interaction 
between GAGs and chemokines has been demonstrated in vitro (Witt and Lander 
1994; Hoogewerf, Kuschert et al. 1997; Kuschert, Coulin et al. 1999) and in vivo 
(Rot 1993). Cells expressing GPCRs that are specific for a certain chemokine will 
migrate towards the origin of that chemokine secretion. GAGs display a medium 
to high affinity for chemokines, and it has been hypothesized that if it were not for 
such immobilization, chemokine gradients would be disrupted by diffusion, 
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especially in the presence of flow in blood vessels and draining lymph nodes, and 
thus become diluted to such low concentrations that directional signals for 
migration cease (Johnson, Proudfoot et al. 2005). GAG-binding deficient mutants 
have been observed to be non-functional in vivo (while active in vitro) thus 
showing the importance of GAG-binding in chemokine function (Rueda, 
Balabanian et al. 2008; O'Boyle, Mellor et al. 2009). Chemokines which are 
bound to cell-surface GAGs, are then presented to their receptors, GPCRs, and 
rface, facilitating receptor binding and downstream signalling. 
 through the oligomerisation of chemokines and 
the fa AG sequences 
(Handel, Johnson et al. 2005).  
induce conformational changes that trigger intracellular signalling pathways 
implicated in cell movement and activation, explained in more detail below. 
Paradoxically, chemokines are simple and small proteins yet they orchestrate a 
myriad of biological functions. Thus, their interactions with GAGs explain the 
ability of such simple proteins to have access to such a wide range of functions. 
Current models suggested that GAGs enhance chemokine immobilization, local 
concentration, compartmentalisation, oligomerisation (Johnson, Proudfoot et al. 
2005; Veldkamp, Peterson et al. 2005), formation of haptotactic gradients of the 
protein along cell surfaces or within the ECM, directional cues for migrating cells 
(Campanella, Grimm et al. 2006), protect chemokines from enzymatic 
degradation (Sadir, Imberty et al. 2004), and promote local high concentrations at 
the cell su
However, structurally how the chemokines react with GAGs is not fully 
understood. 
As mentioned above, determining the binding site between a GAG fragment and 
its protein binding partner is complex. A technique to determine the GAG binding 
sites is to mutate basic residues within linear sequences which contain the typical 
‘GAG-binding motif’, BBXB. However, despite chemokines acting as monomers 
under biological conditions, they tend to dimerise/oligomerise when interacting 
with GAGs which suggests that there may be larger or more binding epitopes 
involved in the context of higher order complexes when compared to a monomer 
(McCornack, Boren et al. 2004; Jin, Shen et al. 2007). Oligomerisation may 
increase the affinity for GAG binding as a larger binding surface is created which 
could be important in cell-surface presentation during blood flow (Salanga and 
Handel 2011). Another powerful way of generating diversity and specificity in 
chemokine-GAG interactions is
ct that different oligomeric states may bind to different G
3.4.5.1 Activities of the GAG­CXCL12 complex 
While immobilized heparan sulphate is essential for the biological activity of 
chemokines, demonstrated by inactive GAG-binding deficient mutants in vivo 
(Proudfoot, Handel et al. 2003), soluble heparin has been shown to inhibit the 
biological effects of chemokines as demonstrated in vitro (Kuschert, Coulin et al. 
1999) and in vivo (Johnson, Kosco-Vilbois et al. 2004). In 2007, Murphy et al., 
also showed that soluble heparin and heparan sulphate negatively affected 
chemotaxis in vitro mediated by CXCL12α and using NMR and X-ray 
crystallographic techniques, they show that there are two heparin binding sites on 
the CXCL12α dimer interacting with a heparin disaccharide; one lies at the β-
strands of the dimer interface (forming hydrogen bond contacts with the following 
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residues: His25, Lys27 and Arg41) and the other lies at the amino-terminal loop 
and the α-helix (making contacts with Ala20, Arg21, Asn30 and Lys64) (Murphy, 
Cho et al. 2007). Taken together with the fact that treatment of cells with 
heparitinases (enzymes that degrade GAGs) induces a significant reduction of 
CXCL12α binding to cells (Mbemba, Benjouad et al. 1999; Mbemba, Gluckman 
et al. 2000), a mechanism can be proposed in which GAGs bind to CXCL12α 
dimers so as to sequester the chemokines and present them to their CXCR4 
receptors, and that this mechanism is disrupted/regulated in the presence of 
solubl ctions can be an 
effective strategy to target inflamm
 synthesizing GAGs and the extreme complexity and diversity of 
ing study confirmed the involvement of Lys24, Lys27, 
e GAGs. Thus, interfering with chemokine-GAG intera
ation. 
3.4.5.2 The GAG component of the complex 
Heparan sulphate interacts with a large array of proteins (as discussed in Chapter 
2) and it has been thought that protein recognition by HS resides within specific 
epitopes, are characterised by precise N and O-sulphation distributions. In order to 
correlate the structure of HS with their binding activities, one would require high 
resolution information on GAG:Chemokine interactions with oligosaccharide 
chains that are longer than a disaccharide, which would be more biologically 
relevant. For this, homogeneous compositions of GAG chains would be required 
for structural analysis and due to the inability to synthesize GAG from a template, 
challenges in
these molecules, there is a lack of detailed molecular information on these 
interactions. 
Chemokines display 4 classes of non-overlapping HS binding sites and thus 
represent a specific binding signature for each group of chemokine (Lortat-Jacob, 
Grosdidier et al. 2002). Of the four classes, cluster 2, which has only been 
observed in CXCL12α, forms a crevasse at the interface between the β-strands, 
where three basic amino acids in both β(1) and β(2) strands characterize the binding 
site. In 1999 and 2001, Amara et al., and Sadir et al., identified through site-
directed mutagenesis and surface plasmon resonance experiments, that Lys24 and 
Lys27 on CXCL12α are essential for the interaction with heparin (Amara, 
Lorthioir et al. 1999; Sadir, Baleux et al. 2001). Arg41 and Lys43 are also 
involved in the interaction, however are not essential. They also showed that a 
minimum size of 12-14 monosaccharides are required for the efficient binding 
interaction and a dock
Arg41 and including Lys1 in the binding for the polysaccharide (Sadir, Baleux et 
al. 2001) (Figure 3.4).  
More recently, Laguri et al., used 15N-CXCL12α to titrate a solution of 13C 
labelled octasaccharide, which is homogeneously N- and 6-O-sulphated on its 
glucosamine residues and unmodified on its glucuronic residues and called 
dp8NS,6S. The binding interaction was followed by multidimensional NMR 
spectroscopy and a structural model of the CXCL12α-HS complex was made 
(Laguri, Sapay et al. 2010). With this tool, a more accurate and detailed map of 
the GAG binding residues on chemokines can be identified. Significant chemical 
shifts were detected in the same HS binding site that was observed in the previous 
model from Sadir et al., in addition to another 20 other residues on CXCL12α that 
occur outside the HS binding site. This observation was attributed to a heparin-
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induced dimerisation event as has been observed previously (Veldkamp, Peterson 
et al. 2005). An advantage of performing this titration with a 13C labelled 
octasaccharide was that the sugars which participate in the interaction were able to 
complex polysaccharides with proteins. An 
oform of CXCL12 that is particularly interesting is CXCL12γ due to its unusual 
tructure and high affinity for GAGs. 
n from (Sadir, 
Baleux e 13 belled octasaccharide 
onto one 010). 
be defined. All the N-sulphated and 6-O-sulphated glucosamine residues 
collectively contributed to the interaction (Figure 3.4).  
Understanding how HS binds to proteins and regulates their functions is thus of 
great interest, however, it has been hindered by the extreme complexity and 
chemical heterogeneity of these polysaccharides. Using chemokines is a useful 
tool to study the interactions of these 
is
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Model for the interaction between dimeric CXCL12α and an oligosaccharide (A) 
The CXCL12α is represented as a ribbon and the heparin oligosaccharide as well as the 
basic amino acids involved in the interaction are represented as sticks. Take
 
t al. 2001). (B) Superimposition of 10 structures of the C la
 CXCL12α ribbon structure. Taken from (Laguri, Sapay et al. 2
3.4.6 Liaison with CXCR4 (Proposed Model) 
The receptor binding domain is located in the N-terminus for almost all 
chemokines (Clark-Lewis, Schumacher et al. 1991; Clark-Lewis, Kim et al. 1995). 
The first proposed model for binding and receptor activation is a “two site” model 
for signalling through the coreceptor (Crump, Gong et al. 1997). The chemokine 
core (RFFESH) is proposed to bind first to the CXCR4; this serves as the initial 
docking step, “site one”. Then the N-Terminal residues of the CXCL12α bind to 
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the more hidden CXCR4 acidic pocket amongst the extracellular loops 2 or 3 
within the coreceptor (signal trigger, “site two”) (Figure 3.5). More precisely, 
extensive mutational, structural and functional studies have revealed that the 
receptor activation requires Lysine 1 and Proline 2 within the N-terminal region 
and N-loop residues (between the second cysteine and the 310 helix) (Crump, 
Gong et al. 1997). The first two residues (Lys1 and Pro2) activate the receptor 
through binding to the transmembrane helices and this has been demonstrated by 
showing that deletion or modification of the N-termini results in chemokines that 
do not induce signalling (Gong and Clark-Lewis 1995; Hemmerich, Paavola et al. 
1999; Jarnagin, Grunberger et al. 1999). Also, Skelton et al., determined the 
structure of CXCL8 in complex with a CXCR1 peptide and showed how the N-
terminus of the receptor binds CXCL8 in such as way that the chemokines’ N-
ding and downstream signalling (Clark-Lewis, 
chumacher et al. 1991; Farrens, Altenbach et al. 1996; Crump, Gong et al. 1997; 
rado, Suetomi et al. 2007).  
the CXCR4 N-terminus, this is followed by the N-
terminus is oriented towards the receptor helices for receptor activation (Skelton, 
Quan et al. 1999).  
This then induces a conformational change within the CXCR4, allowing 
intracellular G-protein bin
S
P
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 The “two site” binding model for the CXCL12α-CXCR4 interaction. Firstly, the 
N-loop of CXCL12α interacts with 
terminus of CXCL12α binding the CXCR4 transmembrane region to trigger coreceptor 
activation (Crump, Gong et al. 1997). 
Kofuku et al., reported an interaction between full-length CXCR4 and CXCL12α 
and between CXCR4 and CXCL12α in the presence of the AMD3100 antagonist 
using NMR where they provide structural evidence supporting the theory that 
there are two independent interactions that occur between CXCL12α and CXCR4 
(Kofuku, Yoshiura et al. 2009) – this supports the “two-site” binding model, and 
reveals many residues involved in addition to those proposed in the first model. 
This was the first time that an interaction was shown between the full-length 
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CXCR4 and CXCL12α. Using triple resonance experiments, 13C- and 15N-labelled 
MetCXCL12α was combined with CXCR4 expressed and purified from insect 
cells in the presence or absence of AMD3100. They showed that an extended 
surface on CXCL12α (consisting of the β-sheet, 50s loop and N-loop) first binds 
to the CXCR4 extracellular region which places the chemokine in a position to 
search the deeply buried binding pocket in the CXCR4 transmembrane region, 
where the CXCL12α N-terminus will bind - they call this the ‘fly-casting’ 
mechanism. They showed that AMD3100 could displace the CXCL12α N-
terminus from
domain (Kofuku, Yoshiura et al. 2009). 
ps (Farzan, Mirzabekov et al. 1999; Cormier, Persuh et al. 
ar Overhauser Effect (NOE) correlations with the sTyr21 ring of CXCR4 
f the first 38 amino acid 
 the CXCR4 receptor without displacing the chemokine core 
3.4.6.1 Characterisation of  the CXCR4 N­terminus­CXCL12 
complex 
Previous studies have confirmed the involvement of the N-terminal of the receptor 
in chemokine binding. Many chemokine receptors have O or N-linked-
glycosylations and/or are sulphated in their N-termini (CCR2, CCR5, CCR8, 
CXCR4, CX3CR1 …) and this post-translational modification increases the 
affinity of receptors for their generally basic ligands (Farzan, Mirzabekov et al. 
1999; Farzan, Vasilieva et al. 2000; Bannert, Craig et al. 2001; Farzan, Babcock et 
al. 2002; Fong, Alam et al. 2002; Wang, Babcock et al. 2004). Tyrosine 
sulphation on chemokine coreceptors CCR2, CCR5 and CXCR4 increases their 
binding affinity with both chemokines and HIV-1 through their negatively 
charged sulphate grou
2000; Preobrazhensky, Dragan et al. 2000; Bannert, Craig et al. 2001; Farzan, 
Babcock et al. 2002). 
In 2006, Veldkamp et al., showed that a single sulphotyrosine-containing N-
Terminal CXCR4 peptide has an increased affinity for CXCL12α (Veldkamp, 
Seibert et al. 2006). They showed using fluorescence polarisation experiments that 
the monomer-dimer equilibrium of CXCL12α is shifted towards a dimer in the 
presence of the sulphated peptide, as shown for chemokines in the presence of 
heparan sulphate (Veldkamp, Peterson et al. 2005). Veldkamp et al., showed that 
the CXCR4 N-terminus bridges the CXCL12α dimer interface between the N-loop 
and the β3 strand and makes both polar and electrostatic contacts which are not 
observed with the monomer CXCL12α (Crump, Gong et al. 1997; Veldkamp, 
Seibert et al. 2008). The CXCL12α side chains Val18, Arg47 and Val49 make 
Nucle
showing that the sulphotyrosine is only 5 Å away from these residues (Figure 
3.6). 
It has been suggested that the post-translational modification of the N-terminus of 
CXCR4 (tyrosine sulphation) contributes to the high affinity binding and 
recognition of CXCL12α (Farzan, Mirzabekov et al. 1999). In 2008, Veldkamp et 
al., showed that CXCL12α dimerises in the presence o
residues of the N-terminal of CXCR4, containing 3 sulphotyrosines (positions 7, 
12, 21) (Veldkamp, Seibert et al. 2008) (Figure 3.6 A).  
Seibert et al., 2008 found that CXCL12α, has an augmented binding affinity for 
CXCR4 (N-terminal residues1-38) with the increasing number of sulphated 
tyrosines, and this suggests that there is a potential physiological role for the 
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sulphation of the three tyrosine residues at the N terminus of CXCR4 (Seibert, 
Veldkamp et al. 2008). The structure resolution of CXCR4 has provided new 
d activate the neighbouring receptor. 
ct... the current CXCR4 
structu  
by alte
(Veldkamp, Seibert et al. 2008)  stimulated a transient increase in ERK1/2 with 
insights and brought forward new questions regarding the interactions between 
CXCR4 and CXCL12α (Wu, Chien et al. 2010).  
The structures of CXCR4 were determined as complexes with an antagonist small 
molecule (IT1t) and a cyclic peptide (CVX15) (Wu, Chien et al. 2010). The 
receptor crystallized as a homodimer in all five structures which suggests that 
there could be multiple binding configurations for CXCL12α and CXCR4. In the 
article, they propose three different binding models for CXCR4 and CXCL12α; 
either 1:1, 1:2 or 2:2 ligand:receptor complexes are feasible. Either monomeric 
CXCL12α binds monomeric CXCR4, or dimeric CXCR4 binds monomeric 
CXCL12α or dimeric CXCR4 binds dimeric CXCL12α. In the case of the 1:2 
configuration, CXCL12α could bind one receptor with its core domain and in 
trans bind into the trans membrane pocket an
The neighbouring coreceptor could be CXCR4 (homodimer) or CXCR7 
(heterodimer), however, this is speculative.  
Importantly, the non-structured N-terminus of CXCR4 was not present in the 
crystal structures and thus there are still speculations as to how the ligand binds 
CXCR4 in the presence of the N terminus. Molecular modelling studies and NMR 
studies by Veldkamp et al., have predicted the orientation and stoichiometry of 
the chemokine binding to the N-terminal of CXCR4. Veldkamp et al., proposes a 
CXCL12α dimer binding two N-terminal CXCR4 peptides, while Wu et al., 
proposes three models, two of which constitute a CXCL12α monomer which 
binds either a monomer of CXCR4 or a homodimer of CXCR4 (Veldkamp, 
Seibert et al. 2008; Wu, Chien et al. 2010).Thus these two models are not in full 
agreement. However the exact understanding of this binding mechanism between 
the N-terminus of CXCR4 and the chemokine (in context of the entire coreceptor) 
is still not fully understood. The hyper-flexible and unstructured nature of the N-
terminal of CXCR4, has rendered structural studies involving this region hugely 
challenging, nevertheless, all these models may be corre
res are compatible with emerging concepts of signalling diversity induced
rnative binding modes of the ligands (Figure 3.6).  
3.4.6.2 Signalling Activities of the CXCR4­CXCL12 complex 
Recently, Drury et al., showed that CXCL12α monomers and dimers exert 
opposing effects on migration; migration in cell culture systems was detected with 
low concentrations of wild type CXCL12α, however, when low concentrations of 
constitutively dimeric CXCL12α was used or high concentrations of wild type 
CXCL12α, no migration was detected. Importantly, both the monomer and the 
dimer CXCL12α do activate their CXCR4 receptor to a lesser or greater extent (as 
shown by cell radioligand binding assays, intracellular calcium mobilization 
detection, CXCR4 internalisation etc) and they each activate discrete signalling 
profiles. In addition, the preferentially monomeric CXCL12α stimulated F-actin 
polymerisation mediated though β–arrestin and evoked a prolonged 
phosphorylation of ERK1/2. However, the constitutive dimer (disulphide bonds 
covalently locking two symmetric CXCL12α monomers [L36C/A65C]) 
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minimal recruitment of β–arrestin and actin mobilisation. Could these differential 
migrational and signalling profiles of the monomer and dimer CXCL12α result 
 dimer CXCL12α forms and thus their plausibility is highly 
uestionable. 
 CXCL12α binding to CXCR4 revealed 
by molecular modelling (Salanga and Handel 2011).  
3.4.7 Oligomerisation 
e discussed in detail, 
from two different binding interactions between the chemokine and the receptor?  
Drury et al., proposes that when the N-terminal of CXCR4 is bound to a 
CXCL12α monomer, the first 10 residues are bound to the chemokine, however, 
when the N-terminal of CXCR4 is bound to the dimer, the first 10 residues of 
CXCL12α are more flexible, leading to the hypothesis that different oligomers of 
CXCL12α lead to different signalling pathways (Drury, Ziarek et al. 2011). 
However, this model is highly speculative due to the forced creation of the 
monomer and
q
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Comparison of proposed binding of (A) the 38aa sulphotyrosine peptide binding 
to a CXCL12α dimer revealed by NMR. The zoomed section shows the side chains CXCL12 
residues Val18, Arg47 and Val49 that are involved in binding the sTyr21 of CXCR4 
(Veldkamp, Seibert et al. 2008) and in (B) a monomer
 
 
The physiological relevance of the chemokine monomer-dimer equilibrium and 
the interaction between chemokines, GAGs and receptors is all not yet fully 
understood and highly controversial and thus will not b
however, it is important and thus is mentioned.  
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Most chemokines, including CXCL12α, tend to dimerize at high concentrations 
(Holmes, Consler et al. 2001; Gozansky, Louis et al. 2005; Veldkamp, Peterson et 
al. 2005; Baryshnikova and Sykes 2006; Veldkamp, Seibert et al. 2006). 
Monomeric variants of chemokines have been shown to be fully functional in 
chemotaxis assays in vitro, indicating that monomers are sufficient to activate 
receptors. However, several chemokines require oligomerisation in vivo, and all 
data suggest that this requirement is related to GAG-binding (as shown for MCP-
e functional role of chemokine monomers and 
oligomers and the regulation of the equilibrium between the different forms and 
their different physiological roles. 
ng through CXCR4 and the role played by cell-
 
1, MIP-1β, CXCL10 [IP-10] and RANTES) (Proudfoot, Handel et al. 2003; 
Campanella, Grimm et al. 2006). 
It has been shown that receptors oligomerise (homodimers [CXCR4:CXCR4] and 
heterodimers [CXCR4:CXCR7]) and chemokines oligomerise (in the presence of 
GAGs and the N-terminal of CXCR4). Chemokine oligomers, including 
CXCL12α, appear to be functional and to induce alternative signalling responses, 
such as cellular activation or signals to halt migration (Veldkamp, Seibert et al. 
2008), which give rise to the concept that these complexes dynamically change 
their stoichiometries and structures as part of their functional regulation. Further 
studies are required to elucidate th
3.4.8 CXCL12γ 
Not only are there many unanswered questions pertaining to the regulation and 
specificity of CXCL12α signalli
surface and cell-free GAG oligosaccharides, but there are many unanswered 
questions about CXCL12γ too.  
The mRNA of CXCL12γ was first identified in the heart of rats (Gleichmann, 
Gillen et al. 2000) and the structure-function relationships of this isoform are still 
not fully understood. Santiago et al., have recently shown that CXCL12γ
accumulates at the endothelium and on dendritic cells which are two important 
interfaces for T-cell recruitment and activation (Santiago, Izquierdo et al. 2011).  
CXCL12γ is an alternative splice variant of CXCL12. Of the 98 amino acid 
residues which comprise CXCL12γ, the first 68 residues resemble a three 
dimensional structure which is closely related to that of the α isoform. However, 
the 30 residues at the C-terminal adopt an unstructured form which suggests a 
functional role due to its length, basic charge and mobility (Laguri, Sadir et al. 
2007). Interestingly, 60% (18 basic residues) of the C-terminus of CXCL12γ are 
comprised of positively charged amino acids (lysine and arginine) and four HS 
binding motifs (BBXB) are found (Figure 3.3). This is why the C terminus of 
CXCL12γ has an extremely high affinity for negatively charged HS (KD=0.9 nM 
versus 30nM for CXCL12α). This interaction is very stable, rendering the highest 
affinity interaction ever observed for any chemokine (Altenburg, Jin et al.; Laguri, 
Arenzana-Seisdedos et al. 2008; Rueda, Balabanian et al. 2008) (Figure 3.7). 
CXCL12γ is thus retained at the cell surface by the HS more so than the other 
isoforms. The C-terminal domain regulates the function of CXCL12γ as it is less 
active as compared to CXCL12α in terms of chemoattraction (Rueda, Balabanian 
et al. 2008), however, it broadens the GAG spectrum to which the chemokine can 
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bind. Rueda and colleagues showed that CXCL12γ signals through CXCR4 on 
lymphoid T cells, however, with a much lower agonist potency as compared to the 
CXCL12α isoform (Rueda, Balabanian et al. 2008). Interestingly, mutants of 
CXCL12γ that do not posses the BXBB HS binding motifs, show an increased 
affinity and activation of CXCR4 compared to the wild type (Laguri, Sadir et al. 
007; Rueda, Balabanian et al. 2008). The affinity of CXCL12γ for CXCR4 has 
ever been calculated before. 
 or DS activated sensorchips. The response in RU 
, is it not known (and highly debatable) whether the 
 CXCL12γ has a much higher affinity for GAGs when 
ately 
2
n
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Analysis of CXCL12 binding to HP, HS and DS. SPR sensorgrams measured 
when CXCL12 was injected over HP, HS
was recorded as a function of time (s) for CXCL12α (26 to 300 nM) and γ (2.6 to 30 nM). 
Adapted from (Laguri, Sadir et al. 2007). 
The molecular and functional identity of this splice variant is heavily reliant on its 
unprecedented high affinity for GAGs and thus suggests that this chemokine may 
be under specific regulation by the HS found on the cell surface (Laguri, Sadir et 
al. 2007; Rueda, Balabanian et al. 2008). However, very little is known about the 
role played by this chemokine in homeostatic and pathological processes and its 
regulation by GAGs. Also
inhibitory effect of soluble GAGs as seen for CXCL12α signalling can be applied 
to the CXCL12γ isoform. 
Altenburg et al., showed that CXCL12γ was the most potent at blocking CXCR4-
tropic HIV-1 (Altenburg, Jin et al. 2010). The point in common between the 
anionic GAG fragments and the N-terminus of CXCR4 is the negatively charged 
residues; the sulphate groups along the oligosaccharide and the sulphated 
tyrosines respectively.
compared to the other isoforms and thus may have a higher affinity for the N-
terminus of CXCR4.  
The binding interactions between gp120 and chemokines with their cognate 
receptors as well as their interaction and regulation by GAGs are intim
linked. Understanding the structural basis for these interactions will provide 
valuable insight into the designing of better inhibitors of these interactions. 
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Another binding interaction that is highly speculative, is that between CXCL12 (α 
and γ) and CXCR7. There is only one tyrosine in the N-terminal of CXCR7, and 
the literature to date does not mention that this tyrosine is sulphated. From the 
work performed by Rueda et al., in 2008, and as mentioned above, CXCL12α and 
CXCL12γ bind in an identical manner to CXCR7 (Rueda, Balabanian et al. 2008), 
which is clearly not the case for CXCR4. We can infer from these results that 
perhaps CXCL12γ binds to CXCR7 in a similar fashion to that of CXCL12α. It 
would thus be interesting to measure the signalling activity produced through 
CXCL12γ binding to CXCR7 and compare it to that of CXCL12α signalling 
through CXCR7. Also, with the recent discovery of CXCR7:CXCR4 
heterodimers, one could imagine a scenario where the chemokine (for example 
CXCL12γ), binds the CXCR4 N-terminal via its elongated basic C-terminal and is 
able to reach to and signal through the adjacent CXCR7 chemokine. A similar 
scenario could be imagined for the CXCR4:CXCR4 homodimer; whereby a 
monomer CXCL12γ binds to the N-terminal of one CXCR4, and due to its 
heightened flexibility, is able to reach to the active site on the adjacent CXCR4 
and induce a signal thorugh the adjacent CXCR4, while being tethered to the first 
CXCR4. The same situation could occur with CXCL12α, whereby it binds to one 
coreceptor (CXCR4 or CXCR7) and signals through the adjacent coreceptor in the 
imer (CXCR4); this has already been proposed by Wu et al., (Wu, Chien et al. 
010). In order to confirm these hypotheses, much futher experimentation is 
quired. 
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Chapter 4: The Objectives of This Project 
4.1 Les objectifs du projet (sommarie en français) 
Au cours des 30 dernières années depuis la découverte du VIH-1, d'importants 
efforts ont été consacrés à la lutte contre ce virus. Malgré l’existence de nombreux 
anti rétroviraux, leur toxicité ainsi que le développement de virus résistants aux 
médicaments exigent l’emploi de stratégies d’attaques plus efficaces et 
innovantes. Une approche prometteuse et récente consiste à cibler l'entrée virale, 
et aujourd'hui, deux inhibiteurs d'entrée destinés au traitement ont déjà été 
approuvés par la Food and Drug Administration (FDA) et l'Agence européenne 
des médicaments (EMEA). Cependant, il existe déjà une résistance décelable ainsi 
que des effets secondaires indésirables associés à ces deux nouveaux 
médicaments. L'objectif global de ce projet consistait à mettre en place une plate-
forme (de criblage), par laquelle différentes molécules pourraient être testées pour 
leur capacité à inhiber la liaison de la glycoprotéine de l'enveloppe virale (la 
gp120) à ses ligands de la surface cellulaire :  les récepteurs couplés aux protéines 
G (GPCRs: CXCR4 et CCR5), le CD4 et les  glycosaminoglycanes (GAG), 
inhibant ainsi l'entrée virale. 
Des anticorps (17b, E51, 48d etc) ont été utilisés en tant que « mimes de 
corécepteurs » dans de nombreuses études, car ils lient la région cryptique de la 
gp120 qui n’est exposée qu’une fois que CD4 est déjà lié à l'enveloppe, c’est-à-
dire les sites induit par CD4 (CD4i). L'utilisation de tels anticorps est moins 
fastidieuse et plus simple que l’utilisation de corécepteurs natifs, en raison des 
complications associées à la manipulation des protéines membranaires. Toutefois, 
l'utilisation d’anticorps en tant que mime de corécepteurs est problématique car 
l'anticorps n’est qu’un mime partiel et ne représente qu’une partie des épitopes 
qui sont réellement impliqués dans la liaison au corécepteur natif. 
 
• C'est pour cette raison nous voulions mettre en place un système d'interaction 
qui permette la capture des corécepteurs natifs et leur utilisation dans une analyse 
d’interaction. 
Traditionnellement, l'interaction gp120-corécepteur a été analysée avec des gp120 
marquées ainsi que des cellules entières. Par conséquent, cette approche peut 
entrainer la liaison de gp120 à de nombreuses molécules à la surface des cellules. 
De tels systèmes sont donc mal adaptés aux tests de criblage car l'interaction 
gp120-corécepteur n'est pas isolée de la cellule entière. L'utilisation de 
corécepteurs isolés/purifiés, où la liaison gp120-CCR5 est détectée, est très peu 
abordée dans la littérature (Babcock, Mirzabekov et al 2001;.. Navratilova, 
Sodroski et al 2005). De surcroit, jusqu'à présent, l'affinité de l’interaction gp120-
CXCR4 avec des corécepteurs CXCR4 isolés n'a jamais été détectée. 
 
Les exemples de l'utilisation des protéines membranaires dans le contexte de la 
résonance plasmonique de surface sont aussi très rares dans la littérature.  Ceci 
s’explique par l'extrême complexité des composants du tampon nécessaires pour 
maintenir la fonctionnalité de ces grandes protéines hydrophobes. L’un des 
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principaux objectifs de ce travail consistait à mettre en place et à utiliser cette 
technique dans le laboratoire. La mise en place de la méthode, qui consiste à 
solubiliser les corécepteurs et les immobiliser à une surface solide, tout en 
conservant leur fonctionnalité, représente une grande partie de notre travail, et 
constitue la principale évolution technique réalisée dans le cadre de cette thèse. 
Un tel système d'interaction mets à profit l'interaction de forte affinité entre 
l'étiquette C-terminal du corécepteur CXCR4 et l'anticorps immobilisé 1D4 à la 
surface BIAcore. Le récepteur solubilisé est à la fois purifié et concentré sur la 
surface du capteur. Ceci est réalisé en présence d'un tampon contenant des lipides 
et des détergents qui pour garder la structure native des corecepteurs (GPCRs). 
Afin de valider la fonctionnalité ce système d'interaction avec des corécepteurs 
solubilisés, nous avons d'abord utilisé le ligand naturel de CXCR4, CXCL12α / 
SDF1α. Des anticorps sensibles à la conformation de leur cible ont été utilisés afin 
de vérifier si nos corécepteurs solubilisés fonctionnaient ou pas, et si, en utilisant 
des techniques alternatives, leur interaction reflète les données cinétiques 
comparables aux études précédentes dans la littérature. 
• Nous avons donc utilisé ce nouveau test d'interaction biochimique pour 
comparer la liaison de CXCL12α avec celle de CXCL12γ et leur partenaire 
CXCR4 [Chapitre 5]. 
 
• Une fois que la fonctionnalité du système a été validée, notre but ultime 
consistait à utiliser la plate-forme pour cribler plusieurs banques d'inhibiteurs 
d'entrée qui empêcheraient la liaison des complexes gp120-CD4 aux corécepteurs 
solubilisés et immobilisés [Chapitre 6]. 
En utilisant cette technique de résonance plasmonique, les corécepteurs solubilisés 
conservent leur fonctionnalité car des données cinétiques peuvent être déterminées 
entre les corécepteurs et leurs ligands respectifs. Cette technique met en évidence 
des informations sur les mécanismes de liaison des interactions spécifiques entre 
les GPCRs et leurs ligands, et fournit une plate-forme pour le criblage des 
antagonistes moléculaires. Ce système a été utilisé pour cribler diverses molécules 
inhibitrices de l’entrée du VIH-1. En plus de tester des molécules inhibitrices 
issues de nos programmes de recherche, nous nous sommes également servis de 
cette plate-forme pour cribler la capacité des petites molécules inhibitrices d'une 
entreprise commerciale à inhiber/empêcher l'entrée du VIH-1. 
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4.2 Objectives 
During the last 30 years since the discovery of HIV-1, enormous efforts have been 
devoted to combating this virus. Many anti-retrovirals exist, however due to their 
toxicity and the development of drug resistant viruses, novel and more effective 
attacking strategies need to be employed. Targeting viral entry is a promising and 
recent approach and today, two entry inhibitors have been already approved by the 
FDA and EMEA for treatment. However, there is already detectable resistance 
and undesirable secondary effects associated with these two new drugs. The 
overall aim of this project was to set up a (screening) platform, whereby different 
molecules could be tested for their ability to inhibit the viral envelope 
glycoprotein, gp120, from binding to its ligands on the host cell surface, G-protein 
coupled receptors (GPCRs: CXCR4 and CCR5), CD4 and glycosaminoglycans 
(GAGs) respectively – thereby inhibiting viral entry.  
Antibodies (17b, E51, 48d etc) have been used as ‘coreceptor mimics’ in many 
studies, as they bind the cryptic region on gp120 that is exposed only once CD4 
has already been bound to the envelope, the CD4 induced site (CD4i). The use of 
such antibodies is less tedious and simpler than using native full-length 
coreceptors, due to the complications associated with manipulating membrane 
proteins. However, the draw-back to using antibodies as coreceptor mimics is that 
the antibody is only a partial mimic and does not fully represent all the epitopes 
that are actually involved in native coreceptor binding.  
• It was for this reason desirable to set up an interaction system that enabled 
the native full-length coreceptor to be captured and used in a binding 
interaction analysis. 
The gp120-coreceptor interaction has been traditionally analysed with labelled 
gp120 and whole cells; thus this approach could lead to gp120 binding to many 
cell-surface molecules. Such systems are poorly adapted for screening purposes as 
the gp120-coreceptor interaction is not isolated from the whole cell. The use of 
isolated/purified coreceptors, has been reported in very few papers (Babcock, 
Mirzabekov et al. 2001; Navratilova, Sodroski et al. 2005) where gp120-CCR5 
binding has been detected, but up until now, the affinity of the gp120-CXCR4 
interaction has never been detected with isolated CXCR4 coreceptors.  
Reports of the use of membrane proteins in the context of surface plasmon 
resonance is very rare in the literature due to the extreme complexity of buffer 
components required to maintain the functionality of these large hydrophobic 
proteins. A major objective of this work was to set up and use this technique in 
the laboratory. Setting up the method (solubilising the coreceptors and 
immobilizing them on the solid surface, while retaining their functionality) 
represents a large part of our work and is the main technical development realized 
in the context of this thesis. 
Such an interaction system takes advantage of the high affinity interaction 
between the C-terminal tag on the CXCR4 coreceptor and the immobilized 1D4 
antibody on the biacore surface. The solubilized receptor is both purified and 
concentrated onto the sensor surface. This is performed in the presence of a 
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lipid/detergent containing buffer that mimics the bilayer where the coreceptors are 
naturally found.  
In order to validate the functionality of the newly set-up solubilized coreceptor 
interaction system, we first used the natural ligands of CXCR4, CXCL12α 
/SDF1α. Conformationally binding-sensitive antibodies were used, as tools to 
verify whether our solubilized coreceptors were functional or not and if their 
interaction reflected comparable kinetic data to previous studies in literature using 
alternative techniques.  
• Therefore, we made use of this new biochemical interaction assay to 
compare the binding of CXCL12α with that of CXCL12γ and their 
CXCR4 partner [Chapter 5].  
• Once the functionality of the system had been validated, our final 
endeavour was to use the platform to screen several banks of entry 
inhibitors which prevented the gp120-CD4 complex from binding to the 
solubilized immobilized coreceptors [Chapter 6]. 
Solubilized coreceptors retain their functionality, using this surface plasmon 
technique, whereby kinetic data can be determined between coreceptors and their 
respective ligands. This technique elucidates information on the binding 
mechanisms of specific interactions between GPCRs and their ligands and 
provides a platform to screen for molecular antagonists. This system was used to 
screen for various inhibitory molecules of HIV-1 entry; not only were inhibitory 
molecules tested from collaborators but this platform was also used to screen 
small entry inhibitor molecules from a commercial company. 
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B: EXPERIMENTAL WORK  
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Chapter 5: GAGs  differently  effect  the  liaison  of 
CXCL12α and CXCL12γ with CXCR4 
5.1  L’héparane sulfate régule de façon différentielle  la  liaison de 
CXCL12 α et γ avec CXCR4 (sommaire en français) 
L’héparane sulfate (HS), est apparu comme un régulateur clé de nombreux 
processus biologiques fondamentaux. Beaucoup de protéines, parmi lesquelles les 
chimiokines se lient à HS et cette interaction est fonctionnellement importante. 
CXCL12, une chimiokine dont les nombreuses fonctions biologiques sont 
médiées par un récepteur particulier couplé aux protéines G (CXCR4), existe dans 
six différentes isoformes, les plus étudiées étant CXCL12α. Des études antérieures 
ont montré que CXCL12α interagit avec HS avec une affinité de 50 nM, tandis 
que l'isoforme CXCL12γ affiche une affinité inhabituellement élevée pour cet 
GAG (Kd = 0,9 nM) (Laguri, Sadir et al. 2007). La base de cette différence a été 
attribuée à un long stretch  de résidus basiques qui caractérisent le domaine C-
terminal de CXCL12γ et absent dans CXCL12α. Des études in vivo ont montré 
que la liaison avec HS permet à CXCL12γ de promouvoir les activités biologiques 
avec beaucoup plus d’efficacité par rapport à CXCL12α. Nous avons comparé 
l'interaction de ces deux isoformes avec CXCR4, et étudié le rôle des HS dans 
cette liaison. Ici nous avons utilisé la technologie SPR dans lequel CXCR4 
solubilisé a été capturé dans un environnement lipidique / détergent sur une 
surface de biocapteur afin de mesurer la liaison de CXCL12α et CXCL12γ en 
temps réel. Les affinités obtenues (Kd de 13 et 0,7 nM pour les isoformes α et γ, 
respectivement) sont en corrélation avec les valeurs déterminées pour les 
récepteurs membranaires dans d’autres études (pour CXCL12α). La préincubation 
de CXCL12α avec HS n'a pas modifié sa liaison à CXCR4, mais a fortement 
diminué celle de la de l'isoforme CXCL12γ, un point qui a été confirmé par 
cytométrie de flux sur des des cellules. Cela suggère que la partie  C-terminale de 
CXCL12γ contribue à la liaison à CXCR4, vraisemblablement en interagissant 
avec l'extrémité N-terminale sulfatée de CXCR4 (les tyrosines 7, 12 et 21 dans le 
domaine N-terminal sont sulfatées). Ceci a été confirmé par une expérience de 
titration en utilisant des approches de RMN. Lorsque la protéine recombinante 
CXCL12γ 15N marquée a été titrée avec des peptides sulfatés du  N-terminus de 
CXCR4, les données suggèrent que des sulfotyrosines dans le domaine N-terminal 
de CXCR4 renforcent l'interaction avec CXCL12γ, et que le C-terminal de la 
chimiokine CXCL12γ est responsable de l’augmentation de l'affinité avec le 
corécepteur. L'analyse de phosphorylation de ERK induite par CXCL12α et 
CXCL12γ montre que les deux isoformes activent différemment la cascade de 
signalisation, suggérant un rôle du domaine C-terminal de la chimiokine. 
Ensemble, ces données montrent que le C-terminal basique et allongé  de 
CXCL12γ interagit à la fois avec les HS et la séquence sulfatée  N-terminale de 
CXCR4 et nous proposons une éventuelle régulation  de l'activité de l'isoforme 
CXCL12γ par HS. 
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5.2 Introduction  
An assay that permits the isolation and immobilization of functional G protein 
coupled coreceptors / GPCRs is extremely valuable as it permits the analysis of 
very complex molecular interactions that occur at the cell membrane so that they 
can be studied with the least amount of other or non-specific binding partners 
present. Not only is it of paramount importance to search for an effective HIV-1 
entry inhibitor that can inhibit both CCR5 and CXCR4 tropic HIV-1 entry, but the 
mechanisms of chemokines binding to their coreceptors are not fully understood 
and such an assay can help understand these complicated binding mechanisms as 
well as assess the roles played by glycosaminoglycans in these interactions, which 
is also poorly understood.  
Our collaborators (Francoise Baleux, Institut Pasteur) synthesized the different 
isoforms of CXCL12 (α, γ and mutants used in this study). Using this protein as a 
ligand for the solubilized CXCR4 on the biacore is strategic for two reasons: i) 
firstly it is a relatively small (8-10 kDa), soluble protein that will render 
information on whether or not the solubilized CXCR4 coreceptors are functional 
and ii) since our collaborators synthesize these proteins, they are available in 
large, homogeneous amounts, as well as mutants of these proteins. 
Membrane proteins are notoriously difficult to manipulate once they have been 
removed from their natural environment. Their large hydrophobic domains 
required the presence of a delicate balance of certain lipids and detergents to 
retain their functional three-dimensional structure once they have been extracted 
from the cell membrane. Failure to solubilize the coreceptors in the correct 
cocktail of lipids and detergents, results in denatured or only partially folded 
coreceptors which are not recognized by their ligands and thus are not functional 
and consequently irrelevant in binding studies. Very few groups in the world 
endeavour to solubilize and capture GPCRs on a biacore surface for binding 
studies (Navratilova, Sodroski et al. 2005). Some studies perform binding 
interactions on whole cells using labelled ligands (Doranz, Baik et al. 1999), 
however, this can lead to non-specific binding of the ligands to the cell surface 
molecules (such as glycosaminoglycans). Other groups incorporate the solubilized 
GPCRs into proteoliposomes for binding studies (Babcock, Mirzabekov et al. 
2001; Zhukovsky, Basmaciogullari et al. 2010). Such work with proteoliposomes 
requires labelling of the ligand which could alter the binding properties of the 
ligand. Thus, the approach of solubilising and immobilizing solubilized GPCRs 
on a static surface allows for the least amount of non-specific binding, no 
requirement for ligand labelling and the reaction can be followed in real-time. 
In the context of the objectives of this work, in order to set up an interaction 
system whereby the binding events between immobilized GPCRs (CXCR4 and 
CCR5) and their partners (gp120 and CD4) can be monitored and the inhibitory 
capacity of the mCD4-HS12 evaluated and further improved, a binding assay was 
first set up between CXCR4 and CXCL12α, to verify the integrity of the 
immobilized coreceptors. Below, is a cartoon representation of the immobilization 
of the solubilized coreceptors through their interaction with the 1D4 antibody 
which is coupled to the dextran surface by amine coupling chemistry (see 
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section 8.10.5.2). Various proteins and antibodies are seen interacting with the 
solubilized coreceptors and these are representations of what we have studied 
using the biacore. In every experiment, a reference cell was used whose binding 
response data was subtracted from the test cell so as to remove any non-specific 
signal if any and to correct for bulk effect associated to ligand injection (Figure 
.1). 
ecific antibodies, ligands and 
compounds. Adapted from (Navratilova, Dioszegi et al. 2006). 
5.3 Results 
5.3.1 Preparation and control of cells expressing CXCR4 
3 days) and detached from the 
culture flasks easily in the presence of versene.  
5
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Cartoon of the capture of C9 tagged GPCRs through their interaction with the 
1D4 immobilized antibody and the binding of conformation sp
The canine thymocytes (Cf2Th cells) that were used in this assay are adherent 
cells that have been stably transfected with the human clones of either CCR5 
(Cf2Th.CCR5) or CXCR4 (Cf2Th.CXCR4) and thus constitutively express high 
levels (0.5 - 1.0 x 106) of human CCR5 and CXCR4 coreceptors per cell 
respectively. The clones were originally made by (Dr. Tajib Mirzabekov and Dr. 
Joseph Sodroski) and a C-terminal tag (TETSQVAPA [C9]) was incorporated into 
the sequence (Mirzabekov, Bannert et al. 1999). The C9 tag has a high affinity for 
the 1D4 antibody and thus this tag-antibody recognition system allows for an 
efficient strategy to purify the coreceptors from crude membrane extractions. 
These cells were cultured in standard DMEM media supplemented with serum 
and antibiotics as previously described (Mirzabekov, Bannert et al. 1999). The 
cells were serially passaged five times before harvesting. On the day of a 
coreceptor extraction, the cells were washed in PBS, and detached from the flask 
with versene (0.48 mM EDTA in phosphate-buffered saline). The Cf2Th cells 
grew relatively very fast (confluent within 2-
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Before the interaction system was set up using surface plasmon resonance (SPR), 
we initially verified the expression of the GPCRs on the surface of the Cf2Th cells 
using flow cell cytometry. The conformationally sensitive antibodies 2D7 (Lee, 
Sharron et al. 1999; Khurana, Kennedy et al. 2005) and 12G5 (Baribaud, Edwards 
et al. 2001) were systematically used to detect CCR5 and CXCR4 respectively on 
the cells using flow cell cytometry analysis (Figure 5.2).  
Briefly, 1 x 106 cells (expressing either CCR5 or CXCR4) were detached from the 
cell culture flasks and washed in PBS. They were then incubated with the primary 
antibodies (2D7 and 12G5-FITC respectively) for one hour at 4°C. The unbound 
antibodies were washed away three times in PBS and the secondary FITC-labelled 
antimouse antibody was used to detect the bound 2D7 to the cells. The 12G5 was 
coupled to FITC directly and did not require a secondary antibody. The FITC-
labelled cells were fixed in 4% paraformaldehyde and detected in the flow 
cytometer. As can be seen from the intensity of the bound antibodies to the Cf2Th 
cells, the presence and integrity of the coreceptors was verified (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Cf2Th cells expressing either C-terminal C9 tagged CXCR4 or CCR5 (10x) and 
corresponding flow cytometric analysis depicting a positive stain for 12G5-FITC binding to 
CXCR4 expressing Cf2Th and 2D7 binding to CCR5 expressing Cf2Th cells. 
5.3.2 Alternative methods to measure binding 
Initially, we sought to develop a flow cell cytometry-based technique, whereby 
the binding of conformationally dependent antibodies to their coreceptors (e.g. 
12G5 binding to CXCR4) was displaced in the presence of competing molecules 
(T134 or gp120-CD4) or binding was restored in the presence of ‘inhibited’ 
competing molecules (CXCL12α non-binding mutants or complexes of gp120-
CD4 + inhibitor). For example, as shown in Figure 5.3, for both normal cells and 
cells that had been stored in 0.4 M sucrose (Sadir, Lortat-Jacob et al. 2000), 
12G5-FITC binding was diminished in either the presence of non-labeled 12G5 or 
in the presence of T134, a CXCR4 antagonist (Xu, Tamamura et al. 1999). Thus 
techniques seemed feasible for the use of T134, however, in our hands we were 
unable to show diminished 12G5-FITC binding in the presence of competing 
molecules such as gp120. 
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Figure 5.3 The upper panels show cells that have been treated with 2% paraformaldehyde  
(pf) before staining with the 12G5-FITC secondary antibody and the lower panels were not 
fixed in pf. Panels on the left were performed with cells stored in 0.4M sucrose and panels on 
the right are fresh cells. Unlabelled CXCR4 expressing cells (red), pre-incubation with 
5µg/ml T134 (dark and light green), pre-incubation with 12G5 (purple and pink), and cells 
directly labelled with FITC-12G5 (blue and orange) are shown. 
5.3.3 Solubilization of the CXCR4 membrane protein 
Following this, we analysed whether solubilised coreceptors, despite the abrasive 
treatment to solubilise them from the cell membranes, retained their integrity and 
were still able to be detected by their ligands (12G5, CXCL12α). This would give 
us an indication whether or not the solubilization process would be suitable to 
capture functional coreceptors on the SPR surface for binding analysis.  
Due to the hydrophobic nature of the coreceptors, combinations of lipids (DOPC : 
DOPS) and detergents (DDM, CHAPS and CHS) in different buffer compositions 
were tested to identify the conditions that retain the functionality of the solubilised 
coreceptors. To confirm the integrity of the immobilized coreceptors, antibodies 
and the CXCR4/CXCL12α interaction was analysed. The solubilization buffer and 
protocol used in this study was slightly adapted from that of Navratilova et al., 
(Navratilova, Sodroski et al. 2005). Usually 5 x 106 cells per ml of solubilization 
solution were solubilized for the preparation of the membrane-derived coreceptors 
and this solubilization solution was tested for its ability to retain the functional 
integrity of the coreceptors during and after the solubilization.  
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5.3.4 SPR Analysis of solubilized CXCR4 
The solubilized coreceptors were then captured onto a 1D4 immobilized chip 
surface. For this purpose, the 1D4 antibody surface was prepared as previously 
described (Navratilova, Sodroski et al. 2005). Briefly, the carboxylmethyl surface 
was activated with a 1:1 mixture of EDC/NHS which activated the carboxyl 
groups on the sensorchip surface (see section 8.10.5.2 for details). Following this, 
the 1D4 (anti-C9 tag) antibody was injected onto the sensorchip in a Na Acetate 
buffer with a pH of 4.2 (a buffer with a pH that is usually 1 unit down from the 
proteins’ pI), so as to ensure that the antibody was protonated and thus with its 
overall positive charge will aid its attraction to the activated carboxyl surface. An 
injection of about 12 minutes at 5µl/min ensured that a sufficient (~7000 response 
units) amount of 1D4 was immobilized onto the surface. The remaining free 
activated carboxyl groups were blocked with a 10 minute injection of 1M 
ethanolamine pH 8.5. A representative antibody and coreceptor immobilization 
profile are shown in Figure 5.4 A. This ‘ID4 surface’ was the pre-requisite for 
capturing the solubilized coreceptors via their C-terminal tag (C9). 
Once the ID4 surface was formed, the buffer was changed from the HEPES 
Buffered saline to the running buffer containing lipids and detergents. The 
solubilized coreceptors were injected in the latter buffer for a period of 30-60 
minutes at a low flow rate (5µl/min) to ensure maximum coreceptor capture via 
the 1D4-C9 tag interaction over the ID4 surface (Figure 5.4B). 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 (A) Representative sensorgram of EDC/NHS injection, 200µg/ml 1D4 
immobilization and ethanolamine blocking on the CM4 sensor chip surfaces to ~7000 ru of 
1D4. (B) Representative sensorgram of coreceptor immobilization via the C9 tag -1D4 
interaction to ~3000 ru. 
 
Initially, a previously published buffer (Navratilova, Dioszegi et al. 2006) was 
used to analyse interactions between CXCR4 and its ligands (12G5, CXCL12α 
etc) using SPR, however, the binding curves were often not smooth and not 
reproducible. Thus we altered the buffer slightly and used a new composition, the 
Rebecca Rich buffer. Even further optimization was required to obtain 
reproducible binding data and we finally ended up with a completely unique 
buffer (New buffer) (Table 5). The interaction between between immobilized HS 
and CXCL12α has been reported previously in a standard aqueous buffer (10mM 
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HEPES pH 7.4, 150mM NaCl) (Amara, Lorthioir et al. 1999). In order to verify 
that our complex buffer constituents did not alter the binding properties of 
CXCL12α, we tested the binding of this classical and well-known SPR 
interaction, between CXCL12α and immobilized HS, in the presence of the New 
buffer. Equivalent binding responses between immobilized HS and CXCL12α in 
the New buffer were reproduced as compared to those observed by Amara et al.,. 
This verified that the complex buffer components do not alter CXCL12α’s 
binding properties to its partner HS and thus we could proceed to perform further 
tests with CXCL12α in the presence of the New buffer. 
Table 5. Summary of the different buffers tested during the optimization of the BIACORE 
running buffer. The final buffer used is the New buffer.  
Classical 
Buffer 
Navratilova Buffer 
(Navratilova, 
Dioszegi et al. 
2006) 
Rebecca Rich Buffer New Buffer (This 
work) 
50mM 
HEPES pH 
7.4 150mM 
NaCl 
50mM HEPES pH 
7.0 
150mM NaCl 
1 mM CaCl2 
5 mM MgCl2 
0,1 % DOM 
0,1 % CHAPS 
0,02 % CHS 
50 nM 7:3 DOPC 
:DOPS 
0,1 mg/ml of BSA 
50mM HEPES pH 
7.0 
150mM NaCl 
5 µM CaCl2 
1 µM MgCl2                
0,1 % DDM 
0,1 % CHAPS 
0,02 % CHS                
500 nM 7:3 DOPC 
:DOPS                         
0,2 mg/ml of BSA       
5% glycerol 
5 % PEG 8000 
3% DMSO 
50mM HEPES pH 
7.0 
150mM NaCl         
5 µM CaCl2 
1 µM MgCl2 
0,1 % DOM 
0,1 % CHAPS 
0,02 % CHS              
50 nM 7:3 DOPC 
:DOPS                
0,1 mg/ml of BSA     
5% glycerol 
5 % PEG 8000 
 
Since it was established that the New buffer retained the full functionality of the 
CXCL12α, the crude preparations of coreceptors in the New buffer described 
above were injected over the 1D4 immolbilized surface as described in Figure 5.4 
(Test surface). In parallel, the negative surface was used, this surface contained 
only the 1D4 antibody and any non-specific binding between the CXCR4 ligands 
and the 1D4 antibody, were subtracted from the test surface for the final binding 
curve. 
To confirm the integrity and functionality of the immobilized coreceptors, 
interactions between conformational antibodies and chemokine ligands were 
monitored. For this purpose, 25nM 12G5 was injected over the coreceptor and 
1D4 (negative) surfaces. The mAb 12G5 recognises complex conformationally-
dependant epitopes in the first and second extracellular loops of CXCR4 (requires 
an intact C28-C274 disulfide bond) and thus this antibody was used to asses the 
integrity and functionality of the immobilized coreceptors (Brelot, Heveker et al. 
1999). The CXCR4 surface interacted with the 12G5 and to confirm that this 
interaction was specific, 1µM of T134, a small molecule CXCR4 inhibitor (14 
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amino acid peptide antagonist) was injected over the surface in the presence of 
25nM 12G5. T134 was previously shown to inhibit 12G5 binding to CXCR4 
expressing cells at a similar concentration (Xu, Tamamura et al. 1999). The T134 
almost completely inhibited 12G5 binding, confirming that the 12G5/CXCR4 
interaction was specific (Figure 5.5 A).  
Now that we were convinced that the solubilized CXCR4 coreceptors were 
functional, through the specific binding of the 12G5 antibody, we then injected 
50nM of CXCL12α over the CXCR4 surface and this chemokine gave rise to a 
typical binding sensorgram (association phase followed by a dissociation phase 
returning to the baseline after the end of the injection) (Figure 5.5 B). CXCL12α 
binding to CXCR4 has been described as a two step process; whereby the N-loop, 
as well as residues in the β-sheet and 50-s loop first make contact with the N-
terminal of CXCR4, this is then followed by the first three residues in the 
chemokine N-terminal which reach deep into the trans-membrane region of 
CXCR4 for receptor activation (Crump, Gong et al. 1997; Kofuku, Yoshiura et al. 
2009).  
To confirm specificity of the CXCL12α/CXCR4 interaction, we injected two 
different mutants over the CXCR4 surface; CXCL12α 2-67 and CXCL12α 5-67. 
Each mutant was truncated within the receptor activation domain (the first KP 
residues). Thus, in agreement with the model, these residues are crucial to CXCR4 
binding, without these residues, the chemokine binds less to the coreceptor 
(Figure 5.5 B). This further suggests that the solubilized captured coreceptors 
adopt a conformation that is very close to their native one. 
 
 
 
 
 
 
 
 
 
Figure 5.5 (A) 25nM 12G5 binding to immobilized CXCR4 in the absence (red curve) and 
presence (black curve) of 1µM T134 antagonist. (B) Native CXCL12α (50nM, blue curve), 
mutant CXCL12α 2-67 (red curve) and mutant CXCL12α 5-67 (green curve) binding to 
immobilized CXCR4.  
 
Our collaborators have also synthesized the CXCL12γ isoform. As mentioned 
above, this is the longest CXCL12 isoform, consisting of the same first 68 amino 
acids found in CXCL12α, however, there are an additional 30 amino acids on its 
C-terminal which are the product of alternate splicing. This extended C-terminal 
contains three classic BBXB heparan sulphate binding domains. Whether or not 
the recently described CXCL12γ isoform and CXCL12α isoform interact in a 
similar fashion with their receptor, CXCR4 was then investigated. Dose response 
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experiments were performed for a range of concentrations (5 – 50nM) with both 
CXCL12α and CXCL12γ isoforms over the immobilized CXCR4 surfaces. Visual 
inspection of the curves (Figure 5.6 A) immediately illustrates that CXCL12α and 
CXCL12γ display remarkable differences both in the intensity of the binding 
curves and in the stability of the complex formed once injected over the CXCR4.  
We fitted the responses for the CXCL12α /CXCR4 interaction to a 1:1 langmuir 
interaction model and the on rates (kon or ka) were calculated as 2.58 x 106 ± 5.9 x 
105 M-1s-1 and off rates (koff or kd) calculated as 3.36 x 10-2 ± 5.9 x 10-3 s-1. The 
CXCL12α/CXCR4 was not very stable as seen by the rapid dissociation of the 
binding curves, however, the affinity (KD) of this interaction was relatively high 
and calculated at 13 ± 1.6 nM. The value obtained for the affinity of 
CXCL12α/CXCR4 is in the same range as that reported by a similar technique 
(Navratilova, Dioszegi et al. 2006) and a 125I-labelled CXCL12α binding assay 
(Crump, Gong et al. 1997) with membrane-associated receptor (Di Salvo, Koch et 
al. 2000) (Figure 5.6 A). Thus, this technique of measuring binding interactions of 
ligands to solubilized coreceptors is functional. 
As for CXCL12α, we observed a concentration dependant binding response for 
CXCL12γ. The responses (in RU) were much stronger for this isoform compared 
to those of CXCL12α as can be seen from the binding curves (Figure 5.6 B).The 
dose response curves were fitted to a 1:1 interaction model with mass transfer 
because the binding was limited by diffusion. This means that the kinetic binding 
rate is significantly higher than the rate of transfer of analyte to the surface. In 
such a case, the association phase is slower due to the analyte not reaching the 
surface fast enough and the dissociation phase is also slowed down because the 
analyte is not transferred away fast enough from the surface and can thus rebind. 
Hence when there is a mass transfer limitation, a higher flow rate and lower 
surface density is recomended to increase the rate of transfer of analyte to the 
surface and decrease the surface binding capacity respectively.  
When fitting the data, this mass transfer effect was taken into consideration. The 
calculated affinity is also higher as seen by the very slight dissociation of the 
chemokine at each concentration. The kon for CXCL12γ was calculated as kon = 
1.05 x 107 ± 1.2 x 107 M-1s-1 and dissociation rate constant was calculated as koff = 
5.6 x 10-3 ± 5.3 x 10-3 s-1. The affinity was calculated as a ratio between the kon 
and the koff values; KD = 0.7 ± 0.3 nM, this is the first time an affinity has been 
calculated for this isoform (Figure 5.6 B). The kon and the koff values have been 
determined as a median of two independant experiments and such a large 
variation is seen with the standard deviations because this reaction happens very 
quickly, and such a high affinity reaction pushes the detection limits of the biacore 
apparatus. The on-rate is so fast that almost all of the dissociation is limited by 
mass transport and the flow rate cannot remove dissociating ligands away fast 
enough. 
Interestingly, CXCL12α rapidly dissociated from the immobilized coreceptors 
while CXCL12γ formed tight complexes as seen in the case for the CXCL12γ 
chemokine binding to HP, HS and DS (Laguri, Sadir et al. 2007). Since the sole 
structural difference between CXCL12α and CXCL12γ is the extended basic C-
Terminal of CXCL12γ, these results suggests the involvement of this extension in 
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CXCR4 binding and that this region may be responsible for the heightened 
affinity of CXCL12γ for CXCR4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 (A) Binding of a range of concentrations (from top to bottom) 50, 30, 20, 10, 5nM 
of CXCL12α or the same range of concentrations of CXCL12γ (B) over immobilized 
CXCR4. The black traces correspond to the experimental data and the red traces 
correspond to the fitted data using a 1:1 langmuir model (A) and a 1:1 Langmuir model with 
mass transfer (B).  
5.3.5 The role played by GAGs 
Laguri et al., demonstrated that the γ isoform of CXCL12 displays an 
unprecedented high affinity for heparan sulphate (KD = 0.9 nM). The unfolded 30 
amino acid C-terminal tail of CXCL12γ distinguishes itself from the α isoform 
and thus it is this extended basic C-terminal of the chemokine that binds to HS. 
Previous studies have shown that the high affinity that CXCL12γ has for HS 
(Laguri, Arenzana-Seisdedos et al. 2008; Rueda, Balabanian et al. 2008) 
demonstrates a strong participation of the CXCL12γ C-terminal in the interaction. 
Advantage was taken of this high affinity interaction to investigate the importance 
of the CXCL12γ C-terminal tail and the possible role of GAGs played in 
regulating binding of the chemokine to its receptor. 
We thus performed an assay where either CXCL12α or CXCL12γ was injected 
over a CXCR4 immobilized surface in the presence or absence of HP12 (dp 12 of 
heparin). A 12mer was chosen since this length was identified (using SPR 
techniques, confirmed by molecular modelling) for maximal binding capacity to 
CXCL12α (Sadir, Baleux et al. 2001; Sadir, Imberty et al. 2004).  
As shown in Figure 5.7A, 50nM CXCL12α in the presence of 1µg/ml HP12 (~278 
nM), shows no significant change compared to the binding between CXCL12α 
and CXCR4. This observation is consistent with the fact that the HS and the 
CXCR4 binding sites on CXCL12α do not overlap (Laguri, Arenzana-Seisdedos 
et al. 2008).  However, when 50nM CXCL12γ is injected in the presence of 
1µg/ml HP12, there is a 7 fold decrease in the steady state equilibrium compared 
to 50nM CXCL12γ binding to CXCR4 (Figure 5.7B). This suggests that in the 
presence of a 12mer oligosaccharide, the CXCL12γ chemokine binds substantially 
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less to its immobilized CXCR4 receptor. Interestingly, after the injection of 50nM 
CXCL12γ in the presence of HP12, the binding curve resembles more that of 
50nM CXCL12α implying that when CXCL12γ is in the presence of HP12, thus 
with a ‘blocked’ C-terminal, it ‘behaves’ in a similar way to CXCL12α.  
An alternative conclusion to this result may be that only a partial amount of 
CXCL12γ bound to the free HP12, inhibiting a percentage of the chemokine from 
binding the immobilized CXCR4 and that the small binding signal that is 
observed (Figure 5.7 B red curve) is that of the non-HP12-bound CXCL12γ 
binding the immobilized coreceptor. However, this conclusion is ruled out 
because a 5-fold molar excess of oligosaccharide (~278 nM) is used when 
incubated with the CXCL12γ chemokine (50 nM), thus there is virtually no 
chance of non-HP12-bound CXCL12γ binding the immobilized coreceptor. 
 
 
 
 
 
 
 
 
  
Figure 5.7 Effect of 1µg/ml HP12 (red) on binding of 50nM CXCL12α (blue) (A) and 50nM 
CXCL12γ (blue) (B) to CXCR4. 
We confirmed this result in the context of mammalian Cf2Th cells where CXCR4 
was in its natural membrane-bound environment. To investigate whether HP12, in 
the context of the cell surface, differently affected the binding of CXCL12α and 
CXCL12γ with cell surface CXCR4, we compared the absorption of these two 
isoforms onto the CXCR4+ T lymphocyte cell line (CEM cells) by flow 
cytometry. Before this investigation, the absence of cell-surface GAGs required 
determination by flow cell cytometry so as to be sure of the absence of any 
competing / contaminating GAGs in the system. CEM cells express little to no 
GAGs on their cell surface, however, to make sure that all GAGs were absent, the 
cells were systematically treated with a cocktail of heparinase I and II and 
chondroitinase A, B, C prior to CXCL12 incubation (Figure 5.8). The following 
antibodies were used for the detection of GAGs: anit-chondroitin-6-sulphate, anti-
chondroitin-4-sulphate and 4G10. Due to the fact that there is a very low 
expression of cell-surface GAGs on CEM cells, the digestion (using heparinase I 
and II and chondroitinase A, B, C) was also performed on the epithelial cells 
(Cf2Th cells, which display more pronounced GAG expression profile) to confirm 
the enzymes’ functionality and efficacy (Figure 5.8).  
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Figure 5.8 Systematic treatment of CEM cells with heparinase I and II and chondroitinase A, 
B,C prior to CXCL12 binding experiments. Cf2Th cell digestion is shown to illustrate the 
efficacy of the GAG digesting enzymes as there are little to no GAGs on the CEM cell 
surface. For all graphs, red = unstained cells only, green = anti-mouse FITC antibody, light 
blue = anti-chondroitin-4-sulphate, orange = anti-heparan sulphate (10E4) and pink = anti-
chondroitin-4-sulphate. (A) Non-digested CEM cells, (B) GAG-digested CEM cells, (C) non-
digested Cf2Th cells, (D) GAG-digested Cf2Th cells. 
The GAG digest was thus effective as shown by the significant decrease in 
staining intensity of the antibodies (chondroitin-6-sulphate recognises, anti-
chondroitin-4-sulphate and 4G10) in the Cf2Th cells. Since the pre-digest staining 
of the Cf2Th cells show a significant level of GAG expression and in the post-
digestion essentially all cell-surface GAGs were removed, we can thus infer that 
the digestion was complete for the CEM cells too, despite the much lower level of 
initial GAG expression on these cells. 
Now that all cell-associated GAGs were removed from the equation, we 
proceeded to test the binding of α-FITC labelled CXCL12α and IC12 labelled 
CXCL12γ binding to the GAG-digested CEM cells in the absence and presence of 
cell-free HP12 oligosaccarides. 
The monoclonal antibody IC12 (from Fernando Arenzana-Seisdedos, Institut 
Pasteur) which recognises the C-terminal of CXCL12γ, was used for the 
experiments with CXCL12γ and a directly labelled CXCL12α-FITC was used for 
monitoring CXCL12α binding to cell-associated CXCR4 on GAG-digested cells. 
Data reported in Figure 5.9 A shows that the 1µg/ml HP12 had no effect on 
CXCL12α binding to CXCR4 (blue curve) as compared to CXCL12α binding 
CXCR4 in the absence of the oligosaccharide (pink curve). However in Figure 5.9 
B, there is a significant displacement of the intensity to the left of the cell surface 
CXCR4-bound CXCL12γ in the presence of HP12 (blue curve) as compared to 
CXCL12γ alone (pink curve). The orange curve in Figure 5.9 B represents the 
background binding of IC12 to cell surface CXCR4. The green curves correspond 
to 12G5-FITC binding to verify for cell-surface CXCR4 expression. These results 
are in agreement with the biacore data showing that when HP oligosaccharides are 
pre-incubated with CXCL12γ and subsequently injected over or incubated with 
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CXCR4-expressing, GAG-digested cells, the association with CXCR4 is 
markedly decreased, which is not the case for CXCL12α. Thus, these data provide 
more evidence for the argument that the C-terminal of CXCL12γ, containing an 
elongated basic tail enriched in BXBB HS binding motifs, is also involved in 
binding to the CXCR4. 
 
 
 
 
 
 
 
 
Figure 5.9 Effect of 1µg/ml HP12 on binding of 50nM CXCL12α and 50nM CXCL12γ to 
CXCR4 expressing, GAG-digested cells was tested using FACS analysis. CXCL12α (A) and 
CXCL12γ (B) binding to CXCR4 on CEM cells in the absence (magenta) and presence (blue) 
of 1µg/ml HP12. 12G5-FITC binding is shown (green) to demonstrate CXCR4 expression. 
The orange curve in (B) is the non-specific binding of the 1C12 antibody. 
The mutant M1 is the CXCL12γ isoform where many (9) of the basic residues in 
the C-terminal tail were mutated into Serines in order to destroy the BBXB HS 
consensus binding sequences. Thus the following basic residues were mutated 
into Ser: Lys77, Lys78, Lys80, Lys83, Lys84, Arg86, Lys88, Lys89 and Lys91 
(Figure 5.10).  
 
 
 
 
 
 
 
 
Figure 5.10 The basic amino acids (K and R) that are highlighted in red in the sequences are 
amino acids that have been shown to be implicated in GAG-binding. ** KP signalling 
residues, ****** RFFESH initial contact/docking site with receptor and GAG-binding 
domains (BBXB) are indicated in the CXCL12γ sequence by the black brackets and the 
structures of each isoform are shown. M1 is depicted, showing the BBXB HS binding motifs 
in the C-terminal being destroyed by mutation of certain basic residues to serines. Chemical 
shift variations upon GAG addition (dp4) are represented on M1 in colour; Red residues 
bind the most to GAGs and orange residues bind less and yellow residues bind the least 
(Laguri, Sadir et al. 2007). 
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A further confirmation that the C-terminal of CXCL12γ was implicated in the 
high affinity binding of CXCL12γ with CXCR4 was the use of the mutant M1 in 
the SPR and FACS analysis. All the BXBB HS binding sites in the C-terminal of 
CXCL12γ have been removed by the mutation of 9 basic amino acids within these 
regions into Serines. As seen in Figure 5.11 A, 50nM M1 displays a much lower 
binding profile than that of CXCL12γ, and after the injection, M1 dissociates from 
the immobilized CXCR4 (binding curves eventually returned back to the 
baseline), as seen for  CXCL12α. Also, as seen for the CXCL12α:CXCR4 
interaction, HP12 had a minimal effect on the interaction between M1 and 
CXCR4. This was confirmed in the FACS analysis as pre-incubation of M1 with 
HP12 had no effect on the binding with the cell-surface CXCR4, as similarly seen 
with CXCL12α (Figure 5.11 B). Thus, the BXBB HS binding sites found in the C-
terminal of CXCL12γ are responsible for the strong affinity between this 
chemokine and CXCR4 and HP12mer oligosaccharides are capable of disrupting 
this interaction. 
 
 
 
 
 
 
 
 
Figure 5.11 (A) Effect of 1µg/ml HP12 (red) on binding of 50nM M1 (blue) on immobilized 
CXCR4 and 50nM M1 in the presence (blue) and absence (magenta) of 1µg/ml HP12 binding 
to CXCR4 expressing CEM cells (red). 12G5-FITC (green) is shown to demonstrate CXCR4 
expression (B). 
5.3.5.1 Hypothesis  for  the  Role  played  by  GAGs  in  the 
context of signalling 
Since CXCL12γ demonstrates a more significant interaction with CXCR4 due to 
its elongated and basic C-terminal and that this stable interaction is disrupted by 
HS12 oligosaccharides, we hypothesised that the N-terminal sulphotyrosines 
might be involved in the binding of CXCL12γ and that this may explain the 
differences observed between CXCL12γ and CXCL12α binding to CXCR4.  
We decided to investigate this hypothesis using two experimental approaches; 
This phenomenon was investigated using Surface Plasmon Resonance (SPR) and 
Nuclear Magnetic Resonance (NMR) for the following reasons:  
Initially, we wanted to verify the presence of the sulphotyrosines on the CXCR4 
by the detection of a monoclonal antibody binding that specifically recognises 
sulphotyrosines, called anti-sulphotyrosine. The antibody bound to the CXCR4 
surface, confirming the presence of the sulphotyrosines (Figure 5.12 A red curve, 
G). Following this, pre-incubation of the CXCR4 surface with 50nM CXCL12γ, 
blocked the mAb anti-sulphotyrosine from binding to the CXCR4 surface. As can 
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be seen in the blue curve of Figure 5.12 A and E, CXCL12γ is injected onto the 
CXCR4 surface from -500 to 0 RU on the y-axis showing a strong binding 
response, after which 0.5µg/ml antisulphotyrosine is injected and appears not to 
bind at all to the surface. In order to rule out the concern that the bulky 
monoclonal anti-sulphotyrosine antibody was not sterically restricted from 
binding to the sulphotyrosines once CXCL12γ was already bound, we performed 
the same experiment but with an antibody (4G10) that binds the first 38 N-
terminal amino acids of CXCR4, independently of the presence of the sulphate 
groups (Figure 5.12 B red curve). Here, it was shown that once CXCL12γ was 
bound to the CXCR4 surface, an injection of 0.5µg/ml 4G10 is also able to 
recognise and bind the N-terminal of CXCR4. This proves that there is no steric 
hindrance between CXCL12γ binding and anti-sulphotyrosine, and that the 
binding site of anti-sulphotyrosine and that of CXCL12γ are mutually exclusive 
unlike 4G10 and CXCL12γ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Injection of antisulphotyrosine alone over the CXCR4 surface (A [red curve], C) 
and injection of 50nM CXCL12γ onto CXCR4 directly followed by antisulphotyrosine (A 
[blue curve], E). The control injection of 4G10 onto the CXCR4 surface alone (B [red curve], 
D) or injection of 50nM CXCL12γ onto CXCR4 directly followed by 4G10 (B [blue curve], 
F).   
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This result has been further investigated using the second technique, NMR 
spectroscopy. NMR is a complex type of spectroscopy that allows one to see 
where each residue in the protein places in space and in relation to the 
surrounding residues as it can provide information on every atom that has an odd 
number of protons e.g.1H, 13C and 15N. Very simply put, proteins are hit with 
radio waves while they're in a strong homogeneous magnetic field which causes 
the protons of each atom in the protein to align (nuclear magnetic dipoles). The 
radio wave causes the nuclear dipoles to begin to tilt and when the radio wave is 
stopped, the nuclear dipoles return to their original orientation. Since each amide 
1H and 15N are within a distinct environment (in terms of their neighbouring 
residues in the peptide sequence and neighbouring residues in the three-
dimensional structure) the resonance frequencies of each amide 1H and 15N will 
differ slightly from one another. It is these slight differences in resonance 
frequencies that are plotted on a two dimensional grid reflecting the chemical shift 
(change in resonance frequency) of each amide 15N in the protein as a function of 
its corresponding amide 1H shift (Figure 5.13 B). The 15N-1H amide chemical 
shifts for CXCL12γ were monitored in the presence of either a sulphated or non-
sulphated N-Terminal CXCR4 peptide. Thus, each residue in the protein is 
depicted as a dot on the Heteronuclear Multiple Quantum Correlation (HMQC) 
graph and consequently when the protein undergoes a structural re-arrangement 
due to the presence of a ligand (in this case, the N-terminal of CXCR4), the 
chemical shift between the two states (bound and un-bound) can be compared for 
each residue. Hence we can detect precisely which residues moved (and by how 
much) when the different ligands were added. Therefore, providing that each 
residue is well depicted in the HMQC plot, NMR is a very appropriate technique 
for determining the precise residues that are involved in a specific binding 
interaction. 
Here, recombinant 15N labelled CXCL12γ was titrated with either a sulphated or 
non-sulphated chemically synthesized CXCR4 N-terminal peptide. The peptides 
comprised the first 29 amino acids of the CXCR4 N-Terminus: 
MEGISIYTSDNYTEEMGSGDYDSMKEPAF. Residue C28 was replaced with 
an alanine so as to prevent oxidative peptide dimer formation (Veldkamp, Seibert 
et al. 2006). The interaction was monitored for two different peptides, one 
containing 3 sulphotyrosines at positions 7, 12 and 21 and the other peptide 
contained un-modified tyrosines (peptide synthesis by collaboration with 
Françoise Baleux, Institut Pasteur). Briefly, 100µM 15N labelled CXCL12γ was 
inserted into an NMR tube and either the non-sulphated or sulphated N-terminal 
peptides were titrated into the CXCL12γ in the NMR buffer (20mM Na-Phosphate 
pH 5.7, 0.01% azide, 2% complete protease inhibitors, 10% 2H2O). Spectra were 
recorded after each incremental addition of the peptide (non-sulphated or 
sulphated) and little/no precipitation was observed when the peptide was added. 
When the recombinant 15N labelled CXCL12γ was titrated with the non-sulphated 
CXCR4 N-terminal peptide, the core domain (the part of CXCL12γ that 
corresponds to the CXCL12α isoform, first 68 amino acids [CXCL12γ1-68]) 
displayed chemical shifts, and nothing was seen in the C-terminal of CXCL12γ. 
Interestingly, a similar result was found by Veldkamp and colleagues where 
CXCL12α was titrated with non-sulphated N-Terminal CXCR4 peptide, the 
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region 1-68 of CXCL12α was bound. We found exactly same chemical shifts for 
the CXCL12γ1-68 bound to the non-sulphated peptide (the red bars in the graph 
in Figure 5.13 A), independently of the C-terminal of CXCL12γ. Veldkamp and 
colleagues also demonstrated that when CXCL12α was titrated with a single-
sulphated (sulphated on Tyr 21) N-Terminal CXCR4 peptide, no changes were 
seen on the CXCL12α (Veldkamp, Seibert et al. 2006). This means that the 
sulphates on the N-terminal CXCR4 peptide are not significantly involved in the 
contact with the 1-68 domain of CXCL12α.  
When the recombinant 15N labelled CXCL12γ was titrated with the sulphated N-
terminal CXCR4 peptide, the CXCL12γ1-68 part of CXCL12γ interacted with the 
sulphated peptide in exactly same manner as it did with the non-sulphated N-
Terminal CXCR4 peptide – thus confirming the results of Veldkamp and 
colleagues that the sulphates are not important to the interaction with the 1-68 
domain. It was re-assuring that our results for CXCL12γ1-68 mirrored those that 
Veldkamp and colleagues obtained for CXCL12α and it proves that our protein is 
functional and that the experiment was performed correctly. However, when the 
labelled CXCL12γ came into contact with the sulphated N-Terminal CXCR4 
peptide, the C-Terminal of CXCL12γ was also modified (Figure 5.13 A blue 
bars). Therefore, the presence of the sulphates on the N-Terminal of CXCR4, 
enables the CXCR4 peptide to bind the C-Terminal of CXCL12γ.  
The following individual residues were found to be implicated in the interaction 
surface between CXCL12γ1-68 and the sulphated N-terminal peptide involving the 
N-loop: (F13), β1(K24,H25), β2(39-42), β3(48-50) and the α-helix (W57, Y61, 
L62). The CXCL12γ core domain (CXCL12γ1-68) strongly binds the N-terminal of 
CXCR4 (with and without the sulphated tyrosines) – the residues that are involved 
in the binding of the N-terminal are denoted by the red bars and the height of the 
bar corresponds to the intensity of the interaction (Figure 5.13 A). Exactly the 
same chemical shifts were observed for the CXCL12α in Veldkamp and 
colleagues’ work.  
The sulphated CXCR4 peptide causes stronger chemical shifts on the CXCL12γ 
isoform compared with the non-sulphated peptide, particularly in the C-terminal 
basic extension compared to the non-sulphated peptide. These chemical shifts are 
quite low, thus they do not represent a large movement of the residues in the 
presence of the sulphated peptide. However, due to the highly disordered and 
flexible nature of the CXCL12γ C-terminal and the fact that there are multiple 
BBXB motifs all possessing similar amino acid repeats, all the specific residues 
that participate in the liaison with the sulphated N-terminal CXCR4 peptide are 
not able to be pin-pointed. Thus, we are not able to detect the chemical shift data 
for several amino acid residues in the C-terminal of CXCL12γ, which may in fact 
be high – but are undetectable with this technique. Despite this, a large group of 
amide peaks (residues 68-98) in the chemokine C-terminal displayed significant 
chemical shifts in the presence of the sulphated peptide (Figure 5.10 B CXCL12γ 
C-Ter). This suggests that sulphotyrosines in the CXCR4 N-terminal strengthen 
the interaction with CXCL12γ, and that the C-terminus of the chemokine is 
responsible for the increased affinity with the coreceptor.  
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NMR experiments show that the interaction of CXCL12γ with the CXCR4 
peptides involves both the N-terminal folded domain of the chemokine, as well as 
the C-terminal tail.  
Unlike CXCL12α as shown in Veldkamp et al., (Veldkamp, Seibert et al. 2006) in 
our experiment, CXCL12γ does not seem to dimerise. It remains to be confirmed, 
however, we believe that CXCL12γ does not dimerise in the presence of the N-
terminal of CXCR4. The functional ramifications for this phenomenon are yet to 
be elucidated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 15N labelled CXCL12γ was observed interacting with chemically synthesized 
peptides comprising the first 29 amino acids of the CXCR4 N-Terminus. (A) Amino acid 
residues that interact with both the sulphated and non-sulphated peptide (shown in red) and 
those that interact with the sulphated peptide (shown in blue). The amino acids that interact 
exclusively with the sulphated peptide are found both in the core domain and in the C-
terminal of CXCL12γ. (B) The chemical shift perturbation observed for the CXCL12γ 
interacting with the non-sulphated peptide (red) overlayed with the chemical shift 
pertubations observed for CXCL12γ interacting with the sulphated peptide (blue)  in the C-
terminal region (CXCL12γ C-Ter). Single amino acids cannot be determined due to the 
repeating BBXB motifs in the CXCL12γ C-terminal and its non-structured mobility. 
To further confirm the data using a different experiment, we immobilized either 
the sulphated or non-sulphated peptides through amine coupling chemistry onto 
96 well plates and tried to determine the binding of CXCL12γ or the C-terminal of 
CXCL12γ. However, these experiments still require optimization to be 
demonstrative. 
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Based on the above data and from previously proposed ideas of the role played by 
GAGs in vivo (Kuschert, Coulin et al. 1999), we propose a model for the role of 
glycosaminoglycans and CXCR4 in modulating chemokine activity, summarised 
here as a “chemokine interactome” (Figure 5.14) .Five scenarios are depicted for 
CXCL12 signalling through CXCR4 and the role played by GAGs is depicted in 
the cartoon. CXCL12α signals through CXCR4 via the interaction of its N-
terminal residues within the transmembrane region of CXCR4 (1), however, at 
equivalent concentrations, CXCL12γ is known to be inhibited from signalling 
through CXCR4, and we propose that this could be due to the liaison of the basic 
C-terminal of CXCL12γ with the anionic N-terminal of CXCR4 which posseses 
sulphotyrosines (yellow stars). This interaction would place the N-terminal of 
CXCL12γ too far from the site of activation within CXCR4 (2). When in the 
presence of GAGs (3), CXCL12α signalling is possible through the CXCR4 
coreceptor as the GAG binding site and the CXCR4 binding site do not overlap 
(Crump, Gong et al. 1997; Amara, Lorthioir et al. 1999; Sadir, Baleux et al. 
2001). In the case of CXCL12γ, the presence of GAGs could increase the 
signalling capacity of CXCL12γ as the anionic GAG oligosaccharide 
competitively binds the basic C-terminal of CXCL12γ, displacing it from the N-
terminal of CXCR4. In doing so it would sterically liberate CXCL12γ and allow 
the N-terminal of the chemokine to easily access its activation site within the 
transmembrane region of CXCR4 (4).  
In terms of the oligomerisation of chemokines, the dimer form of CXCL12α has 
been shown to bind GAGs and when bound to CXCR4, induces Ca2+ mobilization 
but inhibits chemotaxis (Veldkamp, Seibert et al. 2008). Based on the recent 
crystal structure of the homodimer CXCR4 (Wu, Chien et al. 2010), we propose 
that the CXCL12α dimer, when bound to a homodimer of CXCR4, interacts with 
two N-termini of the two CXCR4 molecules, thus restricting the movement of the 
N-terminal of the CXCL12α dimer within the extracellular loops of CXCR4 and 
thus does not induce cell migration. 
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Figure 5.14 Proposed “chemokine interactome”. CXCL12α monomers signal similarly 
through CXCR4 in the absence (1) and presence (3) of GAGs. However, CXCL12γ signals 
very weakly though CXCR4 in the absence of GAGs (2) and a stronger signalling is seen in 
the presence of GAGs [preliminary data] (4). Cell-surface glycosaminoglycans can induce 
dimer formation of the CXCL12α chemokine as can the sulphated N-terminal of CXCR4, 
which does not result in functional chemotaxis (5). 
5.4 Discussion 
Analysing the binding interactions between GPCRs (CCR5 and CXCR4) and their 
ligands in real-time and without the need for labeling is hugely advantageous. Not 
only are these receptors the coreceptors for HIV-1 (and assessing the ability of 
molecules to target the coreceptor binding site of gp120 would be possible with 
such a platform), but very little is known about how CXCL12 and the different 
isoforms bind CXCR4 and about the role played by heparan sulphate. 
We chose to use the surface plasmon binding assay as this technique has many 
advantages; it allows for the isolation of purified coreceptors from their natural 
environment and their immobilization for subsequent interaction analysis. The 
solubilized coreceptors are not labeled (although tagged) and neither are their 
ligands which allows the study of an isolated interaction where there is slight 
possibility for non-specific binding. SPR allows for the generation of real-time 
binding data which makes it a technique that is well suited to the analysis of 
binding kinetics. The association and dissociation rate constants and equilibrium 
constants are all easily calculated when a range of concentrations of the analyte 
are injected over the ligand, regenerating the surface in between injections. 
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However, this technique does come with certain difficulties too: this assay took 
almost two years of relentless optimisation of the solubilization buffer, chip 
surface type and running buffer conditions. 
Other techniques that are used to measure the equilibrium dissociation constants 
(KD) are often performed with labelled ligands (Rueda, Balabanian et al. 2008) 
which might change the three-dimentional conformation of the protein and 
therefore change its binding properties and affinity for its receptor. In the latter 
case, coreceptors are often used in their cell-bound environment for affinity tests 
and thus cell-associated glycosaminoglycans and other cell bound receptors are 
often present on the cell surface. Such molecules include sphingolipids, like HS, 
which can be bound by CXCL12 (Sandhoff, Grieshaber et al. 2005). These other 
molecules, in particular GAGs, can bind to the ligands and contribute to a false 
positive signal of ligands binding to the receptors on the cell surface. This would 
be particularly true for CXCL12γ which binds to a range of different GAGs. In 
other studies, proteoliposomes or pseudovirions containing CXCR4 are captured 
onto the biacore surface and kinetic interaction studies are performed with ligands 
that are injected onto the proteoliposome / pseudovirion surface. This approach 
can also cause non-specific binding between the ligand and the large structures of 
the proteoliposomes and pseudovirions (Hoffman, Canziani et al. 2000; 
Zhukovsky, Basmaciogullari et al. 2010). For these reasons, native solubilization, 
purification and stabilization of the receptors outside of the cell / virion / 
proteoliposome, is crucial to understanding their function. 
Although manipulating GPCRs is a challenging task based on their 
transmembrane nature, detergent/lipid containing cocktails have been used to 
solubilize these proteins from their native membranes (Navratilova, Sodroski et al. 
2005). We slightly modified this solubilization cocktail and obtained reproducible 
binding data for the two CXCL12 isoforms and antibodies binding to the 
solubilized immobilized coreceptors. 
Here we report a KD of 13 ± 1.6 nM for CXCL12α and CXCR4 comparable to 
those obtained with either a similar technique or cellular systems where the 
coreceptors remained in their natural environment (Di Salvo, Koch et al. 2000; 
Navratilova, Dioszegi et al. 2006). Also for the first time, the affinity was 
estimated for CXCL12γ and CXCR4 which is KD = 0.7 ± 0.3 nM. Fitting of the 
curves was complicated due to the complex buffer used and the mass transport 
effects created by the very high on rates (that exceed that of diffusion) for the 
CXCL12γ-CXCR4 binding data. Thus, the calculated affinities reported here 
should be considered as estimates. 
Using both surface plasmon resonance and flow cell cytometry we have shown 
that CXCL12α binds to CXCR4 and that this interaction is not influenced by the 
presence of glycosaminoglycans, however, the CXCL12γ isoform which has the 
non-structured basic C-terminal, displays a radical reduction in binding to the 
coreceptor in the presence of HP. We hypothesize that this reduced binding is due 
to the reduced binding of the basic residues in the chemokine C-terminal with the 
sulphotyrosines in the N-terminal of CXCR4 due to the competition with the 
sulphated oligosaccharides. This is supported by the fact that once CXCL12γ is 
bound to immobilized CXCR4, mAb anti-sulphotyrosine can no longer recognise 
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the sulphotyrosines in the N-terminal of CXCR4 as they are presumably bound 
and ‘hidden’ by the chemokine binding the N-terminal of CXCR4.  
What are the implications of this apparent increased binding of CXCL12γ to 
CXCR4 in the absence of GAGs and the apparent decreased binding in the 
presence of GAGs? Could CXCL12γ be a kind of antagonist since its binds 
strongly to CXCR4 although it signals poorly? Or CXCL12γ could be a 
chemokine that is secreted for low and prolonged/sustained levels of signalling 
due to its high affinity for the cell-surface GAGs and CXCR4. CXCL12γ contains 
several serine-protease cleavage sites in its C-terminal region and it has been 
speculated that (as for VEGF-A, vascular endothelial growth factor A), HS 
interacting with CXCL12γ protects this domain from proteolytic attack, therefore 
contributing to the prolonged immobilization and increased half-life of CXCL12γ 
in tissues (Rueda, Balabanian et al. 2008). Following from this hypothesis, the 
proteolytic attack and removal of the C-terminal from CXCL12γ, can also be a 
mechanism for regulating CXCL12γ signalling effects, through the release of the 
CXCL12α-like domain. Cell-based signalling assays need to be performed to 
verify the exact role and mechanism of action of the CXCL12γ and the role 
played by GAGs in vivo in healthy organisms and those in disease states. 
From a spatial stoichiometric point of view, when CXCL12γ is bound to the N-
terminal of CXCR4, it might not reach the activation domain (embedded between 
the transmembrane helices) of CXCR4 easily if the C-terminal of the molecule is 
bound tightly to the N-terminal of CXCR4. Thus in the presence of HP, the 
electrostatic forces cause the binding of the oligosaccharide to the basic C-
Terminal and the CXCL12γ is ‘detached’ from the N-terminal of CXCR4 and can 
reorient itself to trigger its receptor. In addition, NMR analysis showed that the 
sulphations in the N-terminal of CXCR4 cause chemical shifts in the residues 
within the C-Terminal of CXCL12γ, and therefore the C-terminus of the 
chemokine is involved in the binding of the sulphations in the N-terminal of 
CXCR4, based on the stronger chemical shifts observed for the chemokine in 
presence of the sulphated peptide as compared to the non-sulphated peptide. 
The first 68 residues of CXCL12γ adopt a structure that is closely related to 
CXCL12α and attached to this is a highly unstructured and flexible 30 amino acid 
C-Terminal as was shown by NMR (Laguri, Sadir et al. 2007). Proteins with such 
disordered regions are believed to perform critical functions, including molecular 
recognition through large and accessible interaction surfaces. Thus, due to the 
highly basic nature and disordered state of the CXCL12γ C-terminal as well as the 
importance of glycosaminoglycan (GAG) recognition for chemokine function, it 
is no surprise that CXCL12γ binds a range of GAGs (Laguri, Sadir et al. 2007). 
Heparan sulphate (HS) oligosaccharides are ubiquitously found on the cell surface 
and within the extracellular matrix (Bernfield, Gotte et al. 1999). These highly 
sulphated molecules are implicated in protein regulation and they play a major 
role in chemokine immobilization and the formation of haptotactic gradients of 
chemokines along the cell surfaces thus providing directional cues for migrating 
cells (Campanella, Grimm et al. 2006). 
The chemokine residues that are involved in HS binding are well defined for 
CXCL12α, which include K24, K27 and R41 (Sadir, Baleux et al. 2001). NMR 
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analysis of a 15N-13C-CXCL12γ/dp4 HP complex revealed two binding domains, 
one on the core, which includes K24 and R41 but also includes (R20, V23, K24, 
A40, R41 and N45) and another within the domain of the C-terminal extension 
(K83 – K97) which stabilizes the complex with the GAGs (Laguri, Sadir et al. 
2007).  
A number of other proteins that are involved in different systems also posses 
elongated, basic C-Terminal domains that play an important role in the proteins’ 
function; CCL21 is a chemokine which signals through the CCR7 GPCR required 
for the mobilization of dendritic cells to the lymphoid tissues. CCL21 possesses a 
highly basic C-terminal (40 amino acids of which 12 are Lys or Arg) tail which 
has been suggested to interact with GAGs (as does that of CXCL12γ) to in order 
to facilitate the formation and maintenance of CCL21 gradients (Hirose, 
Kawashima et al. 2002). CCL21 causes random dendritic cell movement as it 
triggers integrin-mediated adhesion when it is bound to the surface through its 
GAG-binding C-Terminal domain. Dendritic cell specific proteases are able to 
cleave the C-Terminus of CCL21, in order to release a soluble fragment that can 
diffuse, form gradients and provide a second nested chemotactic signal, thus 
resembling the soluble CCR7 ligand, CCL19. Schumann and colleagues propose 
that HS-bound-CCL21 triggers adhesion, random polarisation and migration of 
dendritic cells, whereas soluble chemokine gradients introduce directional bias. 
Thus CCL21 has both an adhesive and a chemotactic function implying that the 
mode of chemokine presentation may determine the cellular response (Schumann, 
Lammermann et al. 2010); this may also be the case for CXCL12α and CXCL12γ. 
C-terminal extensions enriched in basic residues binding to DNA have been 
documented in the context of DNA-binding proteins. Such extended basic tails 
increase the affinity for DNA and can selectively either activate or repress gene 
transcription (Crane-Robinson, Dragan et al. 2006). Also, extended basic C-
terminals have been documented in helicase proteins which bind to and tether 
RNA for subsequent unwinding (Mallam, Jarmoskaite et al. 2011). Thus, it is not 
un-common for proteins to have unstructured basic C-terminal tails that serve to 
tether anionic binding partners. However, this is the first ever documented 
instance of a GAG oligosaccharide that regulates the binding of such basic C-
terminal tails  in chemokines to their binding partners. 
Tyrosine sulphation is a post-translational modification of certain secreted and 
membrane-bound proteins, however its biological role and regulation have been 
unclear. Recent studies have implicated tyrosine sulphation as a determinant of 
protein-protein interactions involved in leukocyte adhesion, haemostasis and 
chemokine signalling (Kehoe and Bertozzi 2000). Farzan et al., showed in 1999 
that the HIV-1 chemokine coreceptors, CCR5 and CXCR4 are tyrosine sulphated 
(Farzan, Mirzabekov et al. 1999) and that removal of the CCR5 sulphates, either 
with sodium chlorate treatment or by mutation of the sulphotyrosine residues, 
decreased natural chemokine ligand binding and HIV-1 infection respectively 
(Farzan, Mirzabekov et al. 1999). The importance of this sulphation to the 
function of CXCR4 suggests that regulation of this modification could be useful 
in the modulation of immune function or in disease states in which chemokine 
receptors participate (Farzan, Mirzabekov et al. 1999; Bannert, Craig et al. 2001). 
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The sulphotyrosines found in the N-terminus of CCR5 are known to bind a 
surface at the intersection between the bridging sheet and the V3 loop in HIV-1 
gp120 to allow entry. A good electrostatic complementarity was observed 
between the acidic N-terminal of CCR5 and the basic bridging sheet of the gp120 
seen from NMR and crystallographic structures (Huang, Lam et al. 2007). More 
recently, Veldkamp et al., demonstrated that the sulphotyrosines occurring in the 
N-terminal of CXCR4 interact with precise basic residues within CXCL12α 
(Veldkamp, Seibert et al. 2006; Huang, Lam et al. 2007; Veldkamp, Seibert et al. 
2008). Since we have established experimentally that the basic C-terminal of 
CXCL12γ binds both anionic heparan sulphate as well as CXCR4 – we thus 
hypothesised that the three sulphotyrosines present on the N-terminal of CXCR4 
could contribute to CXCL12γ recognition through the basic C-terminal region.  
There is a lot still to be elucidated about the signalling specificity and regulation 
of function of the CXCL12γ isoform. However, what is known is that the unusual, 
unstructured basic C-terminal of CXCL12γ displays an enormous structural 
plasticity and thus enables the protein to bind to multiple partners (GAGs or 
anionic residues on proteins). Another interesting feature of CXCL12γ is its 
decreased motility due to its elongated basic C-terminal. Once CXCL12γ is 
expressed and secreted from its parent cell, it will move out of its original tissue 
compartment at a much slower rate and will access the circulation with much 
slower kinetics (as compared to the CXCL12α isoform) due to its higher affinity 
for GAGs. One could speculate that CXCL12γ signalling is much more localized 
than that of CXCL12α due to this slower diffusion within tissue. Also, depending 
on the composition and extent of GAG sulphation levels (depending on the cell 
type, developmental stage and pathophysiological state of the cell (Turnbull, 
Powell et al. 2001)), the CXCL12γ might display different degrees of kinetics in 
relation to the extent of sulphation. This however, all still needs to be investigated. 
In the presence of GAGs, CXCL12α dimerises (Veldkamp, Peterson et al. 2005) 
and here the GAG-induced dimer can bind the CXCR4 homodimer, as suggested 
by Wu et al., in their model and by Veldkamp et al., from their NMR structure of 
CXCL12α in complex with the N-terminal of CXCR4 (Veldkamp, Seibert et al. 
2008; Wu, Chien et al. 2010). There is no current data as to whether a CXCL12α 
dimer can bind a homodimer of CXCR4 or a heterodimer of CXCR4 and CXCR7. 
In the absence of GAGs, as has been hypothesized from Wu et al., the crystal 
structure of the CXCR4 homodimer, a monomer of CXCL12α can bind to a 
homodimer of CXCR4. The CXCL12α could bind and activate the same CXCR4 
or the CXCL12α could bind one CXCR4 monomer of the homodimer with its 
core region and then activate the neighbouring monomer of the homodimer with 
its first two N-terminal residues, in cis. One hypothesis is that the role played by 
the N-terminal of CXCR4 is to displace the GAGs that have bound to the 
CXCL12α chemokine dimer and allow for signalisation through the receptor (with 
a 1:1 binding of N-terminal and chemokine). However, it has been proposed that a 
2:2 complex of N-terminal and chemokine is a partial agonist and selective 
antagonist as it can stimulate Ca2+ mobilization but cannot stimulate chemotaxis 
and is thus non-functional. This can be seen as a level of regulation of chemokine 
signalling (Veldkamp, Seibert et al. 2008). 
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Heterodimers including CXCR4 can form too. Levoye et al., show that CXCR7 
heterodimerises with CXCR4 and that CXCR7 expression impairs CXCR4-
prompted Gαi protein activation and calcium responses (Levoye, Balabanian et al. 
2009). CXCR7 is phylogenetically homologous to GPCRs and it fails to activate 
the inactive linked Gαi proteins, however it does induce CXCL12α receptor 
mediated cellular responses (Balabanian, Lagane et al. 2005; Naumann, Cameroni 
et al. 2010). The binding of CXCL12α to CXCR7 is very controversial, as this 
interaction was recently discoved and there are a lot of unknowns about this 
binding interaction and its role in CXCL12α signalling regulation. Naumann and 
colleagues described the occurrence of CXCL12α binding to CXCR7 and that 
CXCR7 acts as a scavenger for CXCL12α; CXCR7 internalises CXCL12α and 
targets it for degradation (Naumann, Cameroni et al. 2010). Thus, a possible 
scenario of binding could be a monomer of CXCL12α binding to a heterodimer of 
CXCR4 and CXCR7, causing the internalisation and degradation of CXCL12α in 
order to regulate the chemotactic activity of CXCR4. The issue of CXCL12α 
binding a CXCR4-CXCR7 heterodimer is very interesting in terms of its 
functional role for chemokine-mediated signalling and this needs to be further 
investigated.  
We propose a hypothesis whereby a heterodimer of CXCR4 and CXCR7 can 
exist, or a homodimer of CXCR4 exists and CXCL12γ is bound to the N-Terminal 
of one of the CXCR4’s in either the heterodimer or the homodimer. Once the 
CXCL12γ chemokine is ‘tethered’ or ‘captured’ to one of the CXCR4’s, its 
elongated flexible C-Terminal allows it the mobility to bind and activate the 
adjacent coreceptor, being either the CXCR7 or the CXCR4. CXCR7 possesses 
only one tyrosine in its N-Terminal domain, and the literature thus far does not 
mention that this tyrosine is sulphated. Thus CXCL12α and CXCL12γ could bind 
to CXCR7 in an identical way, which is not the case as for CXCR4 (Rueda, 
Balabanian et al. 2008). Therefore, CXCL12γ may activate CXCR7 in a similar 
way to that of CXCL12α. Further experimentation is required to elucidate this 
hypothesis. 
For the first time, we show that sulphated oligosaccharides differently influence 
the binding of CXCL12α and CXCL12γ to their cognate receptor, CXCR4 and 
that this modulation may play a fundamental role in the regulation of cell 
signalling, leukocyte trafficking and activation and cell migration. 
The binding difference between CXCL12α and CXCL12γ for their receptor, 
CXCR4, is due to two important factors: i) the basic unstructured C-terminal of 
CXCL12γ that is not present in the CXCL12α isoform allows CXCL12γ to have a 
higher affinity for the ii) anionic N-Terminal of CXCR4 which contains 
sulphotyrosines. This has been shown by surface plasmon resonance and NMR.  
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Chapter 6:  A  synthetic  heparan  sulfate­mimetic 
peptide  conjugated  to  a mini  CD4  displays  very  high 
anti­HIV­1 activity independently of coreceptor usage 
6.1  Un mimétique synthétique de l’héparan sulfate‐conjugué à un 
peptide  mini  CD4  a  une  activité  anti‐VIH‐1  très  élevée 
indépendamment de  l'utilisation des  corécepteurs  (sommaire  en 
français) 
Une thérapie anti-rétrovirale même très active (ARV) ne peut pas éradiquer 
complètement le virus VIH-1, ce qui explique pourquoi de nouvelles stratégies 
thérapeutiques, tels que les inhibiteurs de l'entrée virale sont nécessaires. L'entrée 
du VIH-1 est un processus complexe, qui offre de  multiples sites à cibler pour 
l'intervention thérapeutique. Parmi eux, la surface de liaison du corécepteur - 
gp120, qui est hautement conservée dans de nombreuses souches VIH-1, est 
particulièrement attrayante. Cette région devient toutefois exposée, et donc 
sensible à l'inhibition, seulement de façon transitoire et dans un espace restreint 
stériquement, lorsque le virus a déjà été lié par la surface des cellules CD4 et que 
le processus d'entrée est largement engagé. Une molécule hybride (mCD4-HS12) 
constituée d'un peptide mimétique de CD4 couplé à un dodécasaccharide héparane 
sulfate synthétique (HS12) est capable d’empêcher à la fois l'attachement et 
l'entrée du VIH-1 R5 et X4 avec un IC50 1-5 nM dans un test en culture cellulaire 
(Baleux, Loureiro-Morais et al. 2009). Cette activité est due à la formation induite 
du domaine de liaison sur le corécepteur via le groupement mCD4 de la molécule, 
suivie par l'interaction de forte affinité de l'HS12 anionique avec le corécepteur. 
Les HS sont extrêmement complexes dans la nature et leur complexité découle du 
nombre et de la position des groupes sulfates le long de la chaîne. Ainsi les sites 
exacts de contact entre la molécule sulfatée d’HS et la gp120 nécessitent d’être 
étudiés pour pouvoir créer une interaction plus spécifique et de plus forte affinité. 
Afin de réaliser ceci, nous avons d'abord développé et validé une plateforme 
utilisant la technologie des biocapteurs SPR dans laquelle des ligands de gp120, y 
compris les CD4, HS, les anticorps et corécepteurs solubilisés (CCR5 et CXCR4) 
sont immobilisés  à la surface de la sensorchip, (dans un environnement lipide / 
détergent pour les co-récepteurs). Nous pouvons mesurer directement en solution 
et en temps réel les interactions de liaison entre la gp120 ou des complexes 
gp120-CD4 avec les récepteurs mentionnés ci-dessus dans un environnement sans 
étiquette. Ensuite, la plate-forme a été utilisée pour le criblage de banques de 
sucres basées sur des molécules HS différemment sulfatée et autres composés 
naturels mimant les HS. Compte tenu de ces approches, nous avons également 
conçu une série de tridécapeptides «S(XDXS)3 » imitant la dodécamère héparane 
sulfate qui a déjà été montré pour cibler le site de liaison de la gp120 au 
corécepteur. Nous avons montré que l'un de ces composés (où X est une 
sulfotyrosine), lorsqu’il est  lié de façon covalente à un mini-CD4 (mCD4-
P3YSO3) inhibe la liaison des gp120 qu’il soit R5 ou X4-tropique, aux molécules 
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suivantes : CD4, des anticorps dirigés contre le domaine CD4-induit, et CCR5 ou 
CXCR4. L'analyse de liaison est en faveur d'un mécanisme bivalent où le 
fragment mCD4 se lie d'abord, provoquant l'ouverture du site pour le corécepteur 
puis un fort blocage ultérieur par le tridécapeptide. Le conjugué a été beaucoup 
plus efficace qu’un mélange de mCD4 et tridécapeptide isolés, ce qui indique que 
la liaison covalente est essentielle pour produire un effet synergique. Cela suggère 
un concept par lequel une molécule de spécificité relativement faible (le peptide 
sulfaté), couplé à un composé hautement spécifique (le mCD4) peut atteindre des 
affinités très élevées pour sa cible. Ce composé cible donc avec succès deux 
domaines critiques et hautement conservés dans la gp120 de manière corécepteur 
indépendante. Dans des  cultures de cellules sanguines il inhibe la réplication de 
souches de VIH-1 adaptées au laboratoire Ba-L (tropisme R5) et LAI (tropisme 
X4), (pour laquelle il n’existe aucun  inhibiteur antagoniste efficace avec IC50 
aussi bas que 1 nM. Le mCD4-P3YSO3 inhibe également l'entrée du virus 
primaire (sous-type A, B et C). 
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6.2 Preface 
As shown in Chapter 5, the interaction system with solubilized coreceptors has 
been setup and validated with the study of the CXCL12 isoforms. Once the 
coreceptors are solubilized, they retain their functionality when immobilized on 
the biacore surface and kinetic information can be obtained between the 
coreceptors and the chemokine isoforms which corresponds to affinity data 
obtained in cell-based assays. We thus were confident that the coreceptor surfaces 
would be functional and ready to be used in the assay to screen HIV-1 entry 
inhibitors. 
Navratilova et al., have set-up a similar technique, whereby CCR5 coreceptors are 
solubilized and they demonstrate CCR5 utilizing envelopes binding to the 
immobilized CCR5 coreceptors (Navratilova, Sodroski et al. 2005; Navratilova, 
Dioszegi et al. 2006). However, an interaction between CXCR4 utilizing 
envelopes and surface captured isolated CXCR4 has never been reported. 
6.3 Introduction and Preliminary approach 
Almost 30 years after the discovery of human immunodeficiency virus – 1 (HIV-
1), 33 million people globally are infected of which 68% reside in Sub-Saharan 
Africa, and there is still no cure. However, the virus is not eradicated and 
treatment interruption does occur which is the cause of the outgrowth of drug-
resistant viruses. In addition to treatment adherence issues, the long-term adverse 
side-effects as well as the exorbitant financial burden of these therapies are 
counteractive forces especially in developing countries where the epidemics are 
the worst (UNAIDS 2011).     
Targeting HIV-1 entry has recently attracted a lot of attention with already two 
drugs approved and licensed by the food and drug administration (FDA); 
Enfuvirtide [fuzeon] (Matthews, Salgo et al. 2004) and Maraviroc [Selzentry] 
(Dorr, Westby et al. 2005). This stage of the viral life-cycle is particularly 
attractive as when the viral envelope (env) approaches the target CD4+ T cell, the 
primary receptor is engaged (CD4) (Klatzmann, Champagne et al. 1984) and a 
series of conformational changes occur in env which expose/create the cryptic 
coreceptor binding domain, which is briefly exposed before docking onto either 
coreceptor (CCR5 or CXCR4) (Alkhatib, Combadiere et al. 1996; Feng, Broder et 
al. 1996). This cryptic domain is composed of a four-stranded β-sheet, referred to 
as the CD4-induced domain (CD4i) and in conjunction with the V3 loop, they 
play vital roles in coreceptor binding (Rizzuto, Wyatt et al. 1998; Hartley, Klasse 
et al. 2005).    
In the early stages of infection, HIV-1 is transmitted by CCR5-utilizing viruses 
(R5) which infect macrophages, however, as the disease progresses and the 
immune system is further compromised, more virulent variants emerge which are 
CXCR4-utilizing viruses (X4 or R5X4) that infect T-cells (Connor, Sheridan et al. 
1997). Before HIV-1 engages the host CD4 and coreceptor molecules, GAGs 
concentrate the virus on the cell surface and aid to sequester and concentrate the 
virus near its receptors (Roderiquez, Oravecz et al. 1995; Mondor, Ugolini et al. 
1998). Recently, a phenomenal study has shown that when a synthetic 12mer 
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GAG oligosaccharide is covalently linked to a CD4 mimetic peptide (mCD4), the 
mCD4 binds to env, triggering the conformational change necessary to expose the 
CD4i which then permits the covalently attached 12mer GAG to bind the CD4i 
pocket and effectively block both R5 and X4 HIV-1 entry with nM activity 
(Baleux, Loureiro-Morais et al. 2009). This dodecasaccharide is fully sulphated 
(18 sulphates) and is extremely difficult and complex to synthesize. In order to 
perform structure-functional analyses, a large quantity of known sequence would 
be required, thus synthesizing the GAG fragment is almost impossible.          
Glycosaminoglycans are extremely complex molecules; their basic unit is a 
disaccharide of which there are 48 different variations (depending on sulphation 
modifications and COO- epimerisations etc.). Thus if we were to calculate the 
number of different variations for a 12mer, we would reach up to over 10 billion 
possible sequences, a staggering degree of variation on which it is thus impossible 
to perform structure-function analysis. One approach to screen for a HS12mer with 
the optimal sulphation sequence required for CD4i binding and entry inhibition, 
would be to screen a bank of differently sulphated HS12mers.  
6.3.1 Generation of an HS12 differently sulphate Library 
Heparin (HP) dodecasaccharides were prepared by R.Sadir as previously 
described (Sadir, Baleux et al. 2001). Briefly, porcine mucosal HP (10g) was 
depolymerized with heparinase I and the digested mixture was resolved from di-
(dp2) to octa-(dp18) decasaccharide on a Bio-Gel P-10 column. The eluted 
material was detected by absorbency at 232 nm and dp2 up until dp12 were 
further purified by strong anion-exchange HPLC, dialyzed against distilled water, 
and quantified either by a colorimetric assay or weighed.  
The inhibitory action of the oligosaccharide domain of the mCD4-HS12 molecule 
needed to be further studied and optimised in order to improve its specificity and 
affinity. For this purpose, we prepared an HS12 derived molecular library 
(containing 12 initial sub-populations of differently sulphated HS12mers). This 
was obtained by fractionating the HP12 (dodecasaccharide) fraction (obtained 
from the above mentioned depolymerised HP fractionation) under a stong anionic 
gradient on the HPLC (Figure 6.1 A) .The sub-populations were grouped into 12 
larger sub-populations, with each group containing HS12 molecules with 
presumably similar overall charges, however, within each sub-population there are 
many different species with an unequal organisation of sulphate molecules.  
This process is also very time consuming and a low level of purity of each sub-
population of HS12 is obtained due to the highly complex and heterogeneous 
nature of heparan sulphate. A homogeneous population would be almost 
impossible to obtain (Figure 6.1), therefore, this technique was determined to be 
too difficult and unable to isolate a significant amount of a pure molecule.  
For this reason, it is highly advantageous to use peptide GAG-mimetics, As a 
result, our collaborators have synthesized HS mimetics that possess carboxyl, 
hydroxyl and sulphate groups, which mimic those found on an oligosaccharide. 
These GAG mimetics were also screened for their inhibitory capacity of the 
gp120-CD4–coreceptor interaction, using the recently set-up and optimised 
interaction system on the SPR platform. 
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Figure 6.1 A Typical HPLC elution profile of HS12 showing absorbance at 232nm as a 
function of time (min) and B a histogram corresponding to the quantities (in mg) of each 
separated HS12 library fraction. 
R5 viruses enter their target cells through the recognition and binding of the N –
terminus and the second extracellular loop (ECL) of CCR5 (Rucker, Samson et al. 
1996; Farzan, Choe et al. 1998; Cormier, Persuh et al. 2000). Huang et al., 
showed that two sulphated tyrosines (at positions 10 and 14) in the N-terminus of  
CCR5 interact within  a binding pocket on gp120 formed between the base of the 
V3 loop and the bridging sheet (Huang, Lam et al. 2007) and salt bridges are 
made with basic residues in this pocket. Interestingly, sulphotyrosines are also 
found in the N-terminal of CXCR4, as well as in the heavy chain 3rd 
complementary determining region (CDR H3) of CD4i HIV-1 neutralizing 
monoclonal antibodies 412d and E51 (Choe, Li et al. 2003; Huang, Venturi et al. 
2004). Thus, tyrosine sulphation is a post-translational modification that plays a 
critical role in protein-protein interactions and nature has managed to mimic these 
modifications in order to attempt to inhibit certain viruses.  
We thus hypothesized, that due to the fact that peptide synthesis is much simpler 
compared to glycosaminoglycan synthesis (practically speaking), and a peptide 
would be much more amenable to structure-function analysis due to its known and 
homogenous sequences, we produced five peptides (13 amino acids in length) 
each conjugated to mCD4 and containing amino acids that mimic the OH-, COO-
and SO43- residues found in GAGs. The peptide containing 6 sulphated tyrosines 
not only mimics the sulphate residues in GAGs but also mimics those found in the 
N-terminal of both CCR5 and CXCR4. Since the neutralizing antibodies (E51 and 
412d) are induced in patients against the CD4i, their existence proves that 
targeting the cryptic CD4i site with peptides containing sulphotyrosines is a valid 
strategy for HIV-1 inhibition (DeVico 2007). Additionally, peptides are more 
likely to access the small cryptic CD4i site, compared to large cumbersome 
antibodies. The following base sequence was used for peptide synthesis: 
S(XDXS)n where X stands for the different amino acids and n = 3 (the total 
length equivalent to that of a GAG 12mer). Peptide PY3 (where X = non-
sulphated tyrosine), P3YSO3 (where X = sulphotyrosine), P3Asu (where X = 
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aminosuberic acid), P3pF (where X = p-carboxymethyl phenylalanine) and E13 
(where the entire length is glutamic acid – a non-specific polyanion) were 
synthesized by our collaborators. 
In order to test the inhibitory capacity of these peptide GAG-mimetic inhibitors, 
we aimed to assess their capacity to inhibit gp120-CD4 from binding to the 
solubilized immobilized coreceptors (CCR5 and CXCR4). The optimization of the 
surface plasmon resonance (SPR) technique, whereby solubilized coreceptors 
were immobilized on a sensorchip and interactions between their binding ligands 
were monitored in a complex buffer, was performed as described in Chapter 5 for 
CXCR4, and was developed for CCR5 as described in this Chapter. Thus, we used 
this technique to screen the different peptides for their capacity to inhibit gp120 
(either commercial MN [X4] or YU2 [R5]) -CD4 complexes from binding to their 
respective coreceptors, CXCR4 or CCR5. We report affinities of the gp120-CD4 
complexes for their respective coreceptors that equal those reported in other 
studies using either similar or cell-based and proteoliposome-based techniques 
(Doranz, Orsini et al. 1999; Babcock, Mirzabekov et al. 2001; Navratilova, 
Sodroski et al. 2005). The sulphotyrosine containing peptide conjugated to mCD4 
(mCD4-P3YSO3) demonstrated the highest success in inhibiting gp120-CD4 
complexes from binding to the coreceptors and was thus further evaluated in viral 
entry inhibition using peripheral blood mononuclear cell infection assays. This 
molecule inhibits both R5 and X4 viruses with nM activity and is not toxic for the 
cells up to 1µM, unlike most current CCR5 and CXCR4 antagonists. This novel 
entry inhibitor targets the virus and not the host; thus further reducing the risk for 
host-toxicity issues.      
6.4 Results 
We aimed to asses whether the solubilized coreceptors (CCR5 and CXCR4) were 
capable of recognising their gp120 ligands in an immunoprecipitation experiment. 
Here, protein G sepharose beads were coupled to the 1D4 antibody which binds to 
the C9 tag at the C-terminal of CCR5/CXCR4 and purified it from the mass of 
solubilized membrane proteins. Ligands (gp120, antibodies) were 
immunoprecipitated by the bound coreceptors in the absence and presence of 
various inhibitors. The presence of the ligands was determined by antibody 
binding and western blot. These experiments were not sufficiently conclusive and 
would required futher optimization, we thus directly used the SPR approach as 
described on chapter 5. 
6.4.1 Surface Plasmon Resonance Screening platform 
We thus commenced the screening process of the various inhibitors (HS12 
fractionated library and peptide GAG mimetics) over the following surfaces 
prepared on the biacore: 17b, biotinylated HS, mCD4 / full length CD4 or 
solubilized CCR5 / CXCR4 (Figure 6.2). For all the surfaces, except that of the 
solubilized coreceptors, a surface prepared with streptavidin served as the 
negative surface foreseen for background binding subtraction. In the case for the 
GPCR surfaces (Figure 6.2, scenario D), the 1D4 antibody served as the negative 
surface. Since 17b has been used by many previous studies as a surrogate 
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coreceptor, we included a 17b surface in our screening assays, however this mAb 
only partially covers the entire coreceptor binding domain. The coreceptor binding 
site is constituted not only by the bridging sheet but also by the V3 loop (Dragic 
2001; Baleux, Loureiro-Morais et al. 2009; Dervillez, Klaukien et al. 2010) and it 
is for this reason that we decided to use native solubilized coreceptors to 
immobilize on the biacore surface for our binding studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Schematic representing the four different scenarios which were used when 
screening the various entry inhibitor molecules. Scenario A, B and C use streptavidin as a 
reference surface and scenario uses 1D4. Scenarios A has 17b as the test surface, B has 
biotinylated Heparan Sulphate (HSb), C has either full length CD4 or mCD4 and D has 
either CCR5 or CXCR4 solubilized coreceptors. For scenario C, either mCD4 or full length 
CD4 was immobilized and will be indicated in the text. 
Throughout the experiments, laboratory adapted and expressed gp120 MN 
(CXCR4 utilizing envelope) and primary isolate gp120 YU2 (CCR5 utilizing 
envelope) were used when screening for molecules that inhibited gp120-CD4 
from binding to the immobilized coreceptors. Before any inhibitory molecules 
were screened, conformationally dependent monoclonal antibodies (12G5, 4G10 
and 2D7, N-terminal antibody) were injected over the immobilized coreceptors to 
detect whether or not they recognised their respective coreceptors (CXCR4 and 
CCR5) (Figure 6.3). Together with the binding studies described in Chapter 5 
between CXCL12 and CXCR4, we were very confident that our solubilized 
coreceptors were functional and suitable for the screening studies for the entry 
inhibitors. 
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Figure 6.3 Binding of conformational sensitive (12G5 and 2D7) and non structural 
dependant antibodies  (4G10 and 45502) onto solubilized CXCR4 (A) and CCR5 (B) 
respectively immobilized onto CD4 sensor chips through the high affinity interaction with 
1D4. Cartoon diagrams represent the different coreceptors immobilized on the sensor chip 
surface. 
6.4.2 A  synthetic  heparan  sulfate­mimetic  peptide 
conjugated  to  a  mini  CD4  displays  very  high  anti­HIV­1 
activity independently of coreceptor usage 
 
This part of the thesis work has been accepted for publication and thus will be 
inserted here as a ‘manuscript’. 
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SUMMARY 
The HIV-1 envelope gp120, which features both the virus receptor (CD4) and coreceptor 
(CCR5/CXCR4) binding sites, offers multiple sites for therapeutic intervention. However the 
latter becomes exposed, thus vulnerable to inhibition, only transiently when the virus has 
already bound cellular CD4. To pierce this defense mechanism, we engineered a series of 
heparan sulfate mimicking tridecapeptides and showed that one of them target the gp120 
coreceptor binding site with µM affinity. Covalently linked to a CD4-mimetic which binds to 
gp120 and renders the coreceptor binding domain available to be targeted, the conjugated 
tridecapeptide now displays nM affinity for its target. Using solubilized coreceptors captured 
on top of sensorchip we show that it inhibits gp120 binding to both CCR5 and CXCR4 and in 
peripheral blood mononuclear cells broadly inhibits HIV-1 replication with an IC50 of 1 nM. 
 
Highlights: 
• The HIV coreceptors, CCR5 and CXCR4, were functionally captured on sensor surfaces 
• Heparan sulfate mimetic peptides S(XDXS)3 target the gp120 coreceptor binding site 
• Covalently linked to a CD4 mimetic they block gp120 binding to both CCR5 and CXCR4 
A mCD4-S(XDXS)3 conjugate inhibits HIV replication with an IC50 of 1 nM 
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INTRODUCTION 
Although tremendous progress has been made in the development of antiviral drugs to treat 
human immunodeficiency virus (HIV-1) infection (De Clercq 2007) and despite the 
availability of some 25 approved antiretroviral compounds (most of which target HIV-1 
enzymes) the virus continues to be a major concern and remains one of the leading causes of 
death worldwide. The rapid emergence of drug-resistant viral strains, the inability of current 
therapy to completely eradicate the virus and the strong adverse side effects associated with 
their long-term use (Shafer and Schapiro 2008) compromise treatment in patients benefiting 
from these therapies, and make the development of new therapeutic options of utmost 
importance (Flexner 2007). Inhibition of HIV-1 entry, a process based on the sequential 
interaction of the viral glycoprotein (gp120) with the cell surface CD4 (Klatzmann, 
Champagne et al. 1984) and either one of the two chemokine receptors CCR5 or CXCR4 
(Alkhatib, Combadiere et al. 1996; Feng, Broder et al. 1996), holds particular promise in 
addressing complications of current therapy and has become a compelling target for 
controlling viral replication (Tilton and Doms 2010). The recent approval of maraviroc, a 
CCR5 antagonist (Maeda, Nakata et al. 2004; Dorr, Westby et al. 2005), has validated entry 
inhibition as a viable approach. However, to avoid the selection of pre-existing and more 
pathogenic CXCR4-using HIV-1 (for which no effective antagonistic inhibitors yet exist) 
maraviroc has been licensed for the treatment of patients infected with viral strains using 
CCR5 only. 
On the virus side, the gp120 constitutes the central element for all interactive events occurring 
during the pre-entry steps. A wealth of evidence has shown that gp120 binding to CD4 not 
only permits virus attachment, but also triggers extensive conformational changes of the 
envelope that fold and/or expose a four-stranded β-sheet, known as the CD4-induced (CD4i) 
domain (Wu, Gerard et al. 1996). Being critically involved in CCR5/CXCR4 recognition and 
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highly conserved, this domain represents an attractive pharmacological target. Although 
inhibition of protein–protein interactions is clearly challenging, a striking feature of the CD4i 
domain is its basic nature (Kwong, Wyatt et al. 1998; Rizzuto, Wyatt et al. 1998) and, not 
surprisingly, many of this domain’s ligands are characteristically acidic. This includes 
peptides selected by phage display screening (Dervillez, Klaukien et al. 2010), sulfated 
oligosaccharides from the heparan sulfate (HS) family (Vives, Imberty et al. 2005; Crublet, 
Andrieu et al. 2008), aptamers (Cohen, Forzan et al. 2008), peptides derived from neutralizing 
antibodies (Dorfman, Moore et al. 2006), compounds issued from in silico screening of 
molecular libraries (Acharya, Dogo-Isonagie et al.) or peptides derived from the N-terminal 
sequence of CCR5 itself which comprise sulfotyrosines importantly contributing to gp120 
binding (Cormier, Persuh et al. 2000; Farzan, Vasilieva et al. 2000). The cryptic nature of this 
CD4i surface prior to CD4 binding however limits its accessibility both temporally and 
spatially, and makes it a relatively intractable pharmacological target. In that context, we 
recently developed a new class of compounds, in which a CD4 mimetic peptide (mCD4) was 
linked to a HS dodecasaccharide (HS12) and showed that mCD4 exposed the gp120 CD4i 
domain and renders it available to be blocked by the HS12 oligosaccharide (Baleux, Loureiro-
Morais et al. 2009). 
Here, to further develop this concept we engineered a series of tridecapeptides that mimic HS, 
the synthesis of which, although amenable to large scale production, remains extraordinary 
complex (Dilhas, Lucas et al. 2008). We then set up a binding assay in which detergent 
solubilized CCR5 and CXCR4 were both functionally captured on top of sensorchips and 
used them to show that, conjugated to a mini CD4, a HS mimicking peptide efficiently targets 
the CD4i domain of gp120 and blocks its interaction with the coreceptors. This compound 
displays antiviral activity against LAI and Ba-L HIV strains with an IC50 as low as 1 nM, two 
to four orders of magnitude lower than the above described anionic compounds. To our 
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knowledge this is the most potent gp120 targeting molecule, with the unique property to 
simultaneously block two critical and conserved regions of gp120. Importantly it inhibits 
CCR5 and CXCR4 using viruses equally well, and is also highly active against a number of 
viral primary clinical isolates. These results should have strong implications for the 
development of a new anti-HIV-1 therapy. 
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RESULTS 
 
HIV-1 coreceptors immobilisation and gp120 binding 
Assessing the ability of molecules to target the coreceptor binding site of gp120 would 
strongly benefit from a direct coreceptor-gp120 interaction assay. To that end, both HIV-1 
coreceptors were solubilized from Cf2Th cells, recombinantly expressing either CCR5 or 
CXCR4, using a specific cocktail of lipids and detergents that was adapted from that 
previously described (Navratilova, Sodroski et al. 2005). Solubilized coreceptors, which 
feature a C-terminal C9 tag (Mirzabekov, Bannert et al. 1999; Babcock, Mirzabekov et al. 
2001) allowing their oriented capture with the cognate 1D4 antibody, were immobilized on 
top of a sensorchip to a level of ~ 4000 resonance units (RU). To verify whether the 
coreceptors remained functional we first investigated their binding capacity with the 
conformationally sensitive mAb 2D7 for CCR5 (Lee, Sharron et al. 1999; Khurana, Kennedy 
et al. 2005) and 12G5 for CXCR4 (Baribaud, Edwards et al. 2001). As shown in Figure 1AB, 
injection of these mAbs over the CCR5 and CXCR4 functionalized surfaces gave rise to 
strong and coreceptor specific binding signals indicating both the presence of the coreceptor 
on the surface, and the integrity of the corresponding epitopes. 
Following this, we analyzed whether the immobilized coreceptors bound gp120, in a CD4 
dependant manner. For that purpose, 100 nM of either YU2 or MN (R5 and X4 envelopes 
respectively), in the absence or presence of mCD4, a CD4 mimetic peptide that was 
previously found to bind gp120 and induce the conformational change that lead to the 
folding/exposure of the coreceptor binding site (Baleux, Loureiro-Morais et al. 2009), were 
injected over the coreceptor surfaces. Both envelopes interacted with their coreceptors, 
presumably because the CD4i epitope is transiently exposed on the dynamic structure of 
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gp120, as already observed with anti-CD4i antibodies (Thali, Moore et al. 1993). The binding 
responses, however, were significantly enhanced by the presence of mCD4, and efficiently 
inhibited by 1 µM of maraviroc or AMD3100 (Figure 1CD), two compounds targeting CCR5 
and CXCR4 respectively, and having anti-HIV-1 activity (Tilton and Doms 2010). Next, dose 
response experiments were performed with mCD4:gp120 ratios fixed at 1:1, and injected over 
the immobilized CCR5 or CXCR4 surfaces. Sensorgrams were obtained for both envelopes 
(Figure 1EF), which evaluations (see supplemental experimental procedures) returned 
estimated affinities of 11.5 ± 2.9 nM and 154 ± 68 nM for CCR5 and CXCR4 respectively. 
These values were identical to that reported by a similar technique (Navratilova, Sodroski et 
al. 2005) or radioligand binding assay with cell membrane-embedded CCR5 (Doranz, Baik et 
al. 1999) as to that reported for CXCR4, using proteoliposome embedded coreceptors and 
radiolabelled gp120 (Babcock, Mirzabekov et al. 2001). 
We previously reported that the gp120 CD4i epitope can be targeted by HS (Vives, Imberty et 
al. 2005; Crublet, Andrieu et al. 2008), and that a HS dodecasaccharide covalently linked to 
mCD4 (mCD4-HS12) binds gp120 and blocks its subsequent interaction with mAb 17b 
(Baleux, Loureiro-Morais et al. 2009). MAb 17b belongs to a group known as “anti-CD4i” 
antibodies, which recognizes a conserved element of gp120, induced by CD4 and partially 
overlapping the coreceptor binding site (Xiang, Doka et al. 2002). We thus made use of the 
coreceptor binding assay described above to investigate whether mCD4-HS12 would also 
inhibit gp120 binding to CCR5 and CXCR4. As shown in Figure 1GH, both YU2 and MN 
gp120 in complex with mCD4-HS12 featured a strongly reduced ability to recognize CCR5 or 
CXCR4 compared to that of gp120 in complex with mCD4 alone. This suggests that such 
molecules could serve as lead compounds for the future development of a new class of entry 
inhibitors. 
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Chemical synthesis of mCD4 linked HS mimetic peptides 
HS are however notoriously difficult to synthesize. In addition, their inherent sequence 
heterogeneity, in terms of sulfation pattern and saccharide composition, would currently make 
the preparation of a dodecamer series out of reach. Thus, based on the mCD4-HS12 template, 
we tested the hypothesis that the HS moiety could be mimicked by peptides, the chemical 
synthesis of which is more straightforward, and more easily amenable to sequence-activity 
relationship investigation. To display the functional hydroxyl, carboxyl and sulfate groups 
that characterize HS, peptides comprising Ser, Asp, and Tyr, the latter being possibly sulfated, 
were considered. This strategy is supported by the observation that a SYDY tetrapeptide binds 
to the HS binding domain of the vascular endothelial growth factor (Maynard and Hubbell 
2005) and that phage display screenings against the CD4i epitope of gp120 returned 
sequences enriched in YD motifs (Dervillez, Klaukien et al. 2010). It is also worth noting that 
a number of antibodies against the gp120 coreceptor binding domains feature sulfotyrosines 
in their paratope, as does the N-terminus of both CCR5 and CXCR4 (Choe, Li et al. 2003). 
Building of a S(XDXS)n sequence (were X stands for different possible amino acids - see 
below) using the peptide builder of Hyperchem 5, showed that a 13 amino acid peptide (n = 
3), in its extended configuration (ϕ, ψ and ω angles set to 180 °) would have a length 
equivalent to the HS 12 mer (data not shown). Thus a tridecapeptide, alternating OH/COO- 
and OH/SO3- groups, having the sequence: SYSO3DYSO3SYSO3DYSO3SYSO3DYSO3S (X being 
in this case a sulfotyrosine; YSO3) was first synthesized (P3YSO3). The non sulfated 
equivalent (P3Y) was also prepared along with a number of other peptides in which X was 
replaced by p-carboxymethyl phenylalanine (P3pF) or aminosuberic acid (P3Asu), two 
residues that have been shown to functionally mimic sulfotyrosine in cholecystokinin type B 
receptor ligand CCK8 (McCort-Tranchepain, Ficheux et al. 1992) and sulfakinins (Nachman, 
Vercammen et al. 2005). A tridecaglutamate (displaying 13 carboxylic groups) was also 
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prepared (E13) as a non specific poly anionic peptide (Figure 2). In order to maintain an 
appropriate distance between mCD4 and these peptides, enabling the final molecule to reach 
both the CD4 and coreceptor binding sites, a γ-aminobutyric acid (γ-Abu) was introduced on 
their N-terminus. These peptides were derivatized with S-acetylthiopropionic acid to allow 
the coupling to Lys5 of a maleimide-activated mCD4. All compounds were purified to a level 
of 95% by RP-HPLC (see Tables S1 and Figures S1, S2), controlled by mass spectrometry 
and quantified by amino acid analysis as described in the supplemental experimental 
procedures. 
 
mCD4 linked HS mimetic peptides inhibit binding of gp120 to CD4, mAb 17b and 
coreceptors 
To verify that peptide conjugation did not prevent the ability of mCD4 to interact with gp120, 
a competition assay was performed, in which YU2 or MN were incubated with the different 
mCD4 conjugates and injected over a CD4 functionalized surface. Results showed that the 
mCD4-conjugates all very efficiently prevent gp120-CD4 interaction, with greater potency 
than that of unconjugated mCD4 (Figure 3AB). Next, the capacity of the anionic peptides to 
target the gp120 CD4i epitope was investigated by analyzing their ability to prevent gp120 
binding to mAb 17b, in the presence of soluble mCD4. While unliganded gp120 was not 
(MN) or only poorly (YU2) recognized by mAb 17b (Figure 3 CD; blue trace), preincubation 
with mCD4 strongly promoted binding (black trace). When the gp120-mCD4 complexes were 
further incubated with 5 µM of the above described tridecapeptides, strong inhibition was 
observed for P3YSO3 (green trace). The tridecaglutamate (E13) was devoid of activity, 
indicating that the anionic character of the peptide is not sufficient to provide binding, as were 
the unsulfated P3Y or the sequence in which the sulfotyrosine mimetics (pF and Asu) were 
introduced (Figure 3CD; black traces). HS12 (red trace) also fully blocked mAb17b binding to 
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MN-, but not to YU2- gp120. Together, this showed that amongst the different peptides 
investigated only the SYSO3DYSO3 motif competes with mAb 17b to interact with the gp120 
CD4i domain. To better quantify the inhibitory activity of this peptide, the same assay was 
run, with a range of P3YSO3 concentrations, and compared with HS12. A similar 
concentration dependency was observed on both R5 (YU2) and X4 (MN) envelopes, with 
IC50 of 2.9 and 3.1 µM respectively indicating that, interestingly, P3YSO3 interacts with 
gp120 independently of coreceptor tropism. In contrast, HS12 strongly inhibited the 
interaction between MN and mAb 17b (with a concentration as low as 0.5 µM) but was 
ineffective towards YU2, at concentrations up to 10 µM (Figure 3EF). Next, to determine the 
binding mechanism of the mCD4-S(XDXS)3 constructs, X4- and R5- gp120 were 
immobilized on a sensorchip and first allowed to bind to mCD4, mCD4-P3Y or mCD4-
P3YSO3. The resulting complexes were then probed with mAb 17b, the binding of which 
being a marker of the coreceptor binding site accessibility. As expected, mCD4 binding to 
gp120 renders the coreceptor binding site accessible, a point that was also observed, although 
with a lower efficiency, with mCD4-P3Y. These data indicate that while mCD4-P3Y bound 
to gp120, the unsulfated peptide did not sufficiently interact with the newly available surface 
to block mAb 17b recognition. In contrast, when mCD4-P3YSO3 was used instead of mCD4 
or mCD4-P3Y, the mAb 17b was no longer able to interact with the complex. Altogether, 
these data thus support the view that mCD4 first binds to gp120 and exposes the coreceptor 
binding site, with which the P3YSO3 moiety then interacts strongly enough to prevent 
antibody binding (Figure 3GH). Finally, using the direct gp120-coreceptor interaction assay 
described in Figure 1, we also demonstrated that mCD4-P3YSO3 very potently inhibits gp120 
binding to both CCR5 and CXCR4 (Figure 3IJ). This suggests that this compound could be a 
coreceptor independent HIV-1 entry inhibitor. 
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mCD4 linked P3YSO3 peptides display strong antiviral activity 
Having characterized the binding mechanism of these compounds, we investigated whether 
these anionic peptides, either conjugated or not to mCD4 displayed anti-HIV-1 activity. This 
was performed using an assay in which viral replication was measured (reverse transcriptase 
quantification) in the supernatant of blasted peripheral blood mononuclear cells (PBMC) 
isolated from three to four donors, and infected by either of the HIV-1 reference strains R5 
(Ba-L) or X4 (LAI). When used alone, none of the peptides demonstrated antiviral activity at 
the highest concentration tested (500 nM; data not shown). However, when conjugated to 
mCD4, they displayed inhibitory activity against the LAI strain, with effective doses giving 
50% inhibition (ED50) as low as 0.5 nM for mCD4-P3YSO3, which compares well to 1.4 nM 
for mCD4-HS12. Consistently with the biochemical data, the importance of the sulfate groups 
was shown by the large increase of ED50 (98 nM) that characterized mCD4-P3Y, while the 
other anionic peptides (mCD4-P3pF, mCD4-P3Asu and mCD4-E13) displayed 8.2 to 30 nM 
ED50 (Figure 4A). The Ba-L strain was also very strongly inhibited by mCD4-P3YSO3, with 
an ED50 of 1.3 nM, versus 18 nM for mCD4-HS12. None of the other conjugates displayed 
significant antiviral activity (Figure 4B). AZT, used as a reference anti-HIV molecule in the 
same assay returned ED50 of 8.7 and 11 nM for R5 and X4 viruses respectively (Figure 4AB). 
We also observed that mCD4-P3YSO3 does not need to be preincubated with the virus to be 
active. Indeed, addition of the molecule either to the cells, prior to the viral challenge or to the 
virus prior to the cell infection return, identical results (supplementary table S2). This is 
consistent with the high affinity this molecule displays for the viral envelope, presumably 
enabling a fast binding to its target, and also suggests a potential use of this kind of 
compounds as a microbicide, a condition in which inhibitors are present within the host 
tissues, before viral infection. 
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Having established that mCD4-P3YSO3 displayed very strong antiviral activity against LAI 
and Ba-L HIV-1 strains, used as model systems, we extended our investigations to using a 
series of more clinically relevant primary strains, including 92UG029, SF162, 92US723, 
96USHIPS4, 92HT599 and 98IN017. As shown in Table 1, mCD4-P3YSO3 displayed a high 
level of antiviral activity, characterized by ED50 in the range of 0.2 to 1.2 nM for five of them, 
and 29 nM for HIV-1 98IN017. As for the LAI and Ba-L strains, the mCD4 or P3YSO3 were 
only poorly- or in- active, further supporting the very strong synergistic effect induced by the 
coupling strategy. None of the molecules showed cytotoxicity at up to 1 µM (data not shown). 
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DISCUSSION 
Targeting gp120 for HIV-1 inhibition is both attractive (because the protein engages multiple 
interactions key to viral entry, thus offering multiple sites for inhibition) and challenging (in 
the entry complex, the buried surface to block comprises both the gp120-CD4 and gp120-
coreceptor interfaces). Although protein-protein interfaces are often relatively featureless and 
devoid of traditional cavities into which a small molecule can dock, the realization that the 
gp120 coreceptor binding site displays a restricted number of functionally important basic 
residues has very recently attracted the attention of many studies. Many of them reported that 
anionic molecules target the CD4i epitope, as shown by their ability to competitively inhibit 
mAb 17b binding with IC50 in the 1-100 µM range (Cormier, Persuh et al. 2000; Farzan, 
Vasilieva et al. 2000; Cohen, Forzan et al. 2008; Crublet, Andrieu et al. 2008; Brower, Schon 
et al. 2009; Dervillez, Klaukien et al. 2010; Seitz, Rusert et al. 2010; Acharya, Dogo-Isonagie 
et al.; Kwong, Dorfman et al. 2011). HS belongs to this class of CD4i domain targeting 
molecules (Crublet, Andrieu et al. 2008), and a highly sulfated and regular sequence 
comprising 12 monosaccharide units has been recently prepared. Conjugated to mCD4, it 
displays strong anti-HIV-1 activity (Baleux, Loureiro-Morais et al. 2009). However, HS is 
extraordinary complex and heterogeneous in sequence (Esko and Lindahl 2001). Based on the 
48 different units that the polymer theoretically comprises, a 12 mer library would reach 1010 
molecules. Although the reality is less (all the combinations are not possible), it remains much 
more than can be realistically synthesized for structure-activity relationship studies. Thus, to 
further develop this kind of molecule we attempted to design HS mimetic peptides, with the 
general sequence S(XDXS)3 and showed that when X was a sulfotyrosine, it binds to the 
CD4i epitope, blocking mAb 17b with IC50 of 3 µM, thus comparing very well with the above 
mentioned molecules. Interestingly, this peptide interacts equally well with R5 and X4 gp120, 
while HS especially binds to the X4 envelope (Figure 3EF). More importantly, the 
  
132
conjugation of this peptide to mCD4 dramatically enhances its binding activity, the 
conjugated molecule being able to fully prevent the gp120/mAb 17b interaction at low nM 
concentration, showing that the covalent linkage induced a strong synergistic effect. This is 
consistent with the view that high affinity mCD4 binding takes place initially, inducing the 
exposure of the mAb 17b epitope to which the sulfated peptide can then bind. As such this 
molecule is distinct from other mAb 17b blocking peptides that suppress CD4 binding and 
subsequent coreceptor binding site exposure through an allosteric inhibitory effect rather than 
competitive inhibition (Biorn, Cocklin et al. 2004). 
Although widely used as a CCR5 or CXCR4 surrogate, mAb 17b however only imperfectly 
defines the gp120 coreceptor binding site which, in addition to the CD4 induced bridging 
sheet, is also constituted by the V3 loop in particular (Dragic 2001). Thus, to better asses the 
blocking efficiency of molecules targeting the gp120-coreceptor interaction, and taking into 
account domains outside the CD4i epitope itself, CCR5 and CXCR4 were solubilized and 
functionally captured on top of biacore sensorchips. Binding of gp120 to CCR5 and CXCR4 
proved to be both CD4 and concentration dependent and inhibited by specific antagonists. 
Fitting of the binding data was expectedly complicated by several parameters, such as the 
complexity of the buffer system used, the reversible nature of both the 1D4-coreceptor and 
mCD4-gp120 complexes and the conformational flexibility of gp120, thus the calculated 
affinity values reported should probably be considered as estimates only. Nevertheless, we report 
KD’s of 10 and 150 nM for the YU2-CCR5 and MN-CXCR4 interactions respectively, 
comparable to those obtained with cellular systems in which the coreceptors remained in their 
natural cell membrane environment (Doranz, Baik et al. 1999; Babcock, Mirzabekov et al. 
2001). This assay provides a useful, label free method, to identify both binding capacity of 
envelopes and inhibitory activity of potential drugs. This was especially true in the framework 
of this study investigating sulfated/polyanionic compounds to target the gp120 coreceptor 
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binding site. Although tyrosine sulfation of coreceptors has been shown to play a less 
significant role in CXCR4- than in CCR5-dependent HIV-1 entry (Farzan, Babcock et al. 
2002), we found that when conjugated to mCD4 the sulfated P3YSO3 displays very strong 
binding activity toward both R5- and X4- gp120. Using this assay, we indeed report that 
gp120 binding to both CCR5 and CXCR4 was fully inhibited by 1:1 stoichiometric condition 
of mCD4-P3YSO3. The overall positive charge of the V3 loop, which is much higher in X4- 
than in R5-gp120 (Moulard, Lortat-Jacob et al. 2000) strongly influences the electrostatic 
potential of the coreceptor binding region of the protein. In the case of CXCR4-using viruses 
electrostatic interactions between the sulfated peptide and the V3 loop may thus also 
participate in the blocking mechanism. This view is consistent with the fact that the V3 loop 
(which importantly contributes to coreceptor binding) is located close to the CD4i bridging 
sheet and with its known capacity to interact with polyanions (Moulard, Lortat-Jacob et al. 
2000). This is further supported by the observation that all the anionic peptides prepared 
during the course of this study (mCD4-P3Asu, mCD4-P3pF, mCD4-E13 and mCD4-P3Y) 
also display some level of antiviral activity against X4- but not against R5- viruses. This also 
suggests that, in engineering such compounds, it should be advantageous to use sulfated 
peptides with only modest specificity so that they can broadly target distinct envelopes, the 
high specificity of the conjugated bivalent compound being brought by the mCD4 moiety. 
Structural studies of mCD4-P3YSO3, in complex with different gp120 would be interesting 
approaches to further define these aspects. In this regard, it can be noted that sulfated peptides 
would represent an advantage over HS, the crystallography of which, in complex with 
proteins appearing to be specially challenging (Imberty, Lortat-Jacob et al. 2007). 
Although relatively limited in molecular mass (5500 Da) the mCD4-P3YSO3 molecule has the 
remarkable property to target two critical and conserved regions of gp120, and thus to 
simultaneously block two large protein surfaces (i.e. the CD4 and the coreceptor binding site). 
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In complete agreement with the biochemical data, it displays 1 nM ED50 anti-HIV-1 activity, 
for both CXCR4 and CCR5 using model viruses in a cellular assay. Importantly, we also 
found that this compound had a broad neutralizing activity and was very effective against a 
number of HIV-1 clinical isolates, strongly suggesting that this approach deserves further 
investigation toward in vivo evaluation. No effective antagonistic inhibitors yet exist for 
CXCR4. This compound, which at 1 µM is devoid of toxicity, could be a valuable weapon 
against the more aggressive CXCR4-tropic HIV-1 strains or for patients featuring a mixed 
HIV-1 population for which CCR5 antagonist cannot be used. 
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SIGNIFICANCE 
 
While very significant progress has been made in the development of anti-HIV-1 drugs, the 
emergence of drug-resistant viruses, the inability of current therapy to be curative and its 
adverse side effects has led to an urgent need for new blocking strategies. As a target, gp120 
which features the coreceptor binding site is particularly attractive. However its cryptic nature 
makes it a difficult target which up to now has resisted attacks. 
Here we covalently linked a sulfotyrosine containing tridecapeptide that targets the gp120 
coreceptor binding site, to a CD4 mimetic (mCD4). We showed that the mCD4, in interacting 
with gp120, induces conformational changes that expose the coreceptor binding site and 
renders it available to be blocked by the sulfated peptide. In cellular assays, this compound, 
which successfully targets two critical domains of gp120, displays strong antiviral activities 
and neutralizes HIV-1 with 1 nM IC50. 
The conjugate was much more effective than a mixture of mCD4 and tridecapeptide alone, 
indicating that the covalent linkage is essential to produce a synergistic effect. This compound 
establishes a new type of inhibitor and suggests a concept by which a relatively low specific 
molecule (the sulfated peptide), coupled to a highly specific compound (the mCD4) can reach 
very high affinities for its target. Combining these two characteristics, may enable the 
molecule to accommodate mutations that invariably characterize acquired viral resistance. 
These results should have strong implications for the development of a new class of anti-HIV-
1 therapy: the mCD4-conjugate simultaneously blocks the attachment and entry domains of 
gp120 and thus inhibits viral replication at a very early stage of the viral life cycle. Most 
importantly, it has the remarkable and unique property to neutralize both CCR5- and CXCR4-
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tropic HIV-1. This is definitively a strong advantage since HIV-1 may escape from CCR5 
antagonists through selection of CXCR4-using variants. 
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EXPERIMENTAL PROCEDURES 
 
Materials 
A BIAcore 3000 machine, CM4 sensorchip, amine coupling kit and HBS-P  (10 mM HEPES, 
150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20, pH 7.4) were from GE-Healthcare. 
Streptavidin and Piperidin were from Sigma. MN and YU2 gp120 were from 
Immunodiagnostic. Soluble CD4, mAb 17b and Cf2Th coreceptor expressing cells were 
obtained through the NIH AIDS Research and Reference Reagent Program. The antibodies 
12G5 and 2D7 were purchased from R&D systems and BD pharmingen respectively. The 
HIV-1 entry inhibitors AMD3100 and Maraviroc were from Fernando Arenzana (Pasteur 
Institute, Paris). The1D4 antibody was from Flint Box, University of British Columbia. 
Synthetic phospholipid blend 1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-
glycero-3-phospho-L-serine formulation (DOPC/DOPS; 7:3, w/w), the Mini-Extruder kit, 
filter supports and polycarbonate filters with defined pore diameter (100nm) were purchased 
from Avanti Polar Lipids. Detergents, n-dodecyl-β-D-maltopyranoside (DOM), 3-[(3-
Cholamidopropyl)-dimethylammonio]-1-propane sulfonate/N,N-Dimethyl-3-sulfo-N-[3-
[[3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]propyl]-1-propanaminium 
(Chaps) and Cholesteryl hemisuccinate tris salt (CHS) were purchased from Anatrace. 
Complete, EDTA-free protease inhibitor tablets were from Roche Diagnostics. Polyethylene 
glycol 8,000 50% w/v solution was purchased from Hampton research. Resins for peptide 
synthesis were purchased from RAPP Polymere GmbH and Fmoc AAs, HATU, NMP, DMF, 
TFA were from Applied Biosystems. Fmoc-Tyr (SO3.NnBu4)-OH and Fmoc-γ-
Aminobutyric-OH (γ-Abu) were from Novabiochem, (S)-Fmoc-2-amino-octanedioc acid-8-
ter-butyl ester (Asu) from Polypeptides, and Fmoc -L-4 (O-tButylcarboxymethyl)-Phe-OH 
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(pF) from Anaspec. HPLC grade triethylamine acetate buffer was from GlenResearch. N-
succinimidyl-S-acetylthiopropionate (SATP) was from Pierce. 
 
CCR5/CXCR4 solubilization 
The human receptors CCR5 and CXCR4, featuring a C-terminal C9 tag (TETSQVAPA), 
were expressed in Cf2Th canine thymocyte cells as described previously (Mirzabekov, 
Bannert et al. 1999). The CCR5 and CXCR4 solubilization protocol was adapted from a 
described procedure (Navratilova, Sodroski et al. 2005). Briefly Cf2Th.CCR5 or CXCR4 
expressing cells (5-8x106) were solubilized in 1 ml buffer consisting of 100 mM (NH4)2SO4, 
20 mM Tris-HCl (pH 7.5), 10% glycerol, 15% PEG 8000, protease inhibitors, CHS (0.2%), 
DOM (1.5%), CHAPS (1.5%) and 0.33mM DOPC:DOPS liposomes (see detailed buffer 
preparation in the supplemental experimental procedures). The cell suspension was sonicated 
(6 x 1s pulses) and placed on a rotating wheel at 4°C for 3 hours. The solutions containing the 
solubilized coreceptors were centrifuged at 14 000 rpm for 30 minutes at 4°C and the 
supernatants were either used directly in SPR analysis or stored at -80°C until further use.  
 
Surface plasmon resonance (SPR) based binding platform 
The interactions between gp120 and its ligands (CD4, mAb 17b, CCR5 and CXCR4) were 
analyzed by SPR technology. For that purpose, N-ethyl-N’-(diethylaminopropyl)-
carbodiimide (EDC)/N-hydroxy-succimide (NHS) activated CM4 sensorchips were 
functionalized with either 1200 RU of soluble CD4, 700 RU of mAb 17b or 7000 RU of mAb 
1D4 and blocked with pH 8.5 1M ethanolamine. The C9-tagged CCR5 or CXCR4 were 
captured onto the 1D4 mAb to a level of ~ 4000 RU. In some cases, gp120 were also 
immobilized onto CM4 sensorchip. For this, MN (50µg/ml in 5 mM maleate buffer, pH 6) or 
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YU2 (50µg/mL in 10 mM acetate buffer, pH 4.8) were injected at 5 µL/min over an 
EDC/NHS activated flow cell until levels of 4500 RU was obtained. Molecules under 
investigation were injected over the different surfaces and the binding responses were 
recorded as a function of time (see supplemental experimental procedures). 
 
Peptide synthesis and purification 
Peptides were prepared by solid-phase peptide synthesis on H-Ser(tBu)-2-ClTrt-PS-resin  
using Fmoc chemistry excepted for the E13 peptide which was prepared on Fmoc-Glu(tBu)-
PHB-PS-resin. Fmoc-Tyr-(SO3.NnBu4)-OH was used to synthesize the sulfotyrosines 
containing peptide. SATP was used to introduce a protected sulfhydryl groups at the N-
terminus of each purified peptide, which were then conjugated in presence of hydroxylamine 
to a K5 maleimide-activated mCD4, the synthesis of which has been reported elsewhere 
(Baleux, Loureiro-Morais et al. 2009) to yield the desired conjugates mCD4-P3YSO3, mCD4-
P3Y, mCD4-P3pF, mCD4-P3Asu and mCD4-E13. All compounds were purified by RP-
HPLC. Analytical procedures, characterization and quantification of these materials are 
described in the supplemental information. 
 
Antiviral Assay 
Phytohemagglutinin (PHA)-P-activated PBMCs were infected either with the reference 
lymphotropic HIV-1/LAI strain (Barre-Sinoussi, Chermann et al. 1983) or with the reference 
macrophage-tropic HIV-1/Ba-L strain (Gartner, Markovits et al. 1986). These viruses were 
amplified in vitro with PHA-P-activated blood mononuclear cells. Viral stocks (including 
clinical isolates) were titrated using PHA-P-activated PBMCs, and 50% tissue culture 
infectious doses (TCID50) were calculated using Kärber’s formula (Kärber 1931). Viruses 
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(125 TCID50) were incubated for 30 min with five concentrations (1:5 dilutions between 500 
nM and 320 pM) of each of the molecules to be tested and added to 150 000 PBMCs (m.o.i. ~ 
0.001). Cell supernatants were collected at day 7 post-infection and stored at -20 °C. In some 
cases, the compounds were added to the cells prior to viral challenge. Viral replication was 
measured by quantifying reverse transcriptase (RT) activity in the cell culture supernatants 
using the Lenti RT Activity Kit (Cavisi) and AZT was used as reference anti-HIV-1 molecule. 
In parallel, cytotoxicity was evaluated on day 7 in uninfected PHA-P-activated PBMC using a 
colorimetric methyl-tetrazolium salt (MTS/PMS) assay (Promega). Experiments were 
performed in triplicate and 50, 70 and 90% effective doses (ED) were calculated using 
SoftMaxPro software.  
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FIGURE LEGENDS 
 
Figure 1: Ligand binding to CCR5 and CXCR4 immobilized sensorchips 
Carboxy-terminal C9 tagged CCR5 or CXCR4 were solubilized from Cf2Th cells and 
captured on top of a mAb 1D4 activated CM4 sensorchip. CCR5 (left) and CXCR4 (right) 
ligands were injected over the coreceptor surfaces, and the binding responses (in RU) were 
recorded as a function of time (in S). Binding of 25 nM of mAb 2D7 (blue) and mAb 12G5 
(red) to CCR5 (A) and CXCR4 (B). Binding of YU2 gp120 (black), YU2/mCD4 (blue) or 
YU2/mCD4/maraviroc (red) to CCR5 (C) or MN gp120 (black), MN/mCD4 (blue) or 
MN/mCD4/AMD3100 (red) to CXCR4 (D). Binding of the equimolar complex of 
YU2/mCD4 at (from top to bottom) 100, 66, 44, 29, 19 and 12.5 nM to CCR5 (E) or 
equimolar complex of MN/mCD4 at (from top to bottom) 225, 150, 100, 66, 44 and 29 nM to 
CXCR4 (F). The black traces correspond to the experimental data, and the red traces 
correspond to the fitted data using a 1:1 langmuir model. Binding of YU2 or MN gp120 (100 
nM) preincubated with 100 nM of mCD4 (blue) or mCD4-HS12 (red) to CCR5 (G) or CXCR4 
(H). 
 
Figure 2: mCD4-S(XDXS)3 constructs 
A miniCD4 was used as a CD4 binding site (CD4BS) ligand and covalently conjugated 
through an appropriate linker to S(XDXS)3 peptides investigated as potential coreceptor 
binding site (CoRBS) ligands. S and D are serine and aspartic acid residues respectively and 
X is either a sulfotyrosine (YSO3), a p-carboxymethyl phenylalanine (pF) an aminosuberic acid 
(Asu) or a tyrosine (Y). 
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Figure 3: The S(XDXS)3 HS mimetic peptides coupled to mCD4 inhibit gp120-CD4, 
gp120-mAb 17b and gp120-coreceptor interactions through binding to the CD4 and the 
coreceptor binding sites of gp120 
Binding responses measured when YU2 (A) or MN (B) gp120 at 100 nM, either alone (blue) 
or preincubated with 100 nM of mCD4 (pink), mCD4-P3Y (green), mCD4-E13 (turquoise), 
mCD4-P3pF (orange), mCD4-P3Asu (brown) or mCD4-P3YSO3 (red) were injected over a 
CD4 activated surface. YU2-mCD4 (C) or MN-mCD4 (D) complexes (25 nM) were 
preincubated with 5 µM of HS12 (red), P3YS03 (green) or the other HS mimetic peptides 
(none, P3Y, E13, P3pF and P3Asu; all in black) and injected over a mAb 17b activated 
surface. The blue trace shows the binding of gp120 to mAb 17b in the absence of mCD4. The 
P3YSO3 peptide (E) or HS12 (F) at different concentrations were coincubated with YU2-
mCD4 (circle) or MN-mCD4 (square) and injected over a mAb 17b surface. The binding 
response (mean of triplicate experiment) recorded at the end of the injection phase was plotted 
versus the concentration of the inhibitors in µM. Overlay of sensorgrams showing the 
injection of 100 nM of mCD4 (blue), mCD4-P3Y (black) or mCD4-P3YSO3 (red), from 0 to 
600 seconds, over immobilized YU2 (G) or MN (H) gp120, after which 15 µg/ml of mAb 17b 
was injected from 600 to 900 seconds. Binding of YU2 or MN gp120 (100 nM) preincubated 
with 100 nM of mCD4 (blue) or mCD4-P3YSO3 (red) to CCR5 (I) or CXCR4 (J). In all 
graphs, binding signals were recorded in RU as a function of time (S).  
 
Figure 4: Antiviral activity of mCD4 linked to either HS12 or S(XDXS)3 HS mimetic 
peptides 
PHA-P-activated PBMCs were infected with either (A) LAI (X4 tropic) or (B) Ba-L (R5 
tropic) HIV-1 strains, preincubated with each of the drugs under investigation (1:5 dilutions 
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between 500 nM and 320 pM). Molecules and viruses were maintained throughout the 
culture, and cell supernatants were collected at day 7 post-infection. Reverse transcriptase 
activity was quantified from which 50 (black), 70 (grey) and 90% (white) effective doses 
(ED) were calculated. In the absence of the inhibitory compounds, the RT level was in the 
range of 10000-25000 and 6500-10000 pg/ml (depending on the donor) for LAI and Ba-L 
strains respectively. Data are represented as mean of triplicate experiments (± SEM) 
performed on PBMCs from three to four donors. 
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Table 1: Anti-HIV-1 activity of AZT, mCD4-P3YSO3, P3YSO3 and mCD4 against clinical 
HIV-1 isolates 
 
 
 
 
Viral strain: 
Clade-tropism 
 92UG029 
A-X4 
SF162 
B-R5 
92US723 
B-R5/X4 
96USHIPS4 
B-R5/X4 
92HT599 
B-X4 
98IN017 
C-X4 
        
AZT ED50 7±0 8 ±7 8±0.1 19±9 9±4 8±3 
 ED70 16±3 13±8 17±1 27±11 22±5 19±5 
 ED90 61±17 31±3 59 ±19 56±15 110±13 108±25 
 
mCD4-P3YSO3 ED50 0.2±0.0 0.3±0.2 0.3±0.1 1.2±1 0.5±0.2 29±18 
 ED70 0.3±0.1 0.4±0.3 0.35±0.2 1.6±1.2 1.3±0.9 147±9 
 ED90 0.8±0.3 0.9±0.2 0.45±0.2 3±1.4 3.5±0.0 > 500 
 
P3YSO3 ED50 > 500 > 500 > 500 > 500 > 500 > 500 
 ED70 > 500 > 500 > 500 > 500 > 500 > 500 
 ED90 > 500 > 500 > 500 > 500 > 500 > 500 
 
mCD4 ED50 403±76 245±155 23±1 > 500 355±155 > 500 
 ED70 > 500 352±105 34±10 > 500 > 500 > 500 
 ED90 > 500 > 500 52±22 > 500 > 500 > 500 
 
The table shows the effective dose (ED, mean of triplicate determination), in nM (± s.d.) required 
to inhibit 50, 70 and 90 % of HIV-1 replication. 
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A heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti 
HIV-1 activity independently of coreceptor usage 
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Figure S1, related to Figure 2 
RP-HPLC chromatograms overlay of mCD4-P3YSO3, mCD4-P3Y, mCD4-P3pF, mCD4-
P3Asu and mCD4-E13.  
 
Figure S2, related to Figure 2 
MS data for mCD4-P3YSO3, mCD4-P3Y, mCD4-P3pF, mCD4-P3Asu and mCD4-E13. 
 
Table S1, related to Figure 2 
Table reports the synthesis yield and the characterization data (MS and HPLC retention time) 
at each step of the synthesis. 
 
Table S2, related to Figure 4 
Table reports the antiviral activity of AZT, mCD4-P3YSO3, P3YSO3 and mCD4, measured 
when the molecules were either added to the virus prior to infection, or added to the cells 
prior to the viral challenge.  
 
Supplemental experimental procedures, related to the: 
 
• Peptide synthesis, conjugation, purification and characterization 
• Buffer preparation for the solubilisation and capture of CCR5 and CXCR4 
• Biosensor binding experiments 
Supplemental figures 
 
Figure S1. RP-HPLC chromatograms overlay of (from top to bottom) mCD4-P3YSO3, 
mCD4-P3Y, mCD4-P3pF, mCD4-P3Asu and mCD4-E13.  
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Absorbance unit (Au) was acquired by direct injection of each conjugate in an analytical C18 
RP-HPLC column, eluted with linear gradient of CH3CN in 50 mM aqueous NEt3-AcOH over 
20 min. The traces confirmed the high purity (>95%) achieved after purification. 
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Figure S2. MS data for (from top to bottom) mCD4-P3YSO3, mCD4-P3Y, mCD4-P3pF, 
mCD4-P3Asu and mCD4-E13.  
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M/z full scan spectrum was acquired by direct infusion of each conjugate in a Q-Tof Micro 
mass spectrometer using negative mode. Ion spray source cone voltage and collision energy 
were set to 5 V in order to avoid desulfation. Average mass (M), determined using MaxEnt1 
software, unambiguously confirmed the identity of the compounds. 
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Supplemental tables 
Table S1 
peptide Yield  Formula Expected mass 
(monoisotopic) 
Found Retention time (min) 
P3YSO3 31 C82H98N14O49S6 2253.3835 [M-H]- 2253.3164 8.3 (10-30% over 20min) 
P3Y 8 C82H98N14O31 1775.6601 [M+H]+ 1775.6370 11.7 
P3pF 14 C94H110N14O37 2027.7235 [M+H]+ 2027.7490 6.2 
P3Asu 10 C76H122N14O37 1823.8174 [M+H]+ 1823.8474 16.5 (0-10% over 20min) 
E13 73 C69H100N14O41 1781.6170 [M+H]+ 1781.6299 12.1 
Peptide-SATP Yield  Formula Expected mass 
(monoisotopic) 
Found Retention time (min) 
(5-25% over 20min) 
P3YSO3-SATP 60 C87H104N14O51S7 2383.3942 [M-H]- 2383.4316 11.6 
P3Y-SATP 43 C87H104N14O33S1 1903.6533 [M-H]- 1903.6781 16.0 
P3pF-SATP 50 C99H116N14O39S1 2155.7167 [M-H]- 2155.7869 9.3 
P3Asu-SATP 36 C81H128N14O39S1 1953.8262 [M+H]+ 1953.7822 15.2* 
E13-SATP 34 C74H106N14O43S1 1909.6181 [M-H]- 1909.6188 6.3 
Conjugate Yield  Formula Expected mass 
(average) 
Found Retention time (min) 
(20-40% over 20 min) 
mCD4-P3YSO3 47 C221H314N54O88S13 5552.0933 5551.5127 11.5 
mCD4-P3Y 38 C221H314N54O70S7 5071.7081 5071.5005 12.8 
mCD4-P3pF 67 C233H326N54O76S7 5323.9318 5323.5850 10.7 
mCD4-P3Asu 23 C215H338N54O76S7 5119.8291 5119.5283 10.8 
mCD4-E13 58 C208H316N54O80S7 5077.5750 5077.1021 11.4 
*10-30% linear gradient of CH3CN in 0.08% aqueous TFA over 20 min. 
 
The table reports the synthesis yield (%) and the characterization data (MS and HPLC 
retention time) at each step of the synthesis, i.e., the peptides, the SATP peptides and the 
mCD4-peptide conjugates. 
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Table S2: Anti-HIV-1 activity of AZT, mCD4-P3YSO3, P3YSO3 and mCD4 against LAI 
HIV-1  
 
  Pre-treated cells Pre-treated viruses 
    
AZT ED50 16.5 ± 12 20  ± 12 
 ED70 33 ± 18 38 ± 18 
 ED90 96 ± 11 111 ± 40 
    
mCD4- P3YSO3 ED50 0.5 ± 0.2 0.5 ± 0.3 
 ED70 0.6 ± 0.2 0.7 ± 0.3 
 ED90 1 ± 0.2 0.9 ± 0.2 
    
P3YSO3 ED50 > 500 > 500 
 ED70 > 500 > 500 
 ED90 > 500 > 500 
    
mCD4 ED50 310 ± 190 406 ± 94 
 ED70 > 500 474 ± 27 
 ED90 > 500 > 500 
 
The table shows the effective dose (ED, mean of triplicate determinations), in nM (± s.d.) 
required to inhibit 50, 70 and 90 % of HIV-1 replication, when the compounds were 
preincubated either with the cells or with the viruses. 
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Supplemental experimental procedures 
 
Peptide synthesis and purification. Peptides P3YSO3, P3Y, P3pF and P3Asu were 
synthesized on H-Ser(tBu)-2-ClTrt-PS-resin (100 μmoles; 0.78 mmole/g), and E13 on Fmoc-
Glu(tBu)-PHB-PS-resin (100 μmoles; 0.61 mmole/g), using an Applied 433 peptide 
synthesizer. Chain elongation was performed using 10 equivalents of Fmoc amino acids and 
HATU/DIEA activation. Peptides were released from the resin by TFA/TIS/H2O (95/2,5/2,5) 
treatment for 1h30 at room temperature, except for the sulfated peptide which was released at 
4°C (ice bath). The crude peptides were isolated by cold diethyl ether precipitation, 
solubilised in water by adding 3% NH4OH, except the sulfated peptide that was rapidly 
dissolved in 100 mM ammonium hydrogen carbonate buffer. After lyophilisation, the crude 
peptides were purified by C18 RP-HPLC using 50 mM aqueous NEt3-AcOH (100 mM for the 
sulfated and E13 peptides) and CH3CN as eluents.  Purified peptides were analysed by mass 
spectrometry (Waters ionspray Q-TOF–micro) and quantified by amino acid analyses (Hitachi 
L-8800 apparatus). Peptide purity was controlled by analytical C18 RP-HPLC using a linear 
gradient of CH3CN in 50 mM aqueous NEt3-AcOH over 20 min (Waters Symetry C18-300Å, 
3.5 μm, 2.1x100 mm column, 0.35 ml/min flow rate). See Table S1. 
 
S-acetylthiopropionate peptides. For the S-acetylthiopropionate peptides preparation, 
peptides were dissolved in 50 mM sodium phosphate buffer pH 8 (1 mM final concentration). 
The S-acetylthiopropionate group was introduced via stepwise addition of 10 equivalents of 
N-succinimidyl-S-acetylthiopropionate (SATP; 0.26 M in DMSO) over a 40 min period. After 
1h30, S-acetylthiopropionate peptides were purified by C18 RP-HPLC using linear gradient 
of CH3CN in 50 mM aqueous NEt3-AcOH over 20 min (C18-300Å, 5 μm, 10x250 mm 
column, 6 ml/min flow rate). The SATP derived peptides purity was controlled by analytical 
C18 RP-HPLC using linear gradient of CH3CN in 50 mM aqueous NEt3-AcOH over 20 min 
(Waters Symetry C18-300Å, 3.5 μm, 2.1x100 mm column, 0.35 ml/min flow rate). See Table 
S1. 
 
mCD4-peptide conjugates. Maleimide activated miniCD4 (mCD4-Mal) was prepared as 
described in WO/2009/098147, WO/2008/015273 and reference Baleux et al. 2009 of the 
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main manuscript. For peptide coupling to mCD4-Mal, SATP peptides were dissolved in 100 
mM sodium phosphate buffer pH 7.2 (1 mM final concentration), after which 100 μl of 0.5 M 
NH2OH, HCl in 100 mM sodium phosphate buffer (pH adjusted to 7.2 by 4N NaOH) was 
added. Deprotection of the thiol function was monitored by HPLC. After 30 min, 0.3 
equivalent of mCD4-Mal in H2O (1.5 mM) was added. After another 30 min, mCD4-peptide 
conjugates were purified by C18 RP-HPLC using a linear gradient of CH3CN in 50 mM 
aqueous NEt3-AcOH over 20 min (C18-300Å, 5 μm, 10x250 mm column, 6 ml/min flow 
rate). mCD4-peptide conjugates were controlled by analytical C18 RP-HPLC using linear 
gradient of CH3CN in 50 mM aqueous NEt3-AcOH over 20 min (Waters Symetry C18-300Å, 
3.5 μm, 2.1x100 mm column, 0.35 ml/min flow rate), negative mode mass spectrometry and 
quantified by amino acid analysis. See Figure S1, S2 and table S1. 
 
Liposome and buffer preparation for CCR5/CXCR4 solubilisation. To prepare liposomes 
(final concentration of 3.3 mM), a pre-determined volume of synthetic Phospholipid Blend 
DOPC:DOPS (7:3, w/w) was transferred into a glass test tube and a thin lipid film was 
formed on the side walls of the glass tube glass by rotating the tube while evaporating all the 
chloroform using a stream of nitrogen gas. Once all the chloroform had been evaporated, a 
HEPES buffer (50mM Hepes, 150 mM NaCl, pH 7.0) was added to dissolve the dry lipid 
films. The lipid mixture was vortexed to facilitate dissolving the films, then the mixture was 
frozen, thawed, and vortexed four times. Unilamellar vesicles (ULC)/liposomes were 
prepared by classical extrusion through a 100 nm pore diameter polycarbonate filter using an 
Avanti Mini-Extruder kit. Liposomes were freshly extruded for every experiment. The 
0.33mM liposome preparation was then mixed into a solution of 100 mM (NH4)2SO4, 20 mM 
Tris-HCl (pH 7.5), 10% glycerol, 15% PEG 8000, CHS (0.2%), DOM (1.5%), CHAPS 
(1.5%) supplemented with protease inhibitors (EDTA free Complete from Roche) and used 
for CCR5 and CXCR4 solubilisation. 
 
Preparation of the Biacore binding surfaces. For sensorchip immobilization of CCR5 and 
CXCR4, the 1D4 antibody (recognizing the coreceptor C9 C-terminal tag) was first cross 
linked to a level of 7000 RU onto a CM4 sensorchip. This was performed by activation of the 
chip surface with 50 µL of 0.2 M N-ethyl-N’-(diethylaminopropyl)-carbodiimide (EDC) and 
0.05 M N-hydroxy-succimide (NHS) at 5 µL/min followed by a 12 minutes injection of 1D4 
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at 100 µg/ml in 10 mM sodium acetate buffer, pH 4.2 and a 5 mins injection of 1M 
ethanolamine. The 1D4 surface was then equilibrated into a running buffer consisting of 
50mM HEPES pH 7.0, 150 mM NaCl, 5% glycerol, 5 % PEG 8000, 5 µM CaCl2, 1 µM 
MgCl2, 0.1 % DDM, 0.1 % CHAPS, 0.02 % CHS, 5 µM of  7:3 DOPC:DOPS and 0.1 mg/ml 
BSA. Solubilized CXCR4 or CCR5, in the above described liposome preparation, were 
captured via the interaction between its C9 tag and the 1D4 mAb to a level of approximately 
3000-5000 RU. The system was then equilibrated with the running buffer at 5 µl/min for 
approximately 20 minutes. 
Other binding surfaces were prepared by injecting over EDC/NHS activated CM4 sensorchips 
CD4 (10 µg/mL in 10 mM acetate buffer, pH 5), streptavidin (200 µg/mL in 10 mM acetate 
buffer, pH 4.2),  mAb 17b (5 µg/mL in 10 mM acetate buffer, pH 5), MN gp120 (50 µg/ml in 
5 mM maleate buffer, pH 6) or YU2 gp120 (50 µg/mL in 10 mM acetate buffer, pH 4.8). This 
was performed at 5 µL/min until levels of 1200 (for CD4), 700 (for mAb 17b), 3000 (for 
streptavidin) or 4500 (for gp120s) RU were achieved. Surfaces were then blocked with pH 8.5 
1 M ethanolamine during 5 minutes. 
 
Biosensor binding experiments and sensorgram evaluation. Samples under investigation 
were prepared in HBS-P running buffer when injected at 10 µl/ml over CD4, mAb 17b or 5 
µl/mL over the gp120 surfaces. Streptavidin was used as a reference surface, and binding 
signals were recorded with on line subtraction of control sensorgrams. Surfaces were 
regenerated by 1 min injection of 10 mM HCl. For binding studies on immobilized CCR5 or 
CXCR4, samples under investigation were prepared in 50mM HEPES pH 7.0 buffer, 150 mM 
NaCl, 5% glycerol, 5 % PEG 8000, 5 µM CaCl2, 1 µM MgCl2, 0.1 % DDM, 0.1 % CHAPS, 
0.02 % CHS, 5 µM 7:3 DOPC:DOPS and 0.1 mg/ml BSA (running buffer). 1D4 was used as 
a reference surface. After each binding cycle, performed at 30 µl/ml, the 1D4 surface was 
regenerated with 10 mM NaOH containing 1% n-octyl-β-D-glucopyranoside at 100 µl/min, 
and subsequently reloaded with either CCR5 or CXCR4. Alternatively, to avoid this 
regeneration step, the gp120-coreceptor complex was washed with running buffer, until the 
signal returned to the baseline level (usually 30-60 min). 
The binding curves obtained when gp120-CD4 complexes were injected over either CCR5 or 
CXCR4, were evaluated with the Biaevaluation 3.1 software. Data were analyzed by fitting of 
both association and dissociation phases for several concentrations, using a simple 1:1 binding 
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model. Several parameters (including the conformational flexibility of gp120 and the reversible 
nature of the gp120-mCD4 complex) were likely to complicate the binding kinetics and the 
values reported should be considered as estimates only. The affinities (dissociation equilibrium 
constants: Kd) were calculated from the ratio of dissociation and association rate constants (Kd = 
koff/kon). 
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6.5 Discussion 
Currently, there is no effective anti-HIV-1 vaccine and there is no entry inhibitor 
that is capable of inhibiting both X4 and R5 HIV-1 viral strains simultaneously at 
the level of the gp120 – coreceptor interaction. Maraviroc is the first and only 
CCR5 antagonist which has been approved for treatment in HIV-infected patients. 
Maraviroc binds to a small hydrophobic pocket inbetween the transmembrane 
helices and thus induces a slight conformational change in the coreceptors which 
renders it non-recognizable by HIV-1 (Dorr, Westby et al. 2005). However, as 
with most antiretrovirals, the high replication rate and mutation rate of HIV-1 
permits it to eventually develop resistance to Maraviroc and the envelope adapts 
in such a way that it is able to recognize the drug-bound confirmation of the 
CCR5 coreceptor. Another short-coming of the use of an entry inhibitor that 
blocks solely the R5 HIV-1 strain, is the outgrowth of CXCR4-tropic, more 
virulent HIV-1 isolates that were present at low frequencies prior to the initiation 
of therapy or new infections of X4 HIV-1. Thus, it is very important to target both 
R5 and X4 viruses simultaneously. 
In the early stages of HIV-1 infection (via sexual transmission), it is believed that 
heparan sulphate (HS) aids to concentrate the virus on the mucosa (Saidi, Magri et 
al. 2007), thus bringing it into close contact with its host cell receptors, CD4 and 
CCR5. HS has also been shown to play a possible role in transporting HIV-1 
through the blood-brain barrier during the late stages of AIDS (Argyris, 
Acheampong et al. 2003). Also, cells that are treated with HS degrading enzymes, 
demonstrated a reduced HIV-1 attachment and infection, thus these anionic 
polysaccharide molecules were believed to play an important role in HIV-1 
infection (Ohshiro, Murakami et al. 1996; Mondor, Ugolini et al. 1998; Saphire, 
Bobardt et al. 2001). The interaction between HIV-1 gp120 and HS has mainly 
been attributed to the V3 loop, however heparin binding domains have also been 
identified in the V2 loop, in the C-terminal domain and within the CD4 induced 
bridging sheet (Crublet, Andrieu et al. 2008). A bivalent entry inhibitor (mCD4-
HS12) has been developed which consists of a mini CD4 molecule (mCD4) which 
is covalently attached to a highly sulphated 12mer oligosaccharide (HS12, contains 
18 sulphate residues). This molecule initially binds the CD4-binding site 
(CD4BS) on gp120 with the mCD4 moiety, induces the conformational changes 
necessary to expose the coreceptor binding site (CoRBS), and due to the small 
size of the HS12 (3 kDa, 50 times smaller than a neutralizing antibody), it is able 
to rapidly and effectively bind to the CoRBS and block entry through both CCR5 
and CXCR4 pathways, resulting in nanomolar antiviral activity (Baleux, 
Loureiro-Morais et al. 2009). 
Heparan sulphates are exceedingly complex molecules and unlike DNA and 
proteins, they do not have a blue print template or coding sequence. The basic unit 
is a disaccharide which consists of a uronic acid (either α-L-iduronic acid [IdoA] 
or β–D-glucuronic acid [GlcA]) linked (1→4) to a D-Glucosamine (GlcN). 
Specialised enzymes (N-deacetylase/N-sulphotransferase, epimerase, and O-
sulphotransferase) act in an organised and regulated fashion to sculpt the mature, 
sulphated polysaccharide chains. Not all residues in the disaccharide are modified, 
thus there is an enormous level of variation in an HS oligosaccharide chain. For 
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example, a DNA sequence of 6 base pairs can generate 46 or 4096 possible 
different sequences. For a hexapeptide, we can have 206 or 64 million different 
possibilities (Shriver, Liu et al. 2002). However for a 12mer of HS (six 
disaccharide units), there can be 486 (12 billion) different possible sequences, 
which is a staggering degree of variation. The regulation of the HS biosynthetic 
process is poorly understood, however extremely important for a myriad of 
biological processes and pathological states. Enormous structural complexity and 
heterogeneity is thus generated and all these different structures have different 
functions in the biological system. Molecular characterization of GAGs and of 
their interacting partners is still in the early stages of development; they are not 
easily sequenced and there is a lack of routine biosynthetic and analytical tools for 
GAGs. Thus a technique whereby one can easily characterise the structures that 
resemble those of GAGs interacting with proteins, will greatly advance our 
understanding of how their structures relate to different functions.  
In order to further develop the mCD4-HS12 molecule which is fully sulphated and 
which took one year to synthesize, we wanted to determine the minimal sulphate 
residues required for CoRBS binding as well as find a molecule that is faster to 
synthesize/purify from natural sources. One approach would have been to screen 
large libraries of differently sulphated HS12mers. However, this would be virtually 
impossible due to the enormous amount of potential variations as well as the fact 
that obtaining reasonable quantities of pure homogeneous HS12 oligosaccharides is 
difficult if not impossible without using synthetic techniques. Finally, if a highly 
anti-viral HS12 was found, structure-function analysis would be very complicated 
due to the limiting techniques for oligosaccharide structural analysis. During this 
work, a relatively small library (12 populations) of HS12mers was generated 
through several ion exchange chromatography runs. Each member of the HS12 
fractionated library was screened for its ability to inhibit gp120-CD4 complexes 
from binding to 17b on the biacore. Finally, 50µM of the most sulphated fraction 
from the natural fractionated HS12 library was 30 times less efficient than 10µM 
of the HS12 un-fractionated mixture and 30 times less efficient than 5µM of the 
synthetic HS12. The active HS12 molecule might have been ‘lost’ during the 
fractionation process which could indicate that there exists a highly active 
molecule in the mixture which was not identified. Therefore a different approach 
was necessitated to improve the specificity, affinity and speed of production of the 
glyco-moiety of mCD4-HS12. 
It is known that R5 HIV-1 relies heavily on the N-terminal and second 
extracellular loop of CCR5 for entry. Interestingly, the amino terminus contains 
several sulphated tyrosines as well as certain neutralizing antibodies (E51 and 
412d) which both interact with the conserved CCR5 binding site (Farzan, Choe et 
al. 1998; Farzan, Babcock et al. 2002; Choe, Li et al. 2003; Huang, Lam et al. 
2007). Numerous studies have exploited the properties of anionic polyanions, 
sulphated molecules and peptides derived from the N-terminal of chemokine 
coreceptors as potential inhibitors of the 17b mAb binding to the CD4i with µM 
range IC50s  (Cormier, Persuh et al. 2000; Farzan, Vasilieva et al. 2000; Cohen, 
Forzan et al. 2008; Crublet, Andrieu et al. 2008; Brower, Schon et al. 2009; 
Dervillez, Klaukien et al. 2010; Acharya, Dogo-Isonagie et al. 2011; Kwong, 
Dorfman et al. 2011). These studies show inhibition of 17b mAb binding to the 
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CD4i, however, this antibody is only a partial coreceptor surrogate as it only 
recognises the bridging sheet and not the V3 loop (Dragic 2001), which is another 
critical region involved in coreceptor binding. Thus this antibody is a poor 
coreceptor mimic. However, due to the difficulty in manipulating coreceptors, this 
mAb was used as a surrogate coreceptor. 
The present study aimed to replace the mAb 17b as an ‘incomplete’ coreceptor 
surrogate and use actual coreceptors in experiments where potential entry 
inhibitors could be screened for their ability to bind the CoRBS. To do this, we 
captured either coreceptor (CCR5 or CXCR4) on the biacore surface so that HIV-
1 entry inhibiting molecules could be screened for their ability to inhibit gp120-
CD4 complexes from binding to their respective coreceptors. Here, we 
demonstrated two challenging feats in biology; firstly, we have solubilized and 
immobilized both CCR5 and CXCR4 in a lipid/detergent environment preserving 
their functional structures and for the first time, kinetic data has been determined 
for gp120-CD4 complexes binding to CXCR4 using surface plasmon resonance. 
We report a KD of 154 ± 68 nM for X4 gp120-CD4 interaction with CXCR4 and 
KD of 11.5 ± 2.9 nM for R5 gp120-CD4 interacting with CCR5. These affinities 
compare well with those calculated for coreceptors that remain in their natural 
membrane environment (Doranz, Orsini et al. 1999; Babcock, Mirzabekov et al. 
2001). This assay has many advantages; most importantly, it allows the isolation 
of native GPCRs for specific interaction analysis, which is much a more relevant 
and complete approach for HIV-1 entry inhibitor screening assays as compared to 
using a coreceptor surrogate (e.g. mAb 17b). The assay is performed in real-time, 
there is no labelling required of either the ligand or the receptors, the coreceptors 
on the surface are re-usable after a long dissociation period and the results are 
reproducible. It is also very user-friendly to be able to store the pre-solubilized 
coreceptors at -80°C as this allows for rapid preparation time for the SPR 
experiments and the same ‘batch’ of purified coreceptors can be used for several 
different experiments on different days – allowing for standardisation of the 
results. This assay can be used for a multitude of tests to elucidate many 
unanswered questions on the coreceptor binding site of gp120. E.g. one can probe 
the V3 loop of a pre-triggered gp120 with various antibodies in search of new 
broadly neutralizing antibodies. However, the disadvantages of this technique are 
the fact that one is required to work with lipid/detergent mixtures which are 
complex to manipulate as they can form larger micelles and their density in a 
buffer can change over time which can affect binding results. Also, this technique 
requires long dissociation periods (which can reach up to 2 hours each) if the 
same coreceptor surface is required for multiple injections. 
The second challenging feat which was achieved during this work was that GAG- 
mimetic peptides have been produced which contain sulphated amino acids that 
mimic the sulphated residues in the disaccharide building block of oligosaccharide 
chains and these peptides can be used as tools to define the number and placement 
of sulphated residues that are critical for a certain protein-GAG interactions. 
Since, there are few techniques that allow the study of structural characterisation 
and structure-function relationships for GAGs, the use of GAG-mimetic peptides 
can greatly advance this field. 
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Five peptides that mimic GAGs were used in this study; the S(XDXS)3 sequence 
was used to replace the synthetic HS12mer. Thus 13 amino acids residues were the 
equivalent length of a 12mer oligosaccharide. The sulphate, carboxyl and 
hydroxyl groups on a HS disaccharide were mimicked by the use of serine (S) and 
aspartate (D) amino acids in the S(XDXS)3 sequence. Since we were interested in 
mimicking the SO3 group in the GAG chains, several functional groups were 
placed in the S(XDXS)3 sequence in the X position. Either sulphated tyrosines 
was used (P3YSO3), or non-sulphated tyrosines (P3Y), or a p-carboxymethyl 
phenylalanine (P3pF), or a aminosuberic acid (P3Asu), or a charged carboxyl 
chain of 13 glutamic acids (E13) was also tested to see if a non-specific anionic 
polyanion showed an effect. Despite having set up a system where solubilized 
coreceptors could be used instead of mAb 17b to test coreceptor binding, we did 
test the peptide GAG mimics for their ability to prevent gp120-CD4 complexes 
from binding to a 17b surface so as to compare the peptides to existing entry 
inhibitory molecules. The peptide containing 6 sulphotyrosine residues (P3YSO3) 
displayed the lowest IC50 of 3µM, which compares very well to other inhibitors. 
Interestingly, this was demonstrated with the peptide alone, it was not yet 
covalently bound to the mCD4 moiety. 
The importance of the tyrosine sulphation in the N-terminus of CCR5 has been 
well documented for the binding of R5 HIV-1 variants, surprisingly, the existence 
of sulphated tyrosines (at positions 7, 12 and 21) on the HIV-1 coreceptor CXCR4 
(Farzan, Mirzabekov et al. 1999) are not as critical for the binding and entry of X4 
HIV-1 variants (Farzan, Babcock et al. 2002). Interestingly, our results show that 
the peptide containing 6 sulphated tyrosines, when conjugated to the mCD4 
moiety (mCD4-P3YSO3), displayed equivalent potent inhibition for the R5 
gp120-CD4 complexes binding to solubilized CCR5 as it did for X4 gp120-CD4 
complexes binding to solubilized CXCR4. Thus, perhaps the presence of the 
mCD4, brings the sulphated peptide so close to the CoRBS and the basic V3 loop 
of X4 gp120, that it is able to form electrostatic interactions and salt bridges with 
the CoRBS of X4 gp120. This is also true for the R5 gp120. Despite the general 
difference in overall V3 loop charge between X4 gp120 and R5 gp120, such an 
inhibitor targets both envelope tropisms. 
Interestingly, interactions are made between the CoRBS and the inhibitors’ 
sulphotyrosines, however, similar interactions are probably not observed / made 
when the CD4 bound envelope binds to the N-terminal of CXCR4 containing 
sulphotyrosines. This however, would need to be confirmed by crystallographic 
studies of the gp120-CD4 complex together with the mCD4- P3YSO3 inhibitor. 
Owing to the mCD4, the affinity of the ‘triggered’ envelope for the linked-
sulphated peptide is greatly increased and due to its small size, the spatial 
proximity of the sulphated peptide is so high it binds to the CoRBS strongly. 
Thus, a range of differently charged V3 loops (R5 variant possessing a net V3 
loop positive charge of ≤ 5 and that of an X4 variant is typically higher, ≥ 5) can 
be targeted by the linked-GAG mimicking peptide. The sulphated inhibitory 
molecule should contain at least one sulphated tyrosine so that it can inhibit R5 
viruses [as shown by (Huang, Lam et al. 2007), one sulphotyrosine binds at the 
base of the R5 V3 loop as seen in the crystal structure]. Then for the sulphated 
inhibitor molecule to also target X4 envelopes, it can contain more sulphotyrosine 
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residues because a typical X4 V3 loop has a net higher positive charge compared 
to that of the R5 V3 loop. Therefore, for the reason mentioned above, the 
inhibitory peptide must contain ≥ 1 sulphotyrosine, and preferably more 
sulphotyrosines so that it can target R5 envelopes and a range of X4 V3 loops, 
including highly basic V3 loops.  
All the mCD4-linked peptide GAG mimetic inhibitors were tested in a PBMC 
infection assay by our collaborators at the CEA, where laboratory-adapted HIV-1 
strains (HIV-1 LAI [X4] and HIV-1 Ba-L [R5]) were used to infect donor PBMCs 
either in the presence or absence of each inhibitor. Interestingly, when cells were 
infected with the X4 HIV-1 strain, all the bivalent inhibitors (except mCD4-P3Y) 
displayed ED50s that were below that of AZT, a nucleoside analog reverse-
transcriptase inhibitor that was approved for treatment of HIV-1 in 1987. 
However, when the cells were infected with the R5 strain, all the bivalent 
inhibiters were ineffective (except mCD4-P3YSO3) at inhibiting HIV-1 entry. 
Again, this suggests that these anionic compounds bind stronger to the CoRBS of 
X4 envelopes than to the less positively charged CCR5 envelopes due to the 
overall higher charge carried by the V3 loop of X4 envelopes (Moulard, Lortat-
Jacob et al. 2000). Thus, for both strains of HIV-1 (LAI and Ba-L), an ED50 as 
low a 1 nM was necessary for HIV-1 entry inhibition by mCD4-P3YSO3. This is 
currently, the only entry inhibitor that targets both CCR5 and CXCR4 utilizing 
HIV-1 strains with such a low effective dose. In addition, up to 1 µM 
concentration, mCD4-P3YSO3 shows no sign of toxicity towards the cell. This 
molecule has the potential to be used as a prophylactic prevention strategy or as a 
treatment for people already infected with HIV-1 (microbicide). This new bivalent 
molecule is relatively rapid to produce and the usage of chiral amino acids can be 
debated to escape recognition by host proteases and the use of sulphonate (instead 
of sulphate) could be considered which are more stable than sulphates.  
Not only is the sulphated GAG mimetic peptide a huge success for HIV-1 entry 
inhibition, but this mimetic will greatly advance the glycobiology field. This is so 
since structural characterisation of GAGs is so cumbersome, tedious and 
technically challenging that the use of a peptide, where the position and type of 
negative change can be easily and rapidly modified, will enormously aid 
structure-funtion analysis. For example, with the S(XDXS)n sequence, the 
sulphates can be placed at different positions (on one extremity 
S[XSDXSSXDXSXDXS], in the middle S[XDXSXSDXSSXDXS] or throughout 
S[XSDXSSXSDXSSXSDXSS]) and this can give a more refined idea of where and 
which sulphated residues are critical for a certain protein-GAG interaction. 
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Chapter 7: Side­Projects 
7.1 Screening  of  small  natural  molecules  for  HIV­1  entry 
inhibitory capacity 
Our ability to analyse molecules for their ability to block gp120-HS and gp120-
17b interactions, has attracted the attention of a company. In that context, using 
the screening system described in Figure 6.2, we investigated three naturally 
derived small anionic molecules, extracted from natural sources, for their ability 
to inhibit gp120 (either CCR5 utilizing [R5] or CXCR4 utilizing [X4]) from 
binding to heparan sulphate, CD4 or to mAb 17b. These molecules behave strongly 
as HS-like molecules, i.e. they inhibit the binding of envelopes to both HS and (in the 
presence of soluble CD4) mAb17b. This strongly suggests that these compounds bind 
to clusters of basic residues on gp120, which includes the CD4 induced epitope 
(coreceptor binding site) (Vives, Imberty et al. 2005) for R5 and X4 envelopes and 
the V3 and V2 loops (Crublet, Andrieu et al. 2008), at least for X4 envelopes. Further 
details on these experiments are withheld for confidentiality reasons, however, 
micro molar IC50s were calculated for these molecules with one molecule in 
particular displaying a higher affinity compared to the other two. This work is 
currently being prepared for publication.  
7.2 Molecular  mechanisms  underlying  the  increase  in 
resistance to chemokines of R5 viruses in HIV infection 
CCR5-utilizing viruses (R5) are predominant during the chronic, asymptomatic 
stages of HIV-1 infection, while CXCR4-utilizing viruses (X4 or R5/X4) emerge 
after several years later in about half of the infected individuals who progress to 
AIDS. Therefore, the other half of the infected individuals who progress to AIDS, 
develop the disease in the presence of only R5 viruses. Since CCR5 and CXCR4 
are GPCRs, their natural binding partners, chemokines, are able to inhibit viral 
entry by one of two ways; either by sterically inhibiting gp120 from accessing the 
coreceptor binding site or by causing endocytosis of the coreceptor. However, 
according to the literature, some R5 viruses develop increased infectivity and 
resistance to inhibition by the chemokines during infection. To define the 
molecular mechanisms whereby these viruses become resistant to chemokine 
inhibition, our collaborators at the Institut Pasteur (Bernard Lagane) have cloned 
various envelopes from a longitudinal drug-naive cohort, followed-up over several 
years. These envelopes will be evaluated with an aim to test the hypothesis that 
certain changes in the R5 env sequence are associated with the virus’s efficiency 
to enter host cells and resistance to CCR5 chemokine inhibition. They speculate 
that the resistance of certain R5 viruses to inhibition by CCR5 chemokines may 
be related to changes in the virus’s gp120 binding affinity for CD4 and CCR5. In 
order to assess these assumptions, our collaborators will perform molecular 
pharmacology and virology experiments to characterize the receptor binding 
properties of purified and radioactive monomeric gp120 and they will study the 
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ability of  different CCR5 chemokines to prevent gp120 binding to CCR5 and 
viral entry.  
My role in this project has been to asses the binding affinity of various cloned R5 
and X4 envelopes for different binding receptors using SPR (as mentioned in 
Chapter 6), including CD4, HS and 17b. For some of the envelopes, I have also 
tested their ability to bind the solubilized coreceptors. Interestingly, the affinity 
data I have obtained thus far for certain R5 envelopes and full length CD4, 
corresponds to those KD determined by our collaborators using a competition 
experiment on HEK CD4 expressing cells. The binding data I obtained between 
the CD4-bound envelopes and 17b, also correlates with the tendency of certain 
envelopes to bind better to CD4 than others. Preliminary results from my 
experiments and those of our collaborators indicate that affinity of viral envelopes 
for CD4 does not increase in the course of HIV infection. This suggests that 
increasing viral fitness and resistance to chemokine inhibition as the disease 
progresses could rely on changes of other steps of the virus entry process 
including binding to CCR5 or HS. In particular, we propose that later-stage R5 
envelopes might bind the CCR5 receptor differently with probably a higher 
affinity and are thus more virulent. This project will provide clues on some 
aspects of HIV physiopathogenesis, including the mechanisms by which 
phenotypic properties of R5-viruses evolve during the course of infection and 
contribute to disease progression. It will shed light on the mechanisms that 
account for the enhanced ability of R5 viruses to infect cells expressing low levels 
of HIV-1 entry receptors in late stages of infection (i.e. monocytes, MDMs and 
perhaps central memory CD4+ T lymphocytes). 
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Chapter 8: Methods 
8.1 Materials 
8.1.1 Biacore reagents and antibodies  
A BIAcore 3000 machine, CM4 sensorchip, amine coupling kit and HBS-P (10 
mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20, pH 7.4) were 
from GE-Healthcare. Streptavidin was from Sigma. MN and YU2 gp120 were 
from Immunodiagnostic. Soluble CD4, mAb17b and Cf2Th coreceptor expressing 
cells were obtained through the NIH AIDS Research and Reference Reagent 
Program from Dr. Tajib Mirzabekov and Dr. Joseph Sodroski. The antibodies 
12G5, 12G5-conjugated to Fluorescein isothiocyanate (FITC) were purchased 
from R&D systems and 2D7 was from BD pharmingen. The HIV-1 entry 
inhibitors AMD3100, Maraviroc, Azidothymidine (AZT), monoclonal antibody 
(1C12) against CXCL12γ and monoclonal antibody that recognises the N-
Terminal of SDF (K15C) were all kind gifts from Fernando Arenzana (Pasteur 
Institute, Paris). The antibody 1D4 was from Flint Box, University of British 
Columbia. Complete, EDTA-free protease inhibitor tablets were from Roche 
Diagnostics. Polyethylene glycol 8,000 50% w/v solution was purchased from 
Hampton research. Wild type human chemokines CXCL12α, CXCL12γ, 
CXCL12α conjugated to fluorescein isothiocyanate (FITC), M1, the C-Terminal 
of CXCL12γ and the biotinylated C-terminal of  CXCL12γ were chemically 
synthesized by the Merrifield solid phase method on a fully automated peptide 
synthesizer using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry as described 
previously (Amara, Lorthioir et al. 1999) and obtained from Françoise Baleux 
(Institut Pasteur, Paris, France). Antibodies against HS (10E4), chondroitin-4-
sulphate and chondroitin-6-sulphate were purchased from Amsbio (Lugano, 
Switzerland). FITC conjugated anti-mouse antibody was purchased from 
Interchim (Montlucon, France).  
8.1.2 Lipids and detergents  
Synthetic phospholipid blend 1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-
dioleoyl-sn-glycero-3-phospho-L-serine formulation (DOPC/DOPS; 7:3, w/w), 
the Mini-Extruder kit, filter supports and polycarbonate filters with defined pore 
diameter (100nm) were purchased from Avanti Polar Lipids. Detergents, n-
dodecyl-β-D-maltopyranoside (DOM), 3-[(3-Cholamidopropyl)-dimethylamonio] 
1-propane sulfonate/N,N-Dimethyl 3-sulfo-N-3- [3α,5β,7α,12α)-3,7,12-trihydroxy 
-24oxocholan-24-yl] mino]propyl] 1-propanaminium (Chaps) and Cholesteryl 
Hemisuccinate Tris salt (CHS) were purchased from Anatrace (see 
section 8.10.3.1). 
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8.2 Cell Culture and solubilization of co­receptors 
8.2.1 Cell culture 
The human chemokine receptors CXCR4 and CCR5 were over expressed in 
Cf2Th canine thymocyte cells as described previously (Mirzabekov, Bannert et al. 
1999). Both receptors contained a C-terminal linear C9 peptide tag 
(TETSQVAPA) which is recognized by the 1D4 monoclonal antibody (Oprian, 
Molday et al. 1987). Briefly, the Cf2Th cell lines were maintained in 
supplemented Dulbecco’s modified Eagle’s medium (DMEM) from Invitrogen 
(Paris, France) supplemented with 10% heat-activated  Fetal Calf Serum (FCS), 
Glutamax (2 mM) and penicillin (0.5 U/ml)/streptomycin (0.5 U/ml) antibiotics 
from Invitrogen (Paris, France). The Cf2Th.CCR5 expressing cell lines contained 
additional 500µg/ml zeocyn and 500µg/ml G418 from Invitrogen (Paris, France) 
and 3µg/ml puromycin from sigma (Lyon, France). Growth medium for the 
Cf2Th.CXCR4 expressing cell lines was additionally supplemented with 500 
µg/ml G418 from Invitrogen (Paris, France). Cells were grown at 37 °C under 5% 
CO2 atmosphere and detached with EDTA (Versene) purchased from Invitrogen 
(Paris, France). 
8.2.2 Preparation of liposomes 
The liposomes (final concentration of 3.3mM) were prepared as previously 
described (Navratilova, Dioszegi et al. 2006). Briefly, a pre-determined volume of 
synthetic Phospholipid Blend DOPC:DOPS (7:3, w/w) (see section 8.10.4) was 
transferred into a glass test tube and a thin lipid film was formed on the side walls 
of the glass tube by rotating the tube while evaporating all the chloroform using a 
stream of nitrogen gas. Once all the chloroform had been evaporated, a HEPES 
buffer (50mM Hepes, 150mM NaCl, pH 7.0) was added to dissolve the dry lipid 
films. The lipid mixture was vortexed to facilitate dissolving the films. Then the 
mixture was frozen, thawed, and vortexed four times. Unilamellar vesicles 
(ULC)/liposomes were prepared by classical extrusion through a 100nm pore 
diameter polycarbonate filter using an Avanti Mini-Extruder kit. Liposomes were 
freshly extruded for every experiment. 
8.2.3 Coreceptor Solubilization 
The CCR5 and CXCR4 solubilisation protocol was adapted from a described 
procedure (Navratilova, Sodroski et al. 2005). Briefly Cf2Th.CXCR4 expressing 
cells (5-8x106) were solubilised in 1 ml buffer consisting of 100 mM (NH4)2SO4, 
20 mM Tris-HCl (pH 7.5), 10% glycerol, 15% PEG 8000, protease inhibitors, 
CHS (0.2%), DOM (1.5%), CHAPS (1.5%) and 0.33mM DOPC:DOPS liposomes 
The cell suspension was sonicated (6 x 1s pulses) and placed on a rotating wheel 
at 4°C for 3 hours. The solutions containing the solubilised coreceptors were 
centrifuged at 14 000 rpm for 30 minutes at 4°C and the supernatants were either 
used directly in SPR analysis or stored at -80°C until further use. 
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8.3 Protein electrophoresis and Immunodetection of Proteins 
8.3.1 Immunoprecipitation 
Protein G beads (Thermo Scientific) were used to immunoprecipitate either gp120 
(MN or YU2) or previously solubilised GPCR (CXCR4 or CCR5). In general, 
protein G beads were incubated for 1 hour at room temperature under agitation 
with either 2-5µg of the polyclonal goat anti gp120 (D7324, Aalto Bio Reagents) 
or with monoclonal mouse anti C9 (1D4). The D7324 bound- and ID4 bound-
beads were then washed in PBS for 30 minutes. A pre-incubated complex of 2µg 
gp120 with either 1µM mCD4, or 1µM HS12 or 1µM mCD4-HS12 was added to 
the D7324 bound beads and incubated for one hour at room temperature under 
gentle agitation in an incubation buffer (50mM HEPES, 5mM MgCl2, 1mM 
CaCl2, 150mM NaCl pH 7.0). For the 1D4 bounds beads, 100µl of solubilised 
coreceptors (either CCR5 or CXCR4) in the solubilization solution (see 
section 8.2.3) were added and incubated with the beads for one hour at room 
temperature under gentle agitation. The beads were then centrifuged to remove 
any unbound material and 100µl of solubilised GPCRs (either CCR5 or CXCR4) 
was added to the gp120-BB/HS12/mCD4-HS12-bound beads and a pre-incubated 
complex of 2µg gp120 with either 1µM mCD4, or 1µM HS12 or 1µM mCD4-HS12 
was added to the 1D4-bound protein G beads. These complexes were incubated 
for one hour under gentle agitation and then centrifuged and washed three times in 
solubilization solution. After the final washing step, the beads were pelleted and 
resuspended in SDS- Polyacrylamide Gel Electrophoresis (PAGE) sample loading 
buffer (see section 8.10.1.1) and <50µl of solubilization solution and then boiled 
for 10 minutes at 100°C in preparation for gel electrophoresis. The beads were 
then pelleted and the supernatants were deposited onto the gel for electrophoresis. 
8.3.2 Protein Electrophoresis 
Immunoprecipitated proteins (or lipid/detergent solubilised coreceptors) were 
added to a quarter of the volume of 5 x sample buffer (Section 8.10.1.1), and 
boiled for ten minutes. Samples were resolved on 12% SDS-polyacrylamide gels 
according to a standard protocol (Section 8.10.1.2). Gels were then used for 
Western Blotting. 
8.3.3 Immunoblotting (Western Blot)  
Western blotting of gels was performed according to a standard protocol 
(described in section 8.10.2). Two primary antibodies were used during western 
blotting and immunoprecipitation: ID4 and D-7324 were added to the membrane 
for one hour at room temperature. 
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8.4 Removal of cell surface oligosaccharides 
8.4.1 Na Chlorate treatment 
Chlorate is known to be an in vitro inhibitor of ATP– sulphurylase, the first 
enzyme in the biosynthesis of PAPS (3'-Phosphoadenosine-5'-phosphosulfate), the 
high-energy sulphate donor in biological reactions. Chlorate competes with the 
sulphate ions (PAPS) that bind ATP-sulphurylase and thus affects HS 
biosynthesis by reducing N- and O-sulphation (Leong, Morrissey et al. 1995; 
Safaiyan, Kolset et al. 1999). Sodium chlorate is toxic at high concentrations for 
the cells, however at lower doses HS GAG chains are produced but not sulphated. 
Na Chlorate was freshly prepared for each cell culture treatment and cells (CEM 
and Cf2Th) were passaged up to three times in the presence of 30mM Na Chlorate 
each day. Cells were harvested and then used in fluorescence-activated cell sorter 
(FACS) analysis. 
8.4.2 Enzymatic digestion 
The following three enzymes were used in the laboratory; Heparinase I, 
Heparinase III and Chondroitinase ABC. Heparinase I digests the HP and HS at 
the link between hexosamine and O-sulfated uronic acid. Heparinase III cuts the 
link between the hexosamine and glucuronic acid in HS. Chondroitinase ABC 
digests the chondroitin sulfates A, B or C at the link between the hexosamine and 
uronic acid (iduronic or glucuronic). For each enzymatic digestion, 5x106 cells per 
ml were detached from the culture flask with versene (Invitrogen) and 
resuspended in 500µl digestion buffer (5% fetal calf serum, 2mM CaCl2 in RPMI 
medium) containing 50 mu Heparinase I and II and 1 U Chondroitinase ABC. The 
cells were incubated at 37°C for one hour under agitation, washed in PBS and 
then were used in FACS analysis.  
8.5 Separation of dodecasaccharides  
Heparan sulphate (HS) dodecasaccharides were prepared by Rabia Sadir as 
previously described (Sadir, Baleux et al. 2001).  In order to fractionate the HS12 
samples into sub-populations of differently sulphated oligosaccharides, the 
dodecasaccharides were resolved and eluted from a ProPac PA1 9 x 250mm 
HPLC column in NaCl at pH 3.0. Before oligosaccharide elution, the column was 
equilibrated in Mili Q water with the pH adjusted to 3.0 with HPLC grade HCl. A 
three stage linear salt gradient was performed for the elution; from 0 to 400mM 
NaCl for 10 mins, then from 400mM to 1.4M NaCl over one hour and then from 
1.4M to 2M in 5 minutes at a flow rate of 5ml/min. To elute all oligosaccharide 
species from the column, 2M NaCl pH 3.0 was passed through the column for 36 
minutes after each gradient. Fractions (5ml) were collected and pooled according 
to their absorbance profile at 232nm. The pooled fractions were desalted through 
multiple dialysis passages (6 changes of water of 5 hours each) in Mili Q water 
using dialysis membranes (Spectra POR 7 dialysis Membrane, MWCO 1000, 
spectra labs). After a total of 19 runs (equivalent of 95mg of fractionated HS12), 
the desalted oligosaccharides were freeze-dried and then the amount of HS12 was 
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determined by weighing and measurement of UV absorbance at 232 nm. 
Oligosaccharides were stored at -20°C until further use. 
8.5.1 Quantification of HS  
When quantifying the amount of oligosaccharides obtained in the library, two 
measurements were made; that of the weight and the UV absorbance at 232nm. 
The latter required a standard curve and this was made using the HS12 that was 
size-separated using gel-filtration (MW 3300 g/mol). Solutions at 0, 1.25, 2.5, 5, 
10, 20, 30 and 50 µM were prepared and the absorbance at 232 nm was measured 
in a quartz cuvette. 
8.5.2 Estimation of purity 
The purity of each HS12 fraction was assessed by running the samples in a PAGE 
analysis. Oligosaccharides (in H20, 20% glycerol) were run through a stacking gel 
(5% acrylamide [49:1 ratio], 2% temed) at a constant voltage of 150V for one 
hour, then through a separation gel (30% acrylamide [19:1 ratio], 5% temed) at a 
constant current of 25mA for 3-4 hours. The running buffer is 25 mM Tris, 192 
mM Glycine pH 8.3 and the molecular weight maker is a mixture of bromophenol 
blue, phenol red and Xyanol blue in 20% glycerol. Once the oligosaccharides had 
reached the end of the separation gel, bands were visualised by staining with 
0.08% aqueous Azure A for 10 minutes and the gel was subsequently washed to 
remove excess stain. 
8.6 Study  of  protein­protein  interactions  using  surface 
plasmon resonance 
8.6.1 CXCL12 binding to CXCR4 
To study the interaction between CXCR4 and its ligands (antibodies, 
chemokines), CM4 sensorchips were activated with 50 μL of 0.2 M N-ethyl-N’-
(diethylaminopropyl)-carbodiimide (EDC) and 0.05 M N-hydroxy-succimide 
(NHS) at 5 μL/min. Initially, mAb 1D4 (5 μg/mL in 10 mM acetate buffer, pH 5) 
was injected at 5 μL/min over one of the EDC/NHS activated flow cell until levels 
of approximately 7000 response units (ru) were obtained. Solubilized CXCR4 
coreceptors were captured via the interaction between its C9 C-terminal tag and 
the ID4 immobilized on the CM4 chip surface at a flow rate of 5µl/min to yield 
approximately 3000 ru. Surfaces were then blocked with pH 8.5 1 M ethanolamine 
for 5 minutes. The solubilised CXCR4 capture was performed in the running 
buffer (50mM HEPES ph 7.0, 150mM NaCl, 5% glycerol, 5 % PEG 8000, 5 µM 
CaCl2, 1 µM MgCl2, 0,1 % DDM, 0,1 % CHAPS, 0,02 % CHS, 50 nM 7 :3 
DOPC :DOPS, 3% DMSO and 0,2 mg/ml BSA) and then the system was left to 
run at 5µl/min for approximately 20 minutes to allow for reconstitution of the 
lipid bilayer around the captured GPCRs. Interactions between the solubilised 
coreceptors and their natural ligands (CXCL12α and CXCL12γ) and antibodies 
(12G5, 4G10 and antisulphotyrosine), were observed in real-time.  
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Samples were injected over both the coreceptor and control (mAb ID4) surfaces at 
a flow rate of 50-100 µl/min for 1 minute and 5µl/min for 12 minutes for the 
ligand and antibodies respectively. After each CXCL12γ and mAb injection, the 
1D4 surfaces were regenerated with 10mM NaOH containing 1% n-octyl-β-D-
glucopyranoside at 100µl/min (Navratilova, Sodroski et al. 2005). However, no 
regeneration was required between the different concentration injections of 
CXCL12α and the ligand dissociates fully from the bound coreceptors. The 
affinity of the CXCR4-CXCL12α interaction was determined by injecting a range 
of concentrations from lowest to highest (5, 10, 20, 30 and 50nM) over the 
CXCR4 and control surfaces so as to minimise the accumulation of the chemokine 
on the surface. The experiments were all performed in triplicate and binding 
curves were analyzed with BIAevaluation (GE Healthcare). 
When performing biacore kinetic analysis, mass transport limitations and re-
binding are important factors to take into account. Lower surface densities of 
receptor are favoured so as to decrease the rate of kinetic ligand binding and a 
higher flow rate is preferred so as to increase the rate of transfer of the analyte to 
the surface. With lower flow rates, the rate at which the surface binds the analyte 
may exceed the rate at which the analyte can be delivered to the surface; 
consequently, the measured association rate constant (kon) is slower than the true 
kon. Then when the analyte is dissociating, it can rebind to the unoccupied ligand 
before diffusing out of the matrix and being washed from the flow cell; 
consequently, the measured dissociation rate constant (apparent koff) is slower than 
the true koff. Although the dextran matrix may exaggerate these kinetic artefacts 
(mass transport limitations and re-binding), they can affect all surface-binding 
techniques. 
8.6.2 Screening HS mimetic peptides 
The interactions between gp120 and its ligands (CD4, mAb 17b, CCR5 and 
CXCR4) were analyzed by SPR technology. For that purpose, CM4 sensorchips 
were activated with 50 μL of 0.2 M EDC and 0.05 M NHS at 5 μL/min. Then, 
soluble CD4 (10 μg/mL in 10 mM acetate buffer, pH 5), streptavidin (200 μg/mL 
in 10 mM acetate buffer, pH 4.2), mAb 17b (5 μg/mL in 10 mM acetate buffer, 
pH 5) or mAb 1D4 (5 μg/mL in 10 mM acetate buffer, pH 5) were injected at 5 
μL/min over one of the EDC/NHS activated flow cell until levels of 1200 (for 
sCD4), 700 (for mAb 17b), 3000 (for streptavidin) or 6000 (for mAb 1D4) ru 
were achieved. Surfaces were then blocked with pH 8.5 1 M ethanolamine for 5 
minutes. In some cases, gp120 was also immobilized onto CM4 sensorchip. For 
this, MN (50μg/ml in 5 mM maleate buffer, pH 6) or YU2 (50μg/mL in 10 mM 
acetate buffer, pH 4.8) were injected at 5 μL/min over an EDC/NHS activated 
flow cell until levels of 4500 RU was obtained. Surfaces were then blocked with 
pH 8.5 1M ethanolamine for 5 minutes. Molecules under investigation were 
injected over the different surfaces and the binding responses were recorded as a 
function of time. 
The 1D4 surface was then equilibrated into a running buffer consisting of 50mM 
HEPES pH 7.0, 150 mM NaCl, 5% glycerol, 5 % PEG 8000, 5 μM CaCl2, 1 μM 
MgCl2, 0.1 % DDM, 0.1 % CHAPS, 0.02 % CHS, 5 μM of 7:3 DOPC:DOPS and 
0.1 mg/ml BSA. Solubilised CXCR4 or CCR5, in the above described liposome 
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preparation, were captured via the interaction between its C9 tag and the 1D4 
mAb to a level of approximately 3000-5000 ru. The system was then equilibrated 
with the running buffer at 5 μl/min for approximately 20 minutes. Complexes of 
gp120 and mCD4 or inhibitors were injected at 30µl/min over the coreceptor 
surfaces for 2.5 minutes and the dissociation was followed for 4 minutes. 
8.7 Flow cytometric analysis 
For direct and competitive CXCR4 binding assays, CXCL12α, CXCL12γ, C-
Terminal CXCL12γ and M1 binding was detected in both CXCR4+ Cf2Th canine 
thymocytes and CXCR4+ CEM T lymphocytes. Indirect binding experiments were 
performed at 4°C on a rotating wheel with fixed amounts of chemokine in the 
presence or absence of 1µg/ml of HP12. Briefly, cells were washed twice and 
suspended in buffer (1x PBS, 1% BSA, 0.02% Azide, 1mM EDTA) with 50nM of 
each chemokine in the presence or absence of the competitor. The cells were 
incubated for 1 hour and then washed twice in buffer to remove any un-bound 
ligands. To measure the level of cell-bound chemokine, the cells were re-
suspended and incubated for 1 hour with either mAb IC12 (recognises the C-
terminal of CXCL12γ) or CXCL12α which is directly conjugated to FITC. The 
cells were then washed two times in buffer and anti-mouse-FITC secondary 
antibody (1:300) was added to the cells for one hour under agitation. Finally, cells 
were washed two times in buffer, fixed in 4% paraformaldehyde buffer, washed a 
further two times and re-suspended in buffer for fluorescence-activated cell sorter 
FACS analysis (FACSscan, Becton Dickinson, CA). All assays were performed in 
triplicate and included controls with no chemokine to verify the background 
staining. For the verification of enzymatic digestion of cell-surface HS, the 
following primary antibodies were used; 10E4, anti chondroitin-6-sulphate, 
chondroitin-4-sulphate and anti dermatan sulphate. 
8.8 Enzyme­Linked Immunosorbent Assay (ELISA) 
The synthetic peptides (sulphated and non-sulphated; synthesized by Françoise 
Baleux), consisting of the first 29 amino acids of the CXCR4 N-terminus, were 
covalently coupled to the bottoms of 96-well Nunc immobilizer amino plates 
(Thermo Scientific). The patented photo-coupling introduces an ethylene glycol 
spacer and a stable electrophilic group that reacts with nucleophiles such as free 
amines, thiols or hydroxy groups. The peptides were diluted into a coupling buffer 
(100 mM Na Carbonate pH 9.6) and between 0.5 – 5 µg of peptide was 
immobilized in each well, and incubated at 4°C under gentle agitation overnight. 
The plates were washed three times with PBS. Remaining electrophilic groups are 
quenched by adding 10mM ethanolamine in coupling buffer for 1hour at room 
temperature (RT) [to introduce a hydroxyl functional group making the surface 
hydrophilic]. Next, the wells were saturated with PBS-3% BSA for 1.5 hrs at RT 
and washed 4 times in washing buffer (PBS + 0.02% Tween). Either CXCL12γ (0 
- 100 nM) or the biotinylated C-terminal of CXCL12γ (0 – 500 nM) was bound to 
the peptides for 1.5 hours at RT in the presence or absence of 1µg/ml HP12. Then 
each well was aspirated and washed 4 times with washing buffer. Then 5 µl/ml 
antibody (K15C, 4G10 or Antisulphotyrosine) was added for 1 hour at RT in 
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washing buffer, aspirated and wells were again washed 4 times in washing buffer. 
Finally 2 µl/ml of the secondary Anti-mouse Horse Radish Peroxidase (HRP) or 
Anti-extravidin HRP was added for 1 hour at RT. The secondary antibody was 
aspirated and the wells were washed 4 times with washing buffer. The HRP linked 
to the secondary antibodies catalysed the conversion of the substrate 3,3’,5,5’-
Tetramethylbenzidine (TMB) producing a light conversion from yellow to blue, 
which is detectable on a spectrometer (Victor, Perkin Elmer) at 450nm. The 
reaction is stopped by the addition of 4M H2SO4.  
8.9 NMR 
NMR spectra were obtained with a Varian 600 MHz spectrometer equipped with a 
cryo probe. Two-dimensional spectra (correlating protein 15N and 1H nuclei) of 
15N labelled CXCL12γ at 100 µM concentration in NMR buffer (20mM Na-
Phosphate pH 5.7, 0.01% azide, 2% complete, 10% 2H2O) were recorded. The 
freeze-dried N-terminal peptide of CXCR4 (sulphated and non- sulphated) was 
resuspended into the NMR buffer to 1 mM. CXCL12γ spectra were first read for 
the chemokine alone and also following addition of increasing amounts of 
sulphated or non-sulphated CXCR4 peptides. The following readings were taken 
for each peptide/CXCL12γ molar ratio: 0.1, 0.2, 0.3, 0.5, 0.75, 1, 1.5 and 2. 
Negligible precipitation upon addition of the CXCR4 peptide was observed. 
Cédric Laguri produced the 15N labelled CXCL12γ, performed the NMR 
experiments and analysed the data. 
8.10 Standard Protocols and Recipies 
8.10.1 SDS­PAGE 
8.10.1.1 Solutions 
Protein samples were added to a sample buffer (5 x: Tris-HCl 30mM, 1% (m/v)  
SDS, 0.1% (m/v) bromophenol blue, 5% glycerol, pH 6.8) and heated to 100°C 
for 10 minutes before loading onto the gel. The sample stacking gel was prepared 
by adding 4.1 ml dH2O, 750µl 1M Tris pH 6.8, 1ml 30% Acrylamide 37.5:1 and 
60µl 10% SDS. Just prior to pouring the stacking gel, 60µl 10% APS and 60µl 
TEMED were added to the solution. The running gel was prepared as follows; 4.9 
ml dH2O, 3.8ml 1.5M Tris pH 8.8, 6ml 30% Acrylamide 37.5:1 and 150µl 10% 
SDS were combined. Just prior to pouring the gel, 150µl 10% APS and 10µl 
TEMED were added to the solution. A pre-stained protein ladder maker 
(Euromedex) was used to follow the migration of the samples and to estimate the 
molecular weight of the proteins. 
8.10.1.2 Resolving SDS­PAGE gels 
The stacking gel was migrated at 20mA and then the separation/running gel 
migrated under a constant current of 25mA in a running buffer (25mM Tris-HCl, 
192mM glycine, 0.1% SDS) until the dye front was approximately 0.5 cm from 
the bottom of the gel. The gel was subsequently used in a western blot transfer 
and probed with immuno-marking antibodies.  
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8.10.2 Western Blot 
8.10.2.1 Solutions 
After running the SDS-PAGE, the gel was directly transferred to a PVDF 
membrane (Sequi-blot PVDF Membrane, 0.45µm – Millipore) for 2 hours at a 
constant voltage (50V) at 4°C in a transfer buffer (25mM Tris-HCl, 192mM 
Glycine). Following protein transfer, samples were blocked for one hour shaking 
at room temperature or overnight at 4°C in 5% (m/v) fat free milk powder in TBS 
(50mM Tris-HCl, 150mM NaCl, pH 7.4). Three 10-minute washes in TBS-tween 
(TBS + 0.5% Tween) followed before addition of the primary antibody.  
8.10.2.2 Transfer 
After incubation with the primary antibody (as described in section 8.3.3), the 
membrane was washed three times for ten minutes in T-TBS. Depending on the 
primary antibody, the secondary antibody used was either anti-mouse in the case 
of the mouse monoclonal antibodies, or anti-goat in the case of the anti-gp120 
(D7324) and was added at a concentration of 1:7000 or 1:3000 respectively 
diluted in TBS and laid flat on the membrane for one hour. After this incubation, 
the membrane was again washed three times for 10 minutes in TBS-tween before 
protein detection. Bound secondary antibody was detected on Western Blot 
membranes using enhanced chemiluminescence (ECL). A commercial substrate 
(ECL Kit Amersham biosciences, GE Healthcare), was used according to the 
manufacturer’s instructions and the peroxydase catalyses the liberation of light. 
After the enzymatic reaction, membranes were exposed to radiographic films 
(HyperfilmTM ECL, Amersham, GE Healthcare) for varying amounts of time, 
depending on the signal strength, before developing and fixing. 
8.10.3 Detergents and Lipids 
8.10.3.1 Detergents 
Detergents are amphiphiles which means that they are molecules that have two 
different polarities, a hydrophobic polar side and a hydrophilic polar side. 
Surfactants and detergents (molecules that are capable of solubilising fats) are 
often used when studying membrane proteins. Due to their different structures, 
detergents can be classified into one of four different categories; non-ionic, ionic, 
zwitterionic and steroids. 
The work presented here made use of three detergents, n-Dodecyl-β-D-maltoside / 
n-Dodecyl-β-D-maltopyranoside (DOM), 3-[(3-Cholamidopropyl) -dimethyl-
ammonio]-1-propane sulfonate/ N,N-Dimethyl -3-sulfo-N- [3-[[3α,5β,7α,12α)-
3,7,12-trihydroxy- 24-oxocholan-24-yl] amino]propyl] -1-propanaminium 
hydroxide (CHAPS) and Cholesteryl Hemisuccinate Tris Salt (CHS). 
DOM is a non-ionic detergent with a hydrophilic head and due to its short 
hydrocarbon chain (C7-C10), it is a soft and non-denaturing detergent and often 
used when working with membrane proteins. 
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Figure 8.1 Chemical Structure of DOM: MW = 510.6 g/mol, cmc = 0.17 mM (0.0087%), 
Aggregation number = 78-149 
CHAPS is zwitterionic detergent possessing both ionic and non-ionic properties 
and it is very efficient for membrane solubilization, however, it is known to 
denature proteins. 
 
Figure 8.2 Chemical structure of CHAPS: MW = 614.9 g/mol, cmc = 8 mM (0.49%), 
Aggregation number = 10 
CHS is a cholesterol steroid and has weaker denaturing properties with a 
hydrophilic head. 
 
Figure 8.3 Chemical structure of CHS: MW 607.9 g/mol 
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8.10.4 Lipids 
A synthetic phospholipid blend of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
[DOPC] and 1,2-dioleoyl-sn-glycero-3-phospho-l-serine [DOPS] [7:3, w/w] was 
purchased from Avanti Polar Lipids. Incorporating Lipids into the solubilization 
cocktail helped to stabilize the GPCR tertiary structure. 
 
Figure 8.4 Chemical structure of DOPC and DOPS together with an electron micrograph 
taken of the extruded 100nm liposomes (DOPC:DOPS 7:3 [w/w]), 0.26mg/ml in 50mM 
HEPES 150mM NaCl 
8.10.5 SPR  
8.10.5.1 The SPR Principle 
The biomolecular interaction analysis (BIAcore) uses the optical phenomenon of 
SPR in thin metal films under total internal reflection to monitor interactions 
between biomolecules. The resonance angle or output signal (expressed in 
Response Units) of the incident monochromatic p-polarized light (near infra-red) 
can be mathematically derived to represent the changes in the mass concentration 
of macromolecules in contact with the biospecific interface. Essentially, a sensor 
chip is a glass slide, coated with a thin gold film (due to its chemical inertness), to 
which a carboxymethyl dextran matrix is covalently attached. The dextran layer 
has a net negative charge which assists proteins (positively charged in buffers 
with a pH below their pI) to be electrostatically attracted to the dextran.  
When a beam of incoming light passes from a material with a high refractive 
index (e.g. glass) into material with a low refractive index (e.g. water) some light 
is reflected from the interface. When the angle at which the light strikes the 
interface (the angle of incidence or θ) is greater than the critical angle (θC), the 
light is completely reflected (total internal reflection). If the surface of the glass is 
coated with a thin film of a noble metal (e.g. gold), this reflection is not total; 
some of the light is 'lost' into the metallic film. There then exists a second angle 
greater than the critical angle at which this loss is greatest and at which the 
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intensity of reflected light reaches a minimum or 'dip'. This angle is called the 
surface plasmon resonance angle (θSPR). This is due to the oscillation of mobile 
electrons (or 'plasma') at the surface of the metal film. These oscillating plasma 
waves are called surface plasmons. When the wave vector of the incident light 
matches the wavelength of the surface plasmons, the electrons 'resonate', hence 
the term surface plasmon resonance.  
The 'coupling' of the incident light to the surface plasmons results in a loss of 
energy and therefore a reduction in the intensity of the reflected light. An 
evanescent (decaying) electrical field associated with the plasma wave travels for 
a short distance (~300 nm) into the medium from the metallic film. Because of 
this, the resonant frequency of the surface plasma wave (and thus θSPR) depends 
on the refractive index of this medium. If the surface is immersed in an aqueous 
buffer (refractive index or μ ~1.0) and protein (μ ~1.33) binds to the surface, this 
results in an increase in refractive index which is detected by a shift in the θSPR. 
The instrument uses a photo-detector array to measure very small changes in θSPR. 
The readout from this array can be viewed on the BIAcore as 'dips'. The change is 
quantified in resonance units or response units (RUs) with 1 RU equivalent to a 
shift of 10-4
 
degrees which correlates to 1pg of protein/mm2. Apart from the 
refractive index, the other physical parameter which affects θSPR is temperature. 
Thus a crucial feature of any SPR instrument is precise temperature control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5 Binding is measured as a change in the refractive index as the sensor surface. A 
change of 0.001 degrees is equivalent to 1pg of protein bound per mm2.  
 
8.10.5.2 Amine Coupling 
A standard protocol for amine coupling was used. The first step is to activate the 
carboxymethyl groups of the dextran with a mixture of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS),  
thus creating a highly reactive succinimide ester which reacts with the primary 
amine and other nucleophilic groups on proteins to form a covalent bond. The 
second (coupling) step is to inject the protein in a buffer with a pH lower that the 
protein’s pI, thereby driving the coupling reaction. The third (blocking) step, 
blocks the remaining activated carboxymethyl groups by injecting very high 
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concentrations of 1M ethanolamine-HCl pH 8.5. The high concentration of 
ethanolamine also helps to elute any non-covalent bound material. The surface is 
then ready to be used for further binding experiments and can be regenerated by a 
specific regeneration solution which will remove any bound analyte, and the 
ligand that is covalently coupled will remain coupled to the dextran surface. 
 
 
 
 
 
 
 
 
Figure 8.6 Amine coupling ligands to the surface using EDC/NHS. 
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C. DISCUSSION 
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Chapter 9: Conclusions and Perspectives 
9.1 Conclusions et Perspectives (sommaire en français) 
Il y a plus de 10 ans, la purification des GPCR de leurs milieux naturels a souvent 
abouti à des protéines dépourvues de leur conformation native, ce qui rendait leur 
utilisation dans des dosages fonctionnels totalement futile (Gether and Kobilka 
1998; Ji, Grossmann et al. 1998). Ainsi, l'étude des GPCRs a été limitée aux tests 
cellulaires. Toutefois, en raison de l'hétérogénéité de la surface des cellules, 
l'interprétation des résultats de liaison est souvent compliquée. Ceci est 
particulièrement problématique pour les études impliquant des récepteurs de 
chimiokines parce que leurs ligands (qu’ils soient naturels ou viraux) se lient à 
d'autres molécules de la surface cellulaire, y compris des HS. Ainsi, la 
surexpression, solubilisation et purification des protéines pour l'analyse de liaison, 
est une option beaucoup plus attrayante pour mieux comprendre la structure et la 
fonction des GPCRs. La Resonance Plasmonique de Surface (SPR) est une 
technologie innovante pour l'étude des interactions biomoléculaires en temps réel 
sans aucun étiquetage. Nous avons cherché à améliorer la spécificité et l'affinité 
d'un inhibiteur bivalent de l’entrée du VIH-1 qui existe déjà (Baleux, Loureiro-
Morais et al. 2009). Pour ce faire, nous avions besoin d'une plateforme qui nous 
permettrait d'immobiliser les corécepteurs de VIH-1 natifs (CCR5 et CXCR4) et 
de cribler différentes molécules pour leur capacité à inhiber la liaison des 
complexes gp120-CD4 aux corécepteurs immobilisés. Ici, on a donc immobilisé 
des récepteurs de chimiokines solubilisés et comme contrôle de ce processus, nous 
avons étudié des chimiokines liant ces corécepteurs. Ce système étant fonctionnel, 
nous avons pu également l’utiliser pour mieux comprendre la régulation de la 
fonction des chimiokines par les GAGs. Une fois que nous étions sûrs que les 
corécepteurs étaient fonctionnels, nous avons criblé des molécules qui inhibent la 
liaison du complexe gp120-CD4 aux corécepteurs afin de concevoir des 
molécules plus efficaces qui peuvent empêcher l'utilisation du corécepteur et 
l'entrée des sou airches prim es du VIH-1. 
9.1.1 Etude de la liaison de CXCL12 à CXCR4 
L’efficacité de la  liaison des anticorps (12G5, 4G10 et anti-sulphotyrosine), des 
chimiokines (CXCL12α et γ) et de l'enveloppe virale (X4 gp120) à CXCR4 
solubilisé et immobilisé suggère fortement que la protéine CXCR4 conserve sa 
conformation native. La première partie de ce travail (chapitre 5) est une étude qui 
a porté sur l'utilisation de CXCL12 comme ligand pour le CXCR4 solubilisé et 
immobilisé afin de confirmer son intégrité fonctionnelle. CXCL12 est le ligand 
naturel pour CXCR4 et interagit avec CXCR4 par la liaison de l'extrémité N-
terminale et des deuxième et troisième boucles extracellulaires. Nous avons été en 
mesure de déterminer l'affinité de CXCR4 pour CXCL12α qui a donné un Kd de 
13 ± 1,6 nM, ce qui est cohérent avec des valeurs publiés antérieurement. Pour 
CXCL12γ, l'analyse préliminaire des courbes montre que l'association et les 
constantes de vitesse de dissociation ont été dominées par le transfert de masse. 
Ici, l'isoforme CXCL12γ montre une plus grande affinité pour le CXCR4 
immobilisé et cela signifie que CXCL12γ est un ligand  plus fort pour le CXCR4 
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que CXCL12α. Comme la seule différence entre  les isoformes CXCL12α et 
CXCL12γ est l'extension C-terminale, ces résultats suggèrent que c'est l’extension 
C-terminale, non-structurée qui est responsable de l'affinité augmentée de 
CXCL12γ pour CXCR4. Le mutant M1 (9 acides aminés basiques ont été mutés 
dans son extrémité C-terminale) a été un intermédiaire entre les deux et, de façon 
intéressante, M1 montré  un profil de liaison pour le CXCR4 proche de celui de 
CXCL12α. Ainsi, le fait que CXCL12γ a une plus grande affinité pour le CXCR4 
et qu'il ne se dissocie pas du corécepteur est lié au nombre de résidus basiques 
présent dans le domaine C-terminal. Puisque selon nos données, la haute affinité 
montré par CXCL12γ pour CXCR4 est due à l’extrémité C-terminale basique, on 
devrait être en mesure de rivaliser la liaison à CXCR4 par la présence de GAGs 
anioniques, qui ont été montrés capables de  lier le C-terminal de CXCL12γ. 
Un oligomère 12mer d’HP (1μg/ml) n'a eu aucun effet sur la liaison de CXCL12α 
ou M1 à CXCR4, que l’analyse soit faite par SPR ou par cytométrie de flux des 
cellules. Cependant, des oligosaccharides de même taille et de même 
concentration ont en effet eu un effet drastique sur la liaison de CXCL12γ sur le 
CXCR4. Nous avons supposé que la queue C-terminale basique et allongée de 
CXCL12γ peut se lier au  N-terminal anionique de CXCR4 qui possède jusqu'à 
trois résidus tyrosine, qui peuvent chacune être sulfatées, contribuant à la forte 
affinité observée entre CXCL12γ et CXCR4. Compte tenu de la complémentarité 
entre la charge de surface des sulfates dans le N-terminal de CXCR4 et le C-
terminal très basique de CXCL12γ, il était logique de proposer que la grande 
affinité qui est observée entre CXCL12γ et CXCR4 est due à l'interaction ionique 
entre les acides aminés basiques dans le C-terminal de CXCL12γ avec les résidus 
tyrosines sulfatées présents dans le domaine N-terminal de CXCR4. Nous avons 
également été en mesure de bloquer la liaison d'un anticorps anti-sulfotyrosine sur 
l'extrémité N-terminale de CXCR4, en présence de CXCL12γ comme autre 
preuve de cette interaction. Toutefois, afin de tester l'hypothèse que le C-terminus 
de CXCL12γ se lie à des  sulfotyrosines dans la partie N-terminale de CXCR4, 
des approches structurales et cellulaires ont été employées. Pour la RMN, 
CXCL12γ marqué au 15N a été titrée avec des ajouts progressifs de  peptide N-
terminal sulfaté ou non sulfaté de manière à  identifier les résidus impliqués dans 
la liaison du peptide sulfaté. Cette expérience de RMN a produit des données 
suggérant fortement que la présence de sulfates, permet la liaison du peptide N-
terminal de CXCR4 au C-terminal du CXCL12γ. Ainsi, la plus grande affinité 
observée entre CXCL12γ et CXCR4 est due à la partie C-terminale de la 
chimiokine. 
Nous proposons l'hypothèse qu'en raison de la forte affinité entre CXCL12γ et le 
N-terminal de CXCR4, cette chimiokine est «captive» sur la partie N-terminale du 
corécepteur et serai spatialement trop loin du site d'activation ; elle est donc une 
chimiokine avec une plus faible signalisation. Conformément à l'hypothèse que la 
plus grande affinité que CXCL12γ a pour CXCR4 est due à l'interaction des 
acides aminés basiques dans le C-terminus de CXCL12γ avec les tyrosines 
sulfatées dans le N-terminus de CXCR4 – des expériences d'activation de ERK 
1/2 avec des chimiokines (CXCL12α, CXCL12γ et M1) en présence et en absence 
d'oligosaccharides ont été effectuées. Nous avons montré que en présence de 10 
µg/ml d'héparine, CXCL12γ induit une activation 4X plus forte de ERK 1/2, alors 
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il n'y a pas de différence d'activation de ERK 1/2 pour CXCL12α et M1, en 
présence d'héparine. Dans notre modèle, en présence de  courts oligosaccharides 
sulfatés, l'interaction CXCL12γ-N-terminal avec CXCR4 est déstabilisée 
permettant de détacher la chimiokine et d’accéder au site d'activation dans les 
boucles extracellulaires de CXCR4, donc l’héparine soluble pourrait améliorer la 
signalisation de CXCL12γ. D'autres hypothèses pourraient être proposées telles 
que: l'héparine soluble est capable de stabiliser l’extrémité C-terminale 
désordonnée de CXCL12γ, lui permettant ainsi de signaliser plus efficacement 
avec moins de liaison non spécifiques. Des expériences  supplémentaires doivent 
étudier si oui ou non CXCL12γ dimerise en présence du GAG, comme le fait 
CXCL12α, ou si l’extrémité C-terminale basique de CXCL12γ éviterait  la 
dimérisation? Nous émettons l'hypothèse que CXCL12γ est exprimée et sécrétée 
sous forme de petits gradients haptotactiqus très concentrés et localisés pour la 
séquestration des cellules immunitaires sur une période beaucoup plus prolongée, 
par opposition aux grands gradients étalés créées avec CXCL12α qui auront une 
durée de vie plus courte, en comparaison. Une autre hypothèse pour la diversité 
fonctionnelle des CXCL12γ est celui de la dégradation protéolytique. Vu que 
CXCL12γ montre une fréquence inférieure d'activation de CXCR4 due à sa 
séquence C-terminale, un niveau de régulation de la signalisation de CXCL12γ 
pourrait être par la digestion de l'extrémité C-terminale? 
9.1.2 L'étude d’un inhibiteur d'entrée 
Afin de cibler l’entrée du VIH-1, un inhibiteur efficace devrait être capable de 
bloquer non seulement de liaison avec CD4 mais aussi la liaison de gp120 à son 
corécepteur (idéalement aux deux corécepteurs CCR5 et CXCR4). C'est une tâche 
particulièrement difficile parce que les surfaces de la glycoprotéine du VIH-1 qui 
sont impliqués dans l'entrée sont soit cryptique (le site CD4i) soit bien cachée par 
un bouclier glycosylé. Il ya beaucoup de médicaments antirétroviraux qui existent, 
dont un inhibiteur d'entrée (seulement contre les virus R5) et un inhibiteur de 
fusion, mais il n'y a toujours pas de médicaments qui peuvent inhiber 
efficacement l'infection par le  VIH-1. Il ya un grand besoin d'un inhibiteur 
d'entrée qui se lie au virus,  qui ait une faible toxicité et inhibe à la fois les 
variants R5 et X4 de VIH-1. Dans ce but, nous avons cherché à augmenter la 
spécificité et l'affinité d’une molécule bivalente (prototype) qui inhibe l’entrée, 
mCD4-HS12. En raison de la nature extrêmement complexe et hétérogène des HS 
(Esko et Lindahl, 2001), sur la base des 48 combinaisons disaccharidiques 
différentes, une banque de 12 mer (486 = 1010) serait inconcevable à  faire 
synthétiser pour des études structure-fonction. De plus, l'assemblage du 12mer 
utilisé dans le prototype a pris 1 an à synthétiser et donc une plus grande banque 
de 12mers différemment sulfatés serait impossible à  produire. Ainsi, la partie 
glycosidique de ce prototype devait être améliorée / optimisée et il y aurait deux 
façons de faire cela : une approche aurait été de fractionner une banque 
d'oligosaccharides naturels 12mer héparane sulfate par chromatographie 
échangeuse d'ions, de purifier et de tester chaque fraction pour sa capacité à 
inhiber laliaison de la gp120-CD4 au corécepteur, puis de purifier la fraction la 
plus active en grandes quantités. Cette approche serait fastidieuse et aussi ne se 
prêterait  pas à une analyse structure-fonctionnelle parce que cette technique de 
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purification est loin d'être précise et qu'une solution homogène d'un type de 
structure 12mer ne serait pas possible d'obtenir. Même si un oligosaccharide 
12mer avec une  affinité de liaison élevée pour la gp120 avait  été identifié, le 
séquençage de ce 12mer pour identifier sa structure disaccharidiques exacte serait 
aussi très fastidieux. 
La seconde approche a été la conception de peptides qui miment les HS, contenant 
des acides aminés chargés négativement qui imitent les fractions HS et cela 
simplifierait le processus de deux manières; les peptides sont simples à synthétiser 
et une séquence peptidique homogène se prêterait à une analyse séquence/activité. 
Pour imiter les groupes fonctionnels hydroxyles, carboxyles et  sulfates trouvés 
sur des fragments d’HS, les peptides contenant des sérines, asparagines et 
tyrosines (sulfatées ou non sulfatées) ont été produits. La séquence S(XDXS)3 a 
été utilisée où X représente un acide aminé et au final cinq peptides ont été 
synthétisés; P3Y (où X = tyrosine non sulfatée), P3YSO3 (où X = sulphotyrosine), 
P3Asu (où X = acide aminosuberic), P3pF (où X = p-carboxyméthyl 
phénylalanine) et E13 (où toute la longueur est de l'acide glutamique - un 
polyanion non spécifique). Les peptides contenant la sulphotyrosine (P3YSO3) ont 
montré une capacité à bloquer l’anticorps monoclonal 17b avec une IC50 de 3 µM, 
qui se compare bien aux molécules déjà publiées.. Lorsque P3YSO3 a été couplé 
de façon covalente à mCD4, un effet synergique a été vu et quantités de quelques 
nM  de mCD4-P3YSO3 étaient nécessaires pour empêcher gp120-CD4 de se lier 
au  mAb 17b. Vu que mAb 17b n'est qu'un mime du corécepteur, la capacité 
d'inhibition du mCD4-P3YSO3 devait être testée sur CCR5 et CXCR4 
fonctionnels et solubilisés immobilisés sur des surfaces BIAcore. En utilisant le 
protocole de solubilisation des GPCR qui avait été mis en place et optimisé dans 
le chapitre 5, CCR5 et CXCR4 ont été immobilisés sur la surface  et les 
interactions entre la gp120, en présence et en absence de mCD4 ont été 
enregistrées. Ce travail montre que conjugué à mCD4, P3YSO3 interagit avec les 
deux gp120 (R5 et X4), alors que  HS12 est surtout actif vis-à-vis des gp120 X4. 
Nous avons obtenu une affinité de 154 ± 68 nM pour l’interaction  gp120/CD4 - 
CXCR4 ce qui est comparable à celle obtenue dans un système cellulaire (Doranz, 
Baik et al 1999; Babcock, Mirzabekov et al 2001.), et les valeurs de 11,5 ± 2,9 nM 
pour l'interaction gp120/CD4-CCR5, également en accord avec celles trouvées par 
une technique similaire (Navratilova, Sodroski et al. 2005). Sur les 5 peptides 
bivalents qui ont été criblés sur les surfaces GPCR, mCD4-P3YSO3 a été le seul 
peptide qui inhibait complètement la liaison entre gp120 et les deux corécepteurs 
CCR5 et CXCR4 avec une stoechiométrie 1:1. Curieusement, les autres peptides 
inhibiteurs bivalents de l’entrée du  VIH-1 (mCD4-PSY, mCD4-P3Asu, mCD4-
P3pF et mCD4-E13) ont  tous montré à des degrés divers, des activités antivirales 
dans l’expérience d'infection des PBMC par la souche LAI (au tropisme X4) du 
VIH-1. Cependant, ils étaient tous inefficaces contre la souche Ba-L (tropisme 
R5). Ainsi, ces autres peptides ne sont pas redondants, ils peuvent également être 
envisagées comme des thérapies antivirales qui sont administrées comme 
traitement de sauvetage, en plus de composés contre des virus à tropisme R5 (par 
exemple, le maraviroc) pour les patients qui ont le virus utilisant CXCR4 ou sont 
infecté par une souche de VIH utilisant un double tropisme. Non seulement ce 
peptide sulfaté représente une possible nouvelle génération d'inhibiteur d'entrée du 
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VIH-1, mais il ouvre également une toute nouvelle stratégie pour la détermination 
de la relation structure-fonction entre les molécules sulfatées et des protéines 
cibles. Cette nouvelle molécule, mCD4-P3YSO3, a une IC50 aussi basse que 1nM 
et mérite donc d'être testée pour son efficacité dans un modèle animal chez des 
macaques dans le modèle SHIV du VIH. Dans approche préventive, mCD4-
P3YSO3 peut être incorporé dans un gel qui sera appliqué sur  la muqueuse 
vaginale et anale et donc être utilisé en tant que microbicide. Dans ce cas, la 
distribution de la drogue sera locale et concentrée sur la muqueuse du tractus 
génital - le premier site d'entrée lors de la transmission sexuelle du virus. 
Cependant, si mCD4-P3YSO3 est utilisé comme un traitement, il devra être 
administré par voie intraveineuse ou sous-cutanée à intervalles réguliers pour 
inhiber la dégradation possible ou l’hydrolyse de la molécule par des protéases 
d’hôte. Ainsi la distribution du médicament dans le sang dépend de la régularité 
des injections. Le mCD4-P3YSO3 est dépourvu de toxicité jusqu'à 1 µM en 
culture cellulaire, ce qui augure bien pour les tests de toxicité dans le modèle 
animal. 
En termes de stabilité de mCD4-P3YSO3, une approche qui pourrait être utilisée 
pour protéger la partie peptide anionique de la molécule bivalente contre  
l'hydrolyse par les  protéases de l’hôte, serait d'utiliser les stéréoisomères de 
chaque acide aminé. Les acides aminés D sont trouvés dans la nature, cependant, 
les acides aminés L sont principalement utilisés pour former des protéines dans les 
organismes (les acides aminés D sont trouvés dans la peau des grenouilles, en 
particulier). Vu que la reconnaissance de la cible pour la partie anionique de la 
molécule bivalente n'est pas strictement dépendante de  la structure (comme c'est 
le cas pour la partie mCD4), des isomères D pourraient être utilisés car ils sont 
encore fonctionnels en plaçant une charge négative à une certaine position, 
indépendamment de leur chiralité. Ainsi, les isomères-D ne seront pas reconnus 
par l'hôte et ne seront donc pas dégradés par les protéases de l’hôte. Concernant la 
production de mCD4-P3YSO3, comme mentionné précédemment, le prototype 
mCD4-HS12 a pris  un an à synthétiser.. Notre inhibiteur d'entrée bivalent de 
seconde génération est donc déjà beaucoup plus rapide à synthétiser par rapport au 
prototype et mCD4-P3YSO3. Dans un effort d’optimisation, le peptide sulfaté 
peut être remplacé par d’autres forme de molécules anioniques. On pourrait 
remplacer le sulfate (SO42-) sur les résidus tyrosines par du sulfonate (SO2O-), qui 
ne diffèrent que par un seul atome d'oxygène et sont techniquement beaucoup plus 
faciles à ajouter à une chaîne peptidique pendant la synthèse. Toutefois, ces 
nouveaux composés devront être examinés pour déterminer leur capacité à inhiber 
la liaison des complexes gp120-CD4 aux corécepteurs de l'hôte. Notre inhibiteur 
d'entrée bivalent (mCD4-P3YSO3) vise à la fois les variants R5 et X4 du VIH-1 et 
cette molécule est peu susceptible d'induire des mutations dans l'enveloppe pour 
échapper à la liaison, puisque  le développement de mutations dans deux parties 
différentes de la protéine simultanément est probablement difficile pour le virus. 
Toutefois, si la résistance se développe à cet inhibiteur il pourrait être utilisé en 
combinaison avec d'autres antirétroviraux ou en tant que traitement 
prophylactique. 
La prochaine étape de notre projet est de cristalliser le complexe  formé par 
mCD4-P3YSO3 avec la gp120 afin que les résultats puissent en être utilisés pour 
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déterminer le site exact de liaison entre mCD4-P3YSO3 et gp120. A partir de ces 
résultats, un inhibiteur ayant une affinité encore plus élevée peut être conçu 
contenant uniquement les sulfotyrosines essentielles impliquées dans l'interaction, 
dont le nombre peut être inférieur à celui se trouvant dans mCD4-P3YSO3. 
Finalement, un trimère mCD4-P3YSO3 peut être modélisé et produit, ce qui sera 
difficile d'un point de vue synthétique, mais très probablement plus efficace pour 
bloquer l'entrée virale parce qu’il  va se lier à l’ensemble de l'enveloppe trimère au 
lieu d'un monomère enveloppe. Ce composé ne présente aucune toxicité jusqu’à 1 
μM et inhibe l'entrée par  CCR5 et CXCR4 en utilisant des virus de laboratoire 
adaptés (LAI [X4] et Ba-L [R5]) ainsi que les souches virales primaires à partir de 
divers sous-types avec une ED50 de 1 nM. Le mCD4-P3YSO3 a montré un ED50 
faible (0,2 - 1,2 nM) pour 5 isolats cliniques primaires (clade A X4 [92UG029], 
clade B R5 [SF162], X4R5 clade B [92US723], X4R5 clade B [96USHIPS4], X4 
clade B [92HT599]) et il apparaît une ED50 de 29 nM pour un virus clade C 
[98IN017] à tropisme X4. Cette activité antivirale à tropisme double est sans 
précédent pour tout autre inhibiteur d'entrée du VIH-1. 
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9.2 Setting up the GPCR Immobilization Platform 
Interactions between membrane-bound receptors and their ligands have been 
studied by incorporating GPCRs into retrovirus particles and capturing these 
particles on a biosensor surface (Hoffman, Canziani et al. 2000). Despite the 
advantages of not having to solubilize, purify and reconstitute the membrane 
proteins into liposomes, this technique presents many complications; the quantity 
of functional GPCRs incorporated into the viral particles cannot be regulated, the 
surface for potential non-specific binding is increased due to the nature of the 
large spherical particles and a lower density of GPCRs is present on the biosensor 
surface due to their immobilization within the viral particles. Another 
disadvantage of this approach is that when the surface is regenerated with a 
regeneration solution, there is a risk that the GPCRs imbedded within the viral 
membrane become denatured and/or damaged and are thus not optimal for further 
binding experiments.  
Other techniques such as the use of paramagnetic proteoliposomes (PMPLs) have 
been described, which allow the study of membrane-associated solubilized native 
GPCRs (Mirzabekov, Kontos et al. 2000; Babcock, Mirzabekov et al. 2001; 
Devesa, Chams et al. 2002). Essentially, the solubilized GPCRs are captured on a 
magnetic bead via an affinity tag and following this, a liposome is reconstituted 
during detergent removal. Proteoliposomes, on the other hand do not have a 
central magnetic bead; they are essentially liposomes that have been formed by 
detergent removal through dialysis in the presence of purified CD4 and CXCR4 
(Zhukovsky, Basmaciogullari et al. 2010). Despite the advantage of the CD4 and 
CXCR4 molecules being able to move laterally within the membrane, which is 
not the case for PMPLs, they are randomly oriented in either direction when 
incorporated into the proteoliposomes and thus the quantity of functional 
molecules could be halved. This technique allows for interaction studies between 
host membrane proteins and viral envelopes as well as thermal stability studies on 
the HIV-1 coreceptors, however, optimized efficiency is required due to the high 
non-specific binding between proteoliposomes and cell membranes (Zhukovsky, 
Basmaciogullari et al. 2010). 
Surface Plasmon Resonance (SPR) is an innovative technology for studying 
biomolecular interactions in real-time without any labeling (Fagerstam, Frostell-
Karlsson et al. 1992). As opposed to structural techniques such as X-ray 
crystallography, NMR, electron microscopy and sequence analysis, SPR is a 
technique that gives detailed information on the dynamic interaction between 
molecules/proteins, providing more than just a snapshot of the interaction frozen 
in time. Other techniques such as affinity chromatography, immunological 
techniques and isothermal titration calorimetry, are able to obtain valuable 
information on the conditions and specificity of the interaction. However these 
techniques are unable to use such low quantities of unlabelled protein. Often, 
large quantities of purified protein are required as well as a form of labeling in 
spectrophotomeric techniques, and the labeling could interfere with the 
binding/active-site of the protein. However, the SPR technique may not require 
protein purification or labeling of any kind and is highly useful for weak and 
strong biological interactions. Unlike radioligand assays, SPR is able to determine 
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the amount of active receptor that has been immobilized on the surface. This is 
indicated by the amount of analyte binding to the immobilized ligand on the 
surface. The ligand of interest is covalently coupled (either directly, or a capturing 
molecule is first covalently coupled to the surface) using amine-coupling 
chemistry (see Section 8.10.5.2) to the hydrophilic dextran. The analyte is injected 
over the immobilized ligand and the interaction is observed by monitoring the 
change in resonance signal and kinetic information on the interaction derived from 
the rate of change of the signal (see section 8.10.5.1). 
SPR biosensors have been used for years to measure kinetics and affinities of 
molecular interactions, mostly involving soluble hydrophilic proteins. However, 
recently, the biosensor has been used as a tool to capture membrane solubilized 
GPCRs (Fagerstam, Frostell-Karlsson et al. 1992; Navratilova, Sodroski et al. 
2005; Navratilova, Dioszegi et al. 2006). The advantages of such a binding assay 
are numerous; it can be used as a tool to screen GPCR function under different 
solubilization conditions, to better understand the mechanism of chemokine 
interactions with GPCRs, assessing the ability of molecules to target the 
coreceptor binding site of gp120 and it can eventually be used to screen for 
inhibitors of HIV-1 entry.  
More than a decade ago, purification of GPCRs from their natural environments 
often resulted in proteins devoid of their native conformation, rendering their use 
in functional assays completely futile (Gether and Kobilka 1998; Ji, Grossmann et 
al. 1998). Thus, studying GPCRs was restricted to cell-based assays. However, 
due to the heterogeneity of the cell surface, often the interpretation of binding 
results is complicated. This is particularly problematic for studies involving 
chemokine receptors as their ligands bind to other cell-surface molecules 
including HS. Thus, over-expression, protein solubilization and purification for 
binding analysis, is a much more attractive option to better understand GPCR 
structure and function.  
In the context of the objectives of this study, we sought to improve upon the 
specificity and affinity of a pre-existing bivalent HIV-1 entry inhibitor (Baleux, 
Loureiro-Morais et al. 2009). In order to do this, we required a platform whereby 
we could immobilize the native HIV-1 coreceptors (CCR5 and CXCR4) and 
screen different molecules for their ability to inhibit gp120-CD4 complexes from 
binding to the immobilized coreceptors.  
Thus for the purpose of our studies, we decided to use SPR whereby C-terminal 
tagged HIV-1 coreceptors were solubilized and immobilized in an orientated 
fashion so that they could interact with their ligands. Here, we reduced the amount 
of variables that could cause non-specific binding (i.e. incorporation of cell 
membranes and other cell expressed membrane proteins) and we took advantage 
of the relatively small amount of material that is required for Biacore experiments. 
The Cf2Th-CCR5 and Cf2Th-CXCR4 cell lines which were obtained from the 
NIH AIDS research and reference reagent program, stably express their respective 
coreceptors and each coreceptor possesses a C-Terminal 9 amino acid (C9) tag. 
Owing to the high affinity interaction between the C9 Tag and the 1D4 antibody 
which is covalently attached to the biosensor surface, we were able to capture the 
solubilized coreceptors within the apparatus. Thus, we chose to solubilize the 
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HIV-1 coreceptors and immobilize them on the SPR surface as this technique did 
not require any laborious purification steps nor any handling of radioactive 
material and there is a well-equipped Biacore platform at the IBS institute. 
We have shown that with a solubilization cocktail (containing three detergents and 
a phospholipid blend, adapted from Navratilova et al., 2006), both CCR5 and 
CXCR4 are solubilized, maintaining their functionality. Refining the 
solubilization protocol for these two coreceptors served as the foundation to the 
two studies which were conducted using this immobilized coreceptor platform:  
1. Initially, in order to verify that the coreceptors retained their functionality 
after the solubilization process and immobilization, we required a positive 
control. Thus we decided to study the binding of the natural chemokine 
ligand, CXCL12, to CXCR4 in order serve as the proof of concept for this 
technique. This work constitutes the study of CXCL12α and CXCL12γ 
binding to CXCR4 and the role played by soluble HS. 
2. The second part of this work constitutes an extensive study whereby novel 
entry inhibitor molecules were screened for their ability/efficiency to 
inhibit the gp120/CD4 – coreceptor interaction (for both CCR5 and 
CXCR4).  
Here we immobilized solubilized chemokine receptors to study chemokine 
binding both in the absence and presence of soluble GAGs and to screen for 
molecules that inhibit gp120-CD4 binding to the coreceptors. We aimed to better 
understand the regulation of chemokine function by GAGs and to design more 
effective molecules that may prevent coreceptor utilization and entry of primary 
HIV-1 strains. 
9.2.1 Study of CXCL12 Binding to CXCR4 
The first objective of this work was to set up a functional surface of solubilized 
GPCRs whereby binding interactions could be studied in real time and kinetic 
data could be derived from the interaction curves. We initially worked with 
CXCR4 as there is a substantial repertoire of ligands that can be used to asses the 
functionality of CXCR4, namely; CXCL12 (natural chemokines [isoforms α and 
γ], conformational antibodies and the HIV-1 envelope glycoprotein). Once the 
solubilization and immobilization protocol was set-up for CXCR4, we would use 
the technique to screen for potential HIV-1 entry inhibitors. 
Initially, the solubilized coreceptors were used in simple immunoprecipitation 
experiments, using a solubilization solution that was previously described 
(Navratilova, Dioszegi et al. 2006) which revealed by western blot that the 
abovementioned ligands did recognise the solubilized coreceptors. These results 
were positive and reassuring and thus we proceeded to using the solubilized 
coreceptors in the SPR experiments. The efficient binding of antibodies (12G5, 
4G10 and anti-sulphotyrosine), chemokines (CXCL12α and γ) and viral envelope 
(X4 gp120) to the solubilized and immobilized CXCR4 strongly suggests that the 
CXCR4 protein retains its native conformation. 12G5 is a conformationally 
sensitive antibody that was chosen to asses whether or not the solubilized CXCR4 
was correctly folded. The monoclonal conformationally sensitive antibody 12G5 
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binds a complex epitope, influenced by the integrity of the second extracellular 
loop and the disulphide bond between cysteine 28 and 274 (Carnec, Quan et al. 
2005). The first part of this work (Chapter 5) is a study that was borne from using 
CXCL12 as a ligand to bind the solubilized and immobilized CXCR4 in order to 
confirm its functional integrity. CXCL12 is the natural ligand for CXCR4 and 
interacts with CXCR4 through binding of the N terminus and the second and third 
extracellular loops (Juarez, Bendall et al. 2004; Gozansky, Louis et al. 2005). 
The SPR signal measured by the optical biosensor is sufficiently sensitive to 
detect low molecular mass compounds (such as chemokines) with a relatively low 
Rmax. Fitting of the CXCL12α binding curves using a 1:1 langmuir interaction 
model returned on rates (kon or ka) of 2.58 x 106 ± 5.9 x 105 M-1s-1 and off rates 
(koff or kd) of 3.36 x 10-2 ± 5.9 x 10-3 s-1. We were able to determine the affinity of 
CXCL12α for CXCR4 giving rise to a KD of 13 ± 1.6 nM which is consistent with 
previously published assays; 3.6 ± 1.6 nM, 4.7 ± 1.6nM and between 1.2 – 27 nM 
for a similar SPR assay (Crump, Gong et al. 1997; Di Salvo, Koch et al. 2000; 
Navratilova, Dioszegi et al. 2006). The affinity was also in the same range (3.29 ± 
0.52 nM) as an assay using 125I-CXCL12α binding to recombinant CXCR4 (Zhou 
and Tai 1999). For CXCL12γ, preliminary analysis of the curves showed that the 
association and dissociation rate constants were dominated by mass transfer (the 
rate at which the surface binds the analyte exceeds the rate at which the analyte 
can be delivered to the surface) and thus the binding curves were fitted to a 1:1 
langmuir binding model that compensated for mass transport. The association rate 
constant for CXCL12γ was calculated as kon = 1.05 x 107 ± 1.2 x 107 M-1s-1 and 
dissociation rate constant was calculated as koff = 5.6 x 10-3 ± 5.3 x 10-3 s-1. As for 
CXCL12α, a concentration-dependent binding response was observed for 
CXCL12γ and we calculated an affinity KD of 0.7 ± 0.3 nM. Interestingly, 
CXCL12α displayed a lower association rate constant for CXCR4 and the 
dissociation rate constant for CXCL12γ is slower that for CXCL12α. Here, the 
CXCL12γ isoform displayed a higher affinity for the immobilized CXCR4 and 
this meant that CXCL12γ binds stronger to CXCR4 than CXCL12α. Since, the 
only difference between the CXCL12α and CXCL12γ isoforms is the C-terminal 
extension, these results suggest that it is this non-structured basic C-terminal 
extension that is responsible for the augmented affinity that CXCL12γ has for 
CXCR4.  
The mutant M1 is the CXCL12γ chemokine, however, 9 basic amino acids have 
been mutated in its C-terminal, thus it has an overall less positive charge than that 
of the CXCL12γ. However M1 still posseses 9 positive charges in its C-terminal 
domain, thus is more positively charged than CXCL12α. The M1 mutant was an 
intermediate between the two and interestingly, M1 displayed a binding profile to 
CXCR4 much like that of CXCL12α. M1 did not stay bound to CXCR4; it 
dissociated from CXCR4 as did CXCL12α. However its RMax is greater than that 
of CXCL12α, in the same order of magnitude as that of CXCL12γ. Thus, the fact 
that CXCL12γ has a higher affinity for CXCR4 and that it does not dissociate 
from the coreceptor is linked to the high number of basic residues found in the C-
Terminal. 
Since from our data, the high affinity displayed by CXCL12γ for CXCR4 is due 
to the basic C-terminal, one should be able to complete the binding to CXCR4 
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through the presence of anionic GAGs, which have been shown to bind the C-
Terminal of CXCL12γ (Laguri, Sadir et al. 2007). Hence, we studied the effect of 
soluble GAG chains on the interaction between CXCL12α, M1 and CXCL12γ 
with CXCR4. A 12mer HP oligomer (1µg/ml) did not have any effect on the 
binding of either CXCL12α or M1 to CXCR4, shown either by SPR or by flow 
cell cytometry. However, the same size and concentration of oligosaccharide had 
a drastic effect on CXCL12γ binding to CXCR4. With both techniques (SPR and 
FACS analysis), the oligosaccharide significantly diminished the binding of 
CXCL12γ to its coreceptor. This effect was most likely due to a competition 
between the anionic oligosaccharide and the coreceptor with the basic C-Terminal 
of CXCL12γ. Again, this effect was not seen in M1, meaning that the competitive 
binding is taking place in the C-terminal of CXCL12γ. As expected, the M1 
binding to CXCR4 was not affected by the presence of 12mer HP 
oligosaccharides, thus confirming that the strong affinity that CXCL12γ has for 
CXCR4 is due to its elongated C-terminal. We hypothesised that the basic 
elongated C-Terminal tail of CXCL12γ may bind to the anionic N-Terminal of 
CXCR4 which posseses up to three tyrosine residues which can each be 
sulphated, contributing to the high affinity seen between CXCL12γ and CXCR4. 
Tyrosine sulphation occurs in about 1% of the total protein content of a cell and it 
is mediated post-translationally by tyrosine sulphotransferases in the trans-golgi 
network (Huttner 1988). Sulphated tyrosines have been detected in several 
chemokine receptors (CCR2B, CCR5 and CX3CR1) and is important for the 
interactions with their respective ligands (Preobrazhensky, Dragan et al. 2000; 
Farzan, Babcock et al. 2002; Fong, Alam et al. 2002). Site-directed mutagenesis 
studies have shown that Tyr26 is sulphated in CCR2B, the monocyte chemotactic 
protein-1 (MCP-1) receptor and the lack of this sulphation inhibits the biological 
function of the receptor (Preobrazhensky, Dragan et al. 2000). Interestingly, the 
addition of heparin does not inhibit chemotaxis, as the heparin binds at the basic 
C-terminal domain of MCP-1, which is opposite to the site of receptor binding. 
Preobrazhensky et al., propose a mechanism whereby MCP-1 may be bound to 
cell-surface GAGs and the N-terminal of CCR2B “grabs” the tethered MCP-1 in 
order to favour the chemokine binding to the receptor (Preobrazhensky, Dragan et 
al. 2000). Another example of sulphated tyrosines found in receptors is that of the 
N-terminal of CCR5 which contributes to the binding of macrophage 
inflammatory protein -1α, -1β and Regulated on Activation Normal T cell 
Expressed (RANTES) in leukocyte chemotaxis and activation (Bannert, Craig et 
al. 2001; Farzan, Babcock et al. 2002) and gp120-CD4 complex binding (Farzan, 
Mirzabekov et al. 1999). In addition to the sulphated tyrosine, sialylated O-
glycans within the N-terminal of CCR5 exert little effect on HIV-1 binding, 
however, are critical for MIP-1α and -1β high affinity binding (Farzan, Choe et al. 
1998; Farzan, Mirzabekov et al. 1999; Bannert, Craig et al. 2001; Wang, Babcock 
et al. 2004). 
Considering the complementarity in surface charge of the sulphates in the CXCR4 
N-terminal and the highly basic CXCL12γ C-terminal, it was logical to propose 
that the high affinity that is observed between CXCL12γ and CXCR4 is due to the 
ionic interaction between the basic amino acids in the C-terminal of CXCL12γ 
with the sulphated tyrosine residues present in the N-terminal of CXCR4. Thus 
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we analysed the binding of CXCL12γ on the immobilized CXCR4 surface and 
subsequent injection of the anti-sulphotyrosine antibody (which recognises the 
sulphotyrosines in the N-terminal of CXCR4). Once the CXCL12γ was already 
bound, recognition of the coreceptor by the antisulphotyrosine antibody was 
blocked. This demonstrated that these two binding events are mutually exclusive. 
To rule out the effect of steric hindrance preventing the anti-sulphotyrosine 
antibody from binding once CXCL12γ has already bound, we performed the same 
experiment with 4G10 (an antibody raised against a non-sulphated N-terminal 
CXCR4 peptide). Here, both the 4G10 and the CXCL12γ were able to bind the 
immobilized CXCR4 simultaneously.  
CXCR4 is modified by a chondroitin sulphate at Ser18 in some cell lines, 
however, neither HIV-1 entry nor CXCL12α binding is affected by the loss of this 
glycosaminoglycan (Farzan, Babcock et al. 2002). In addition to this modification, 
Asn11 is post-translationally modified by N-linked glycosylation and this 
alteration is important for high affinity CXCL12α binding and when mutated 
permits infection of R5 HIV-1 strains and enhances infection by X4 strains (Zhou 
and Tai 1999; Chabot, Chen et al. 2000; Wang, Babcock et al. 2004). The 
significance of the N-linked glycan was not investigated here due to the 
complexity of the experiment. The glycan at Asn 11 is important, however, not 
essential for binding and we report biochemical and structural data on the 
significance of the sulphated tyrosines and their roles played in CXCL12γ 
chemokine binding. Further studies will need to scrutinise the significance of N-
linked glycans in CXCL12γ binding to CXCR4.   
In 2006, Veldkamp et al., showed that a dynamically disordered CXCR4 peptide 
(first 38 residues), enzymatically modified to contain one sulphotyrosine residue 
at position 21, bound the CXCL12α dimer with a low µM affinity and formed a 
salt bridge with Arg47 on the chemokine (Veldkamp, Seibert et al. 2006). We 
sought to test the hypothesis that the C-terminal of CXCL12γ binds to the 
sulphotyrosines in the N-terminal of CXCR4. To this end, structural and cell-
based approaches were employed. In our NMR experiment, we obtained two 
synthetic peptides (produced by collaborators at the Institut Pasteur) which 
consisted of the N-terminal peptide (29 residues long) of CXCR4. One of the 
peptides possessed three sulphated tyrosines (7, 12 and 21) and the other peptide 
contained tyrosines that were not sulphated. For each experiment, 15N labelled 
CXCL12γ was titrated with incremental additions of either sulphated or non-
sulphated N-terminal peptide to identify the residues that were involved in 
sulphated peptide binding.  
We assigned 15N-1H amide chemical shifts of 15N labelled CXCL12γ using 
standard NMR methods and mapped these onto the CXCL12γ sequence. When 
the 15N labelled CXCL12γ was titrated with incremental additions of the non-
sulphated peptide, the core domain (CXCL12γ 1-68) was affected, however the C-
Terminal of CXCL12γ was not at all affected. A similar result was seen with 
Veldkamp et al., where the N-terminal of the CXCR4 interacted with CXCL12α 1-
68 as shown in a similar experiment which produced almost identical chemical 
shifts for the N-terminal folded part of the chemokine (Veldkamp, Seibert et al. 
2006; Veldkamp, Seibert et al. 2008). Veldkamp and collegues also showed that 
even with one sulphated tyrosine on the CXCR4 N-Terminal peptide, no change 
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in the chemical shifts of CXCL12α 1-68 were identified. Therefore, they concluded 
that the sulphates are not significantly involved in the binding of CXCL12α 1-68. 
However, when the 15N labelled CXCL12γ was titrated with incremental additions 
of the sulphated peptide, the same result was seen for the ‘CXCL12α-like’ part of 
CXCL12γ (CXCL12γ 1-68), thus confirming the work which Veldkamp and 
collegues performed, and the C-Terminal was also modified. This NMR 
experiment revealed compelling data that the presence of the sulphates, enables 
the binding of the CXCR4 N-Terminal peptide to the C-Terminal of CXCL12γ. 
Thus the higher affinity observed between CXCL12γ and CXCR4 is due to the C-
terminus of the chemokine. This was apparent as the C-terminal of the CXCL12γ 
displayed stronger chemical shifts in the presence of the sulphated peptide as 
opposed to the non-sulphated peptide. Due to the repetitive sequence and highly 
unstructured and disordered nature of the C-terminal of CXCL12γ, specific 
residue information is not available for most residues in this domain. However, a 
large group of amine peaks in the C-terminal region of the chemokine 
significantly shift upon addition of the sulphated peptide, confirming that the 
many basic amino acids in the C-terminal of CXCL12γ considerably contribute to 
the binding of the sulphated tyrosines in the N-terminal of CXCR4. 
The following CXCL12γ residues showed large shift perturbations and thus were 
shown to interact with the peptide which includes residues from the N-loop; 
(F13), β1(K24,H25), β2(39-42), β3(48-50) and the α-helix (W57, Y61, L62). 
Similar data was shown by Veldkamp et al., and the chemokine N-terminus does 
not participate in the interaction with the N-terminal of CXCR4, which is 
consistent with the “two site” binding model of CXCL12 for CXCR4 (Crump, 
Gong et al. 1997; Veldkamp, Seibert et al. 2006).  
We have attempted to show, with ELISA based-assays, that the affinity between 
the CXCL12γ and the CXCR4 N-terminal sulphated peptide was slightly 
augmented as compared to that for that of CXCL12γ and the CXCR4 non-
sulphated peptide. However, the bulk of the interaction between CXCL12γ and 
the N-terminal of CXCR4 occurs between the N-terminal of the chemokine and 
not the C-terminal and thus results from these assays are not 100% conclusive.  
In chemotaxis experiments, CXCL12γ has a much weaker effect through cell-
surface CXCR4 as compared to CXCL12α (Rueda, Balabanian et al. 2008).  The 
reason for this has never been well understood. Only at high concentrations 
(100nM and higher) of CXCL12γ is a significant signalling effect seen through 
CXCR4, which equals that of CXCL12α seen at only 1nM. We hypothesized that 
due to the high affinity between CXCL12γ and the N-terminal of CXCR4, this 
chemokine is ‘tethered’ to the N-terminal of the coreceptor and is spatially too far 
from the activation site and is thus a weaker signalling chemokine. In accordance 
with the hypothesis that the higher affinity that CXCL12γ has for CXCR4 is due 
to the interaction of the basic amino acids in the C-terminal of CXCL12γ with the 
sulphated tyrosines in the N-terminal of CXCR4 – ERK 1/2 activation 
experiments with the chemokines (CXCL12α, CXCL12γ and M1) in the presence 
and absence of oligosaccharides were performed.  
Our aim was to ‘detach’ tightly bound CXCL12γ from the N-terminal of CXCR4 
so that the chemokine may move closer towards the activation site (which was 
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previously spatially too far) between the extracellular loops and activate the 
coreceptor. Here, CEM cells were used as they have very little/ no GAGs 
expressed on their surface and thus cell-surface GAGs will not obscure results 
obtained when soluble GAGs are added to the system. When comparing ERK 1/2 
activation by the three different chemokines (CXCL12α, M1 and CXCL12γ), the 
following concentration range of chemokines was used to compare ERK 1/2 
activation, 0.5, 5, 50 and 200nM. Since CXCL12γ signals less stongly than 
CXCL12α (data not shown), when comparing the effect of cell-free GAGs on 
chemokine induced ERK 1/2 activation, 50nM of CXCL12γ was used to detect an 
equivalent ERK 1/2 activation detected with 5nM of CXCL12α. We have shown 
that when in the presence of 10 µg/ml heparin, CXCL12γ induces a 4X stronger 
activation of ERK 1/2, whereas there is no difference in ERK 1/2 activation for 
CXCL12α and M1 in the presence of heparin.  I.e. the strength of the ERK 1/2 
activation signal seen at 50nM together with the presence of heparin is equivalent 
to that seen at 200nM of CXCL12γ in the absence of the oligosaccharide. This 
supports our hypothesis that CXCL12γ signals less compared to CXCL12α due to 
its strong interaction with the sulphotyrosines in the N-terminal of CXCR4. In our 
model, when in the presence of short sulphated oligosaccharides, the CXCL12γ-
N-Terminal CXCR4 interaction is destabilized permitting the chemokine to detach 
and access the activation site within the extracellular loops of CXCR4, thus 
soluble heprain could enhance the CXCL12γ signalisation (Figure 5.14 in Chapter 
5). Other hypotheses could be proposed such as; the soluble heparin is able to 
stabilize the disordered C-Terminal of CXCL12γ, thus allowing it to signalise 
more efficiently and leading to less non-specific binding occuring. Further studies 
need to investigate whether or not CXCL12γ dimerises in the presence of GAGs, 
as does CXCL12α, or would the basic C-Terminal of CXCL12γ prevent 
dimerisation? 
We propose a binding model for CXCL12γ and CXCR4 in the presence of cell-
associated or cell-free GAGs. When CXCL12γ is bound to the N-terminal of 
CXCR4, spatially it is restricted from accessing the activation site within the 
extracellular loops of CXCR4. However, in the proximal presence of either a cell-
associated or cell-free GAG, the electrostatic interaction between the C-terminal 
of the CXCL12γ and the N-terminal of the CXCR4 is disrupted by the presence of 
the GAG and thus the CXCL12γ is ‘released’ and can access the activation site 
within the CXCR4, allowing signalling. This mechanism only occurs for the 
CXCL12γ isoform, as seen in the scheme in Chapter 5 Figure 5.14; the CXCL12α 
is not tethered by the N-terminal of the CXCR4 and can easily access the 
activation site within the extracellular loops of CXCR4. 
Until now, very little has been known about the signalling dynamics of CXCL12γ 
through CXCR4 and the involvement of GAGs in this process. We have started to 
decrypt this process, however, further cell-based assays should be performed to 
confirm the effect of GAGs in CXCL12γ-CXCR4 signalling. For example, 
chemotaxis analysis and calcium mobilization experiments should be performed 
for the CXCL12γ isoform. Recently, monomeric and dimeric CXCL12α has been 
shown to inhibit metastasis through different mechanisms depending on their 
interaction with CXCR4 (Drury, Ziarek et al. 2011). This is partly explained by 
the different interaction that takes place between the tyrosine sulphated N-
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Terminal of CXCR4 and the CXCL12α monomer and CXCL12α dimer which as 
shown by NMR, binds the preferential monomer of CXCL12α differently from 
how it binds the constitutive dimer (Drury, Ziarek et al. 2011). However, these 
results are highly controversial and need to be demonstrated with non-mutant 
chemokines. It could be an interesting assay to perform the same experiment but 
with CXCL12γ to see if a similar phenomenon occurs. This may shed light on the 
differences in signalisation between CXCL12α and CXCL12γ. 
CXCL12 is known to participate in a plethora of both homeostatic and 
pathological processes concerning the immune system, however the mechanisms 
of regulation of these two opposing forces are unclear. When comparing the 
functions of CXCL12α and CXCL12γ, it is apparent that due to the difference in 
structure, these two chemokine isoforms are likely to have diverse functions.  
Based on numerous studies, CXCL12α binds readily to cell-surface 
glycosaminoglycans (Sadir, Baleux et al. 2001; Lortat-Jacob, Grosdidier et al. 
2002) as well as the sulphated N-terminal of CXCR4 (Veldkamp, Seibert et al. 
2006) as does CXCL12γ, however the latter with a 10x higher affinity. CXCL12α 
will bind to cells expressing a significant quantities of sulphated GAGs (Santiago, 
Izquierdo et al. 2011), and the degree of binding will be directly correlated with 
the degree of sulphation of the GAGs. Depending on the cell type, developmental 
stage and pathophysiological state, the GAG expression profile may vary and this 
may play a role in the regulation of CXCL12α signalling during development and 
disease states. Conversely, CXCL12γ has such a a high affinity for GAGs that it 
may bind to immune cells which express any range of oligosaccharides; from a 
slight/low expression to a large level of expression and sulphation. Thus the 
repertoire of immune cells to which these two isoforms will bind and recruit 
immune cells, might be different. In addition to the different target cells to which 
the chemokines bind, the kinetics of signalling and motility between these two 
isoforms is vastly different; CXCL12α has a half life of being bound to the cell 
surface and its receptor is much shorter than that of CXCL12γ due to their 
different affinities for their anionic binding partners; this might lead to drastic 
differences in the extent of signalling.  
We hypothesize that the CXCL12γ is expressed and secreted for highly 
concentrated, local and small haptotactic gradients for sequestration of immune 
cells over a much more prolonged period of time as opposed to the larger spread-
out gradients that are created with CXCL12α which will comparatively be shorter 
lived. Further studies will be needed to determine if the differential expression of 
GAGs in vivo correlates with a differential retention and downstream signalling 
effects of either chemokine isoform. 
Another hypothesis for the functional diversity of CXCL12γ is that of proteolytic 
degradation. Since CXCL12γ displays a lower activation frequency of CXCR4 
due to its C-Terminal sequence, a level of regulation of CXCL12γ signalling 
could be through the digestion of the C-terminal. This could occur via proteases 
including matrix metalloproteinases or serine proteases which could remove the 
C-terminal of CXCL12γ. This is highly speculative and would need to be 
thoroughly investigated, but it could be a level of CXCL12γ signalling regulation.  
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As can be seen, the biological relevance of the chemokine-GAG interaction and 
chemokine-CXCR4 interaction has clearly been described. However, this complex 
process has still much to be discovered; the role played by GAGs is particularly 
intricate as GAGs are structurally hypervariable and this structural variability may 
have specific functional significance (depending on the level of sulphation, length 
of GAG chain etc). Many questions are raised such as, for a specific GAG 
structure, which chemokine ligand is bound, what is the strength and duration of 
this interaction, what its state of oligomerisation and while bound does it have an 
ability to signal efficiently and how is this all regulated? Numerous inhibitors 
have been developed to interfere with these interactions, whether they are 
chemokines that are mutated to be coreceptor or GAG binding antagonists or 
whether GAG mimicking peptides or oligosaccharides have been used as 
chemokine decoys. Thus, while there has been huge progress made in the search 
for anti-inflammatory molecules and anti-cancer drugs, further understanding of 
the ‘chemokine interactome’ will improve existing therapeutic approaches and 
possibly create new ones.  
It is known that as a prerequisite to an array of cellular processes and regulatory 
events, proteins bind to GAGs. In particular, the chemokine system is intimately 
associated with GAGs as a means to ensure their correct positioning and transport 
within tissues (Colditz, Schneider et al. 2007; Rot 2010). CXCL12γ’s disordered 
C-terminal tail contributes to the unprecedented high affinity for GAGs and forms 
a stable complex. An equivalent high affinity occurs with CXCL12γ and CXCR4. 
The C-terminal tails on CXCL12γ arises from alternative splicing of the Cxcl12 
gene and this has been thought of as natures’ way to generate functional diversity 
without structural modification nor the appearance of separate proteins (Laguri, 
Sadir et al. 2007). 
9.2.2 The Entry Inhibitor Study 
In order to target HIV-1 entry, a successful inhibitor will have to not only block 
CD4 binding but also block gp120 from binding to its cognate coreceptor (ideally 
both CCR5 and CXCR4). This is an incredibly challenging task as the HIV-1 
glycoprotein surfaces that are involved in entry are well hidden by a glycosylated 
shield as well as a hidden cryptic CD4i.  
Since the discovery of HIV-1 thirty years ago, many different drugs that target the 
virus have been discovered and approved for treatment in patients. Recently, a 
new class of molecules has attracted a lot of attention; the entry inhibitors.  
As a result of strong positive selection, the occurrence of the 32 base pair deletion 
(CCR5 Δ32 allele) in certain individuals results in the altered and reduced 
expression of CCR5 and thus confers natural immunity to HIV-1 without any 
negative effects on health (Stephens, Reich et al. 1998). This fact has sparked a lot 
of interest in developing CCR5 ligands with antiviral properties, such as 
chemically modified chemokines (Mack, Luckow et al. 1998; Pastore, Picchio et 
al. 2003), monoclonal antibodies (Trkola, Ketas et al. 2001; Safarian, Carnec et al. 
2006) and low molecular weight non-peptidic compounds.  
The latter class of entry inhibitors includes Maraviroc (UK-427857, marketed as 
Selzentry or Celsentry) which has recently been approved in 2007 for treatment of 
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patients harboring only CCR5 utilizing viruses (Dorr, Westby et al. 2005) as it is a 
molecule that binds to the host CCR5 coreceptor. Maraviroc is also used to 
prevent HIV-1 transmission. Some promising data was shown by PRO 542 which 
is the tetravalent CD4-immunoglobulin containing D1 and D2 domains of CD4, 
however, this compound is no longer being developed. Ibalizumab (TNX-355) is 
a monoclonal antibody that binds the second domain of CD4 and has also shown 
promising results. Other CCR5 antagonists  have been discontinued (Aplaviroc, 
INCB009471) or are entering phase III trials (Vicriviroc [SCH417692 or SCH-D]) 
(McNicholas, Wei et al. 2011), however, there is no existing CXCR4 antagonist. 
This is not surprising as there are no known naturally occurring mutations leading 
to the absence of CXCR4 and its expression is essential to the development and 
immunosurveillance of our organism and blocking this receptor can lead to grave 
complications. Thus due to toxicity effects, the development of AMD3100 a 
CXCR4 antagonist, was put on hold. Lastly, a fusion inhibitor that has been 
approved by the FDA for clinical use, Enfuvirtide (T-20), prevents the association 
of HR1 and HR2 of gp41. Enfuvirtide is administered to treatment-experienced 
patients with resistant viruses, however, usage is limited to short term use due to 
pain at the injection site and resistance develops relatively quickly (Wild, Shugars 
et al. 1994; Lalezari, Henry et al. 2003; Lazzarin, Clotet et al. 2003). 
9.2.2.1 mCD4­HS12 and mCD4­P3YS03 
There is a great need for a novel entry inhibitor that binds to the virus which has 
low toxicity and inhibits both CCR5 and CXCR4-tropic HIV-1 variants. For this 
purpose we aimed to increase the specificity and affinity of the prototype bivalent 
entry inhibitor molecule, mCD4-HS12 (Baleux, Loureiro-Morais et al. 2009). 
It is known that in order to target the vulnerable coreceptor binding pocket (CD4i 
epitope), a molecule with anionic properties would be required to 
complementarily dock into the CD4i epitope comprising a number of basic 
residues. Several studies have shown that anionic molecules are able to inhibit 
mAb 17b binding with IC50 in the 1-100µM range (Cormier, Persuh et al. 2000; 
Farzan, Vasilieva et al. 2000; Cohen, Forzan et al. 2008; Crublet, Andrieu et al. 
2008; Brower, Schon et al. 2009; Dervillez, Klaukien et al. 2010; Acharya, Dogo-
Isonagie et al. 2011; Kwong, Dorfman et al. 2011; Seitz, Rusert et al. 2011). 
Crublet et al., showed that HS belongs to this group of anionic CD4i targeting 
molecules and when a 12mer was conjugated to a mini CD4, this bivalent 
molecule had profound antiviral properties (Baleux, Loureiro-Morais et al. 2009). 
Due to the extremely complex and heterogeneous nature of HS (Esko and Lindahl 
2001), based on the 48 different disaccharide combinations, a 12 mer library (486 
= 1010) would be inconceivable to synthesize for structure-function studies. In 
addition, assembling the 12mer used in the prototype took 1 year to synthesize 
and thus a larger library of differently sulphated 12mers would be impractical to 
produce.   
Thus, the glyco-portion of the prototype needed to be improved/optimized and 
there were two ways to do this: one approach would have been to fractionate a 
library of natural 12mer heparan sulphate oligosaccharides by means of ion-
exchange chromatography under the influence of an increasing salt gradient, 
purify and test each fraction for its ability to inhibit gp120-CD4 binding to the 
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coreceptor and then purify the most active fraction in large quantities. This 
approach would be tedious and also not amenable to structure-function analysis as 
this purification technique is far from accurate and a homogeneous solution of one 
type of 12mer structure would not be possible to obtain. Even if an 
oligosaccharide 12mer with high binding affinity to gp120 was identified, 
sequencing of this 12mer to identify its exact disaccharidic structure would also 
be very tedious. 
The second approach was the design of HS-mimetic peptides containing 
negatively charged amino acids that mimic the HS moieties and this would 
simplify the process twofold; the peptides are straightforward to synthesize and a 
homogeneous known peptide sequence would be amenable to sequence-activity 
investigation. To mimic the functional hydroxyl, carboxyl and sulphate groups 
found on HS moieties, peptides containing serine, asparagine and tyrosines (either 
sulphated or non-sulphated) were produced. The S(XDXS)3 sequence was used 
where X represents any amino acid and five peptides were synthesized; P3Y 
(Where X = non-sulphated tyrosine), P3YSO3 (where X = sulphotyrosine), P3Asu 
(where X = aminosuberic acid), P3pF (where X = p-carboxymethyl 
phenylalanine) and E13 ( where the entire length is glutamic acid – a non-specific 
polyanion). The sulphotyrosine-containing peptides (P3YSO3) were shown to 
block mAb 17b with an IC50 of 3µM, which compares well to the previously 
published molecules, additionally, when conjugated to mCD4, P3YSO3 interacted 
with both R5 and X4 gp120, however HS12 bound the X4gp120 with preference. 
When P3YSO3 was covalently coupled to mCD4, a synergistic effect was seen 
and low nM amounts of mCD4-P3YSO3 were needed to prevent gp120-CD4 from 
binding to mAb 17b. Since mAb 17b is only a rough surrogate coreceptor, the 
inhibitory capacity of mCD4-P3YSO3 needed to be tested on functional 
solubilized CCR5 and CXCR4 immobilized on biacore surfaces. 
Using the GPCR solubilization protocol that had been set-up and optimized in 
Chapter 5, both CCR5 and CXCR4 were immobilized on the chip and interactions 
between gp120, in the presence and absence of mCD4 were monitored. Binding of 
gp120 to its coreceptor was CD4 dependent, however, there was binding between 
the coreceptor and the gp120 in the absence of CD4. This can be explained by a 
percentage of the envelopes being ‘CD4-independent’ or ‘pre-triggered’. This 
phenomenon has been documented by different techniques; previously, CCR5-
containing proteoliposomes have been shown to bind R5 gp120 in the absence of 
soluble CD4, however, a stronger binding interaction is seen in the presence of 
sCD4 (Mirzabekov, Kontos et al. 2000; Babcock, Mirzabekov et al. 2001). To the 
contrary, Babcock et al., did not detect CD4 independence for CXCR4 utilizing 
envelopes. 
Babcock et al., calculated the affinity of HXBc2 gp120 for CXCR4 to be ~200nM 
(Babcock, Mirzabekov et al. 2001), nearly 100-fold lower than that of R5 HIV-1 
estimated by Wu et al., (Wu, Gerard et al. 1996). A similar affinity was calculated 
for gp120 binding to CXCR4 (~500nM) for virion-like particles incorporating 
CXCR4 (Hoffman, Canziani et al. 2000). Binding of the gp120-CD4 complexes to 
the solubilized GPCRs was also dose-dependent. We obtained an affinity of 154 ± 
68 nM for the X4 gp120/CD4 – CXCR4 interaction which is comparable to that 
 
 
210
obtained in a cellular system (Doranz, Baik et al. 1999; Babcock, Mirzabekov et 
al. 2001) and 11.5 ± 2.9 nM for the gp120/CD4-CCR5 interaction which are in 
agreement with that found for a similar technique (Navratilova, Sodroski et al. 
2005). The preference for HIV-1 isolates to infect CCR5-expressing host cells in 
the early stages of infection could be explained by this apparent ‘lower’ affinity 
for CXCR4. As our assay results are consistent with previously published data for 
the affinities of gp120-CD4 complexes for their respective coreceptors, our 
system was clearly functional and we proceeded to investigate the inhibitory 
capacity of the above mentioned synthetic peptides.  
Out of the 5 bivalent peptides that were screened on the GPCR surfaces, mCD4-
P3YSO3  was the only peptide that fully inhibited the gp120 binding to both CCR5 
and CXCR4 coreceptors with a 1:1 stoichiometry. One of the criticisms of many 
new potential entry inhibitors is how the molecule will inhibit both CCR5 and 
CXCR4-utilizing viruses. This will be achieved by mCD4-P3YSO3 through its 
bivalent nature; it is known that the V3 loop which comprises part of the 
coreceptor binding domain (Dragic 2001) has a more basic charge in X4 
envelopes as compared to that of R5 envelopes (Moulard, Lortat-Jacob et al. 
2000). Thus in order for the mCD4-P3YSO3 peptide to target a wide range of 
envelopes with a range of different overall charges in their V3 loop, we propose 
sulphated peptides that have moderate levels of sulphation and that the specificity 
of the binding interaction will be attributed to the mCD4 moiety.  
Interestingly, the other bivalent HIV-1 entry inhibitor peptides (mCD4-PSY, 
mCD4-P3Asu, mCD4-P3pF and mCD4-E13) all displayed varying degrees of 
antiviral activities in the PBMC infectivity assay against the LAI (X4 tropic) HIV-
1 strain. However, they were all ineffective against the Ba-L (R5 tropic) strain. 
This is understandable as the other peptides all contained negatively charged 
amino acids (carboxyl groups) which most likely bound to the basic V3 loop of 
the gp120, which carries a particularly higher positive charge in X4 tropic HIV-1 
strains (De Jong, De Ronde et al. 1992). Thus, these other peptides are not 
redundant, they can also be envisaged as antiviral therapies that are administered 
as a salvage therapy in addition to compounds against R5-tropic viruses (eg 
Maraviroc) for patients who have CXCR4-utilizing or dual-tropic HIV-1 strains. 
By replacing the glyco-moiety of mCD4-HS12 with a tyrosine sulphated peptide, 
one can begin to have a rough idea of the quantity and position of sulphated 
residues that are minimally required to bind to a certain epitope on a protein. Not 
only is this sulphated peptide of value as a new generation HIV-1 entry inhibitor 
but it also opens up a whole new strategy for determining the structure-function 
relationship between sulphated molecules and target proteins.  
This new molecule, mCD4-P3YSO3, has an IC50 as low as 1 nM and thus deserves 
to be tested in macaques against the SHIV model of HIV for its efficacy in an 
animal model. Many questions are raised when novel therapeutic drugs pass in the 
pipeline from basic research to animal models and finally to clinical trials; such 
questions concern the molecule’s distribution in the host, its stability, 
immunogenicity, ease of production and what if resistance develops in the virus 
against the drug. Depending on whether mCD4-P3YSO3 is used as a treatment or 
whether it is used as a prevention strategy, this will affect the molecules’ 
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distribution. As a preventative approach, mCD4-P3YSO3 can be incorporated into 
a mucosal gel that will be applied to the vaginal and anal mucosa and thus be used 
as a microbicide. In this case, the distribution of the drug will be local and 
concentrated at the genital mucosal tract – the first site of entry of the virus during 
sexual transmission of the virus. However, if mCD4-P3YSO3 is used as a 
treatment, it will need to be administered intravenously or subcutaneously at 
regular intervals to counteract the possible degradation or hydrolysis of the 
molecule by host proteases. Thus the drug’s distribution within the blood will 
depend upon the regularity of the injections. Since the mCD4-P3YSO3 is devoid 
of toxicity up to 1 µM in cell culture, this bodes well for toxicity tests in the 
animal model.  
In terms of mCD4-P3YSO3 stability, one approach that could be used to protect 
the anionic peptide part of the bivalent molecule from host protease hydrolysis, 
will be to use the stereoisomers of each amino acid. D amino acids are found in 
nature, however, L amino acids are mostly used to form proteins in organisms (D 
amino acids are found in frogs skin, in particular). Since the target recognition for 
the anionic part of the bivalent molecule is not strictly reliant on the structure (as 
is the case for the mCD4 part), D isomers can be used as they will still serve their 
function by placing a negative charge at a certain position, regardless of their 
chirality. Thus, D isomers will not be recognized by the host and thus not 
degraded by the host proteases.  
Immunogenicity screening needs to be performed in an animal model to test the 
ability of mCD4-P3YSO3 to produce an immune response. Due to the fact that the 
mCD4 moiety is 27 amino acids in length, containing only several amino acids 
dereived from the host CD4 protein, when conjugated to the ‘HS mimetic’ moiety 
(P3YSO3), the final molecule is essentially a short peptide containing 
sulphotyrosines. The very small size of this molecule reduces the chances for the 
host to mount an autoimmune reaction against it. 
Concerning the production of mCD4-P3YSO3, as mentioned previously, the 
prototype mCD4-HS12 took up to one year to synthesize and the HS12 moiety is 
very unstable. Our second generation bivalent entry inhibitor is thus already much 
faster to synthesize compared to the prototype and mCD4-P3YSO3 is much more 
stable compared to mCD4-HS12. To further reduce the production time of mCD4-
P3YSO3, one could replace the sulphate (SO42-) residues on the tyrosines with 
sulphonate (SO2O-) residues, which only differ by one oxygen atom and are 
technically much easier to add to a peptide chain being synthesized. However, 
sulphonate containing peptides will need to be screened for their ability to inhibit 
gp120-CD4 complexes from binding to host coreceptors. 
In addition to the usual problems associated with anti-viral drug design 
(selectivity, oral bioavailability, etc.), development of novel HIV-1 entry 
inhibitors are hindered by problems associated with rapid evolution of the virus, 
leading to drug resistance. For example, by blocking only CCR5-utilizing viruses 
from entry into host cells, the CXCR4-utilizing viruses could become dominant. 
This is the problem for CCR5 antagonists, which could potentially accelerate the 
progress of the disease by promoting the evolution of more virulent, CXCR4-
dependent variants. Our bivalent entry inhibitor (mCD4-P3YSO3) targets both 
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CCR5- and CXCR4-utilizing HIV-1 variants and this molecule is unlikely to 
induce mutations within the envelope to escape binding, as development of 
mutations in two different parts of the protein simultaneously is probably difficult 
for the virus. However, if resistance does develop to this inhibitor it could be used 
in combination with other antiretrovirals or as prophylactic treatment.  
Structural information of the mCD4-P3YSO3 interacting with HIV-1 gp120 is 
critical for understanding the molecular basis of the viral - coreceptor (CCR5 and 
CXCR4) interactions. This information will shed light on the HIV-1 entry 
mechanism and aid in developing other specific inhibitors of these interactions. In 
2007 Huang et al., and colleagues showed the interaction between the tyrosine 
sulphated CCR5 N-terminus (NMR structure) and the tyrosine sulphated 412d 
antibody (X-Ray crystal structure) each in complex with gp120 and CD4 (Huang, 
Eshleman et al. 2007). Here, we are privileged to see the exact contacts that are 
formed between the sulphated tyrosine (from the N-terminal of CCR5 and the 
412d extended loop) and the gp120 binding pocket. Tyr10 interacts with the 
gp120 core and forms a salt bridge with Arg327 of gp120 and the Tyr14 packs 
against the bridging sheet (Huang, Eshleman et al. 2007). The next step for our 
project is to crystallize the complex of mCD4-P3YSO3 together with gp120 so 
that the results can be used to determine the exact binding sites between mCD4-
P3YSO3 and gp120. From these an even higher affinity inhibitor can be designed 
containing only the essential sulphotyrosines involved in the binding interaction, 
which may be less than are found in mCD4-P3YSO3. Eventually a trimeric 
mCD4-P3YSO3 can be modeled and produced, which will be challenging from a 
synthetic point of view, but most likely more efficient at blocking viral entry as it 
will bind an entire envelope trimer instead of an envelope monomer (however, 
this might be less bioavailable). 
This compound shows no toxicity up to 1µM and inhibits entry of CCR5 and 
CXCR4 utilizing laboratory adapted viruses (LAI [X4] and Ba-L [R5]) as well as 
primary viral strains from diverse subtypes with an ED50 of 1nM. The mCD4-
P3YSO3 demonstrated a low nM ED50 (0.2 – 1.2 nM) for 5 clinical primary 
isolates (X4 clade A [92UG029], R5 clade B [SF162], X4R5 clade B [92US723], 
X4R5 clade B [96USHIPS4], X4 clade B [92HT599]) and it displayed an ED50 of 
29nM for an X4 tropic clade C virus [98IN017]. This dual tropic antiviral activity 
is unprecedented for any HIV-1 entry inhibitor. These data further demonstrate 
the high anti-viral capacity of this molecule. The information provided by this 
study will be useful for future design of novel anti-viral molecules as therapeutics 
for HIV-1 infection as well as other therapeutic molecules against pathogens 
whose activity relies on recognising a host receptor as well as an anionic surface 
GAG.  
 
 
213
  
214
PUBLICATIONS AND COMMUNICATIONS 
 
Publications 
 
Accepted  
Connell BJ, Françoise Baleux, Yves-Marie Coic, Pascal Clayette, David 
Bonnaffé and Hugues Lortat-Jacob. 2012. A Synthetic heparan sulphate-mimetic 
peptide conjugated to a mini CD4 displays very high anti-HIV-1 activity 
independently of coreceptor usage, Chemistry & biology 19:131-139. 
 
In preparation 
 
Connell BJ, Sadir R, Laguri C, Baleux F, and Lortat-Jacob H. (2012) Heparan 
Sulphate differentially regulates the binding of SDF α and γ to CXCR4.  
 
Connell BJ, INDUS© authors, Lortat-Jacob H. (2012) Cinnamon derived 
compounds display anti-HIV-1 activity by blocking the heparan sulfate and the 
coreceptor binding sites of gp120. 
 
Communications 
 
Connell BJ, Baleux F, Hersant Y, Bonnaffé D, and Lortat-Jacob H (2011). A 
Surface Plasmon Resonance (SPR) Based Screening Assay for the Development 
of Glyco-Based Anionic Molecules as HIV-1 Entry Inhibitors. Keystone 
Conference: "HIV Evolution, Genomics and Pathogenesis", March 2011, 
Whistler, British Columbia, Canada 
 
Connell BJ, Sadir R, Laguri C, Baleux F, and Lortat-Jacob H. (2011) Heparan 
Sulphate differentially regulates the binding of SDF α and γ to CXCR4. 7th 
International Conference on Proteoglycans held in conjunction with the Matrix 
Biology Society of Australia and New Zealand Annual Meeting. 16-20 October 
2011, Sydney Australia. 
 
 
215
  
216
Chemistry & Biology
Article
A Synthetic Heparan Sulfate-Mimetic Peptide
Conjugated to a Mini CD4 Displays Very High Anti-
HIV-1 Activity Independently of Coreceptor Usage
Bridgette Janine Connell,1 Franc¸oise Baleux,2 Yves-Marie Coic,2 Pascal Clayette,3 David Bonnaffe´,4
and Hugues Lortat-Jacob1,*
1CEA, CNRS, Universite´ Joseph Fourier – Grenoble 1, Institut de Biologie Structurale Jean-Pierre Ebel, UMR 5075, 38000 Grenoble, France
2Institut Pasteur, unite´ de Chimie des Biomole´cules, URA CNRS 2128, 75015 Paris, France
3Laboratoire de Neurovirologie, Bertin Pharma, CEA, 92265 Fontenay aux Roses, France
4Laboratoire de Chimie OrganiqueMultifonctionnelle, Equipe Glycochimie Mole´culaire et Macromole´culaire, ICMMOUMRCNRS-UPS 8182,
Universite´ Paris-Sud 11, 91405 Orsay, France
*Correspondence: hugues.lortat-jacob@ibs.fr
DOI 10.1016/j.chembiol.2011.12.009
SUMMARY
The HIV-1 envelope gp120, which features both the
virus receptor (CD4) and coreceptor (CCR5/CXCR4)
binding sites, offers multiple sites for therapeutic
intervention. However, the latter becomes exposed,
thus vulnerable to inhibition, only transiently when
the virus has already bound cellular CD4. To pierce
this defense mechanism, we engineered a series
of heparan sulfate mimicking tridecapeptides and
showed that one of them target the gp120 coreceptor
binding site with mM affinity. Covalently linked to
a CD4-mimetic that binds to gp120 and renders the
coreceptor binding domain available to be targeted,
the conjugated tridecapeptide now displays nano-
molar affinity for its target. Using solubilized core-
ceptors captured on top of sensorchip we show
that it inhibits gp120 binding to both CCR5 and
CXCR4 and in peripheral blood mononuclear cells
broadly inhibits HIV-1 replicationwith an IC50 of 1 nM.
INTRODUCTION
Although tremendous progress has been made in the develop-
ment of antiviral drugs to treat human immunodeficiency virus
(HIV-1) infection (De Clercq, 2007) and despite the availability
of some 25 approved antiretroviral compounds (most of which
target HIV-1 enzymes), the virus continues to be amajor concern
and remains one of the leading causes of death worldwide. The
rapid emergence of drug-resistant viral strains, the inability
of current therapy to completely eradicate the virus, and the
strong adverse side effects associated with their long-term use
(Shafer and Schapiro, 2008) compromise treatment in patients
benefiting from these therapies and make the development of
new therapeutic options of utmost importance (Flexner, 2007).
Inhibition of HIV-1 entry, a process based on the sequential inter-
action of the viral glycoprotein (gp120) with the cell surface CD4
(Klatzmann et al., 1984) and either one of the two chemokine
receptors CCR5 or CXCR4 (Alkhatib et al., 1996; Feng et al.,
1996), holds particular promise in addressing complications of
current therapy and has become a compelling target for control-
ling viral replication (Tilton and Doms, 2010). The recent approval
of maraviroc, a CCR5 antagonist (Dorr et al., 2005; Maeda et al.,
2004), has validated entry inhibition as a viable approach.
However, to avoid the selection of pre-existing and more patho-
genic CXCR4-using HIV-1 (for which no effective antagonistic
inhibitors yet exist) maraviroc has been licensed for the treat-
ment of patients infected with viral strains using CCR5 only.
On the virus side, the gp120 constitutes the central element for
all interactive events occurring during the pre-entry steps. A
wealth of evidence has shown that gp120 binding to CD4 not
only permits virus attachment, but also triggers extensive
conformational changes of the envelope that fold and/or expose
a four-stranded b sheet, known as the CD4-induced (CD4i)
domain (Wu et al., 1996). Being critically involved in CCR5/
CXCR4 recognition and highly conserved, this domain repre-
sents an attractive pharmacological target. Although inhibition
of protein-protein interactions is clearly challenging, a striking
feature of the CD4i domain is its basic nature (Kwong et al.,
1998; Rizzuto et al., 1998) and, not surprisingly, many of this
domain’s ligands are characteristically acidic. This includes
peptides selected by phage display screening (Dervillez et al.,
2010), sulfated oligosaccharides from the heparan sulfate (HS)
family (Crublet et al., 2008; Vive`s et al., 2005), aptamers (Cohen
et al., 2008), peptides derived from neutralizing antibodies (Dorf-
man et al., 2006), compounds issued from in silico screening of
molecular libraries (Acharya et al., 2011), or peptides derived
from the N-terminal sequence of CCR5 itself that comprise sul-
fotyrosines importantly contributing to gp120 binding (Cormier
et al., 2000; Farzan et al., 2000). The cryptic nature of this CD4i
surface prior to CD4 binding, however, limits its accessibility
both temporally and spatially andmakes it a relatively intractable
pharmacological target. In that context, we recently devel-
oped a class of compounds, in which a CD4 mimetic peptide
(mCD4) was linked to a HS dodecasaccharide (HS12), and
showed that mCD4 exposed the gp120 CD4i domain and
renders it available to be blocked by the HS12 oligosaccharide
(Baleux et al., 2009).
Here, to further develop this concept we engineered a series
of tridecapeptides that mimic HS, the synthesis of which,
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although amenable to large-scale production, remains extraor-
dinary complex (Dilhas et al., 2008). We then set up a binding
assay in which detergent solubilized CCR5 and CXCR4 were
both functionally captured on top of sensorchips and used
them to show that, conjugated to a mini CD4, a HS mimicking
peptide efficiently targets the CD4i domain of gp120 and blocks
its interaction with the coreceptors. This compound displays
antiviral activity against LAI and Ba-L HIV strains with an IC50
as low as 1 nM, two to four orders of magnitude lower than
the above-described anionic compounds. To our knowledge,
this is the most potent gp120 targeting molecule, with the
unique property to simultaneously block two critical and
conserved regions of gp120. Importantly it inhibits CCR5 and
CXCR4 using viruses equally well, and is also highly active
against a number of viral primary clinical isolates. These results
should have strong implications for the development of a new
anti-HIV-1 therapy.
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Figure 1. Ligand Binding to CCR5 and
CXCR4 Immobilized Sensorchips
Carboxy-terminal C9 tagged CCR5 or CXCR4
were solubilized from Cf2Th cells and captured on
top of a mAb 1D4 activated CM4 sensorchip.
CCR5 (left) and CXCR4 (right) ligands were in-
jected over the coreceptor surfaces, and the
binding responses (in RU) were recorded as
a function of time (in S). Binding of 25 nM of mAb
2D7 (blue) and mAb 12G5 (red) to CCR5 (A) and
CXCR4 (B). Binding of YU2 gp120 (black), YU2/
mCD4 (blue), or YU2/mCD4/maraviroc (red) to
CCR5 (C) or MN gp120 (black), MN/mCD4 (blue),
or MN/mCD4/AMD3100 (red) to CXCR4 (D).
Binding of the equimolar complex of YU2/mCD4
at (from top to bottom) 100, 66, 44, 29, 19, and
12.5 nM to CCR5 (E) or equimolar complex of
MN/mCD4 at (from top to bottom) 225, 150, 100,
66, 44, and 29 nM to CXCR4 (F). The black traces
correspond to the experimental data, and the red
traces correspond to the fitted data using a 1:1
langmuir model. Binding of YU2 or MN gp120
(100 nM) preincubated with 100 nMofmCD4 (blue)
or mCD4-HS12 (red) to CCR5 (G) or CXCR4 (H).
RESULTS
HIV-1 Coreceptors Immobilization
and gp120 Binding
Assessing the ability of molecules to
target the coreceptor binding site of
gp120would strongly benefit fromadirect
coreceptor-gp120 interaction assay. To
that end, both HIV-1 coreceptors were
solubilized from Cf2Th cells, recombi-
nantly expressing either CCR5 or CXCR4,
using a specific cocktail of lipids and
detergents that was adapted from that
previously described (Navratilova et al.,
2005). Solubilized coreceptors, which
feature a C-terminal C9 tag (Babcock
et al., 2001; Mirzabekov et al., 1999)
allowing their oriented capture with the
cognate 1D4 antibody, were immobilized on top of a sensorchip
to a level of 4,000 resonance units (RU). To verify whether the
coreceptors remained functional, we first investigated their
binding capacity with the conformationally sensitive mAb 2D7
for CCR5 (Khurana et al., 2005; Lee et al., 1999) and 12G5 for
CXCR4 (Baribaud et al., 2001). As shown in Figures 1A and 1B,
injection of these mAbs over the CCR5 and CXCR4 functional-
ized surfaces gave rise to strong and coreceptor-specific
binding signals, indicating both the presence of the coreceptor
on the surface and the integrity of the corresponding epitopes.
Following this, we analyzed whether the immobilized corecep-
tors bound gp120, in a CD4-dependent manner. For that
purpose, 100 nM of either YU2 or MN (R5 and X4 envelopes
respectively), in the absence or presence of mCD4, a CD4
mimetic peptide that was previously found to bind gp120 and
induce the conformational change that lead to the folding/
exposure of the coreceptor binding site (Baleux et al., 2009),
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was injected over the coreceptor surfaces. Both envelopes inter-
acted with their coreceptors, presumably because the CD4i
epitope is transiently exposed on the dynamic structure of
gp120, as already observed with anti-CD4i antibodies (Thali
et al., 1993). The binding responses, however, were significantly
enhanced by the presence of mCD4 and efficiently inhibited
by 1 mM of maraviroc or AMD3100 (Figures 1C and 1D), two
compounds targeting CCR5 and CXCR4 respectively, and
having anti-HIV-1 activity (Tilton and Doms, 2010). Next, dose-
response experiments were performed with mCD4:gp120 ratios
fixed at 1:1 and injected over the immobilized CCR5 or CXCR4
surfaces. Sensorgrams were obtained for both envelopes
(Figures 1E and 1F), which evaluations (see Supplemental
Experimental Procedures) returned estimated affinities of
11.5 ± 2.9 nM and 154 ± 68 nM for CCR5 and CXCR4, respec-
tively. These values were identical to that reported by a similar
technique (Navratilova et al., 2005) or radioligand binding assay
with cell membrane-embedded CCR5 (Doranz et al., 1999) as
to that reported for CXCR4, using proteoliposome embedded
coreceptors and radiolabeled gp120 (Babcock et al., 2001).
We previously reported that the gp120 CD4i epitope can be
targeted by HS (Crublet et al., 2008; Vive`s et al., 2005), and
that a HS dodecasaccharide covalently linked to mCD4
(mCD4-HS12) binds gp120 and blocks its subsequent interaction
with mAb 17b (Baleux et al., 2009). mAb 17b belongs to a group
known as ‘‘anti-CD4i’’ antibodies, which recognizes a conserved
element of gp120, induced by CD4 and partially overlapping the
coreceptor binding site (Xiang et al., 2002). We thus made use of
the coreceptor binding assay described above to investigate
whether mCD4-HS12 would also inhibit gp120 binding to CCR5
and CXCR4. As shown in Figures 1G and 1H, both YU2 and
MN gp120 in complex with mCD4-HS12 featured a strongly
reduced ability to recognize CCR5 or CXCR4 compared to that
of gp120 in complex with mCD4 alone. This suggests that
such molecules could serve as lead compounds for the future
development of a new class of entry inhibitors.
Chemical Synthesis of mCD4 Linked HS Mimetic
Peptides
HSs are, however, notoriously difficult to synthesize. In addition,
their inherent sequence heterogeneity, in terms of sulfation
pattern and saccharide composition, would currently make the
preparation of a dodecamer series out of reach. Thus, based
on the mCD4-HS12 template, we tested the hypothesis that
the HS moiety could be mimicked by peptides, the chemical
synthesis of which is more straightforward, and more easily
amenable to sequence-activity relationship investigation. To
display the functional hydroxyl, carboxyl, and sulfate groups
that characterize HS, peptides comprising Ser, Asp, and Tyr,
the latter being possibly sulfated, were considered. This strategy
is supported by the observation that a SYDY tetrapeptide binds
to the HS binding domain of the vascular endothelial growth
factor (Maynard and Hubbell, 2005) and that phage display
screenings against the CD4i epitope of gp120 returned
sequences enriched in YD motifs (Dervillez et al., 2010). It is
also worth noting that a number of antibodies against the
gp120 coreceptor binding domains feature sulfotyrosines in their
paratope, as does the N terminus of both CCR5 and CXCR4
(Choe et al., 2003).
Building of a S(XDXS)n sequence (were X stands for different
possible amino acids; see below) using the peptide builder of
Hyperchem 5, showed that a 13 amino acid peptide (n = 3), in
its extended configuration (4, c, and u angles set to 180) would
have a length equivalent to the HS 12 mer (data not shown).
Thus, a tridecapeptide, alternating OH/COO- and OH/SO3
-
groups, having the sequence: SYSO3DYSO3SYSO3DYSO3SYSO3
DYSO3S (X being in this case a sulfotyrosine; YSO3) was first
synthesized (P3YSO3). The nonsulfated equivalent (P3Y) was
also prepared along with a number of other peptides in which
X was replaced by p-carboxymethyl phenylalanine (P3pF) or
aminosuberic acid (P3Asu), two residues that have been shown
to functionally mimic sulfotyrosine in cholecystokinin type B
receptor ligand CCK8 (McCort-Tranchepain et al., 1992) and
sulfakinins (Nachman et al., 2005). A tridecaglutamate (display-
ing 13 carboxylic groups) was also prepared (E13) as a nonspe-
cific poly anionic peptide (Figure 2). In order to maintain an
appropriate distance between mCD4 and these peptides,
enabling the final molecule to reach both the CD4 and corecep-
tor binding sites, a g-aminobutyric acid (g-Abu) was introduced
on their N terminus. These peptides were derivatized with
S-acetylthiopropionic acid to allow the coupling to Lys5 of a
maleimide-activated mCD4. All compounds were purified to
a level of 95% by RP-HPLC (see Table S1 and Figures S1
and S2 available online), controlled by mass spectrometry and
CD4BS ligand 
CoRBS ligand 
X S(XDXS)3 name 
YSO3 P3YSO3
pF P3pF 
Asu P3Asu 
Y P3Y 
Figure 2. mCD4-S(XDXS)3 Constructs
A miniCD4 was used as a CD4 binding site (CD4BS) ligand and covalently
conjugated through an appropriate linker to S(XDXS)3 peptides investigated as
potential coreceptor binding site (CoRBS) ligands. S and D are serine and
aspartic acid residues respectively and X is either a sulfotyrosine (YSO3),
a p-carboxymethyl phenylalanine (pF) an aminosuberic acid (Asu) or a
tyrosine (Y). See also Figures S1 and S2 and Table S1.
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quantified by amino acid analysis as described in the Supple-
mental Experimental Procedures.
mCD4 Linked HS Mimetic Peptides Inhibit Binding
of gp120 to CD4, mAb 17b, and Coreceptors
To verify that peptide conjugation did not prevent the ability of
mCD4 to interact with gp120, a competition assay was per-
formed, in which YU2 or MN were incubated with the different
mCD4 conjugates and injected over a CD4 functionalized
surface. Results showed that the mCD4 conjugates all very effi-
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BA Figure 3. The S(XDXS)3 HS Mimetic Peptides
Coupled to mCD4 Inhibit gp120-CD4, gp120-mAb
17b, and gp120-Coreceptor Interactions through
Binding to the CD4 and the Coreceptor Binding
Sites of gp120
Binding responses measured when YU2 (A) or MN (B)
gp120 at 100 nM, either alone (blue) or preincubated with
100 nM of mCD4 (pink), mCD4-P3Y (green), mCD4-E13
(turquoise), mCD4-P3pF (orange), mCD4-P3Asu (brown),
or mCD4-P3YSO3 (red) were injected over a CD4 activated
surface. YU2-mCD4 (C) or MN-mCD4 (D) complexes
(25 nM) were preincubated with 5 mM of HS12 (red),
P3YS03 (green), or the other HS mimetic peptides (none,
P3Y, E13, P3pF, and P3Asu; all in black) and injected over
a mAb 17b activated surface. The blue trace shows the
binding of gp120 to mAb 17b in the absence of mCD4. The
P3YSO3 peptide (E) or HS12 (F) at different concentrations
were coincubated with YU2-mCD4 (circle) or MN-mCD4
(square) and injected over a mAb 17b surface. The binding
response (mean of triplicate experiment) recorded at the
end of the injection phase was plotted versus the con-
centration of the inhibitors in mM. Overlay of sensorgrams
showing the injection of 100 nM of mCD4 (blue), mCD4-
P3Y (black) or mCD4-P3YSO3 (red), from 0 to 600 s, over
immobilized YU2 (G) orMN (H) gp120, after which 15 mg/ml
of mAb 17b was injected from 600 to 900 s. Binding of
YU2 or MN gp120 (100 nM) preincubated with 100 nM of
mCD4 (blue) or mCD4-P3YSO3 (red) to CCR5 (I) or CXCR4
(J). In all graphs, binding signals were recorded in RU as
a function of time (S).
ciently prevent gp120-CD4 interaction, with
greater potency than that of unconjugated
mCD4 (Figures 3A and 3B). Next, the capacity
of the anionic peptides to target the gp120
CD4i epitope was investigated by analyzing
their ability to prevent gp120 binding to mAb
17b, in the presence of soluble mCD4. While un-
liganded gp120 was not (MN) or only poorly
(YU2) recognized by mAb 17b (Figures 3C and
3D; blue trace), preincubation with mCD4
strongly promoted binding (black trace). When
the gp120-mCD4 complexes were further incu-
batedwith 5 mMof the above-described trideca-
peptides, strong inhibition was observed for
P3YSO3 (green trace). The tridecaglutamate
(E13) was devoid of activity, indicating that the
anionic character of the peptide is not sufficient
to provide binding, as were the unsulfated P3Y
or the sequence in which the sulfotyrosine
mimetics (pF and Asu) were introduced (Figures
3C and 3D, black traces). HS12 (red trace) also fully blocked
mAb17b binding to MN-, but not to YU2-gp120. Together, this
showed that among the different peptides investigated only the
SYSO3DYSO3 motif competes with mAb 17b to interact with the
gp120 CD4i domain. To better quantify the inhibitory activity of
this peptide, the same assay was run, with a range of P3YSO3
concentrations, and compared with HS12. A similar concentra-
tion dependency was observed on both R5 (YU2) and X4 (MN)
envelopes, with IC50 of 2.9 and 3.1 mM, respectively, indicating
that, interestingly, P3YSO3 interacts with gp120 independently
Chemistry & Biology
Novel gp120 Targeting HIV-1 Entry Inhibitor
134 Chemistry & Biology 19, 131–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserved
of coreceptor tropism. In contrast, HS12 strongly inhibited the
interaction between MN and mAb 17b (with a concentration as
low as 0.5 mM) but was ineffective toward YU2, at concentrations
up to 10 mM (Figures 3E and 3F). Next, to determine the binding
mechanism of the mCD4-S(XDXS)3 constructs, X4- and R5-
gp120 were immobilized on a sensorchip and first allowed to
bind to mCD4, mCD4-P3Y, or mCD4-P3YSO3. The resulting
complexeswere then probedwithmAb 17b, the binding of which
being a marker of the coreceptor binding site accessibility. As
expected, mCD4 binding to gp120 renders the coreceptor
binding site accessible, a point that was also observed, although
with a lower efficiency, withmCD4-P3Y. These data indicate that
while mCD4-P3Y bound to gp120, the unsulfated peptide did not
sufficiently interact with the newly available surface to blockmAb
17b recognition. In contrast, when mCD4-P3YSO3 was used
instead of mCD4 or mCD4-P3Y, the mAb 17b was no longer
able to interact with the complex. Altogether, these data thus
support the view that mCD4 first binds to gp120 and exposes
the coreceptor binding site, with which the P3YSO3 moiety
then interacts strongly enough to prevent antibody binding
(Figures 3G and 3H). Finally, using the direct gp120-coreceptor
interaction assay described in Figure 1, we also demonstrated
that mCD4-P3YSO3 very potently inhibits gp120 binding to
both CCR5 and CXCR4 (Figures 3I and 3J). This suggests that
this compound could be a coreceptor independent HIV-1 entry
inhibitor.
mCD4 Linked P3YSO3 Peptides Display Strong Antiviral
Activity
Having characterized the binding mechanism of these com-
pounds, we investigated whether these anionic peptides, either
conjugated or not to mCD4 displayed anti-HIV-1 activity. This
was performed using an assay in which viral replication was
measured (reverse transcriptase quantification) in the superna-
tant of blasted peripheral blood mononuclear cells (PBMCs) iso-
lated from three to four donors and infected by either of the HIV-1
reference strains R5 (Ba-L) or X4 (LAI). When used alone, none of
the peptides demonstrated antiviral activity at the highest con-
centration tested (500 nM; data not shown). However, when
conjugated to mCD4, they displayed inhibitory activity against
the LAI strain, with effective doses giving 50% inhibition (ED50)
as low as 0.5 nM for mCD4-P3YSO3, which compares well to
1.4 nM for mCD4-HS12. Consistently with the biochemical
data, the importance of the sulfate groups was shown by
the large increase of ED50 (98 nM) that characterized mCD4-
P3Y, whereas the other anionic peptides (mCD4-P3pF, mCD4-
P3Asu, and mCD4-E13) displayed 8.2–30 nM ED50 (Figure 4A).
The Ba-L strain was also very strongly inhibited by mCD4-
P3YSO3, with an ED50 of 1.3 nM versus 18 nM for mCD4-HS12.
None of the other conjugates displayed significant antiviral
activity (Figure 4B). AZT, used as a reference anti-HIV molecule
in the same assay returned ED50 of 8.7 and 11 nM for R5 and X4
viruses, respectively (Figures 4A and 4B).
We also observed that mCD4-P3YSO3 does not need to be
preincubated with the virus to be active. Indeed, addition of
the molecule either to the cells prior to the viral challenge or to
the virus prior to the cell infection return identical results (Table
S2). This is consistent with the high affinity this molecule displays
for the viral envelope, presumably enabling a fast binding to its
target, and also suggests a potential use of this kind of
compounds as a microbicide, a condition in which inhibitors
are present within the host tissues, before viral infection.
Having established that mCD4-P3YSO3 displayed very strong
antiviral activity against LAI and Ba-L HIV-1 strains, used as
model systems, we extended our investigations to using a series
of more clinically relevant primary strains, including 92UG029,
SF162, 92US723, 96USHIPS4, 92HT599, and 98IN017. As
shown in Table 1, mCD4-P3YSO3 displayed a high level of anti-
viral activity, characterized by ED50 in the range of 0.2–1.2 nM for
five of them and 29 nM for HIV-1 98IN017. As for the LAI and
Ba-L strains, the mCD4 or P3YSO3 were only poorly active or
inactive, further supporting the very strong synergistic effect
induced by the coupling strategy. None of themolecules showed
cytotoxicity at up to 1 mM (data not shown).
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Figure 4. Antiviral Activity of mCD4 Linked to Either HS12 or
S(XDXS)3 HS Mimetic Peptides
PHA-P-activated PBMCs were infected with either (A) LAI (X4 tropic) or
(B) Ba-L (R5 tropic) HIV-1 strains, preincubated with each of the drugs under
investigation (1:5 dilutions between 500 nM and 320 pM). Molecules and
viruses were maintained throughout the culture, and cell supernatants were
collected at day 7 postinfection. Reverse transcriptase activity was quantified
from which 50 (black), 70 (gray), and 90% (white) effective doses (ED) were
calculated. In the absence of the inhibitory compounds, the RT level was in the
range of 10,000–25,000 and 6,500–10,000 pg/ml (depending on the donor) for
LAI and Ba-L strains respectively. Data are represented as mean of triplicate
experiments (±SEM) performed on PBMCs from three to four donors. See also
Table S2.
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DISCUSSION
Targeting gp120 for HIV-1 inhibition is both attractive (because
the protein engages multiple interactions key to viral entry,
thus offering multiple sites for inhibition) and challenging (in the
entry complex, the buried surface to block comprises both
the gp120-CD4 and gp120-coreceptor interfaces). Although
protein-protein interfaces are often relatively featureless and
devoid of traditional cavities into which a small molecule can
dock, the realization that the gp120 coreceptor binding site
displays a restricted number of functionally important basic resi-
dues has very recently attracted the attention of many studies.
Many of them reported that anionic molecules target the CD4i
epitope, as shown by their ability to competitively inhibit mAb
17b binding with IC50 in the 1–100 mM range (Acharya et al.,
2011; Brower et al., 2009; Cohen et al., 2008; Cormier
et al., 2000; Crublet et al., 2008; Dervillez et al., 2010; Farzan
et al., 2000; Kwong et al., 2011; Seitz et al., 2010). HS belongs
to this class of CD4i domain targeting molecules (Crublet et al.,
2008), and a highly sulfated and regular sequence comprising
12 monosaccharide units has been recently prepared. Conju-
gated to mCD4, it displays strong anti-HIV-1 activity (Baleux
et al., 2009). However, HS is extraordinary complex and hetero-
geneous in sequence (Esko and Lindahl, 2001). Based on the 48
different units that the polymer theoretically comprises, a 12 mer
library would reach 1010 molecules. Although the reality is less
(all the combinations are not possible), it remains much more
than can be realistically synthesized for structure-activity rela-
tionship studies. Thus, to further develop this kind of molecule
we attempted to design HS mimetic peptides, with the general
sequence S(XDXS)3 and showed that, when X was a sulfotyro-
sine, it binds to the CD4i epitope, blocking mAb 17b with IC50
of 3 mM, thus comparing very well with the above-mentioned
molecules. Interestingly, this peptide interacts equally well with
R5 and X4 gp120, whereas HS especially binds to the X4 enve-
lope (Figures 3E and 3F). More importantly, the conjugation of
this peptide to mCD4 dramatically enhances its binding activity,
the conjugated molecule being able to fully prevent the gp120/
mAb 17b interaction at low nM concentration, showing that the
covalent linkage induced a strong synergistic effect. This is
consistent with the view that high-affinity mCD4 binding takes
place initially, inducing the exposure of the mAb 17b epitope to
which the sulfated peptide can then bind. As such, this molecule
is distinct from other mAb 17b blocking peptides that suppress
CD4 binding and subsequent coreceptor binding site exposure
through an allosteric inhibitory effect rather than competitive
inhibition (Biorn et al., 2004).
Although widely used as a CCR5 or CXCR4 surrogate, mAb
17b, however, only imperfectly defines the gp120 coreceptor
binding site which, in addition to theCD4 induced bridging sheet,
is also constituted by the V3 loop in particular (Dragic, 2001).
Thus, to better assess the blocking efficiency of molecules
targeting the gp120-coreceptor interaction, and taking into
account domains outside the CD4i epitope itself, CCR5 and
CXCR4 were solubilized and functionally captured on top of bia-
core sensorchips. Binding of gp120 to CCR5 and CXCR4 proved
to be both CD4 and concentration dependent and inhibited by
specific antagonists. Fitting of the binding data was expectedly
complicated by several parameters, such as the complexity of
the buffer system used, the reversible nature of both the
1D4-coreceptor and mCD4-gp120 complexes and the confor-
mational flexibility of gp120, thus the calculated affinity values
reported should probably be considered as estimates only.
Nevertheless, we report KDs of 10 and 150 nM for the YU2-
CCR5 and MN-CXCR4 interactions respectively, comparable
to those obtained with cellular systems in which the coreceptors
remained in their natural cell membrane environment (Babcock
et al., 2001; Doranz et al., 1999). This assay provides a useful,
label-free method, to identify both binding capacity of envelopes
and inhibitory activity of potential drugs. This was especially true
in the framework of this study investigating sulfated/polyanionic
compounds to target the gp120 coreceptor binding site.
Although tyrosine sulfation of coreceptors has been shown to
play a less significant role in CXCR4- than in CCR5-dependent
HIV-1 entry (Farzan et al., 2002), we found that when conjugated
to mCD4 the sulfated P3YSO3 displays very strong binding
activity toward both R5- and X4- gp120. Using this assay, we
indeed report that gp120 binding to both CCR5 and CXCR4
Table 1. Anti-HIV-1 activity of AZT, mCD4-P3YSO3, P3YSO3, and mCD4 against Clinical HIV-1 Isolates
Viral Strain
Clade-Tropism
92UG029
A-X4
SF162
B-R5
92US723
B-R5/X4
96USHIPS4
B-R5/X4
92HT599
B-X4
98IN017
C-X4
AZT ED50 7 ± 0 8 ± 7 8 ± 0.1 19 ± 9 9 ± 4 8 ± 3
ED70 16 ± 3 13 ± 8 17 ± 1 27 ± 11 22 ± 5 19 ± 5
ED90 61 ± 17 31 ± 3 59 ± 19 56 ± 15 110 ± 13 108 ± 25
mCD4-P3YSO3 ED50 0.2 ± 0.0 0.3 ± 0.2 0.3 ± 0.1 1.2 ± 1 0.5 ± 0.2 29 ± 18
ED70 0.3 ± 0.1 0.4 ± 0.3 0.35 ± 0.2 1.6 ± 1.2 1.3 ± 0.9 147 ± 9
ED90 0.8 ± 0.3 0.9 ± 0.2 0.45 ± 0.2 3 ± 1.4 3.5 ± 0.0 >500
P3YSO3 ED50 >500 >500 >500 >500 >500 >500
ED70 >500 >500 >500 >500 >500 >500
ED90 >500 >500 >500 >500 >500 >500
mCD4 ED50 403 ± 76 245 ± 155 23 ± 1 >500 355 ± 155 >500
ED70 >500 352 ± 105 34 ± 10 >500 >500 >500
ED90 >500 >500 52 ± 22 >500 >500 >500
The table shows the effective dose (ED, mean of triplicate determination), in nM (±SD) required to inhibit 50%, 70%, and 90% of HIV-1 replication.
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was fully inhibited by 1:1 stoichiometric condition of mCD4-
P3YSO3. The overall positive charge of the V3 loop, which is
much higher in X4- than in R5-gp120 (Moulard et al., 2000)
strongly influences the electrostatic potential of the coreceptor
binding region of the protein. In the case of CXCR4-using
viruses, electrostatic interactions between the sulfated peptide
and the V3 loop may thus also participate in the blocking mech-
anism. This view is consistent with the fact that the V3 loop
(which importantly contributes to coreceptor binding) is located
close to the CD4i bridging sheet and with its known capacity to
interact with polyanions (Moulard et al., 2000). This is further sup-
ported by the observation that all the anionic peptides prepared
during the course of this study (mCD4-P3Asu, mCD4-P3pF,
mCD4-E13, and mCD4-P3Y) also display some level of antiviral
activity against X4- but not against R5- viruses. This also sug-
gests that, in engineering such compounds, it should be advan-
tageous to use sulfated peptides with only modest specificity so
that they can broadly target distinct envelopes, the high speci-
ficity of the conjugated bivalent compound being brought by
the mCD4 moiety. Structural studies of mCD4-P3YSO3, in
complex with different gp120 would be interesting approaches
to further define these aspects. In this regard, it can be noted
that sulfated peptides would represent an advantage over HS,
the crystallography of which, in complex with proteins appearing
to be specially challenging (Imberty et al., 2007).
Although relatively limited in molecular mass (5,500 Da) the
mCD4-P3YSO3 molecule has the remarkable property to target
two critical and conserved regions of gp120, and thus to simul-
taneously block two large protein surfaces (i.e., the CD4 and
the coreceptor binding site). In complete agreement with the
biochemical data, it displays 1 nM ED50 anti-HIV-1 activity, for
both CXCR4 and CCR5 using model viruses in a cellular assay.
Importantly, we also found that this compound had a broad
neutralizing activity and was very effective against a number of
HIV-1 clinical isolates, strongly suggesting that this approach
deserves further investigation toward in vivo evaluation. No
effective antagonistic inhibitors yet exist for CXCR4. This
compound, which at 1 mM is devoid of toxicity, could be a valu-
able weapon against the more aggressive CXCR4-tropic HIV-1
strains or for patients featuring a mixed HIV-1 population for
which CCR5 antagonist cannot be used.
SIGNIFICANCE
While very significant progress has been made in the devel-
opment of anti-HIV-1 drugs, the emergence of drug-resis-
tant viruses, the inability of current therapy to be curative,
and its adverse side effects have led to an urgent need for
new blocking strategies. As a target, gp120 that features
the coreceptor binding site is particularly attractive. How-
ever, its cryptic nature makes it a difficult target that up to
now has resisted attacks.
Here, we covalently linked a sulfotyrosine containing
tridecapeptide that targets the gp120 coreceptor binding
site, to a CD4 mimetic (mCD4). We showed that the mCD4,
in interacting with gp120, induces conformational changes
that expose the coreceptor binding site and renders it
available to be blocked by the sulfated peptide. In cellular
assays, this compound, which successfully targets two
critical domains of gp120, displays strong antiviral activities
and neutralizes HIV-1 with 1 nM IC50.
The conjugate was much more effective than a mixture of
mCD4 and tridecapeptide alone, indicating that the covalent
linkage is essential to produce a synergistic effect. To our
knowledge, this compound establishes a new type of in-
hibitor and suggests a concept by which a relatively low
specific molecule (the sulfated peptide), coupled to a highly
specific compound (themCD4) can reach very high affinities
for its target. Combining these two characteristics may
enable the molecule to accommodate mutations that invari-
ably characterize acquired viral resistance.
These results should have strong implications for
the development of a new class of anti-HIV-1 therapy: the
mCD4-conjugate simultaneously blocks the attachment
and entry domains of gp120 and thus inhibits viral replication
at a very early stage of the viral life cycle. Most importantly, it
has the remarkable and unique property to neutralize both
CCR5- and CXCR4-tropic HIV-1. This is definitively a strong
advantage since HIV-1 may escape from CCR5 antagonists
through selection of CXCR4-using variants.
EXPERIMENTAL PROCEDURES
Materials
A BIAcore 3000 machine, CM4 sensorchip, amine coupling kit and HBS-P
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20
[pH 7.4]) were from GE-Healthcare. Streptavidin and Piperidin were from
Sigma. MN and YU2 gp120 were from Immunodiagnostic. Soluble CD4,
mAb 17b and Cf2Th coreceptor expressing cells were obtained through the
NIH AIDS Research and Reference Reagent Program. The antibodies 12G5
and 2D7 were purchased from R&D systems and BD Pharmingen, respec-
tively. The HIV-1 entry inhibitors AMD3100 andMaraviroc were from Fernando
Arenzana (Pasteur Institute, Paris). The1D4 antibody was from Flint Box,
University of British Columbia. Synthetic phospholipid blend 1,2-dioleoyl-sn-
glycero-3-phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-L-serine for-
mulation (DOPC/DOPS; 7:3, w/w), the Mini-Extruder kit, filter supports and
polycarbonate filters with defined pore diameter (100 nm) were purchased
from Avanti Polar Lipids. Detergents, n-dodecyl-b-D-maltopyranoside
(DOM), 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate/N,N-
Dimethyl-3-sulfo-N-[3-[[3a,5b,7a,12a)-3,7,12-trihydroxy-24-oxocholan-24-yl]
amino]propyl]-1-propanaminium (Chaps) and Cholesteryl hemisuccinate tris
salt (CHS) were purchased from Anatrace. Complete, EDTA-free protease
inhibitor tablets were from Roche Diagnostics. Polyethylene glycol 8,000
50% w/v solution was purchased from Hampton research. Resins for peptide
synthesis were purchased from RAPP Polymere GmbH and Fmoc AAs, HATU,
NMP, DMF, and TFA were from Applied Biosystems. Fmoc-Tyr (SO3.NnBu4)-
OH and Fmoc-g-Aminobutyric-OH (g-Abu) were from Novabiochem,
(S)-Fmoc-2-amino-octanedioc acid-8-ter-butyl ester (Asu) from Polypeptides,
and Fmoc -L-4 (O-tButylcarboxymethyl)-Phe-OH (pF) from Anaspec. HPLC
grade triethylamine acetate buffer was from GlenResearch. N-succinimidyl-
S-acetylthiopropionate (SATP) was from Pierce.
CCR5/CXCR4 Solubilization
The human receptors CCR5 and CXCR4, featuring a C-terminal C9 tag
(TETSQVAPA), were expressed in Cf2Th canine thymocyte cells as described
previously (Mirzabekov et al., 1999). The CCR5 and CXCR4 solubilization
protocol was adapted from a described procedure (Navratilova et al., 2005).
Briefly Cf2Th.CCR5- or CXCR4-expressing cells (5–8 3 106) were solubilized
in 1 ml buffer consisting of 100 mM (NH4)2SO4, 20 mM Tris-HCl (pH 7.5),
10% glycerol, 15% PEG 8000, protease inhibitors, CHS (0.2%), DOM
(1.5%), CHAPS (1.5%), and 0.33 mM DOPC:DOPS liposomes (see detailed
buffer preparation in the Supplemental Experimental Procedures). The cell
suspension was sonicated (6 3 1 s pulses) and placed on a rotating wheel
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at 4C for 3 hr. The solutions containing the solubilized coreceptors were
centrifuged at 14,000 rpm for 30 min at 4C and the supernatants were either
used directly in SPR analysis or stored at 80C until further use.
Surface Plasmon Resonance-Based Binding Platform
The interactions between gp120 and its ligands (CD4, mAb 17b, CCR5, and
CXCR4) were analyzed by surface plasmon resonance (SPR) technology.
For that purpose, N-ethyl-N0-(diethylaminopropyl)-carbodiimide (EDC)/N-
hydroxy-succimide (NHS) activated CM4 sensorchips were functionalized
with either 1,200 RU of soluble CD4, 700 RU of mAb 17b, or 7,000 RU of
mAb 1D4 and blocked with pH 8.5 1 M ethanolamine. The C9-tagged CCR5
or CXCR4 were captured onto the 1D4 mAb to a level of 4,000 RU. In
some cases, gp120 were also immobilized onto CM4 sensorchip. For this,
MN (50 mg/ml in 5mMmaleate buffer [pH 6]) or YU2 (50 mg/ml in 10mMacetate
buffer [pH 4.8]) were injected at 5 ml/min over an EDC/NHS activated flow cell
until levels of 4,500 RU was obtained. Molecules under investigation were
injected over the different surfaces and the binding responses were recorded
as a function of time (see Supplemental Experimental Procedures).
Peptide Synthesis and Purification
Peptides were prepared by solid-phase peptide synthesis on H-Ser(tBu)-2-
ClTrt-PS-resin using Fmoc chemistry excepted for the E13 peptide which
was prepared on Fmoc-Glu(tBu)-PHB-PS-resin. Fmoc-Tyr-(SO3.NnBu4)-OH
was used to synthesize the sulfotyrosines containing peptide. SATP was
used to introduce a protected sulfhydryl groups at the N terminus of each puri-
fied peptide, which were then conjugated in presence of hydroxylamine to a K5
maleimide-activated mCD4, the synthesis of which has been reported else-
where (Baleux et al., 2009) to yield the desired conjugates mCD4-P3YSO3,
mCD4-P3Y, mCD4-P3pF, mCD4-P3Asu and mCD4-E13. All compounds
were purified by RP-HPLC. Analytical procedures, characterization, and quan-
tification of these materials are described in the Supplemental Information.
Antiviral Assay
Phytohemagglutinin (PHA)-P-activated PBMCs were infected either with the
reference lymphotropic HIV-1/LAI strain (Barre´-Sinoussi et al., 1983) or with
the reference macrophage-tropic HIV-1/Ba-L strain (Gartner et al., 1986).
These viruseswere amplified in vitro with PHA-P-activated bloodmononuclear
cells. Viral stocks (including clinical isolates) were titrated using PHA-P-
activated PBMCs, and 50% tissue culture infectious doses (TCID50) were
calculated using Ka¨rber’s formula (Ka¨rber, 1931). Viruses (125 TCID50) were
incubated for 30 min with five concentrations (1:5 dilutions between 500 nM
and 320 pM) of each of the molecules to be tested and added to 150,000
PBMCs (moi 0.001). Cell supernatants were collected at day 7 postinfection
and stored at 20C. In some cases, the compounds were added to the cells
prior to viral challenge. Viral replication was measured by quantifying reverse
transcriptase (RT) activity in the cell culture supernatants using the Lenti RT
Activity Kit (Cavisi) and AZT was used as reference anti-HIV-1 molecule. In
parallel, cytotoxicity was evaluated on day 7 in uninfected PHA-P-activated
PBMC using a colorimetric methyl-tetrazolium salt (MTS/PMS) assay (Prom-
ega). Experiments were performed in triplicate and 50, 70 and 90% effective
doses (ED) were calculated using SoftMaxPro software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2011.12.009.
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